<tstset trglang="any" setid="test" srclang="any">
<doc sysid="Edinburgh" docid="doc">
<seg id="1">"" "" "" "the present document is a summary of the European Public Fund (EPAR), in which explains how the Committee for Human Use (CHMP) evaluates the studies with regard to recommendations concerning the application of the medication." "" "" ""</seg>
<seg id="2">"" "" "" "if you need further information about your disease or treatment, please check the package age (also part of the EPAR) or contact your doctor or pharmacist." "" "" ""</seg>
<seg id="3">"" "" "" "if you wish further information regarding the recommendations of the CHMP, please read the scientific discussion (also part of EPAR)." "" "" ""</seg>
<seg id="4">It is available as 5 mg / 10 mg, 15 mg and 30 mg tablets (tablets that dissolve in the mouth) as a solution to redeem (1 mg / ml) and as a solution for injection (7.5 mg / ml).</seg>
<seg id="5">B. wirres thinking and speech, hallucinations (hearing or vision of things that are not present), Misstrust and deludelines; • Bipolar-I disturbance (Periods of abnormal highes) alternately with periods of normal mood.</seg>
<seg id="6">"" "" "" "Abilify is used to treat moderate to severe emical episodes and to prevent academic episodes in patients, which have addressed in the past to the medicine." "" "" ""</seg>
<seg id="7">"" "" "" "injection solution is applied to rapid control of increased unrest or behavioural disorders, if the oral intake of the medication is not possible." "" "" ""</seg>
<seg id="8">"" "" "" "in both conditions, the solution for intake or the fusion tablets can be applied to patients with the swallowing of tablets." "" "" ""</seg>
<seg id="9">"" "" "" "for patients who take other medicines at the same time, the dose of Abilify should be adapted." "" "" ""</seg>
<seg id="10">"" "" "" "this implies the signal transmission between brain cells by" neurotransmitter, "i.e. chemical substances that enable the communication of nerve cells to each other." "" "" ""</seg>
<seg id="11">"" "" "" "the receptors for the neurotransmitter dopamine and 5-hydroxytryptamin (also called serotonin) is probably effective." "" "" ""</seg>
<seg id="12">This means that Aripiprazole like 5-hydroxytryptamin and dopamine is less than the neurotransmitter in order to activate the receptors.</seg>
<seg id="13">"" "" "" "since dopamine and 5-hydroxytryptamin bear a role in schizophrenia and bipolar disorder, the activity of the brain is reduced to normalize psychotic or manic symptoms." "" "" ""</seg>
<seg id="14">"" "" "" "the effectiveness of obilify, preventing the symptoms occur, was investigated in three studies up to one year." "" "" ""</seg>
<seg id="15">"" "" "" "efficacy of injection solution was compared in two studies in 805 patients with schizophrenia, or similar disorders, compared to increased unrest over a period of two hours compared to a placebo." "" "" ""</seg>
<seg id="16">"" "" "" "in another study, Abilify was examined over twelve weeks to 347 patients with Haloperidol, in another study, compared to 160 patients in which the manic symptoms were stabilized with Abilify." "" "" ""</seg>
<seg id="17">The effectiveness of implant injection solution was compared in a study to 301 patients with bipolar disorder, which had been compared to successive unrest when compared to Lorazepam (another antipsychotic) and placebo over a period of two hours.</seg>
<seg id="18">"" "" "" "in all studies, the changes of the symptoms of patients was studied using a standard scale of bipolar disorder or the number of patients receiving treatment." "" "" ""</seg>
<seg id="19">"" "" "" "furthermore, the company also conducted studies to investigate as the body absorbs the fusion tablets and the solution to capture absorbers (taking up)." "" "" ""</seg>
<seg id="20">"" "" "" "in the two trials involving the injection solution, patients who received Abilify in doses of 5.25 mg, 9.75 mg or 15 mg, significantly higher reduction in symptoms of increased unrest than those who received a placebo." "" "" ""</seg>
<seg id="21">"" "" "" "when used to treat bipolar disorder, Abilify in four of the five language studies manic symptoms more effective than placebo." "" "" ""</seg>
<seg id="22">"" "" "" "Abilify had also prevented for up to 74 weeks more effective than placebo, reoccur Manian episodes for previously treated patients and when it was administered in addition to an existing treatment." "" "" ""</seg>
<seg id="23">"" "" "" "Abilify injections in 10- or 15-mg doses have also more effective than placebo, increased unrest and were similar to Lorazepam." "" "" ""</seg>
<seg id="24">The most common adverse events of Abilify to take (observed at 1 to 10 of 100 patients) are extrapyramidal disorders (instiction), vomiting and exhaustion (instipation), fatigue and exhaustion, restlessness, indsomnia (insomnia) and anxiety.</seg>
<seg id="25">"" "" "" "in the conclusion that the benefits of Abilify in the treatment of schizophrenia and of moderate to severe incidents diagnosed with bipolar-I disorder and the prevention of a new lack of episodes on the treatment with Aripiprazol, compared with the risks." "" "" ""</seg>
<seg id="26">"" "" "" "also, the Committee came to the result that the benefits of injustice with schizophrenia and behavioural disorders in patients with schizophrenia or patients with manic episodes are not suitable to outweigh the risk." "" "" ""</seg>
<seg id="27">"" "" "" "in June 2004, the European Commission issued Otsuka Pharmaceutical Europe Ltd. approved for placing the traffic of Abilify in the entire European Union." "" "" ""</seg>
<seg id="28">"" "" "" "ABILIFY is indicated for the treatment of moderate to severe incidents of bipolar disorders, and for the prevention of a new manic episode which had mainly manische episodes and discussed the manic episodes on the treatment with Aripiprazol (see Section 5.1)." "" "" ""</seg>
<seg id="29">The recommended starting dose for ABILIFY is 10 or 15 mg / day at a maintenance dose of 15 mg / day once daily regardless of meals.</seg>
<seg id="30">"" "" "" "an increased effectiveness of doses above a daily dose of 15 mg was not proven, although individual patients can benefit from a higher dose." "" "" ""</seg>
<seg id="31">The recommended starting dose for ABILIFY is 15 mg once daily, regardless of meals as monotherapy or combination therapy (see section 5.1).</seg>
<seg id="32">Efficacy of ABILIFY in the treatment of schizophrenia and bipolar-i- disturbance in patients from 65 years has not been proven.</seg>
<seg id="33">"" "" "" "with regard to the higher sensitivity of this patient group, a lower initiate dose should be considered if clinical factors justify them (see Section 4.4)." "" "" ""</seg>
<seg id="34">"" "" "" "if the CYP3A4-induction included in combination therapy, the recommended dosage should be reduced to the recommended dose (see Section 4.5)." "" "" ""</seg>
<seg id="35">"" "" "" "the occurrence of suicidal behavior includes psychotic disorders and affective disturbances, and was reported in some cases after the start or change of an antipsychotic medication, even in treatment with Aripiprazole (see Section 4.8)." "" "" ""</seg>
<seg id="36">"" "" "" "results of an epidemic study showed that in patients with bipolar disturbance, there was no elevated risk risk associated with Aripiprazole compared to other antipsychotics." "" "" ""</seg>
<seg id="37">Ariophazol should be used with caution in patients with well-known carcinogenic diseases (myocardial infarction), heart failure disease, hypovolaemia (treatment with bloodhobic doses) or hypertonia (including acute and malignant form).</seg>
<seg id="38">"" "" "" "3 Spätdyskinesia: in clinical trials that lasted a year or less, there was occasional reports about the treatment with Aripiprazol concerned Dyskinesia." "" "" ""</seg>
<seg id="39">"" "" "" "if the patients treated with ABILIFY therapy signs and symptoms of a late dyoiesis should occur in considerations, reduce the dose or cancell the treatment." "" "" ""</seg>
<seg id="40">"" "" "" "when a patient developed signs and symptoms appearing on a mns, or unclear fever without an additional clinical manifestation of mns, all antipsychotics must be absent including ABILIFY." "" "" ""</seg>
<seg id="41">"" "" "" "therefore, Ariophazole should be applied in patients with seizures in the Anamnese or with conditions associated with caution." "" "" ""</seg>
<seg id="42">56 - 99 years) associated with Ariophazol in patients with psychosis who were treated with the Alzheimer's disease; patient treated with Aripiprazole had an elevated risk of death compared to placebo.</seg>
<seg id="43">"" "" "" "however, in one of these studies, there was a study with fixed dose, a significant relationship between the dosage and response to undesirable cerebrovascular events treated with Aripiprazol." "" "" ""</seg>
<seg id="44">"" "" "" "hyperglycemia, in some cases extremely and associated with ketoazide or hyperosmolar coma or death, was reported in patients with atypical antipsychotic agents, including ABILIFY." "" "" ""</seg>
<seg id="45">"" "" "" "there is no precise risk assessment for hyperglycemia-related events with ABILIFY and other atypical antipsychotic drugs treated, which allow direct comparisons." "" "" ""</seg>
<seg id="46">Polydipsy, polyurie (polyphagie and weakness) are observed and patients suffering from diabetes mellitus or with risk factors for diabetes mellitus should regularly be monitored in relation to deterioration of glucose levels.</seg>
<seg id="47">"" "" "" "in general, a weight gain is generally found in schizophrates patients and patients with bipolarisation, the application of antipsychotics, with which weight gain as side effect is observed and could lead to severe complications." "" "" ""</seg>
<seg id="48">"" "" "" "due to the primary effect of Aripiprazole, caution is careful when Aripiprazole is taken in combination with alcohol or other central effective drug side effects such as sediment (see Section 4.8)." "" "" ""</seg>
<seg id="49">"" "" "" "the H2 and agonist Famotidine, a gastric-blocker, reduces the absorption rate of Aripiprazole, but this effect is considered clinically irrelevant." "" "" ""</seg>
<seg id="50">"" "" "" "in a clinical study with healthy subjects, a highly effective CYP2D6 inhibitor increased the AUC from Aripiprazole by 107%, while the Cmax remained unchanged." "" "" ""</seg>
<seg id="51">"" "" "" "it is expected that other highly effective inhibitors of CYP2D6, such as fluoxetine and paroxetine, have similar effects and therefore should have similar dosistions." "" "" ""</seg>
<seg id="52">CYP2D6 'bad' (= "Poor") Metabolism can result together with highly effective inhibitors of CYP3A4 in higher Plasma concentrations as a result of CYP2D6 extensive metabolism.</seg>
<seg id="53">If the common gift of Ketoconazole or other highly effective CYP3A4 inhibitors are considered to be considered the potential benefit of potential risks for the patient.</seg>
<seg id="54">Other highly effective inhibitors of CYP3A4 such as Itraconazole and HIV proteins have similar effects and therefore similar doses should be made.</seg>
<seg id="55">"" "" "" "after setting the CYP2D6- or 3A4-inhibitors, the dose of ABILIFY should be raised to the dose height before beginning of the accompanying therapy." "" "" ""</seg>
<seg id="56">Diltiazem or Escitalopram) or CYP2D6 can be given together with ABILIFY to be expected with a moderate increase in Aripiprazol- concentrations.</seg>
<seg id="57">Clinical studies demonstrated doses of 10-30 mg Aripiprazole per day not a significant effect on the metabolism of CYP2D6 (Dextromethysts) and 2C19 (Omeprazol) and 3A4 (Dextromethorphan).</seg>
<seg id="58">"" "" "" "patients should be advised to inform their doctor if they are pregnant, or plan a pregnancy during the treatment with Aripiprazole." "" "" ""</seg>
<seg id="59">"" "" "" "due to insufficient data base for people and due to the concerns in pregnancy, this medicine may not be applied in pregnancy, unless the potential benefit justifies the potential risk of fetus." "" "" ""</seg>
<seg id="60">"" "" "" "however, in other antipsychotics the patients should be warned of, dangerous machines, including motor vehicles, to operate, until they are certain that Aripiprazole had no negative influence on them." "" "" ""</seg>
<seg id="61">"" "" "" "the following adverse events were more common (≥ 1 / 100) than placebo, or were classified as possible medical-relevant side effects (*):" "" "" ""</seg>
<seg id="62">The frequency of the side effects listed below is defined according to the following criteria: frequently (&gt; 1 / 100, &lt; 1 / 10); occasional (&gt; 1 / 1.000) &lt; 1 / 100).</seg>
<seg id="63">Schizophrenia - In a controlled long-term study about 52 weeks were treated with Aripiprazol (25.8%) in EPS including Parkinsonicism, Akulatory and Dyskinesia. compared to patients who were treated with Haloperidol (57.3%).</seg>
<seg id="64">"" "" "" "in a placebo-controlled trial over 26 weeks, the incidence of EPS 19% in patients under Aripiprazole and 13.1% were under placebo." "" "" ""</seg>
<seg id="65">"" "" "" "in a different controlled long-term study of over 26 weeks, the incidence of EPS 14.8% was treated with Aripiprazol, and 15.1% in patients with dazzapine therapy." "" "" ""</seg>
<seg id="66">Manical episodes with bipolar-I disturbance - in a controlled study of over 12 weeks was the incidence of EPS 23,5% in patients under Aripiprazol- treatment and 53.3% in patients with Haloperidol treatment.</seg>
<seg id="67">"" "" "" "in another study over 12 weeks, the incidence of EPS is 26.6% in patients under Aripiprazole and 17.6% for those under lithium treatment." "" "" ""</seg>
<seg id="68">During long-term recovery about 26 weeks in a placebo-controlled trial the incidence of EPS 18.2% for patients under Aripiprazol- treatment and 15.7% for patients treated with placebo treated patients.</seg>
<seg id="69">"" "" "" "a comparison between the patient groups under Aripiprazole and placebo, in which potentially clinically significant changes of the routinely controlled laboratory parameters appeared, no medical characterisation resulted." "" "" ""</seg>
<seg id="70">Increases the CPK (creatine Phosphokinase) in general temporarily and asymptomatic patients were observed in 3.5% of patients treated with Aripiprazol in comparison to 2.0% of patients treated with placebo.</seg>
<seg id="71">"" "" "" "in addition to the side effects that occur in connection with an antipsychotic syndrome, Spätdyskinesis and occlusion with older dementia patients, hyperglycemia and diabetes mellitus (see Section 4.4)." "" "" ""</seg>
<seg id="72">"" "" "" "in clinical trials and since the market launch, unintended or deliberative overdosages were observed with Aripiprazole alone in adult patients with estimated doses of up to 1260 mg and without cause." "" "" ""</seg>
<seg id="73">"" "" "" "although there is no information about the efficacy of a hematalysis in treating an overdosage with Aripiprazole, however, it is unlikely that Aripiprazole has a high plasma tray." "" "" ""</seg>
<seg id="74">It is thought that the effectiveness of Aripiprazol in schizophrenia and bipolar-I interruption involves the combination of a partial agonistic effect on dopamine d2 and serotonin 5HT1a- receptors and an antagonistic effect on serotonin 5HT2a receptors.</seg>
<seg id="75">"" "" "" "in vitro, Aripiprazol showed a high affinity to the dopamine D2- and 5HT2a receptor as well as a moderate affinity to the dune 5HT2c- and 5HT7-, to the alpha-1-adrennet and for histamine-H1receptor." "" "" ""</seg>
<seg id="76">In the gift of Aripiprazole in dosages of 0.5 to 30 mg once a day over 2 weeks of healthy volunteers the Positons Emission Tomography showed a dose- dependent reduction of 11C-Racloprid, a D2 / D3-receptor-Liganyone. at Nucleus caudatus and on the coup.</seg>
<seg id="77">"" "" "" "in three placebo-controlled short-time studies (4 to 6 weeks), Ariophazole showed statistically significant improvement of psychotic symptoms compared to placebo." "" "" ""</seg>
<seg id="78">"" "" "" "in a Haloperidol-controlled trial in week 52 the proportion of Responsibility patients held their response to the study medication, in both groups (Aripiprazole 77% and Haloperidol 73%)." "" "" ""</seg>
<seg id="79">"" "" "" "current values of measurement scales, which were defined as secondary study potential, including PANSS and the Montgomery-Asgomery-scale, showed significantly stronger improvement than with Haloperidol." "" "" ""</seg>
<seg id="80">In a placebo-controlled trial over 26 weeks to stabilized patients with chronic schizophrenia showed significantly higher reduction of the decline rate that was 34% in the Aripiprazol group and 57% under Placebo.</seg>
<seg id="81">"" "" "" "in a dazzapin-controlled, multinational double-blind study included in schizophrenia (N = 18 or 13% of the evaluated patients' weight gain) (i.e. an increase of at least 5,6 kg) with an average weight of approx. 5%." "" "" ""</seg>
<seg id="82">In two placebo-controlled monotherapy studies with a flexible dose of 3 weeks in patients with a manic or mixed episode of the Bipolar-I error showed Aripiprazol a placebo over 3 weeks.</seg>
<seg id="83">"" "" "" "in a placebo-controlled monotherapy study on 3 weeks with fixed dose of patients with a manic or mixed episode of the Bipolar-I error, Ariophazole showed no superior efficacy against placebo." "" "" ""</seg>
<seg id="84">"" "" "" "in two placebo and actively controlled monotherapy studies about 12 weeks in patients with a manic or mixed episode of a bipolar-I disturbance, Aripiprazol indicated a result in placebo with lithium or Haloperidol in week 12." "" "" ""</seg>
<seg id="85">"" "" "" "in addition, Ariophazole was present 12 of patients with symptomatic remission of the mania on like lithium or Haloperidol in week." "" "" ""</seg>
<seg id="86">"" "" "" "in a placebo-controlled study on 6 weeks in patients with a manic or mixed episode of a bipolar-I disturbance, with or without psychotic symptoms that were not applied on lithium or Valproat-Monotherapy in comparison to monotherapy in comparison to monotherapy with lithium or Valproat." "" "" ""</seg>
<seg id="87">10 In a placebo-controlled trial over 26 weeks followed by a long-term expansion phase over 74 weeks followed by Aripiprazol in relation to the prevention of a bipolar back in regard to the prevention of a bipolar back.</seg>
<seg id="88">"" "" "" "based on in vitro studies, the enzyme CYP3A4 and CYP2D6 are responsible for dehydration, and hydroxycozol." "" "" ""</seg>
<seg id="89">The middle Eliminationary life is approximately 75 hours for Aripiprazole with extensive metabolism over CYP2D6 and nearly 146 hours at 'bad' (= "Poor") Metabolism over CYP2D6.</seg>
<seg id="90">"" "" "" "in Aripiprazole, there are no differences in pharmacokinetics between male and female healthy subjects as well as in a pharmacokinetic study of schizophrine patients either no sexually efficient effects." "" "" ""</seg>
<seg id="91">"" "" "" "a multiplicity-specific evaluation for pharmacokinetics gave no notice to clinically significant differences in ethnic origin or the impact of smoking on the pharmacokinetics of Aripiprazole." "" "" ""</seg>
<seg id="92">The pharmacokinetic properties of Aripiprazole and Dehydro-Aripiprazole were similar to patients with severe kidney failure compared to young healthy volunteers.</seg>
<seg id="93">"" "" "" "a single dose study of subjects with a common liver cirrhosis (Child-Pugh class A, B and C) showed no significant effect regarding the impact of the liver function on the pharmacokineosis of class C, which is not sufficient to draw conclusions on their metabolic capacity." "" "" ""</seg>
<seg id="94">"" "" "" "based on conventional concepts for safety pharmacology, toxicity in repeated declaratory, reproductive toxicity, genotoxicity and for kanzerogens, the preclinical data did not recognize any particular hazards for human beings." "" "" ""</seg>
<seg id="95">"" "" "" "toxicological effects were observed only at doses or expositions, which clearly exceeded the maximum dosage or exposure to human beings, they have limited or no meaning for clinical use." "" "" ""</seg>
<seg id="96">"" "" "" "with its recommended maximum dose of 60 mg / kg / day (AUC) with a recommended maximum dose of 60 mg / kg / day (AUC) with a recommended maximum dose of 60 mg / kg / day (AUC), the recommended maximum daily dose of 60 mg / kg / day (AUC) with the recommended maximum dose of humans)." "" "" ""</seg>
<seg id="97">"" "" "" "also, a Cholelixasis was found as a result of the precipitation of the hydroxycycline from 25 to 125 mg / kg / day (1 to 3times of the recommended maximum dose of humans based on mg / m2)." "" "" ""</seg>
<seg id="98">"" "" "" "however, those at the highest recommended daily dose of 30 mg. of found at the highest recommended daily dose of hydroxyz Aripiprazole not exceed 6% of the concentrations in the galle of monkeys, and lie far below the limit values (6%) of in vitro solubility." "" "" ""</seg>
<seg id="99">"" "" "" "in rabbits these effects were observed after doses of 3- and 11times the mean Steady State AUC during the recommended clinical trials." "" "" ""</seg>
<seg id="100">"" "" "" "perforated blister packs for dispensing of single boxes in folding cartons with 14 x 1, 28 x 1, 49 x 1, 98 x 1 tablets." "" "" ""</seg>
<seg id="101">"" "" "" "15 Spätdyskinesia: in clinical trials that lasted a year or less, there was occasional reports about the treatment with Aripiprazol." "" "" ""</seg>
<seg id="102">It is thought that the effectiveness of Aripiprazol in schizophrenia and bipolar-I interruption involves the combination of a partial agonistic effect on dopamine d2 and serotonin 5HT1a- receptors and an antagonistic effect on serotonin 5HT2a receptors.</seg>
<seg id="103">22 weeks in a placebo-controlled trial over 26 weeks followed by a long-term expansion phase over 74 weeks followed by Aripiprazol in relation to the prevention of a bipolar back in regard to the prevention of a bipolar back.</seg>
<seg id="104">"" "" "" "27 Spätdyskinesia: in clinical trials that lasted a year or less, there was occasional reports about the treatment with Aripiprazol concerned Dyskinesia." "" "" ""</seg>
<seg id="105">It is thought that the effectiveness of Aripiprazol in schizophrenia and bipolar-I interruption involves the combination of a partial agonistic effect on dopamine d2 and serotonin 5HT1a- receptors and an antagonistic effect on serotonin 5HT2a receptors.</seg>
<seg id="106">34 years in a placebo-controlled trial over 26 weeks followed by a long-term expansion phase over 74 weeks followed by Aripiprazol in relation to the prevention of a bipolar back in regard to the prevention of a bipolar back.</seg>
<seg id="107">"" "" "" "39 Spätdyskinesia: in clinical trials that lasted a year or less, there was occasional reports about the treatment with Aripiprazol." "" "" ""</seg>
<seg id="108">It is thought that the effectiveness of Aripiprazol in schizophrenia and bipolar-I interruption involves the combination of a partial agonistic effect on dopamine d2 and serotonin 5HT1a- receptors and an antagonistic effect on serotonin 5HT2a receptors.</seg>
<seg id="109">46 weeks in a placebo-controlled trial over 26 weeks followed by a long-term expansion phase over 74 weeks followed by Aripiprazol in relation to the prevention of a bipolar back in regard to the prevention of a bipolar back.</seg>
<seg id="110">The recommended starting dose for Aripiprazole is 10 or 15 mg / day in an maintenance dose of 15 mg / day once a day independently of meals.</seg>
<seg id="111">Patients who have trouble when swallowing ABILIFY tablets can take the hot tablets alternatively to ABILIFY tablets (see section 5.2).</seg>
<seg id="112">"" "" "" "in some cases, the occurrence of suicidal diseases also includes psychotic disorders and affective disturbances in some cases, also with Aripiprazole (see Section 4.8)." "" "" ""</seg>
<seg id="113">"" "" "" "Spätdyskinesia: in clinical trials that lasted a year or less, there was occasional reports about the treatment with Aripiprazole breeding Dyskinesia." "" "" ""</seg>
<seg id="114">Clinical manifestations of a mns are high fever, muscle wrdity, alternating consciousness and symptoms of autonomous instability (irregular pulse or blood pressure, tachykarmic, sweating and heart rhythm disorders).</seg>
<seg id="115">"" "" "" "in general, weight gain is generally found in schizophrates patients and patients with bipolarisation, the application of antipsychotics, which is well known as side effects and could result in severe complications." "" "" ""</seg>
<seg id="116">If pregnant women should be advised to notify your doctor if pregnant or pregnancy during the treatment with Aripiprazole</seg>
<seg id="117">"" "" "" "the following adverse events were more common (≥ 1 / 100) than placebo, or were classified as possible medical-relevant effects of medication (*):" "" "" ""</seg>
<seg id="118">In two placebo-controlled monotherapy studies with a flexible dose of 3 weeks in patients with a manic or mixed episode of the Bipolar-I error showed Aripiprazol a placebo over 3 weeks.</seg>
<seg id="119">"" "" "" "58 weeks in a placebo-controlled trial with a manic or mixed episode of a bipolar-I disturbance, with or without psychotic symptoms that had not been applied on lithium or Valproat-Monotherapy in comparison to monotherapy in comparison to monotherapy with lithium or Valproat." "" "" ""</seg>
<seg id="120">In a placebo-controlled trial over 26 weeks followed by a long-term expansion phase over 74 weeks followed by Aripiprazol in relation to the prevention of a bipolar back in terms of prevention of a bipolar back.</seg>
<seg id="121">"" "" "" "in rabbits these effects were taken to dositions, which recommended to expositions of 3- and 11x of the mean Steady State AUC at the recommended clinical trial" "" "" ""</seg>
<seg id="122">Patients who have trouble when swallowing ABILIFY tablets can take the hot tablets alternatively to ABILIFY tablets (see section 5.2).</seg>
<seg id="123">"" "" "" "Spätdyskinesia: in clinical trials that lasted a year or less, there was occasional reports about the treatment with Aripiprazole breeding Dyskinesia." "" "" ""</seg>
<seg id="124">71 In a placebo-controlled study on 6 weeks in patients with a manic or mixed episode of a bipolar-I disorder; with or without psychotic characteristics which had not been applied on lithium or Valproat-Monotherapy in comparison to demonic symptoms compared to monotherapy with Lithium or Valproat.</seg>
<seg id="125">Patients who have trouble when swallowing ABILIFY tablets can take the hot tablets alternatively to ABILIFY tablets (see section 5.2).</seg>
<seg id="126">"" "" "" "Spätdyskinesia: in clinical trials that lasted a year or less, there was occasional reports about the treatment with Aripiprazole breeding Dyskinesia." "" "" ""</seg>
<seg id="127">84 "" "" "" "84 In a placebo-controlled study on 6 weeks with a manic or mixed episode of a bipolar-I disturbance, with or without psychotic symptoms that had not been applied on lithium or Valproat-Monotherapy in comparison to monotherapy in comparison to monotherapy with lithium or Valproat." "" "" ""</seg>
<seg id="128">200 mg of fructose per ml 400 mg of sugar-hydroxybenzoat (E218) per ml 0.2 mg of propyl-4 hydroxybenzoat (E216) per ml.</seg>
<seg id="129">The recommended starting dose for ABILIFY is 15 mg once daily, regardless of meals as monotherapy or combination therapy (see section 5.1).</seg>
<seg id="130">"" "" "" "to prevention of recurrarian episodes in patients who have already received Aripiprazole, the treatment should be continued with the same dose." "" "" ""</seg>
<seg id="131">"" "" "" "Spätdyskinesia: in clinical trials that lasted a year or less, there was occasional reports about the treatment with Aripiprazole breeding Dyskinesia." "" "" ""</seg>
<seg id="132">"" "" "" "hyperglycemia, in some cases extremely and associated with ketoazide or hyperosmolar coma or death, was reported in patients with atypical antipsychotic agents, including ABILIFY." "" "" ""</seg>
<seg id="133">"" "" "" "there is no precise risk assessment for hyperglycemia-related events with ABILIFY and other atypical antipsychotic drugs treated, which allow direct comparisons." "" "" ""</seg>
<seg id="134">92 In a clinical study with healthy subjects increased their highly effective CYP2D6-inhibitor (Chinidin) the AUC from Aripiprazole by 107% while the Cmax remained unchanged.</seg>
<seg id="135">Diltiazem or Escitalopram) or CYP2D6 can be given together with ABILIFY to be expected with a moderate increase in Aripiprazol- concentrations.</seg>
<seg id="136">Manical episodes with bipolar-I disturbance - in a controlled study of over 12 weeks was the incidence of EPS 23,5% in patients under Aripiprazol-</seg>
<seg id="137">It is thought that the effectiveness of Aripiprazol in schizophrenia and bipolar-I interruption involves the combination of a partial agonistic effect on dopamine d2 and serotonin 5HT1a- receptors and an antagonistic effect on serotonin 5HT2a receptors.</seg>
<seg id="138">"" "" "" "in a dazzapin-controlled, multinational double-blind study included in schizophrenia (N = 18 or 13% of the evaluated patients' weight gain) (i.e. an increase of at least 5,6 kg) with an average weight of approx. 5%." "" "" ""</seg>
<seg id="139">97 In a placebo-controlled monotherapy study of 3 weeks with fixed dose of patients with a manic or mixed episode of the Bipolar-I disturbance Ariophazole showed no superior efficacy against placebo.</seg>
<seg id="140">In a relative bioavailability study in which the pharmacokinetic study was compared with 30 mg Aripiprazole in pill form of healthy subjects. the ratio between the geometric Cmax -mean value of the solution and the value of tablets at 122% (N = 30) was compared.</seg>
<seg id="141">99 We have found a cholthiostasis as a result of the precipitation of sulfate-conjugate in the gall of monkeys from 25 to 125 mg / kg / day (1 to 3times of the recommended maximum dose of humans based on mg / m2).</seg>
<seg id="142">"" "" "" "in rabbits these effects were observed after doses of 3- and 11times the mean Steady State AUC during the recommended clinical trials." "" "" ""</seg>
<seg id="143">"" "" "" "ABILIFY injection solution is used for fast control of Aspects and behavioural disorders in patients with schizophrenia or patients with manic episodes of bipolar-I error, if an oral therapy is not appropriate." "" "" ""</seg>
<seg id="144">"" "" "" "once it is clinically attached, the treatment with Aripiprazole should be terminated and started with the oral application of Aripiprazol." "" "" ""</seg>
<seg id="145">To increase the absorption and minimize the variability, an injection is recommended in the gluteus maximus or deep into the gluteus-maximus muscle under relocation of adipous regions.</seg>
<seg id="146">"" "" "" "a lower dose of 5,25 mg (0.7 ml) can be applied, depending on the individual clinical status, which are previously applied to the treatment or acute treatment (see Section 4.5)." "" "" ""</seg>
<seg id="147">If any other oral treatment with Aripiprazole is indicated see the summary of the characteristics of the medication by using ABILIFY tablets, ABILIFY melting tablets or ABILIFY solution to capture.</seg>
<seg id="148">There are no investigations about the efficacy of Aripiprazol injections in patients with Aspects and behavioural disorders caused by schizophrenia and manic episodes of bipolar-I error.</seg>
<seg id="149">"" "" "" "in case an parenteral therapy with benzodiazepines is additionally considered to be an arithmetic injection solution, the patients should be observed in extreme conditions or blood pressure (see Section 4.5)." "" "" ""</seg>
<seg id="150">Tests for safety and efficacy of Ariophazol injections are not available for patients with alcohol or drug poisoning (by means of distorted or illegal drugs).</seg>
<seg id="151">Ariophazol should be used with caution in patients with well-known carcinogenic diseases (myocardial infarction), heart failure disease, hypovolaemia (treatment with bloodhobic doses) or hypertonia (including acute and malignant form).</seg>
<seg id="152">"" "" "" "Spätdyskinesia: in clinical trials that lasted a year or less, there was occasional reports about the treatment with Aripiprazole breeding Dyskinesia." "" "" ""</seg>
<seg id="153">Clinical manifestations of a mns are high fever, muscle-rigidity, alternating consciousness and symptoms of autonomous instability (irregular pulse or blood pressure, tachykarmic, sweating and heart rhythm disorders).</seg>
<seg id="154">Polydipsy, polyurie (polyphagie and weakness) are observed and patients with diabetes mellitus or with risk factors for diabetes mellitus should regularly be monitored in relation to deterioration of glucose levels.</seg>
<seg id="155">"" "" "" "in general, weight gain is generally observed in schizophrates patients and patients with bipolarisation, the application of antipsychotics, which is well known as side effects and could result in severe complications." "" "" ""</seg>
<seg id="156">"" "" "" "nevertheless the intensity of Sedan was compared to the sole gift of Aripiprazole, in a study, in the healthy subjects of Aripiprazole (15 mg dose) and once received Lorazepam (2 mg dose)." "" "" ""</seg>
<seg id="157">"" "" "" "105 The H2 and agonist Famotidin, a gastric-blocker, reduces the absorption rate of Aripiprazole, but this effect is considered clinically irrelevant." "" "" ""</seg>
<seg id="158">CYP2D6 'bad' (= "Poor") Metabolism can result in a common application with highly effective inhibitors of CYP3A4 in higher plasma concentrations of Aripiprazole.</seg>
<seg id="159">Other highly effective inhibitors of CYP3A4 such as Itraconazole and HIV- Proteaseinhibitors were to have similar effects and therefore similar doses should be made.</seg>
<seg id="160">"" "" "" "after setting the CYP2D6- or 3A4-inhibitors, the dose of ABILIFY should be raised to the dose height before beginning of the accompanying therapy." "" "" ""</seg>
<seg id="161">"" "" "" "106 lauazepam (2 mg dose) was intramuscular, the intensity of Sedation was compared to the sole gift of Aripiprazole." "" "" ""</seg>
<seg id="162">The following adverse events were more commonly classified in clinical trials (≥ 1 / 100) than under placebo or were classified as possible medical-relevant side effects (*): (see section 5.1):</seg>
<seg id="163">"" "" "" "the incidence of the side effects listed below is defined according to the following criteria: often (≥ 1 / 100, &lt; 1 / 10); occasionally (≥ 1 / 1,000, &lt; 1 / 100)." "" "" ""</seg>
<seg id="164">107 The following adverse events came more frequently (≥ 1 / 100) than under Placebo or were classified as possible medical-relevant side effects (*) (see section 5.1):</seg>
<seg id="165">In a placebo-controlled trial for over 26 weeks the incidence of EPS 19% in patients under Aripiprazol- treatment and 13.1% were under placebo.</seg>
<seg id="166">"" "" "" "in another study over 12 weeks, the incidence of EPS is 26.6% in patients under Aripiprazol- treatment and 17.6% for those under lithium treatment." "" "" ""</seg>
<seg id="167">During long-term recovery about 26 weeks in a placebo-controlled trial the incidence of EPS 18.2% for patients under Aripiprazol-treatment and 15.7% for patients treated with placebo treated patients.</seg>
<seg id="168">"" "" "" "a comparison between the patient groups under Aripiprazole and placebo, in which potentially clinically significant changes of the routinely controlled laboratory parameters appeared, no medical characterisation resulted." "" "" ""</seg>
<seg id="169">Increases the CPK (Kreatinphosphokinase) in general temporarily and asymptomatic patients were observed in 3.5% of patients treated with Aripiprazol in comparison to 2.0% of patients treated with placebo.</seg>
<seg id="170">"" "" "" "in addition to the side effects that occur in connection with an antipsychotic syndrome, Spätdyskinesis and occlusions of elderly patients, hyperglycemia and diabetes mellitus, include hyperglycemia and diabetes mellitus (see Section 4.4)." "" "" ""</seg>
<seg id="171">110 and behavioural disorders was linked with statistically significantly bigger improvements of Aspects / behavioural disorders compared to placebo and was similar to Haloperidol.</seg>
<seg id="172">In a placebo-controlled short-time study (24 h) with 291 patients with bipolar disturbance and behavioural disturbances in contrast to placebo and behavioural disorders in comparison to placebo and similar to the Lorazepam- reference.</seg>
<seg id="173">The observed middle improvement from the starting point on the PANSS Excitement component in the primary 2-hour final point was 5.8 for placebo, 9.6 for Lorazepam and 8.7 for Aripiprazole.</seg>
<seg id="174">"" "" "" "in analyses of subgroups in patients with mixed episodes or patients with heavy aura, was observed a similar effectiveness in terms of the entire population, but a statistical significance could be found due to a reduced patient number." "" "" ""</seg>
<seg id="175">"" "" "" "in three placebo-controlled short-time studies (4 to 6 weeks), Ariophazole (oral) showed statistically significant improvement of psychotic symptoms." "" "" ""</seg>
<seg id="176">"" "" "" "in a Haloperidol-controlled trial in week 52 the proportion of Responsibility patients held their response to the study medication, in both groups (Aripiprazole 77% (oral) and Haloperidol 73%)." "" "" ""</seg>
<seg id="177">"" "" "" "current values from measuring scales, which were defined as secondary study potential, including PANSS and the Montgomery-Asberg-Depression-Scale, showed significantly stronger improvement than with Haloperidol." "" "" ""</seg>
<seg id="178">In a placebo-controlled trial over 26 weeks to stabilized patients with chronic schizophrenia showed significantly higher reduction of the decline rate that amounted to 34% in the Aripiprazol- (oral) group and 57% under Placebo.</seg>
<seg id="179">In a dazzapin-controlled, multinational double-blind study included in schizophrenia over 26 weeks with an average weight gain of at least 7% compared to the initial value (i.e. an increase of at least 5.6 kg) with an average weight of approx. 5%.</seg>
<seg id="180">111 In a placebo-controlled study on 6 weeks in patients with a manic or mixed episode of a bipolar-I disturbance with or without psychotic characteristics which had not to be applied on lithium or Valproat-Monotherapy in comparison to demonic symptoms compared to monotherapy with Lithium or Valproat.</seg>
<seg id="181">"" "" "" "in a placebo-controlled trial over 26 weeks followed by a 74-week study extension with Aripiprazole, in relation to the prevention of a bipolar back, predominantly in the prevention of a bipolar relapse, predominantly in the prevention of a bipolar relapse." "" "" ""</seg>
<seg id="182">The Aripiprazol AUC is 90% greater in the first 2 hours after intramuscular injection 90% greater the AUC according to the same dose as tablet; the systemic exposure was similar between the two formulations.</seg>
<seg id="183">"" "" "" "in 2 studies with healthy volunteers, the average time until reaching the maximum plasma level was 1 to 3 hours after application." "" "" ""</seg>
<seg id="184">The gift of Aripiprazol injections was tolerated by rats and monkeys in no direct toxicity of a target organ according to a systemic exposure (AUC) which intramuscular complaints from 30 mg were intramuscular.</seg>
<seg id="185">"" "" "" "in studies on the reproduction of reproduction for intravenous application, no safety relevant concerns on maternally exposure showed the 15- (rats) and 29-times (rabbits) on maximum human therapeutic exposure of 30 mg." "" "" ""</seg>
<seg id="186">"" "" "" "based on conventional studies with Ariophazole (oral) on safety pharmacology, toxicity in repeated declaratory, reproductive toxicity and for kanzerogens, the preclinical data did not recognize any particular hazards for human beings." "" "" ""</seg>
<seg id="187">"" "" "" "toxicological effects were observed only at doses or expositions, which clearly exceeded the maximum dosage or exposure to human beings; they have limited or no meaning for clinical use." "" "" ""</seg>
<seg id="188">"" "" "" "with its recommended maximum dose of 60 mg / kg / day (AUC) with a recommended maximum dose of 60 mg / kg / day (AUC) with a recommended maximum dose of 60 mg / kg / day (AUC), with recommended maximum dose of 60 mg / kg / day (AUC) with recommended maximum dose for humans)." "" "" ""</seg>
<seg id="189">"" "" "" "also, a Cholelixasis was found as a result of the precipitation of Sulphprazole in the gall of monkeys from 25 to 125 mg / kg / day (1 to 3 times the recommended maximum dose of humans based on mg / m2)." "" "" ""</seg>
<seg id="190">"" "" "" "in rabbits these effects were observed after doses of 3- and 11-times the mean Steady stats AUC during the recommended clinical trials." "" "" ""</seg>
<seg id="191">"" "" "" "the authorisation holder must ensure that before and while the product is marketed, the pharmacovigilance system is described, as it is described in version 1.0 of module 1.8.1. of the application order." "" "" ""</seg>
<seg id="192">"" "" "" "according to the CHMP Guideline on Risk Management Systems for HighStep for Human use, the updated risk management plan must be submitted simultaneously with the next Periodic Safety Update Report (PSUR)." "" "" ""</seg>
<seg id="193">"" "" "" "moreover, a updated risk management plan must be submitted so that new security data, the pharmacovigilance plan or the measures for minimization has been achieved, on request the EMEA." "" "" ""</seg>
<seg id="194">14 x 1 tablets 28 x 1 tablets of 49 x 1 tablets 56 x 1 tablets 98 x 1 tablets</seg>
<seg id="195">EU / 1 / 04 / 276 / 001 14 x 1 tablets EU / 1 / 04 / 04 / 05 / 04 / 04 / 05 / 04 / 04 / 05 / 04 / 04 / 05 / 04 / 04 / 05 / 05 / 04 / 05 / 05 / 05 / 05 / 05 / 05 / 05 / 05 / 05 / 05 / 05 / 05 / 05 / 05 / 05 / 05 / 05 / 05 / 05 / 05 / 05 / 05 / 05 / 05 / 05 / 05 / 05 / 05 / 05 / 05 / 05 / 05 / 05 / 05 / 05 / 05 / 05 / 05 / 05 / 05 / 05 / 05 / 05 / 05 / 05 / 05 / 05 / 05 / 05 / 05 / 05 / 05 / 05 / 05 / 05 / 05 / 05 / 05 / 05 / 05 / 05 / 05 / 05 / 05 / 05 / 05 / 05 / 05 / 05 / 05 / 05 / 05 / 05 / 05 / 05 / 05 / 05</seg>
<seg id="196">EU / 1 / 04 / 276 / 006 14 x 1 tablets EU / 1 / 04 / 04 / 008 49 x 1 tablets EU / 1 / 04 / 04 / 009 56 x 1 tablets EU / 1 / 04 / 04 / 010 98 x 1 tablets</seg>
<seg id="197">EU / 1 / 04 / 04 / 011 14 x 1 tablets EU / 1 / 04 / 04 / 013 49 x 1 tablets EU / 1 / 04 / 04 / 014 56 x 1 tablets EU / 1 / 04 / 04 / 015 98 x 1 tablets</seg>
<seg id="198">EU / 1 / 04 / 04 / 016 14 x 1 tablets EU / 1 / 04 / 04 / 017 49 x 1 tablets EU / 1 / 04 / 04 / 019 56 x 1 tablets EU / 1 / 04 / 04 / 020 98 x 1 tablets</seg>
<seg id="199">"" "" "" "if one of the common side effects will affect you significantly, or you may notice any side effects listed in this manual information, please inform your doctor or pharmacist." "" "" ""</seg>
<seg id="200">"" "" "" "it is applied for the treatment of adults who is marked with symptoms like hearing, seeing or feeling of things that are not present, Misstrust, deluilding, inrelated language, wirres and spatter mood." "" "" ""</seg>
<seg id="201">"" "" "" "ABILIFY is used in adults to treat a condition with excessive uptightness, to feel excessive energy than usual, very fast speaking with quickly changing ideas and sometimes powerful irritability." "" "" ""</seg>
<seg id="202">High blood sugar or cases of diabetes (diabetes disease) in the family of Ancident diseases in particular in the face of heart or vascular diseases in the family, stroke or temporary paralysis of brain (transitory ischaemic attack / TIA). abnormal blood pressure.</seg>
<seg id="203">"" "" "" "if you suffer as an older patient to dementia (loss of memory or other intellectual abilities), you should be asked if you ever had a stroke or a temporary deficiency of the brain." "" "" ""</seg>
<seg id="204">"" "" "" "inform your doctor immediately when you suffer from sore muscles or stiffness, with high fever, sweating, altered state of mind or very rapid or irregular heartbeat." "" "" ""</seg>
<seg id="205">"" "" "" "children and adolescents, ABILIFY is not to spend with children and youths, since patients under 18 years of age have not been studied." "" "" ""</seg>
<seg id="206">Taking ABILIFY with other medicines Please tell your doctor or pharmacist if you use other medicines consuming / apply / apply recently as if it is not prescription medicine.</seg>
<seg id="207">Pharmaceuticals for treating heart rhythmia antidepressants or herbal medicines which are applied to treat depression and anxiety drugs for the treatment of HIV infection anticonvulcanva that can be applied to the treatment of epilepsy</seg>
<seg id="208">"" "" "" "pregnancy and breastfeeding should not take ABILIFY if you are pregnant, unless you discussed this with your doctor." "" "" ""</seg>
<seg id="209">"" "" "" "we should not drive car and serve machines, nor operate machines or machines until you know how ABILIFY works with you." "" "" ""</seg>
<seg id="210">"" "" "" "please take this medicine after consultation with your physician, if you know it is known that you suffer from incompatibility to certain sugars." "" "" ""</seg>
<seg id="211">"" "" "" "please contact your doctor or pharmacist if you have the impression that the effect of ABILIFY is too strong or weak." "" "" ""</seg>
<seg id="212">"" "" "" "even if you feel better, change or put the daily dose of ABILIFY not without asking your doctor before." "" "" ""</seg>
<seg id="213">If you have taken a larger amount of ABILIFY as you should realize you have taken more ABILIFY tablets or if someone has taken some of your ABILIFY tablets (or if someone has taken some of your ABILIFY pills) immediately contact your doctor.</seg>
<seg id="214">"" "" "" "if you forget the intake of ABILIFY if you have a dose, take the forgotten dose as soon as you think it does not take on one day the double dose." "" "" ""</seg>
<seg id="215">"" "" "" "frequent side effects (in more than 1 of 100, less than 1 out of 10 treated) uncontrollable atmosphere, headache, increased memory, sleep problems, anxiety, drowsiness, trembling and blurred vision." "" "" ""</seg>
<seg id="216">"" "" "" "occasional side effects (in more than 1 of 1,000, less than 1 out of 100 treated) Some people can feel dizzy, especially if they stand out of lying or sitting position, or they can determine a accelerated pulse." "" "" ""</seg>
<seg id="217">"" "" "" "please inform your doctor or pharmacist if one of the listed side effects will affect you significantly, or you may notice any side effects listed in this manual information." "" "" ""</seg>
<seg id="218">"" "" "" "like ABILIFY and content of the package ABILIFY 5 mg tablets are rectangular and blue, with embossing A-007 and 5 on one page." "" "" ""</seg>
<seg id="219">"" "" "" "inform your doctor immediately when you suffer from sore muscles or stiffness, with high fever, sweating, altered state of mind or very rapid or irregular heartbeat." "" "" ""</seg>
<seg id="220">"" "" "" "even if you feel better, change or put the daily dose of ABILIFY not without asking your doctor before." "" "" ""</seg>
<seg id="221">"" "" "" "like ABILIFY and content of the package ABILIFY 10 mg tablets are rectangular and pink, with embossing A-008 and 10 on one page." "" "" ""</seg>
<seg id="222">"" "" "" "inform your doctor immediately when you suffer from sore muscles or stiffness, with high fever, sweating, altered state of mind or very rapid or irregular heartbeat." "" "" ""</seg>
<seg id="223">"" "" "" "even if you feel better, change or put the daily dose of ABILIFY not without asking your doctor before." "" "" ""</seg>
<seg id="224">"" "" "" "like ABILIFY and contents of ABILIFY 15 mg tablets are round and yellow, with embossing from A-009 and 15 on one page." "" "" ""</seg>
<seg id="225">"" "" "" "inform your doctor immediately when you suffer from sore muscles or stiffness, with high fever, sweating, altered state of mind or very rapid or irregular heartbeat." "" "" ""</seg>
<seg id="226">"" "" "" "even if you feel better, change or put the daily dose of ABILIFY not without asking your doctor before." "" "" ""</seg>
<seg id="227">"" "" "" "like ABILIFY and contents of ABILIFY 30 mg tablets are round and pink, with embossing A-011 and 30 on one page." "" "" ""</seg>
<seg id="228">171. if you suffer as an older patient suffering from dementia (loss of memory or other intellectual activity) if you have ever asked a stroke or a temporary deficiency of the brain.</seg>
<seg id="229">"" "" "" "inform your doctor immediately when you suffer from sore muscles or stiffness, with high fever, sweating, altered state of mind or very rapid or irregular heartbeat." "" "" ""</seg>
<seg id="230">Important information on certain other components of ABILIFY patients who are not allowed to take phenylalanine in order to include ABILIFY melting tablets Aspartame as source for phenylalanine.</seg>
<seg id="231">"" "" "" "take off immediately after opening the blister packs, tablet with dry hands and put the melting rate in the whole on the tongue." "" "" ""</seg>
<seg id="232">"" "" "" "even if you feel better, change or put the daily dose of ABILIFY not without asking your doctor before." "" "" ""</seg>
<seg id="233">If you have taken a larger amount of ABILIFY as you should realize you have taken more ABILIFY melting tablets (or if someone has taken some of your ABILIFY melting tablets), contact your doctor promptly.</seg>
<seg id="234">"" "" "" "calcium hydrocarbate, Crospoolar sodium, Crospoons dioxide, Xylitol, anti-crystalline cellulose, vanilla flavouring (contains Vanillin and Ethylvanillin), branylic acid, iron (III) - oxide (E172)." "" "" ""</seg>
<seg id="235">"" "" "" "like ABILIFY and content of the package The ABILIFY 10 mg melting tablets are round and pink, with embossing from" A "over" 640 "on one side and" 10 "on the other." "" "" ""</seg>
<seg id="236">"" "" "" "177 If you suffer from an older patient to dementia (loss of memory or other intellectual capabilities), you should be asked if you ever had a stroke or a temporary deficiency of the brain." "" "" ""</seg>
<seg id="237">"" "" "" "inform your doctor immediately when you suffer from sore muscles or stiffness, with high fever, sweating, altered state of mind or very rapid or irregular heartbeat." "" "" ""</seg>
<seg id="238">"" "" "" "calcium hydrocarbate, Crospoo-sodium, Croisitol, Xylitol, anti-crystalline cellulose, fiddine and ethylvanillin acid, iron (III) - hydroxide-oxide by H2O (E172)." "" "" ""</seg>
<seg id="239">"" "" "" "like ABILIFY and content of the package The ABILIFY 15 mg melting tablets are round and yellow, with embossing from" A "over" 641 "on one side and" 15 "on the other." "" "" ""</seg>
<seg id="240">183 If you suffer as an older patient suffering from dementia (loss of memory or other intellectual activity) if you have ever asked a stroke or a temporary deficiency of the brain.</seg>
<seg id="241">"" "" "" "inform your doctor immediately when you suffer from sore muscles or stiffness, with high fever, sweating, altered state of mind or very rapid or irregular heartbeat." "" "" ""</seg>
<seg id="242">"" "" "" "like ABILIFY and content of the package The ABILIFY 30 mg melting tablets are round and pink, with embossing from" A "over" 643 "on one side and" 30 "on the other." "" "" ""</seg>
<seg id="243">"" "" "" "inform your doctor immediately when you suffer from sore muscles or stiffness, with high fever, sweating, altered state of mind or very rapid or irregular heartbeat." "" "" ""</seg>
<seg id="244">"" "" "" "we should not drive car and serve machines, nor operate machines or machines until you know how ABILIFY works with you." "" "" ""</seg>
<seg id="245">190 Important information on certain other components of ABILIFY ANY LTILIFY solution to take-take contains 200 mg of fructose and 400 mg of sucrosis.</seg>
<seg id="246">"" "" "" "if your doctor has informed you that you suffer from intolerance to certain sugars, please contact your doctor before taking this medicine." "" "" ""</seg>
<seg id="247">The dose to ABILIFY solution must be measured with the gearing measured mug or the gearing 2 ml dropppipette that are contained in the package.</seg>
<seg id="248">"" "" "" "please contact your doctor or pharmacist if you have the impression that the effect of ABILIFY is too strong or weak." "" "" ""</seg>
<seg id="249">If you have taken a larger amount of ABILIFY as you should realize you have taken more ABILIFY solution to take advantage (or if someone has taken ABILIFY solution to take) contact your doctor promptly.</seg>
<seg id="250">Dinatumedat, Fructose, Glycosis, Glycl-4-hydroxybenzoat (E216), procrosis, purified water and natural orange-cream flavour with other natural flavourings.</seg>
<seg id="251">"" "" "" "like ABILIFY and content of the package ABILIFY 1 mg / ml solution to intake is a clear, colorless and light yellow liquid in bottles with a child-safe polypropylene seal cap and 50 ml, 150 ml or 480 ml." "" "" ""</seg>
<seg id="252">"" "" "" "ABILIFY injections are applied to the rapid treatment of increased unrest and desperate behavior that cannot exist as symptoms of a disease which are not present, Misstrust, deluilding, unrelated language, wirres and spatter mood." "" "" ""</seg>
<seg id="253">"" "" "" "people with this disease can also feel depressed, anxious or clumsy, feeling excessive enough sleep to have a lot less sleep than usual, very fast speech with changing ideas and sometimes powerful irritability." "" "" ""</seg>
<seg id="254">"" "" "" "inform your doctor immediately when you suffer from sore muscles or stiffness, with high fever, sweating, altered state of mind or very rapid or irregular heartbeat." "" "" ""</seg>
<seg id="255">"" "" "" "when using ABILIFY with other medicines, please inform your doctor or pharmacist if you use other medicines or applied recently, even if it is not prescription medicine." "" "" ""</seg>
<seg id="256">Medicine for treating heart rhythmia antidepressants or herbal medicines that are applied to treat depression and anxiety drugs for the treatment of HIV infection anticonvulcanva that can be applied to the treatment of epilepsy.</seg>
<seg id="257">"" "" "" "196 pregnancy and lactation period you should not use ABILIFY if you are pregnant, unless you discussed this with your doctor." "" "" ""</seg>
<seg id="258">"" "" "" "if you do not drive car or machines, don't use any tools or tools when using ABILIFY injections." "" "" ""</seg>
<seg id="259">"" "" "" "if you have concerns that you receive more ABILIFY injections, please contact your doctor or care about it." "" "" ""</seg>
<seg id="260">Common side effects (for more than 1 of 100 (less than 1 out of 10 treated) by ABILIFY injections are tiredness, dizziness, headache, restlessness, nausea and vomiting.</seg>
<seg id="261">"" "" "" "occasional side effects (for more than 1 of 1,000, less than 1 of 100 treated) Some persons can feel dizzy, especially when sintered from lying down or sitting, or a quick pulse have a drying feeling in the mouth or feeling popped off." "" "" ""</seg>
<seg id="262">"" "" "" "frequent side effects (in more than 1 of 100, less than 1 out of 10 treated) uncontrollable atmosphere, headache, sleep problems, sleep-ness, anxiety, drowsiness, trembling and blurred vision." "" "" ""</seg>
<seg id="263">"" "" "" "if you need further information about your disease or treatment, please check the package age (also part of the EPAR) or contact your doctor or pharmacist." "" "" ""</seg>
<seg id="264">Abraxane is intended only under the supervision of a qualified oncologist in to the application of cytostatics (breakdown of cells) specialized departments.</seg>
<seg id="265">"" "" "" "in patients with certain side effects occur on the blood or the nervous system, the dose may be reduced or interrupted treatment." "" "" ""</seg>
<seg id="266">(44-20) 74 18 84 00 fax (44-20) 74 18 84 16 E-mail: e-mail: / / www.emea.europa.eu © EMEA 2007 Reproduction and / or distribution of this document is contained in the "nanoparticles" to an expression of the name albumin.</seg>
<seg id="267">"" "" "" "the efficacy of Abraxane was studied in a major study, in which 460 women participated with metastatic breast cancer, of which about three quarters formerly had received anthracycline." "" "" ""</seg>
<seg id="268">The effect of Abraxane (in sole gift or as monotherapy) was compared with the conventional Paclitaxel (given in combination with other drugs to reduce side effects).</seg>
<seg id="269">A total of 72 (31%) of the 229 patients with Abraxane treated patients treated to the treatment of 37 (16%) of the 225 patients with conventional Paclitaxel contained medicine.</seg>
<seg id="270">"" "" "" "considered only the patients who were treated for metastatic breast cancer in the first time, there was no difference between the drug and survival." "" "" ""</seg>
<seg id="271">"" "" "" "in contrast, patients found other treatments of their metastatic breast cancer in contrast to these indicators that Abraxane was more effective than conventional Paclitaxel contained medicines." "" "" ""</seg>
<seg id="272">"" "" "" "it must also not be applied by patients, nursing, or before starting treatment and low neutrophils in the blood." "" "" ""</seg>
<seg id="273">"" "" "" "the Committee for Human Use (CHMP) discovered that Abraxane was not more effective than conventional Paclitaxel contained medicines, which may not be given more effective than conventional Paclitaxel missing drugs to reduce side effects." "" "" ""</seg>
<seg id="274">"" "" "" "January 2008, the European Commission issued the company Abraxis BioScience Limited an approval for the placing of Abraxane in the entire European Union." "" "" ""</seg>
<seg id="275">Abraxane-Monotherapy is indexed for the treatment of metastatic breast cancer in patients with first line-line therapy for metastatic disease (see also Section 4.4) for the treatment of metastatic breast cancer.</seg>
<seg id="276">In patients with severe neutropenia (neutrophils) &lt; 0.050 x 109 / l over a period of a week or longer) or severe sensorial Neuropathy during the Abraxane therapy the dose should be reduced to 220 mg / m2.</seg>
<seg id="277">"" "" "" "in sensorial Neuropathy C 3, treatment is to be canceled up to one improvement to level 1 or 2, and in all subsequent cycles the dose must be reduced." "" "" ""</seg>
<seg id="278">"" "" "" "there are currently no adequate data for the recommendation of dose adjustment in patients with mild to moderate impairment of the liver function (see section 4.4. and 5.2)." "" "" ""</seg>
<seg id="279">"" "" "" "there were no studies involving patients with impaired kidney function, and there are currently no adequate data on the recommendation of dose adjustment in patients with impairment of the kidney function (see Section 5.2)." "" "" ""</seg>
<seg id="280">Abraxane is not recommended for the use with children under the age of 18 due to sufficient data on harmlessness and effectiveness.</seg>
<seg id="281">Abraxane is an albumin nanoparticles formulating of Paclitaxel that could be distinctly other pharmacological characteristics described as other formulations of Paclitaxel (see section 5.1 and 5.2).</seg>
<seg id="282">"" "" "" "if an allergic reaction occurs, the medicine should be absorbed immediately and a symptomatic treatment should be initiated, and the patient must not be treated with paclitaxel." "" "" ""</seg>
<seg id="283">"" "" "" "in the patients no new Abraxane treatment cycles should be started, until the neutrophils increase again to &gt; 1.5 x 109 / l has risen again to &gt; 100 x 109 / l." "" "" ""</seg>
<seg id="284">Patients with severe liver failure (bilirubin &gt; 5 x ULN or ASL / ALT &gt; 10 x ULN) should not be treated with Abraxane.</seg>
<seg id="285">"" "" "" "while a clearly identified with Abraxane in connection of cardiotoxicity is not unusual, especially in patients with early Anthracycline treatment or underlying heart or lung disease." "" "" ""</seg>
<seg id="286">"" "" "" "in case of patients after the gift of Abraxane nausea, vomiting and diarrhoea, these can be treated with the usual antifreeze and confertive means." "" "" ""</seg>
<seg id="287">Abraxane is not supposed to be practised in pregnant women or at women in venerous age which are not to be applied except the treatment of mother with Paclitaxel is imperative.</seg>
<seg id="288">Women in common age should apply during and up to 1 month after the treatment of Abraxane a reliable contraceptive method apply.</seg>
<seg id="289">"" "" "" "male patients who are treated with Abraxane is recommended, during and up to six months after the treatment no child could testify." "" "" ""</seg>
<seg id="290">"" "" "" "male patients should be advised in the treatment of a sperm preserving, since the treatment of Abraxane is the possibility of an irreversible infertility." "" "" ""</seg>
<seg id="291">Abraxane may cause side effects such as fatigue (very frequently) and dizziness (often) which can affect the transport of machines and the ability to serve machines.</seg>
<seg id="292">"" "" "" "below are the most common and important incidents of side effects listed in 229 patients with metastatic breast cancer, which were treated in the pivotal clinical phase III study every three weeks with 260 mg / m2 Abraxane." "" "" ""</seg>
<seg id="293">"" "" "" "neutropenia was reported on most important hematological toxicity (at 79% of patients), and was quickly reversible and dosed; leukopenie reported in 71% of patients." "" "" ""</seg>
<seg id="294">Anaemia (Hb &lt; 10 g / l) was observed at 46% of patients treated with Abraxane patients and was severe in three cases (Hb &lt; 8 g / l).</seg>
<seg id="295">"" "" "" "in Table 1 the side effects are listed, which occurred in conjunction with the Gift of Abraxane as monotherapy in every dose and indication (N = 789)." "" "" ""</seg>
<seg id="296">"" "" "" "very common (≥ 1 / 100); frequently (≥ 1 / 100, &lt; 1 / 100); rare (≥ 1 / 10,000, &lt; 1 / 10,000); very rare (&lt; 1 / 10,000)." "" "" ""</seg>
<seg id="297">"" "" "" "occasionally: elevated blood pressure, weight gain, increased latinine in blood, higher blood sugar, increased phosphorus in blood, reduced potassium in the blood, reduced potassium in the blood of heart disease:" "" "" ""</seg>
<seg id="298">"" "" "" "Dyspherical, bloating, tongue burn, dry mouth, gophagums, loose fitting, oesophile, pain in the mouth, oral pain, rectal bleeding disorders of the kidneys and urinary passages:" "" "" ""</seg>
<seg id="299">"" "" "" "pain in chest muscle, weaknesses, body aches, body aches, muscle pain, pain in the skeleton muscles, flank pain, discomfort in the veins, muscle weakness. very frequently:" "" "" ""</seg>
<seg id="300">Restlessness 1 The frequency of hypersensitivity is calculated based on a definitive case in a population of 789 patients</seg>
<seg id="301">"" "" "" "since these events have been reported on a voluntary basis during clinical practice, no estimates of the actual frequency are possible and there was no longer established connection with these events." "" "" ""</seg>
<seg id="302">Paclitaxel is an anti-microtubules active ingredient that promotes the coshift of the microtubules from the tubular indeer and stabilizes the microtubules by inhibition of her deolymerisation.</seg>
<seg id="303">This stabilisation leads to an inhibiting of the normal dynamic reorganisation of the microtubular network which is essential for the vital interphase and the mitotic membrane functions.</seg>
<seg id="304">It is known that Albumin conveyed the transzytosis of plasma components to endothelial cells and in the frame of in-vitro studies was proved that the presence of albumin is supported by the endothelial cells.</seg>
<seg id="305">It is assumed that this improved transendothelial transport is conveyed by the GP-60-Albuminrezeptor (Competited protein acidic rich in Cysteine) a Paclitaxel accumulation in the field of tumor.</seg>
<seg id="306">The application of Abraxane for metastatic breast cancer is supported by data of 106 patients in two incarnate studies and of 454 patients who were treated in a randomised phase III comparative study.</seg>
<seg id="307">"" "" "" "in a study, 43 patients treated with metastatic breast cancer with Abraxane, which was given in the form of an infusion about 30 minutes with a dose of 175 mgs / m2." "" "" ""</seg>
<seg id="308">"" "" "" "in the second study, a dose of 300 mg / m2 was used as an infusion over 30 minutes in 63 patients with metastatic breast cancer." "" "" ""</seg>
<seg id="309">This multi-centric study was performed in patients with metastatic breast cancer (N = 225) or 3-hour infusion with prevention of an allergic reaction (N = 225) or in form of Abraxane 260 mg / m2 as a 30-minute infusion without premedication (N = 229).</seg>
<seg id="310">When recording in the study 64% of patients had a faultless general condition (ECOG 1 or 2) and 79% had a visceral metastases and 76% had more than 3 metastases.</seg>
<seg id="311">"" "" "" "14% of patients had not received chemotherapy, 27% had only one adjuvant chemotherapy, 40% only because of metastasification and 19% due to metastases and adjuvantive treatment." "" "" ""</seg>
<seg id="312">"" "" "" "9 The results for the general contact and time of progression and progression-free survival and survival for patients who received &gt; First-Line therapy, are presented below." "" "" ""</seg>
<seg id="313">"" "" "" "Neurotoxicity compared to Paclitaxel was evaluated by the improvement of a degree for patients who experienced a regeneration of Neuropathy C 3 during therapy." "" "" ""</seg>
<seg id="314">"" "" "" "the natural process of peripheral new ropathy, on baseline, due to the cumulative toxicity of Abraxane According to &gt; 6 treatment courses was not evaluated and is still unknown." "" "" ""</seg>
<seg id="315">The pharmacokinetics of the complete Paclitaxel according to 30- and 180-minute infusions of Abraxane with a dose of 80 to 375 mg / m2 was determined in clinical trials.</seg>
<seg id="316">The amount of active exposure (AUC) increased from 2653 to 16736 ng.h / ml with a dose of 80 to 300 mg / m2.</seg>
<seg id="317">10 According to intravenous gift of Abraxane in patients with metastatic breast cancer at the recommended clinical dose of 260 mg / m2 the Paclitaxel plasma concentration increased in multiashic way.</seg>
<seg id="318">The average distribution volume was 632 l / m2; the high distribution volume has a wide range of extravascular distribution and / or crossover connection of Paclitaxel.</seg>
<seg id="319">"" "" "" "in a study of patients with advanced sound tumors, the pharmacokinetic properties of Paclitaxel were compared to intravenous 30-minute infusion of 175 mg. of m2 of solvent free Paclitaxel." "" "" ""</seg>
<seg id="320">The Clearance of Paclitaxel was above the Abraxane gift higher (43%) than after a solvent containing Paclitaxel injection and the distribution volume was above Abraxane higher (53%).</seg>
<seg id="321">"" "" "" "in the published literature about in-vitro studies of human liver microsome and tissue-coated, Paclitaxel is primarily metabolized in two smaller metabolites (3" -p-hydroxypaclitaxel) and 6α-3 "p-Dihydroxypacel)." "" "" ""</seg>
<seg id="322">After a 30-minute infusion of 260 mg / m2 Abraxane in patients with metastatic breast cancer 4% of the given total dose for cumulative urinary bladder and 3 "p-hydroxypaclitaxel and 3" -p-hydroxypaclitaxel. "</seg>
<seg id="323">"" "" "" "however, more than patients at the age of more than 75 years, however, only 3 patients from this age group participated in the pharmacokinetic analysis." "" "" ""</seg>
<seg id="324">"" "" "" "the chemical and physical stability was found at 2 ° C - 8 ° C in original box, in front of light light over 8 hours." "" "" ""</seg>
<seg id="325">Paclitaxel is a cytotoxic anticinogenic drug and as well as other potentially toxic substances should be maintained when dealing with Abraxane caution.</seg>
<seg id="326">"" "" "" "using a sterile syringe, slowly over a period of at least 1 minute 20 ml of 9 mg / ml (0.09%), sodium chloride infusion solution is injected into a Abraxane transit bottle." "" "" ""</seg>
<seg id="327">"" "" "" "after the complete addition of the solution, the water bottle should rest for at least 5 minutes to ensure a good grip of the solid." "" "" ""</seg>
<seg id="328">"" "" "" "then the barrel bottle should be slowly and / or inadequately ruby and / or inadequately, until a complete reboard of the powder is effected." "" "" ""</seg>
<seg id="329">"" "" "" "if precipitation or smelinks are visible, the blood pressure must be inadequately proportioned in order to achieve a complete Resusboard." "" "" ""</seg>
<seg id="330">"" "" "" "the exact dosages of 5 mg / ml suspension is calculated for the patient, and the corresponding amount of the constituant Abraxane is injected into an empty, sterile PVC- or non-PVC infusion bag." "" "" ""</seg>
<seg id="331">"" "" "" "the holder of the pharmacovigilance system has to ensure that the pharmacovigilance system is described, as described in version 2.0, and works in module 1.8.1. by the application, before and while the medicine is transported in traffic." "" "" ""</seg>
<seg id="332">"" "" "" "risk management board approves the approval and further pharmacovigilance activities described in the pharmacovigilance plan described in version 4 of the risk management system, as well as all subsequent updates of the RMP, which will be arranged with CHMP." "" "" ""</seg>
<seg id="333">"" "" "" "according to CHMP guidelines for risk management systems for application on humans, the updated RMP is to be submitted simultaneously with the next Periodic Safety Update Report (PSUR)." "" "" ""</seg>
<seg id="334">"" "" "" "in addition, a updated RMP is available • If new information could impact on the current security specification, the pharmacovigilance plan or the risk analysis operations (Pharmacovigilance or risk assessment) • On request of the EMEA." "" "" ""</seg>
<seg id="335">"" "" "" "8 hours in the refrigerator, put in the box when it is kept in the box to protect the contents from light." "" "" ""</seg>
<seg id="336">Abraxane is used to treat mammadcarcinoma if other therapies were tried but not successful; and if you are not used for anthracycline contained therapies.</seg>
<seg id="337">Abraxane is not allowed to be applied: • If you are humiliated (allergic) against Paclitaxel or any of the other ingredients of Abraxane. if your white blood cells are decreased (starting values for neutrophils) &lt; 1.5 x 109 / l - your doctor will inform you about it)</seg>
<seg id="338">Special caution when applying Abraxane is necessary: • If you suffer a negatively affected kidney function • if you suffer from severe liver problems - if you suffer from severe liver problems.</seg>
<seg id="339">"" "" "" "when applying Abraxane with other medicines Please inform the doctor if you apply other medicines or have recently been applied, as this may cause a interaction with Abram xane." "" "" ""</seg>
<seg id="340">Women in common age should apply during and up to 1 month after the treatment of Abraxane a reliable contraceptive method apply.</seg>
<seg id="341">"" "" "" "in addition, they should be advised in the treatment of a sperm preserving, since the Abraxane treatment is the possibility of a lasting infertility." "" "" ""</seg>
<seg id="342">"" "" "" "and the use of machines Abraxane may cause side effects such as fatigue (very frequently) and dizziness (often), which can affect the transport of machines." "" "" ""</seg>
<seg id="343">"" "" "" "if you get other medicines in the course of your treatment, you should advise you on driving or serving machines from your doctor." "" "" ""</seg>
<seg id="344">"" "" "" "22 • impact on peripheral nerves (pain and numbness) • pain in one or more joints • pain in the muscles, nausea, diarrhea • vomiting, weakness, and fatigue" "" "" ""</seg>
<seg id="345">"" "" "" "the frequent side effects (at least 1 out of 100 patients) are: • skin rash, itching or pain loss • digestive problems, reduced muscle coordination, pain or stomach pain, painful mouth or sore tongue, painful tongue or sore tongue, mouth soor • sleep disorders." "" "" ""</seg>
<seg id="346">"" "" "" "the rare side effects (reported at least 1 of 10,000 patients) are: • kidney infection, anti-radiation • blood clots." "" "" ""</seg>
<seg id="347">"" "" "" "please inform your doctor or pharmacist if one of the listed side effects will affect you significantly, or you may notice any side effects listed in this manual information." "" "" ""</seg>
<seg id="348">If it is not used immediately it may be stored in the dough for up to 8 hours in the refrigerator (2 ° C - 8 ° C) if this is stored in the box to protect the contents from light.</seg>
<seg id="349">Each bottle contains 100 mg Paclitaxel. • After the reconstruction contains every ml of the suspension 5 mg Paclitaxel. • The other component is albuminrisate and N Acetyltryptophan (Ph.D.)) from the other component.</seg>
<seg id="350">Precautions for preparing and applying paclitaxel is a cytotoxic anticinogenic drug and as well as other potentially toxic substances should be maintained when dealing with Abraxane caution.</seg>
<seg id="351">"" "" "" "using a sterile syringe, slowly over a period of 1 minute 20 ml of 9 mg / ml (0.09%), sodium chloride infusion solution is injected into a Abraxane transit bottle." "" "" ""</seg>
<seg id="352">"" "" "" "after that the bottle is slowly pivoted and / or invert, until a complete refills of the powder is done." "" "" ""</seg>
<seg id="353">"" "" "" "for the patient, calculate the exact dosages of 5 mg / ml suspension and the corresponding amount of the reconstituted Abram xane in an empty, sterile PVC infusion bag type IV." "" "" ""</seg>
<seg id="354">"" "" "" "parenteral medicines should be subjected to any inspection, particles and discoloration if necessary." "" "" ""</seg>
<seg id="355">"" "" "" "stability of unlocked bottles with Abraxane are stable up to the date given on the box, when the sweat water is kept in the box to protect the contents from light." "" "" ""</seg>
<seg id="356">Stability of the constituted Suspension in the fly bottle After the first reconstruction the suspension should be filled immediately in a bag.</seg>
<seg id="357">"" "" "" "" "" "" "" "" "" "" "" "member states must ensure that the holder of the approval for inclusion in dialysis centers and retail stores are provided with the following information and materials:" "" "" ""</seg>
<seg id="358">• training brochure • summary of the characteristics of the medication (professional information), labeling and package age. • With unique image processing of the product mistakenly cooling boxes for transport through the patient.</seg>
<seg id="359">This means that Abseamed on a biological drug is similar in the European Union (EU) and contains the same substance (also called "reference guide").</seg>
<seg id="360">"" "" "" "it is used in patients with normal blood tests, which may occur in connection with a blood transfusion complications, in case a blood-bloodshed is not possible and with which a blood loss from 900 to 1 800 ml is expected." "" "" ""</seg>
<seg id="361">"" "" "" "treatment with abseamed must be led under the supervision of a doctor, the experience in the treatment of patients with illnesses has shown to be shown for the medicine." "" "" ""</seg>
<seg id="362">"" "" "" "in patients with kidney problems and in patients who want to make a self-bloodshed, Abseamed is injected into a vein." "" "" ""</seg>
<seg id="363">The injection can also be made by the patient or its support person if they have received an appropriate guide.</seg>
<seg id="364">"" "" "" "in patients with chronic kidney failure or patients receiving chemotherapy, the hemoglobinds should always lie in the recommended range (between 10 and 12 g per deferiter in adults or between 9.5 and 11 g / dl in children)." "" "" ""</seg>
<seg id="365">"" "" "" "the iron values of all patients can be used before the treatment to ensure that no iron deficiency exists, and iron supplements should be given during the entire treatment." "" "" ""</seg>
<seg id="366">"" "" "" "in patients receiving chemotherapy alone, or in patients with kidney problems an anemia can be caused by a erythropoietinal deficiency, or that the body is not sufficient to the body's own erythropoietin." "" "" ""</seg>
<seg id="367">Erythropoietin is also used to increase the number of red blood cells to reduce the consequences of a blood loss.</seg>
<seg id="368">"" "" "" "it is produced by a cell, into which a gene (DNA) was brought to the formation of epoxettin alfa." "" "" ""</seg>
<seg id="369">"" "" "" "Abseamed was compared with injection as an injection on a vein in the framework of a main study with 479 patients suffering from kidney problems, compared to reference for reference." "" "" ""</seg>
<seg id="370">"" "" "" "all patients participating in this study had been injected at least eight weeks before they had been injected at least eight weeks before they were received, or continued Eprex / Erypo." "" "" ""</seg>
<seg id="371">Main indicative for efficacy was the change of hemoglobinocular values between the beginning of the study and the interval period in weeks 25 to 29.</seg>
<seg id="372">"" "" "" "the company also presented the results of a study, in which the effects of under the skin were investigated by the skin of Eprex / Erypo with 114 cancer patients receiving chemotherapy." "" "" ""</seg>
<seg id="373">"" "" "" "in the study of patients suffering from kidney problems caused by kidney problems, the hemoglobination of patients were treated in the same measurements as in those patients who continued Eprex / Erypo." "" "" ""</seg>
<seg id="374">"" "" "" "in comparison, the patients showed continued Eprex / Erypo, an increase of 0.063 g / l of the output value of 12.0 g / l." "" "" ""</seg>
<seg id="375">The most common side effect of Abseamed is a rise in blood pressure that can sometimes lead to symptoms of abcephalopathy (brain problems) such as sudden faint headache and turbulence.</seg>
<seg id="376">"" "" "" "Abseamed should not be applied in patients who may possibly be insensitive (allergic) against epoxetine alfa or one of the other ingredients." "" "" ""</seg>
<seg id="377">"" "" "" "Abseamed as injections under the skin is not recommended to treat kidney problems, as further studies are necessary to ensure that they are caused by no allergic reactions." "" "" ""</seg>
<seg id="378">"" "" "" "finally, the drug for Human Use (CHMP) reached that the medicine has been demonstrated as Eprex / Erypo for comparable quality, safety and efficacy profile." "" "" ""</seg>
<seg id="379">"" "" "" "for medical professionals, the company, the Abseamed, will provide information about the safety of the drug in all Member States." "" "" ""</seg>
<seg id="380">"" "" "" "August 2007, the European Commission approved the company Medice Medicines GmbH & Co. kg an approval for the placing of Abseamed across the entire European Union." "" "" ""</seg>
<seg id="381">"" "" "" "treatment of anaemia and reduction of transfusion in adults with solid tumours, malignant lymphoma or multiplea myeloma who receive chemotherapy while giving the risk of a transfusion because of chemotherapy in the beginning of chemotherapy)." "" "" ""</seg>
<seg id="382">The treatment should be performed only in patients with moderate anemia (hemoglobin [Hb] 10 - 13 g / l [6.2 - 8.1 mmol / l]; no iron deficiency could be used in case of planned greater operating procedures (4 or more units blood for women; 5 or more units blood in men).</seg>
<seg id="383">"" "" "" "for the reduction of foreign blut, Abseamed can be used in front of a large elective orthopedic treatment in adults without iron deficiency, at which a high risk of transaction compensation is expected." "" "" ""</seg>
<seg id="384">HB 10-13 g / dl) and an expected blood loss of 900-1800 ml can be applied to participate in an autologous hematric program.</seg>
<seg id="385">The hemoglobin target concentration is between 10 and 12 g / l (6,2 - 7.5 mmol / l) except for papatric patients with the hemoglobination between 9.5 and 11 g / l (5.9 - 6.8 mmol / l).</seg>
<seg id="386">"" "" "" "symptoms and symptoms can vary depending on age, gender and total disease-last; therefore, the assessment of individual clinical trials and illness resistance is required by the doctor." "" "" ""</seg>
<seg id="387">A rise in hemoglobin to more than 2 g / l / l (1.25 mmol / l) over a period of four weeks should be avoided.</seg>
<seg id="388">"" "" "" "due to the variability between patients, occasionally, individual hemoglobination values can be observed with or under the hemoglobination target concentration." "" "" ""</seg>
<seg id="389">"" "" "" "in view of these hemoglobinations, a corresponding dose can be tried to achieve the hemoglobin target concentration of 10 g / l (6,2 mmol / l) to 12 g / l (7,5 mmol / l)." "" "" ""</seg>
<seg id="390">If the hemoglobination exceeds more than 2 g / l (1.25 mmol / l) per month or if the permanent hemoglobinje 12 g / l (7,5 mmol / l) exceeds by 25%.</seg>
<seg id="391">"" "" "" "patients should be closely monitored in order to ensure that Epoetin alfa is used in the lowest permitted dose, which is applied to control the anaemia and the dietary symptoms." "" "" ""</seg>
<seg id="392">The present clinical results suggest that patients with initially very low Hb value (&lt; 6 g / dl or &lt; 3,75 mmol / l) may be lower than patients where the initial anaemia is less difficult (Hb &gt; 8 g / l or &gt; 5 mmol / l).</seg>
<seg id="393">The present clinical results suggest that patients with initially very low Hb value (&lt; 6,8 g / l or &lt; 4.25 mmol / l) may be lower than patients where the initial anaemia is less difficult (Hb &gt; 6.8 g / l or &gt; 4.25 mmol / l).</seg>
<seg id="394">Starting dose 50 I.U. / kg three times a week through intravenous application if necessary with a dose of 25 i.U. / kg (three times per week) to the desired target value is done (this should take place in steps of at least 4 weeks).</seg>
<seg id="395">"" "" "" "symptoms and symptoms can vary depending on age, gender and total disease-last; therefore, the assessment of individual clinical trials and illness resistance is required by the doctor." "" "" ""</seg>
<seg id="396">"" "" "" "in view of these hemoglobinations, a corresponding dose can be tried to achieve the hemoglobin target concentration of 10 g / l (6,2 mmol / l) to 12 g / l (7,5 mmol / l)." "" "" ""</seg>
<seg id="397">"" "" "" "patients should be supervised, in order to ensure that Epoetin alfa is used in the lowest permitted dose, which is applied to control of the symptoms." "" "" ""</seg>
<seg id="398">"" "" "" "if after 4 treatment weeks of the hemoglobination of at least 1 g / l (0,62 mmol / l) or the pretikulozytensional count of ≥ 40,000 cells / µl should be retained three times a week or 450 I.U. / kg per week." "" "" ""</seg>
<seg id="399">If the hemoglobination increased &lt; 1 g / l (&lt; 0.62 mmol / l) and the precursor number of &lt; 40,000 cells / µl should be lifted up to 300 I.U. / kg every week.</seg>
<seg id="400">"" "" "" "if after another 4 treatment weeks with 300 I.U. / kg (≥ 0.62 mmol / l) or the reproduction number of cells by ≥ 40,000 cells / µl should be retained three times a week." "" "" ""</seg>
<seg id="401">If the hemoglobination has increased by &lt; 1 g / l (&lt; 0.62 mmol / l) or the pretikulozytenties by &lt; 0.062 mmol / l) and the treatment of epoxetine-alfa therapy is unlikely and the treatment should be demolished.</seg>
<seg id="402">Patients with light anemia (hematocrite 33 - 39%) in which the prescribed storage of ≥ 4 blood-conservative required should be given secluded in a dose of 600 i.E. / kg body weight twice a week for 3 weeks before operating procedure.</seg>
<seg id="403">"" "" "" "with the Iron substitution should be as early as possible - for example a few weeks before the start of the autologous bleeding program, which may be used to treat large iron reserves." "" "" ""</seg>
<seg id="404">6 The recommended dose is 600 I.U. / kg epotin alfa which should be given once weekly for three weeks (day 21: 14 and 7) before operating procedure and the day of the surgery (Day 0).</seg>
<seg id="405">The epoxetine alfa preoperatively 300 I.U. / kg every 10 consecutive days prior to the day of the surgery and 4 days immediately thereafter.</seg>
<seg id="406">"" "" "" "alternatively, the injection can be given at the end of dialysis on the hose of a fistula, followed by 10 ml isotonical cooking salt solution to ensure the hose and ensure adequate injection of the medication." "" "" ""</seg>
<seg id="407">Patients who are reported under the treatment with any Erythropoetin (Pure red Cell Aplasia, PRCA) should be obtained no secluded or another Erythropoetin (see Section 4.4).</seg>
<seg id="408">Heart attacks or stroke within one month before the treatment, instabile angina (e.g. anamnestically known venous throcyber).</seg>
<seg id="409">"" "" "" "in patients who are envisaged for a larger elective orthopedic effect, the application of epoxetine disease, vascular diseases of the disease or cerebrovascular diseases; in patients with recently convening heart attack or cerebrovascular diseases." "" "" ""</seg>
<seg id="410">Erythroblastopover (PRCA) Very rarely was reported on the occurrence of antibody-mediated PRCA following months to years of subcutaneous erythropoetin.</seg>
<seg id="411">"" "" "" "patients with sudden activity loss, defined as a reduction of hemoglobination (1 - 2 g / l per month) with increased need for transfusion (ice, folic acid or inflammation, blood loss and hemmolyse) should be investigated." "" "" ""</seg>
<seg id="412">"" "" "" "when the precursulocyte value, considering taking the anaemia (i.e. the Retikulocyte" Index), and if no other cause of active loss is found, the anti-erythropoetin antibody is considered to be considered an investigation of bone loss for diagnosis of a PRCA. "" "" "" "</seg>
<seg id="413">Data for immunogenicity in subcutaneous application of Abseamed in patients with a risk of anti-induced PRCA (patients with class anemia) are not enough.</seg>
<seg id="414">"" "" "" "8 In cases of chronic kidney failure, in case of maintenance the lower limit of hemoglobin target concentration is not exceeded." "" "" ""</seg>
<seg id="415">In clinical trials an increased mortality risk and risk of severe cardiac ocascular events were observed when Erythropoese-stimulating agents (ESA) were given with a hemoglobin- target concentration of over 12 g / l (7,5 mmol / l).</seg>
<seg id="416">"" "" "" "controlled clinical trials have shown no significant benefit, which is attributable to the gift of epoxetine symptoms and avoiding the control of blood transfusions related to blood transfusions." "" "" ""</seg>
<seg id="417">The hemoglobination intake should be approximately 1 g / l (0.62 mmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of growth in high blood pressure.</seg>
<seg id="418">In case of patients with chronic kidney failure and clinical evidence of congestive heart failure in case of maintenance the upper limit of hemoglobin target concentration should not be exceeded.</seg>
<seg id="419">"" "" "" "according to the present knowledge, the treatment of anaemia should be treated with epoxettin alfa with kidney failure, which are not dialyzed by the disease of the kidney failure." "" "" ""</seg>
<seg id="420">"" "" "" "in tumour patients under chemotherapy, a 2-3-week delay of epotin-alfa-gift and the erythropoetin-answer must be considered (patients who need to be transfused)." "" "" ""</seg>
<seg id="421">If the Hb rise is greater than 2 g / dl (1.25 mmol / l) per month or a Hb value of 13 g / l (8.1 mmol / l) must be adjusted to reduce the risk of possible thrombotical events (see Section 4.2) of patients with chemist anemia - can hold the hemoglobination between 10 g / dl and 12 g / dl).</seg>
<seg id="422">"" "" "" "the decision for application recombinant Erythropoetine should be based on the benefit of risk reduction under the participation of the patient, which should also take into consideration the specific clinical context." "" "" ""</seg>
<seg id="423">"" "" "" "for patients receiving an elective orthopedic surgery, if possible, the cause of anaemia should be studied and treated accordingly." "" "" ""</seg>
<seg id="424">"" "" "" "patients that undergo an elective orthopedic surgery, an appropriate thrombosis was supposed to have an increased risk of thromboteric and vasculartic diseases especially during an adequate cardiovascular disease." "" "" ""</seg>
<seg id="425">"" "" "" "in addition, it cannot be excluded that in the treatment with epotin alfa to patients with an output badge of &gt; 13 g / dl an increased risk of postoperative thrombotical / vascularious events can consist." "" "" ""</seg>
<seg id="426">"" "" "" "in several controlled trials, it was not proven for epochine that patients with symptomatic anaemia would improve the overall survival or reduce the risk of progression." "" "" ""</seg>
<seg id="427">"" "" "" "4 months in patients with metastatic breast cancer, they received chemotherapy; if a hemoglobin target concentration was reduced from 12 - 14 g / l (7,5 - 8.mmol / l)" "" "" ""</seg>
<seg id="428">Will be used with Ciclosporin together with Ciclosporin and should be adapted to the blood levels of Ciclosporin and adjusted with Ciclosporindosis to increasing hematocracy.</seg>
<seg id="429">No references to interaction between epotin alfa and G-CSF or GM-CSF does not result in hematological differentiation or proliferation.</seg>
<seg id="430">"" "" "" "thrombosis, vascular diseases such as myocardium attacks, fungal thrombosis, fungal thrombosis, anthrombosis, anthropothrombosis, anthropothrombosis, anthropothrombosis, anthropothrombosis, anthrothropogenic wounds, such as patients under erythropoetin, thus also reported patients among epoxetine alfa." "" "" ""</seg>
<seg id="431">"" "" "" "the most common adverse effect during treatment with epotin alfa is a dosisdependent increase of blood pressure or deterioration of an existing Hypertension." "" "" ""</seg>
<seg id="432">An increased incidence of thromvascultic events (see Section 4.4 and Section 4.8 - General) was observed in patients under the treatment of erythropoetinen.</seg>
<seg id="433">"" "" "" "irrespective of the erythropoetin treatment, it can occur in surgical patients with cardiovascular risk to thrombh and vascularious complications." "" "" ""</seg>
<seg id="434">The genetically denied epoxetine alfa is glycol and in terms of amino acids and carbohydrates content identical with the endogenous human Erythropoetin that was isolated from the urine.</seg>
<seg id="435">"" "" "" "it could be demonstrated with the help of cultures of human bone martial cells, that epoxetine alfa stimulates and unaffected the leukopoese." "" "" ""</seg>
<seg id="436">389 patients with hemogblastosis (221 multiple myelome, 144 non-Hodgkinlymphoma and 24 other hemogcinoma cells) and 332 patients with solid tumors (172 gynacarcinomas and 22% carcinomas and 21 carcinomas and 30 other patients).</seg>
<seg id="437">"" "" "" "1895 patients with solid tumours (683 mammal carcinomas, 260 bronchial carcinomas, 300 gastrointestinal tumors and 478 other patients and 802 patients with hemostomy." "" "" ""</seg>
<seg id="438">Survival and tumor progression were investigated in five big monitored studies with a total of 2833 patients; four of these studies were double-blind placebo-controlled studies and</seg>
<seg id="439">"" "" "" "in the open study, no difference between the patients treated with recombinant human erythropoetin patients treated patients and the control patient." "" "" ""</seg>
<seg id="440">"" "" "" "in these studies, patients treated with recombinant human erythropoetin patients treated with anemia due to several common malignome consistent, statistically significantly higher mortality rates than in the controls." "" "" ""</seg>
<seg id="441">"" "" "" "overall survival in the studies could not be explained by differences in incidence of thrombosis and related complications, associated with recombinant human erythropoetin patients and with controls." "" "" ""</seg>
<seg id="442">"" "" "" "it is an increased risk for thrombocal events in tumour patients who are treated with recombinant human erythropoetin, and a negative impact on the overall survival can not be excluded." "" "" ""</seg>
<seg id="443">It is not clarified how far the results are treated on the application of recombinant human erythropoetin in tumour patients with the objective of transferring a hemoglobinge under 13 g / dl) as a few patients were included with these characteristics.</seg>
<seg id="444">Epotin-alfa-provisions after repeated intravenous application showed a half-life time of approximately 4 hours for healthy volunteers and an extended half-life of about 5 hours in patients with kidney disease.</seg>
<seg id="445">"" "" "" "after subcutaneous injection, the serum levels of epoxetine alfa are much lower than the serum levels, which are reached after intravenous injection." "" "" ""</seg>
<seg id="446">"" "" "" "there is no grief: the serum levels remain equal, regardless of whether they will be determined 24 hours after the first gift or 24 hours after the last gift." "" "" ""</seg>
<seg id="447">(bone marary fibrosis is a well-known complication of chronic kidney failure in humans and could result in a secondary hyperparathyreoidism or unknown factors.</seg>
<seg id="448">"" "" "" "in a study on hematalysis patients, which were treated with epotin alfa in three years compared to the control group with dialysis patients who were not treated with epotin alfa, not increased)." "" "" ""</seg>
<seg id="449">14. during the experimental studies with nearly the 20x of patients recommended to be recommended in people's recommended dose of Epoetin alfa with a delay of Ossification and a rise in fetal mortality.</seg>
<seg id="450">"" "" "" "these reports are based in vitro findings with cells from human tumour tissue, which are the significance for the clinical situation from unsafe significance." "" "" ""</seg>
<seg id="451">"" "" "" "as part of an outpatient application, the patient underwent a unique one for a period of 3 days outside the cooling barrier and not over 25 ° C." "" "" ""</seg>
<seg id="452">"" "" "" "the syringes are provided with graduation rating and the filling volume is indicated by a glued label, so if necessary, dimensions of partial amounts possible." "" "" ""</seg>
<seg id="453">"" "" "" "treatment with Abseamed must be led under supervision of doctors, have experience in the treatment of patients with the above indications." "" "" ""</seg>
<seg id="454">21 The recommended dose is 600 I.U. / kg epotin alfa which should be given once weekly for three weeks (day 21: 14 and 7) before operating procedure and the day of the surgery (Day 0).</seg>
<seg id="455">23 "" "" "" "23 In cases of chronic kidney failure, in case of maintenance the lower limit of hemoglobin target concentration is not exceeded." "" "" ""</seg>
<seg id="456">The hemoglobination intake should be approximately 1 g / l (0.62 mmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of growth in high blood pressure.</seg>
<seg id="457">"" "" "" "thrombosis, vascular diseases such as myocardium attacks, fungal thrombosis, anthrombosis, anthrombosis, anthrothrombosis, anthropothrombosis, anthropothrombosis, anthropothrombosis, anthropothrombosis, anthropothrombosis, such as patients under erythropoetin, thus also reported patients among epoxetine alfa." "" "" ""</seg>
<seg id="458">An increased incidence of thromvascultic events (see Section 4.4 and Section 4.8 - General) was observed in patients under the treatment of erythropoetinen.</seg>
<seg id="459">389 patients with hemogblastosis (221 multiple myelome, 144 non-Hodgkinlymphoma and 24 other hemogcinoma cells) and 332 patients with solid tumors (172 gynacarcinomas and 22% carcinomas and 21 carcinomas and 30 other patients).</seg>
<seg id="460">29 "" "" "" "29" "" "" "" 29 "" "" "" "" during the experimental studies with nearly the 20s of the week recommended dose, Epoetin alfa was led to diminished grain and a delay of fetal mortality. "" "" "" "</seg>
<seg id="461">"" "" "" "as part of an outpatient application, the patient underwent a unique one for a period of 3 days outside the cooling barrier and not over 25 ° C." "" "" ""</seg>
<seg id="462">"" "" "" "36 The recommended dose is 600 I.U. / kg epotin alfa which should be given once weekly for three weeks (day 21, 14 and 7) before operating procedure and the day of the surgery." "" "" ""</seg>
<seg id="463">38 "" "" "" "38 In cases of chronic kidney failure, in case of maintenance the lower limit of hemoglobin target concentration is not exceeded." "" "" ""</seg>
<seg id="464">The hemoglobination intake should be approximately 1 g / l (0.62 mmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of growth in high blood pressure.</seg>
<seg id="465">"" "" "" "thrombosis, vascular diseases such as myocardium attacks, fungal thrombosis, fungal thrombosis, anthrombosis, anthropothrombosis, anthropothrombosis, anthropothrombosis, anthropothrombosis, anthrothropogenic wounds, such as patients under erythropoetin, thus also reported patients among epoxetine alfa." "" "" ""</seg>
<seg id="466">An increased incidence of thromvascultic events (see Section 4.4 and Section 4.8 - General) was observed in patients under the treatment of erythropoetinen.</seg>
<seg id="467">389 patients with hemogblastosis (221 multiple myelome, 144 non-Hodgkinlymphoma and 24 other hemogcinoma cells) and 332 patients with solid tumors (172 gynacarcinomas and 22% carcinomas and 21 carcinomas and 30 other patients).</seg>
<seg id="468">44 "" "" "" "44 In animal experiments performed approximately 20x of the recommended weekdose, epotin alfa resulted in a diminishing fetting and a delay of fetal mortality." "" "" ""</seg>
<seg id="469">"" "" "" "as part of an outpatient application, the patient underwent a unique one for a period of 3 days outside the cooling barrier and not over 25 ° C." "" "" ""</seg>
<seg id="470">"" "" "" "51 The recommended dose is 600 I.U. / kg epotin alfa which should be given once weekly for three weeks (day 21, 14 and 7) before operating procedure and the day of the surgery." "" "" ""</seg>
<seg id="471">53 In case of chronic kidney failure the lower limit of hemoglobin target concentration is not to be exceeded in paragraph 4.2.</seg>
<seg id="472">The hemoglobination intake should be approximately 1 g / l (0.62 mmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of growth in high blood pressure.</seg>
<seg id="473">"" "" "" "thrombosis, vascular diseases such as myocardium attacks, fungal thrombosis, fungal thrombosis, anthrombosis, anthropothrombosis, anthropothrombosis, anthropothrombosis, anthropothrombosis, anthrothropogenic wounds, such as patients under erythropoetin, thus also reported patients among epoxetine alfa." "" "" ""</seg>
<seg id="474">An increased incidence of thromvascultic events (see Section 4.4 and Section 4.8 - General) was observed in patients under the treatment of erythropoetinen.</seg>
<seg id="475">389 patients with hemogblastosis (221 multiple myelome, 144 non-Hodgkinlymphoma and 24 other hemogcinoma cells) and 332 patients with solid tumors (172 gynacarcinomas and 22% carcinomas and 21 carcinomas and 30 other patients).</seg>
<seg id="476">59 "" "" "" "59 In animal experiments performed approximately 20x of the recommended weekdose, epotin alfa resulted in a diminishing fetting and a delay of fetal mortality." "" "" ""</seg>
<seg id="477">"" "" "" "as part of an outpatient application, the patient underwent a unique one for a period of 3 days outside the cooling barrier and not over 25 ° C." "" "" ""</seg>
<seg id="478">66 The recommended dose is 600 I.U. / kg epotin alfa which should be given once weekly for three weeks (day 21: 14 and 7) before operating procedure and the day of the surgery (Day 0).</seg>
<seg id="479">68 In cases of chronic kidney failure the lower limit of hemoglobin target concentration is not to be exceeded in paragraph 4.2.</seg>
<seg id="480">The hemoglobination intake should be approximately 1 g / l (0.62 mmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of growth in high blood pressure.</seg>
<seg id="481">"" "" "" "thrombosis, vascular diseases such as myocardium attacks, fungal thrombosis, fungal thrombosis, anthrombosis, anthropothrombosis, anthropothrombosis, anthropothrombosis, anthropothrombosis, anthropothrombosis, anthropothrombosis, such as patients under erythropoetin, thus also reported patients among epoxetine alfa." "" "" ""</seg>
<seg id="482">An increased incidence of thromvascultic events (see Section 4.4 and Section 4.8 - General) was observed in patients under the treatment of erythropoetinen.</seg>
<seg id="483">389 patients with hemogblastosis (221 multiple myelome, 144 non-Hodgkinlymphoma and 24 other hemogcinoma cells) and 332 patients with solid tumors (172 gynacarcinomas and 22% carcinomas and 21 carcinomas and 30 other patients).</seg>
<seg id="484">74 In animal experiments performed approximately 20x of the recommended weekdose of men resulted in epetin alfa to diminished serveraged body weight and a delay of fetal mortality.</seg>
<seg id="485">"" "" "" "as part of an outpatient application, the patient underwent a unique one for a period of 3 days outside the cooling barrier and not over 25 ° C." "" "" ""</seg>
<seg id="486">81 The recommended dose is 600 I.U. / kg epotin alfa which should be given once weekly for three weeks (day 21: 14 and 7) before operating procedure and the day of the surgery (Day 0).</seg>
<seg id="487">83 "" "" "" "83. in case of chronic kidney failure, in case of maintenance the upper limit of hemoglobin target concentration is not exceeded." "" "" ""</seg>
<seg id="488">The hemoglobination intake should be approximately 1 g / l (0.62 mmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of growth in high blood pressure.</seg>
<seg id="489">"" "" "" "thrombosis, vascular diseases such as myocardium attacks, fungal thrombosis, fungal thrombosis, anthrothrombosis, anthrothrombosis, anthropothrombosis, anthropothrombosis, anthropothrombosis, anthrothropogenic wounds, such as patients under erythropoetin, thus also reported patients among epoxetine alfa." "" "" ""</seg>
<seg id="490">An increased incidence of thromvascultic events (see Section 4.4 and Section 4.8 - General) was observed in patients under the treatment of erythropoetinen.</seg>
<seg id="491">389 patients with hemogblastosis (221 multiple myelome, 144 non-Hodgkinlymphoma and 24 other hemogcinoma cells) and 332 patients with solid tumors (172 gynacarcinomas and 22% carcinomas and 21 carcinomas and 30 other patients).</seg>
<seg id="492">89 In formal studies with nearly the 20x of the recommended weekdose of men resulted in epetin alfa to diminished serveraged body weight and a delay of the fetal mortality rate.</seg>
<seg id="493">"" "" "" "as part of an outpatient application, the patient underwent a unique one for a period of 3 days outside the cooling barrier and not over 25 ° C." "" "" ""</seg>
<seg id="494">"" "" "" "96 The recommended dose is 600 I.U. / kg epotin alfa which should be given once weekly for three weeks (day 21, 14 and 7) before operating procedure and the day of the surgery." "" "" ""</seg>
<seg id="495">"" "" "" "98 In cases of chronic kidney failure, in case of maintenance the lower limit of hemoglobin target concentration is not exceeded." "" "" ""</seg>
<seg id="496">The hemoglobination intake should be approximately 1 g / l (0.62 mmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of growth in high blood pressure.</seg>
<seg id="497">"" "" "" "thrombosis, vascular diseases such as myocardium attacks, fungal thrombosis, anthrombosis, anthrombosis, anthrothrombosis, anthrothrombosis, anthropothrombosis, anthropothrombosis, anthrombosis and 101 blood clots in artificial kidneys was reported in patients under erythropoetin, so also patients with epoxetine alfa." "" "" ""</seg>
<seg id="498">An increased incidence of thromvascultic events (see Section 4.4 and Section 4.8 - General) was observed in patients under the treatment of erythropoetinen.</seg>
<seg id="499">389 patients with hemogblastosis (221 multiple myelome, 144 non-Hodgkinlymphoma and 24 other hemogcinoma cells) and 332 patients with solid tumors (172 gynacarcinomas and 22% carcinomas and 21 carcinomas and 30 other patients).</seg>
<seg id="500">104 "" "" "" "104 In animal experiments performed approximately 20x of the recommended weekdose, epotin alfa resulted in a diminishing fetting and a delay of fetal mortality." "" "" ""</seg>
<seg id="501">"" "" "" "as part of an outpatient application, the patient underwent a unique one for a period of 3 days outside the cooling barrier and not over 25 ° C." "" "" ""</seg>
<seg id="502">111 The recommended dosage is 600 I.U. / kg epotin alfa which should be given once weekly for three weeks (day 21: 14 and 7) before operating procedure and the day of the surgery (Day 0).</seg>
<seg id="503">113 In cases of chronic kidney failure included in the case of maintenance the lower limit of hemoglobin target concentration is not exceeded.</seg>
<seg id="504">The hemoglobination intake should be approximately 1 g / l (0.62 mmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of growth in high blood pressure.</seg>
<seg id="505">"" "" "" "thrombosis, vascular diseases such as myocardium attacks, fungal thrombosis, anthrombosis, anthrombosis, anthropothrombosis, anthropothrombosis, anthropothrombosis, anthrothropogenic wounds, such as patients under erythropoetin, thus also reported patients among epoxetine alfa." "" "" ""</seg>
<seg id="506">An increased incidence of thromvascultic events (see Section 4.4 and Section 4.8 - General) was observed in patients under the treatment of erythropoetinen.</seg>
<seg id="507">389 patients with hemogblastosis (221 multiple myelome, 144 non-Hodgkinlymphoma and 24 other hemogcinoma cells) and 332 patients with solid tumors (172 gynacarcinomas and 22% carcinomas and 21 carcinomas and 30 other patients).</seg>
<seg id="508">119 "" "" "" "119" "" "" "" 119 times of experimental studies with nearly the 20 times of use recommended in humans, Epoetin alfa was led to diminished serf and a delay of fetal mortality. "" "" "" "</seg>
<seg id="509">"" "" "" "as part of an outpatient application, the patient underwent a unique one for a period of 3 days outside the cooling barrier and not over 25 ° C." "" "" ""</seg>
<seg id="510">126 The recommended dose is 600 I.U. / kg epotin alfa which should be given once weekly for three weeks (day 21: 14 and 7) before operating procedure and the day of the surgery (Day 0).</seg>
<seg id="511">"" "" "" "128 In cases of chronic kidney failure, in case of maintenance the lower limit of hemoglobin target concentration is not exceeded." "" "" ""</seg>
<seg id="512">The hemoglobination intake should be approximately 1 g / l (0.62 mmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of growth in high blood pressure.</seg>
<seg id="513">"" "" "" "thrombosis, vascular diseases such as myocardium attacks, fungal thrombosis, fungal thrombosis, anthrombosis, anthropothrombosis, anthropothrombosis, anthrothropogenic wounds, such as patients under erythropoetin, thus also reported patients among epoxetine alfa." "" "" ""</seg>
<seg id="514">An increased incidence of thromvascultic events (see Section 4.4 and Section 4.8 - General) was observed in patients under the treatment of erythropoetinen.</seg>
<seg id="515">389 patients with hemogblastosis (221 multiple myelome, 144 non-Hodgkinlymphoma and 24 other hemogcinoma cells) and 332 patients with solid tumors (172 gynacarcinomas and 22% carcinomas and 21 carcinomas and 30 other patients).</seg>
<seg id="516">134 "" "" "" "134 In animal experiments performed approximately 20x of the recommended weekdose, epotin alfa resulted in a diminishing fetting and a delay of fetal mortality." "" "" ""</seg>
<seg id="517">"" "" "" "as part of an outpatient application, the patient underwent a unique one for a period of 3 days outside the cooling barrier and not over 25 ° C." "" "" ""</seg>
<seg id="518">141 The recommended dose is 600 I.U. / kg epotin alfa which should be given once weekly for three weeks (day 21: 14 and 7) before operating procedure and the day of the surgery (Day 0).</seg>
<seg id="519">143 In cases of chronic kidney failure included in the case of maintenance the upper limit of hemoglobin target concentration should not be exceeded.</seg>
<seg id="520">The hemoglobination intake should be approximately 1 g / l (0.62 mmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of growth in high blood pressure.</seg>
<seg id="521">"" "" "" "thrombosis, vascular diseases such as myocardium attacks, fungal thrombosis, fungal thrombosis, anthrombosis, anthropothrombosis, anthropothrombosis and 146 blood clamosis, such as patients under erythropoetin, thus also reported patients among epoxetine alfa." "" "" ""</seg>
<seg id="522">An increased incidence of thromvascultic events (see Section 4.4 and Section 4.8 - General) was observed in patients under the treatment of erythropoetinen.</seg>
<seg id="523">389 patients with hemogblastosis (221 multiple myelome, 144 non-Hodgkinlymphoma and 24 other hemogcinoma cells) and 332 patients with solid tumors (172 gynacarcinomas and 22% carcinomas and 21 carcinomas and 30 other patients).</seg>
<seg id="524">149 In formal studies with nearly the 20x of the recommended weekdose of men resulted in epetin alfa to diminished föttosis and a delay of fetal mortality.</seg>
<seg id="525">"" "" "" "as part of an outpatient application, the patient underwent a unique one for a period of 3 days outside the cooling barrier and not over 25 ° C." "" "" ""</seg>
<seg id="526">"" "" "" "prior to the market launch and by agreement with the relevant authorities of the member states, the medical specialist in dialysis centers and retail stores may provide information regarding medical use of the product mistakenly cooling boxes for transport through the patient." "" "" ""</seg>
<seg id="527">"" "" "" "the holder of the approval for the Incorporation has been set up and working in Module 1.8.1 of the application application, before the medicine is applied to traffic and so long before the drug is applied to traffic." "" "" ""</seg>
<seg id="528">"" "" "" "the risk management and additional measures for pharmacovigilance and additional measures for pharmacovigilance, as agreed in Version 5 of the regulatory filing of the risk management plan (RMP), as well as according to any subsequent updating of the risk management plan." "" "" ""</seg>
<seg id="529">A updated RMP should be made available in accordance with the CHMP Guideline on Risk Management System for HighStep for Human use "at the same time with the next updated report on the intentional Safety Update Report (PSUR).</seg>
<seg id="530">"" "" "" "in addition, an updated RMP should be submitted: • upon receipt of new safety specifications (Safety Specification), the pharmacovigilance or risk reduction (excluding the pharmacovigilance or risk reduction)." "" "" ""</seg>
<seg id="531">• If you have suffered a heart attack or stroke within one month prior to your treatment • If you have occurred at unstable Angina pectoris (for the first time ever occurring or reinforced chest pain) - if such a blood cropdrop has occurred earlier.</seg>
<seg id="532">You suffer from severe blood circulation disorders of the heart (coronary heart disease), the arteries of the legs or arms (peripheral lung disease) or brain (cerebrovascular disease) recently suffer a heart attack or stroke.</seg>
<seg id="533">"" "" "" "during treatment with Abseamed, there may be a slight dosage-dependent increase in blood platelet, which can be retracted for further treatment." "" "" ""</seg>
<seg id="534">"" "" "" "your doctor may conduct regular blood investigations in order to check the number of blood platelets, during the first 8 weeks of the treatment." "" "" ""</seg>
<seg id="535">Iron deficiency, dissolution of the red blood cells (molyfish), blood loss, vitamin B12- or folic acid deficiency should be taken into consideration and treated before the treatment with abseamed.</seg>
<seg id="536">Very rare was reported on the occurrence of anti-perverized Erythrobberia after months to years of subcutaneous (under the skin-sprayed) erythropoetin.</seg>
<seg id="537">"" "" "" "if you suffer from Erythroblasty, your therapy is treated with secluded and set how your anemia is best treated." "" "" ""</seg>
<seg id="538">Therefore Abseamed must be given by injections in a vein (intravenous) if you are treated for an anaemia due to kidney disease.</seg>
<seg id="539">A high hemoglobination is the risk of problems associated with the heart or blood vessels and the death of death may be increased.</seg>
<seg id="540">"" "" "" "with elevated or increasing calibration, your doctor may take into account a break in the treatment with Abseamed up until the potassium levels lie in the norm range." "" "" ""</seg>
<seg id="541">"" "" "" "if you suffer from chronic kidney failure and clinical obvious coronary heart disease, your doctor will ensure that your hemoglobined is not exceeds a certain value." "" "" ""</seg>
<seg id="542">"" "" "" "according to the present knowledge, the treatment of blood armrests with Abseamed in adults with chronic kidney failure (kidney failure), which are not yet to be accelerated." "" "" ""</seg>
<seg id="543">A 2-3-week delay between epotin-alfa-gift and the desired effect should be taken into account for the assessment of the effectiveness of diflamed.</seg>
<seg id="544">"" "" "" "200 Your doctor regularly will determine your values of the red blood-colorless (hemoglobin), and match your diflamed dose as possible to keep the risk of blood glucose (thromboteric event) as possible." "" "" ""</seg>
<seg id="545">"" "" "" "in particular, this risk should be very carefully balanced from the treatment with epotin alfa drugs, e.g. if you have an increased risk for thrombothavasculine events (e.g. a deep venenthrombosis or lung bulie)." "" "" ""</seg>
<seg id="546">"" "" "" "in case you are cancer patients, consider that sealamed as a growth factor for blood cells, and at certain circumstances may affect the tumour." "" "" ""</seg>
<seg id="547">"" "" "" "if an orthopedic operation is imminent, the cause of your anemia should be examined and treated accordingly." "" "" ""</seg>
<seg id="548">"" "" "" "if your value of the red blood-colorless (hemoglobin) is too high, you should not get rid of Abseamed because an increased risk of blood crophobias after surgery is made." "" "" ""</seg>
<seg id="549">"" "" "" "please inform your doctor or pharmacist if you use other medicines consuming / apply / apply recently, even if it is not prescription medicine." "" "" ""</seg>
<seg id="550">If you take Ciclosporin (means to oppression of the immune system) during your therapy using Abseamed your doctor will prescribe certain blood tests to measure blood levels of Ciclosporin.</seg>
<seg id="551">Laboratory tests have no interaction between epotin alfa and G-CSF or GM-CSF (G-CSF and GM-CSF) are means of building the immune system e.g. for cancer chemotherapy or at HIV).</seg>
<seg id="552">"" "" "" "depending on how your blood level (anaemia) can be applied to the treatment, the dose may be adjusted for every four weeks until your state is under control." "" "" ""</seg>
<seg id="553">"" "" "" "your doctor may arrange to check out regular blood tests in order to check and ensure the treatment correctly, and your hemoglobination does not exceed a certain value." "" "" ""</seg>
<seg id="554">"" "" "" "once you are adjusting well, you will receive regular doses of absecluded between 25 and 50 I.U. / kg twice weekly, distributed on two equal injections." "" "" ""</seg>
<seg id="555">"" "" "" "your doctor may arrange to check regular blood tests in order to check and ensure the treatment success, your hemoglober value does not exceed a certain value." "" "" ""</seg>
<seg id="556">"" "" "" "depending on how the anemia should be applied to the treatment, the dose may be adjusted for every four weeks until the condition is under control." "" "" ""</seg>
<seg id="557">"" "" "" "to ensure this and ensure that the hemoglober value does not exceed a certain value, the doctor will conduct regular blood tests." "" "" ""</seg>
<seg id="558">"" "" "" "if necessary, to shorten the treatment time before surgery, a dose of 300 I.U. / kg can be given on 10 consecutive days prior to surgery, on the day of intervention and further 4 days after surgery." "" "" ""</seg>
<seg id="559">"" "" "" "however, if your doctor may keep this appropriate, you can also learn how to sprawling itself under the skin." "" "" ""</seg>
<seg id="560">Heart, heart attacks, cerebasis, transient flow disturbances of the brain, deep venous thrombosis, receptacles of the retina and blood clotgun in artificial kidneys have been reported in patients under erythropoetin treatment.</seg>
<seg id="561">"" "" "" "eyelids and lips (Quincke-Ödem), and shoots or allergic reactions including symptoms like criticism, redness, itching and acceleration pulse, were reported in rare cases." "" "" ""</seg>
<seg id="562">Erythroblavisenie means that no longer enough red blood cells in bone marrow can be formed (see section "Special caution when applying Abseamed is required).</seg>
<seg id="563">"" "" "" "after repeated blood donations, it can occur independently of the treatment with Abseamed - to a blood crophobias (thrombothavasculine events)." "" "" ""</seg>
<seg id="564">Treatment with Abseamed can be associated with increased risk of blood test after surgery (postoperative thrombothavascularious events) when your departure point is too high</seg>
<seg id="565">"" "" "" "please inform your doctor or pharmacist if one of the listed side effects will affect you, or if you notice any side effects that are not indicated in this manual information." "" "" ""</seg>
<seg id="566">"" "" "" "when an injection of the fridge has been taken and room temperature has reached (up to 25 ° C), it must be used either within 3 days or be rejected." "" "" ""</seg>
<seg id="567">Aclasta is applied to the treatment of the following diseases: • osteoporosis (a disease affecting the bones are brittle) in women after menopause as well as in men.</seg>
<seg id="568">"" "" "" "it is applied to patients with high risk reduction (bone quarries), including patients who have recently been suffered from a traumatic hill as during the Hinfall; • Morbus Paget of the bone, a disease which changes the normal course of bone growth." "" "" ""</seg>
<seg id="569">"" "" "" "in addition, patients with Morbus Paget should take at least 500 mg of calcium twice daily for at least 10 days before the first infusion a large dose of vitamin D (50 000 to 125 000 IE) or by injection in a muscle." "" "" ""</seg>
<seg id="570">"" "" "" "subsequent symptoms of acetamol or ibuprofen (means of inflammation) can reduce the symptoms occurring in three days after infusion, like fever, muscle pain, flu-like symptoms, joint pain and headache." "" "" ""</seg>
<seg id="571">"" "" "" "for the treatment of the Morbus Paget, Aclasta may only be prescribed by doctors that have experience in treating this disease." "" "" ""</seg>
<seg id="572">"" "" "" "as the active ingredient in Aclasta, is like in Zometa, a part of the data material was drawn to the assessment of Aclasta." "" "" ""</seg>
<seg id="573">"" "" "" "in the first study almost 8 000 older women were involved with osteoporosis, and it was investigated by spinal cord over a three years period." "" "" ""</seg>
<seg id="574">The second study included 2 127 male men and women with osteoporosis for over 50 years which recently suffered a hip cture. the number of fractures were examined over a period of up to five years.</seg>
<seg id="575">"" "" "" "at Morbus Paget, Aclasta has been tested in two studies at a total of 357 patients and compared with Risedronate (one other bisphosphonat)." "" "" ""</seg>
<seg id="576">Main indicative for efficacy was whether the content of alkaline phosphatase in the serum (an enzyme which is broken down) in the blood regalised or decreased by at least 75% compared to the initial value.</seg>
<seg id="577">"" "" "" "in the study with older women, the risk of spinal cord was reduced in patients under Aclasta (without other osteoporosis therapy) over a period of three years compared to placebo 70%." "" "" ""</seg>
<seg id="578">"" "" "" "compared to all patients under Aclasta (with or without other osteoporosis therapy), those under placebo was reduced by 41%." "" "" ""</seg>
<seg id="579">In the study involving men and women with hip fracture 9% of patients under Aclasta had a fracture (92 from 1 065) compared to 13% of patients under placebo (139 of 1 062).</seg>
<seg id="580">"" "" "" "most side effects of Aclasta occur in the first three days of the infusion, and are less frequently repeated infusion in the first three days." "" "" ""</seg>
<seg id="581">Aclasta cannot be applied in patients who may possibly be sensitive (allergic) to ooledronic acid or other bisphosphate or other ingredients.</seg>
<seg id="582">"" "" "" "like all bisphosphate patients, patients at Aclasta are subject to the risk of kidney problems, reactions to the infusion center and osteoneksis (cause of bone tissue) in the jaw." "" "" ""</seg>
<seg id="583">"" "" "" "the manufacturer of Aclasta is prepared for physicians who would use Aclasta for the treatment of osteoporosis, as well as similar material for patients in which the side effects of the medication should be explained and pointed to the physician." "" "" ""</seg>
<seg id="584">"" "" "" "in April 2005, the European Commission issued Novartis Europharm's European Commission approval for the placing of Aclasta in the entire European Union." "" "" ""</seg>
<seg id="585">Conditions ODER limitations with regard to THE MOSICHEN AND REQUIRING OF THE BRNO GUIDING OF CHANING OF CHANING OF CHANING OF CHANING OF CHANING OF CHANING OF CHANING OF THE MOONENT OF THE BRU</seg>
<seg id="586">Treatment of osteoporosis in postmenopausal women and men with increased risk for fractures including patients with a recent low-traumatic hill fracture.</seg>
<seg id="587">"" "" "" "• The patient information package should be provided and the following key messages include: • The package activity • Required physical activity, Non-smoking and a healthy diet • Important symptoms and symptoms for severe side effects • When to access medical or nursing help." "" "" ""</seg>
<seg id="588">Treatment of osteoporosis • in postmenopausal women • in men with increased risk for fractures including patients with a recent low-traumatic hill fracture.</seg>
<seg id="589">"" "" "" "for the treatment of postmenopausal osteoporosis and osteoporosis in men, an intravenous infusion of 5 mg of Aclasta is recommended once a year." "" "" ""</seg>
<seg id="590">In patients with low-traumatic fractions the administration of the infusion of Aclasta is recommended two or more weeks after the operative care of the fracture fracture (see section 5.1).</seg>
<seg id="591">"" "" "" "for the treatment of the Morbus Paget, Aclasta should only be prescribed by doctors that have experience in the treatment of the Morbus Paget." "" "" ""</seg>
<seg id="592">After a treatment of the Morbus Paget with Aclasta a long division was observed in patients who asked for the treatment (see Section 5.1).</seg>
<seg id="593">"" "" "" "in addition, it is advisable to make a sufficient intake of calcium in patients with Morbus Paget to ensure minimum 500 mg of elemental calcium for at least 10 days after the gift of Aclasta (see Section 4.4)." "" "" ""</seg>
<seg id="594">"" "" "" "in patients with a recent low-traumatic convent, an initial dose of 50,000 to 125,000 i.E. oralem or intramuscular type D is recommended prior to the first Aclasta infusion." "" "" ""</seg>
<seg id="595">"" "" "" "the frequency of symptoms which occur within the first three days after administration of Aclasta, can be reduced by the administration of acetamol or ibuprofen or after the application of Aclasta." "" "" ""</seg>
<seg id="596">Patients with kidney failure (see Section 4.4) In patients with a creatinine-Clearance &lt; 35 ml / min is not recommended as limited clinical experiences for these patient group are currently available.</seg>
<seg id="597">"" "" "" "older patients (≥ 65 years) A dose adjustment is not necessary because the bioavailability, distribution and elimination in older patients is similar to younger." "" "" ""</seg>
<seg id="598">Children and adolescents Aclasta is not recommended for the use in children and adolescents under 18 years of age because data are missing to inconsistency and efficacy.</seg>
<seg id="599">Aclasta is not recommended in patients with severe kidney failure (creatininsufficiency &lt; 35 ml / min) as a limited clinical experience for this patient population.</seg>
<seg id="600">An existing hypokalemia is treated before the treatment of Aclasta by sufficient intake of calcium and vitamin D (see Section 4.3).</seg>
<seg id="601">"" "" "" "due to the quick one of the effect of Zoledronylic acid on bone structure, it can develop a transient that occurs under symptomatic hypokalemia whose maximum occurs within the first 10 days after the infusion of Aclasta (see Section 4.8)." "" "" ""</seg>
<seg id="602">"" "" "" "in addition, it is advisable to make a sufficient intake of calcium in patients with Morbus Paget to ensure minimum 500 mg of elemental calcium for at least 10 days after the gift of Aclasta (see paragraph 4.2)." "" "" ""</seg>
<seg id="603">Cancers (chemotherapy, treatment with corticosteroids, poor oral hygiene) should be considered a dental treatment with appropriate preventilating dental treatment.</seg>
<seg id="604">"" "" "" "for patients suffering from dental access, no data is available whether the interruption of treatment with bisphosphonates reduced the risk of osteonecroses in the jaw." "" "" ""</seg>
<seg id="605">"" "" "" "the clinical assessment by the treated doctor should be the basis for the treatment plan of each patient, based on an individual benefit risk assessment." "" "" ""</seg>
<seg id="606">"" "" "" "symptoms of symptoms which occur within the first three days after administration of Aclasta, can be reduced by acetamol or ibuprofen or after the application of Aclasta (see section 4.2)." "" "" ""</seg>
<seg id="607">"" "" "" "the incidence of adverse cases of hopal fibrillation was increased in patients with Aclasta, increased (1.3%) (51 of 3.862) compared to those who received placebo (0.6%) (22 from 3.852)." "" "" ""</seg>
<seg id="608">In osteoporosis studies (PFT HORIZON - Recurrento Fracture Trial [RFT]) the total threading of pre-hopal fibrillation was comparable between Aclasta (2.6%) and placebo (2.1%).</seg>
<seg id="609">"" "" "" "very common (≥ 1 / 100), common (≥ 1 / 100, &lt; 1 / 100), rare (≥ 1 / 10,000, &lt; 1 / 1,000) adverse drug actions are listed in Table 1." "" "" ""</seg>
<seg id="610">Kidney dysfunction Zoledronic acid was associated with kidney dysfunctions (i.e. an increase of serum creatinins) and in rare cases, as acute kidney failure.</seg>
<seg id="611">The change in the Kreatinine-Clearance (annually before the administration) and the occurrence of kidney failure and a restricted kidney function were comparable to osteoporosis in three years comparable to the Aclaim and the placebo group.</seg>
<seg id="612">"" "" "" "a temporary increase in serum creatinins within 10 days of the gift was observed at 1.8% of patients treated with Aclasta, compared to 0.8% of patients treated with placebo." "" "" ""</seg>
<seg id="613">"" "" "" "based on the evaluation of the laboratory findings, the transient asymptomatic calcium values were treated under 2.3% of patients treated with Aclasta in a large clinical study compared to 21% of patients treated with Aclasta in the Morbus-Paget studies." "" "" ""</seg>
<seg id="614">"" "" "" "all patients received additional amounts of vitamin D and calcium in the study on postmenopausal osteoporosis, in the study on prevention of clinical fractures after fracture fracture and in the Morbus-Paget studies (see section 4.2)." "" "" ""</seg>
<seg id="615">"" "" "" "in the study on avoiding clinical aspects, the vitamin D levels were not routinely measured, however, the majority of patients received an initial dose of vitamin D prior to the administration of Aclasta (see section 4.2)." "" "" ""</seg>
<seg id="616">"" "" "" "local reactions After the administration of Zoledronylic acid was reported on local reactions to the infusion centre, such as redness, swelling and / or pain, reported (0.7%)." "" "" ""</seg>
<seg id="617">"" "" "" "osteonekroses, particularly in cancer patients, above osteonekroses (primarily in the jaw-field) reported that with bisphosphonates, including Zoledronylic acid, were treated." "" "" ""</seg>
<seg id="618">"" "" "" "many of these patients had signs for local infections including osteopathy, and the majority of reports refers to cancer patients after tooth extraction and other dental attacks." "" "" ""</seg>
<seg id="619">7 study of 7.736 patients came up in osteoneksis in the orthodontics with Aclasta and in a placebo treated with placebo.</seg>
<seg id="620">"" "" "" "in case of overdosing, which leads to a clinically relevant hypokalemia, can be achieved through the gift of oral calcium and / or an intravenous infusion of calcium gluconate." "" "" ""</seg>
<seg id="621">Clinical effectiveness in the treatment of postmenopausal osteoporosis (PFT G) once a year for 3 consecutive years was recorded in postmenopausal women (7.736 women between 65 and 89 years) with either a bone density filter or a BMD-T-Score for the upper body as ≤ -2.5 with or without signs of existing vertebral fracture.</seg>
<seg id="622">Effects on morphometric spinal cord aclasta significantly reduced over a period of three years and already after a year the frequency of one or several new spinal fractures (see table 2).</seg>
<seg id="623">Aclasta treated patients aged 75 and older had a 60% reduced risk of spinal cord compared to placebo patients (p &lt; 0.0001).</seg>
<seg id="624">Effects on hip fractures Aclasta showed a constant effect over three years which resulted in a reduced risk of acetabulum in a 41% (95% CI, 17% to 58%).</seg>
<seg id="625">Effect on bone density (BMD) Aclasta raised the bone density of the lumbar acid, hips and distal radius compared to placebo treatment (6: 12, 24 and 36 months).</seg>
<seg id="626">9 Increase of the density of lumbar of the lumbar region by 6.7% of the thigh area rose by 5.1% and the distal radius by 3.2%.</seg>
<seg id="627">"" "" "" "bone histology include 152 postmenopausal osteoporosis patients who were treated with Aclasta (N = 82) or placebo (N = 82), a year after the third annual dose of bone biopsies from the pelvis." "" "" ""</seg>
<seg id="628">A microcomputer tomographic (µCT) analysis showed patients treated with Aclasta in comparison to placebo increasing the bearing bones and bone structure.</seg>
<seg id="629">Bones-specific alkaline phosphatase (BSAP) in serum and the beta-C collagen (b-CTX) serum and the beta-C-Telopeptid (b-CTX) serum were determined in periodical intervals throughout the duration of the study.</seg>
<seg id="630">Treatment with an annual 5 mg dose Aclasta reduced BSAP by 30% compared to the initial value and was kept at 28% below the starting point up to 36 months.</seg>
<seg id="631">P1NP was significantly reduced by 61% below the starting point after 12 months and was kept at 52% below output value to 36 months.</seg>
<seg id="632">"" "" "" "B-CTX was reduced significantly at 61% below the output value after 12 months, and was kept at 55% below the starting point up to 36 months." "" "" ""</seg>
<seg id="633">"" "" "" "the vitamin D levels were not routinely measured, but the majority of patients received a initial dose of vitamin D (50,000 to 125,000 I.U. of oral or intramuscular) 2 weeks before the infusion." "" "" ""</seg>
<seg id="634">"" "" "" "the total mortality stood at 10% (101 patients) in the group treated with Aclasta, compared with 13% (141 patients) in the placebo group." "" "" ""</seg>
<seg id="635">Effect on bone mineral density (BMD) In HORIZON-RFT analysis raised the Aclasta treatment in comparison to placebo treatment the BMD on the total balance sheet as at all time points.</seg>
<seg id="636">The Aclasta treatment resulted in comparison for 24 months in comparison to placebo treatment by 5.4% in total and around 4.3% on the net thals.</seg>
<seg id="637">"" "" "" "clinical effectiveness in males in HORIZON-RFT analysis were randomized, and in 185 patients the BMD was evaluated during 24 months." "" "" ""</seg>
<seg id="638">The study was not designed for a reduction in clinical fractures in men; the frequency of clinical fractures was 7.5% in Aclasta-treated men compared to 8.7% in placebo.</seg>
<seg id="639">"" "" "" "in another study of men (study CZOL446M2308), the once-year administration of Aclaise was not related to the percentage change of the lumbar vertebrae-BMD after 24 months in comparison to the initial value." "" "" ""</seg>
<seg id="640">Clinical effectiveness of treatment at Morbus Paget of the bone Aclasta has been studied in patients at the age of 30 years with radiological phosphatase (mean serum levels of alkaline phosphatase in accordance with 2.6x to 3.x-specific upper normal threshold for inclusion in the study).</seg>
<seg id="641">11 The effectiveness of an infusion of 5 mg Zoledronic acid compared to the intake of 30 mg Risedronate once daily for 2 months was proved in two six months comparative studies.</seg>
<seg id="642">"" "" "" "in the combined results, a similar decrease in pain intensity and pain relief was observed in comparison with the initial value for Aclasta and Risedronate after 6 months." "" "" ""</seg>
<seg id="643">Patients who were classified as responsibilities at the end of the six month period (on the therapy) were included in a follow-up phase.</seg>
<seg id="644">Of the 143 patients with Aclasta and the 107 with risedronate treated patients who participated in the follow-up study compared with 71 of the patients treated with Risedronate patients with a mean period of follow-up of 18 months after application.</seg>
<seg id="645">"" "" "" "a unique and multiple 5 and 15 minutes lasting infusions of 2, 4, 8 and 16 mg Zoledronic acid with 64 patients gave the following pharmacokinetic data to be dosed independently." "" "" ""</seg>
<seg id="646">After that the plasma level increased rapidly at &lt; 10% of the maximum value after 4 h and &lt; 1% after 24 h followed by a long lasting phase very low concentration, no more than 0.1% of the highest value.</seg>
<seg id="647">Rapid biphastic disappearance of the great circulation system with half-life hours t / 1 ½ a 1.87 hours followed by a long Eliminational period with a terminal elimination of the elimination period t ½ to 146 hours.</seg>
<seg id="648">"" "" "" "the early distribution hasen (stainless steel and white, with the above mentioned 1 ½ -s) represent the fast resorption in bone and excretion of the kidneys." "" "" ""</seg>
<seg id="649">"" "" "" "in the first 24 h, 39 ± 16% of the desired dose in the urine is found while the rest is mostly bound to bone tissue." "" "" ""</seg>
<seg id="650">"" "" "" "the total body-Clearance is independent of the dose 5,04 ± 2.5 l / h and remains unaffected by gender, age, breed or body weight." "" "" ""</seg>
<seg id="651">An extension of the infusion time of 5 to 15 minutes was reduced by 30% at the end of the infusion but had no effect on the area under the curve (plasma concentration towards time).</seg>
<seg id="652">A diminished clearing of metalous-P450-enzyme for metallized substances is unlikely because Zoledronylic is not metabolized not yet immediate and / or irreversible, material-dependent inhibitor of p450-</seg>
<seg id="653">Special patient groups (see section 4.2) The renal Clearance of Zoledronylic correlated with the Kreatinine Clearance, namely 75 ± 33% of the Kreatinine Clearance and was 84 ± 29 ml / min (range 22 to 143 ml / min).</seg>
<seg id="654">"" "" "" "this results in a light (clcr = 50- 80 ml / min), and an even kidney interference with up to 35 ml / min does not require a dose adjustment of the zoledronylic acid." "" "" ""</seg>
<seg id="655">"" "" "" "as for heavy kidney failure (Kreatinine Clearance &lt; 30 ml / min) only limited data are available, no statements are available for this population." "" "" ""</seg>
<seg id="656">Acute toxicity The highest not-effective intravenous cell dose was 10 mg / kg of body weight and with rats 0.6 mg / kg body weight.</seg>
<seg id="657">"" "" "" "for studies on dogs, single doses of 1.0 mg / kg (based on AUC) were administered at the recommended Human-Therapeutic exposure." "" "" ""</seg>
<seg id="658">"" "" "" "subchronic and chronic toxicity in studies with intravenous application was given a 15-minute infusion in 3-day intervals, resulting in intervals of 2- 3 weeks (a cumulative dose which corresponds to AUC, corresponds to AUC, corresponds)." "" "" ""</seg>
<seg id="659">"" "" "" "in long-term studies with repeated application of cumulated expositions, which exceeded the maximum of intended human-exposure, including the gastrointestinal tract and the liver as well as on intravenous injection site." "" "" ""</seg>
<seg id="660">"" "" "" "the most frequent occurrence of studies with repeated application was an increased primary Spongiosa in the metaphyse of the long bones in the growth phase with almost all dosages, an attack which reflects the pharmacological, antireortive effect of the substance." "" "" ""</seg>
<seg id="661">An Teratogenicity is observed at doses above 0.2 mg / kg as outer and inner (visceral) abnormalities and such a skeleton.</seg>
<seg id="662">In rabbits no teratogenic effects or embryo-fetal effects were observed even though the maternal toxicity was pronounced in 0,1 mg / kg as a result of being low-calcium mirror.</seg>
<seg id="663">"" "" "" "if the medicine is not directly used, the user is responsible for the availability and conditions before application, and should not be exceeded 24 hours at 2 ° C or 8 ° C." "" "" ""</seg>
<seg id="664">Aclasta is supplied as a package with a bottle as a packing unit or as a bundle pack consisting of 5 packs each containing a bottle.</seg>
<seg id="665">Treatment of osteoporosis in postmenopausal women and men with increased risk for fractures including patients with a recent low-traumatic hill fracture.</seg>
<seg id="666">"" "" "" "• The patient information package should be provided and the following key messages contain: • The package activity • Required physical activity, Non-smoking and a healthy diet 17 • Important symptoms and symptoms for severe side effects • When to access medical or nursing help." "" "" ""</seg>
<seg id="667">"" "" "" "July 2007, completed on 29 September 2006, in the 1.8.1 of the application form the Pharmacovigilance system is in force, and works before and while the product is marketed." "" "" ""</seg>
<seg id="668">Risco-Management-Plan The owner of approval for the transaction is undertaken to perform the studies and additional activities of the pharmacovigilance used in the pharmacovigilance plan of the approved version 004 of the risk management software (RMP) in 1.8.2 of the MP's risk-approved version of the RMP.</seg>
<seg id="669">"" "" "" "according to CHMP guideline for risk management systems, the revised RMP should be submitted together with the next" Periodic Safety Update Report (PSUR). "" "" "" "</seg>
<seg id="670">A revised RMP should be submitted • If new information be known that could affect the current statements for safety, pharmacovigilance plan or activity to minimize risk (for pharmacovigilance or minimization). • The requirements of the EMEA.</seg>
<seg id="671">Zoledronylic is a representative of a substance class which is called Bisphosphonate and is used for the treatment of osteoporosis in postmenopausal women who are used osteoporosis in men and murder.</seg>
<seg id="672">Decreasing blood levels of sex hormones, especially oestrogens which are formed from androgens or is playing a role in a gradual loss of bone mass which is observed in men.</seg>
<seg id="673">"" "" "" "at the Morbus Paget, bone structure is too fast, and new bone material is dissolved in an order that makes the bone material weaker than normal." "" "" ""</seg>
<seg id="674">Aclasta works to normalizes the bone structure and thereby ensures normal bone formation and thus lends strength again.</seg>
<seg id="675">"" "" "" "if you need to undergo treatment in dental treatment or if you need to undergo a dental surgery, notify your doctor that you will be treated with Aclasta." "" "" ""</seg>
<seg id="676">"" "" "" "when using Aclasta with other medicines, ask your doctor, pharmacist or nursing staff if you use other medicines consuming / apply respectively, even if it is not prescription medicine." "" "" ""</seg>
<seg id="677">"" "" "" "for your doctor, it's particularly important to know if you are taking medicine, from which it is known that they damage the kidneys." "" "" ""</seg>
<seg id="678">"" "" "" "when using Aclasta together with food and drinks, you are concerned that you take sufficient liquid in accordance with the instructions of your doctor before and after treatment with Aclasta." "" "" ""</seg>
<seg id="679">Osteoporosis The usual dose is 5 mg once a year that will be given to you by your doctor or nursing staff as an infusion in a vein.</seg>
<seg id="680">"" "" "" "if you have recently broken the hips, recommended to make Aclasta two or more weeks after operating the hip break." "" "" ""</seg>
<seg id="681">"" "" "" "Morbus Paget The usual dose is 5 mg, which will be given to you by your doctor or nursing staff as an infusion in a vein." "" "" ""</seg>
<seg id="682">"" "" "" "since Aclasta works for a long time, you may need a further dose only after one year or longer." "" "" ""</seg>
<seg id="683">"" "" "" "it is important to follow these instructions exactly, so that the calcium mirrors will not be too low in your blood in time after infusion." "" "" ""</seg>
<seg id="684">"" "" "" "at Morbus Paget, Aclasta can work for longer than a year, and your doctor will inform you if you need a re-consuming treatment." "" "" ""</seg>
<seg id="685">"" "" "" "when the administration of Aclasta has been missed, please get in touch with your doctor or Hospital in order to make a new appointment." "" "" ""</seg>
<seg id="686">Before completion of therapy with Aclasta Falls you are considering the completion of the treatment with Aclasta please contact your doctor's doctor and discuss this with your doctor.</seg>
<seg id="687">"" "" "" "side effects occur very often in connection with the first infusion (more than 30% of patients), but are less frequent after the subsequent infusion." "" "" ""</seg>
<seg id="688">"" "" "" "fever and chills, muscle or joint pain and headache, occur within the first three days following the administration of Aclasta." "" "" ""</seg>
<seg id="689">"" "" "" "currently it is unclear if Aclasta causes this irregular heartbeat, but you should notice it if you notice such symptoms after you have received Aclasta." "" "" ""</seg>
<seg id="690">"" "" "" "physical activity because of a low calcium concentration in the blood, like muscle clamps or cribating or numbous feeling, especially in the area around the mouth." "" "" ""</seg>
<seg id="691">"" "" "" "flu, sleeplessness, fatigue, pain-pain, diarrhoea, pain, skin dries, tummy pain, skin dries, skin dries, skin drip, skin drip, skin drip, skin drip, tissue drip, tissue injuries and thirst." "" "" ""</seg>
<seg id="692">Persistent pain and / or not healing wounds in the mouth or jaws were reported mainly in patients that were treated with bisphosphonates because of other diseases.</seg>
<seg id="693">"" "" "" "more than allergic reactions, including rare cases of breathing problems, emergency stop and angioedema (e.g. swelling in the face, tongue or throat) was reported." "" "" ""</seg>
<seg id="694">"" "" "" "please inform your doctor, pharmacist or nursing staff, if one of the listed side effects you significantly impaired or you have noticed effects that are not listed in this instruction information." "" "" ""</seg>
<seg id="695">"" "" "" "if the medicine is not directly used, the user is not responsible for the storage period and conditions to use; normally 24 hours at 2 ° C should not be exceeded." "" "" ""</seg>
<seg id="696">"" "" "" "in patients with a low-traumatic skull fracture, it is recommended that infusion from Aclasta two or more weeks after operating the hip fracture." "" "" ""</seg>
<seg id="697">"" "" "" "before and after administration of Aclasta, patients need to be supplied with liquid only; this is particularly important for patients who received a diuretic therapy." "" "" ""</seg>
<seg id="698">"" "" "" "due to the quick one of the effect of Zoledronic acid on bone structure, a temporary, sometimes symptomatic matured, hypokalmia can develop their maximum normally within the first 10 days after the infusion of Aclasta." "" "" ""</seg>
<seg id="699">"" "" "" "in addition, it is advisable to ensure an adequate intake of calcium in patients with Morbus Paget to ensure minimum 10 days after the gift of Aclasta during a minimum of 10 days." "" "" ""</seg>
<seg id="700">"" "" "" "in patients with a low-traumatic skull fracture, a starting dose of 50,000 to 125,000 i.E. oralem or intramuscular type D is recommended prior to the infusion of Aclasta." "" "" ""</seg>
<seg id="701">"" "" "" "if you need further information about your disease or treatment, please check the package age (also part of the EPAR) or contact your doctor or pharmacist." "" "" ""</seg>
<seg id="702">ACOMPLIA is used in addition to a diet and exercise for the treatment of adult patients suffering from a body mass index (body mass index - BMI) from 30 kg / m ² or over or • the overweight (BMI of 27 kg / m ² or above) and beyond that or more</seg>
<seg id="703">"" "" "" "in addition, four trials over 7 000 patients were performed in which ACOMPLIA was used in comparison to a placebo as supporting remedy for smoking." "" "" ""</seg>
<seg id="704">"" "" "" "in contrast to study the smoking attitudes, there were no consistent findings, so that the effect of ACOMPLIA was hard to assess the effect on this application area." "" "" ""</seg>
<seg id="705">Which risk is associated with ACOMPLIA? he found the most common side effects of ACOMPLIA as reported during the studies (nausea) and infections of the upper respiratory tract. ng The full listing which observed in connection with ACOMPLIA had reported side effects.</seg>
<seg id="706">"" "" "" "it may also not be applied to patients who suffer from an existing severe depression or suffering from antidepressants, as it may cause risk of depression in a small minority of patients." "" "" ""</seg>
<seg id="707">Caution is advisable in case of concurrent application by ACOMPLIA with drugs like ketoconazole or Itraconazole (drugs for use at HIV- infection); Telithromycin or Clarithromycin (antibiotics). LN</seg>
<seg id="708">"" "" "" "finally, the Committee on Human Use (CHMP) reached that the efficacy of ACOMPLIA regarding the weight reduction in patients with obesity or overweight." "" "" ""</seg>
<seg id="709">Pharmaceuticals are applied in patients who require medical and non-cosmetic reasons (by providing revisions for patients and physicians) and around the Arz</seg>
<seg id="710">It Additional to diet and exercise for the treatment of obesity (BMI ≥ 30 kg / m ²) or overweight people (BMI &gt; 27 kg / m ²) which also have a number of risk factors such as type 2 diabetes or Dydenpianemia (see section 5.1).</seg>
<seg id="711">"" "" "" "however, ACOMPLIA is not recommended for the application of children and adolescents under the age of 18 due to the lack of data for efficacy and integrity." "" "" ""</seg>
<seg id="712">"" "" "" "La depressive diseases or mood changes with depressive symptoms have been reported at up to 10% of patients receiving the Rimonabant patients, (see Section 4.8)." "" "" ""</seg>
<seg id="713">"" "" "" "and with depressed disturbances, Rimonabant may not be applied, unless the benefit of treatment in individual case weighs the risk (see Section 4.3 and 4.8)." "" "" ""</seg>
<seg id="714">"" "" "" "it also applies to patients who have - besides the obesity - no recognizable risks, may occur depressed reactions." "" "" ""</seg>
<seg id="715">Relatives or other nahattage people are pointed out that it is necessary to monitor the reoccurrence of such symptoms and take immediate medical advice if these symptoms occurring. ln</seg>
<seg id="716">• Elder patients The effectiveness and inconceivable of Rimonabant in the treatment of patients over 75 years have not been shown sufficient.</seg>
<seg id="717">Patients with cardiovascular diseases (myocardial infarction or stroke etc.) was completed by studies with Rimonabant on less than 6 months ago. ln</seg>
<seg id="718">Rifampicin, phenytoin, phenobarbital, carbamazepine, Johannisweed) is not examined that the simultaneous administration of potent CYP3A4 inductors receive the plasma concentration of Rimonabant</seg>
<seg id="719">"" "" "" "we have examined important patients and patients with obesity, and in addition to 3800 patients in further indications." "" "" ""</seg>
<seg id="720">"" "" "" "the following table (Table 1) shows the effects of adverse adverse effects in placebo-controlled studies, which were treated to weight reduction and due to associated metabolic diseases." "" "" ""</seg>
<seg id="721">"" "" "" "it was statistically significant when the corresponding placeborates (for unwanted effects (1%) or if clinically were clinically relevant (for unwanted effects &lt; 1%)." "" "" ""</seg>
<seg id="722">Very common (≥ 10%); often (≥ 0.1% &lt; 1%); occasionally (≥ 0.01; &lt; 0.1%); very t lä</seg>
<seg id="723">"" "" "" "in a tolerability study, in which a limited number of persons was administered up to 300 mg were observed, only slight symptoms were observed." "" "" ""</seg>
<seg id="724">"" "" "" "patients had a BMI of 30 kg / m ² or BMI &gt; 27 kg / m ², compared to existing hypertension and / or Dydenpianemia." "" "" ""</seg>
<seg id="725">N Weight reduction after a year amounted to 1.COMPLIA 20 mg 6.5 kg in relation to the original up to 1.6 kg (difference -4.9 kg) CI95% -5.3; -4.4; p &lt; 0.0001).</seg>
<seg id="726">"" "" "" "patients suffering from ACOMPLIA 20 mg were treated, and 1,2 kg in the placebo (difference to 3.8% -4,4, -3.3; p &lt; 0.0001)." "" "" ""</seg>
<seg id="727">"" "" "" "after 2 years, the difference in weight reduction between ACOMPLIA and placebo -4.2 kg (CI95% -5,0%; -3,4, p &lt; 0.001)." "" "" ""</seg>
<seg id="728">9 weight reduction and further risk factors In patients with no diabetes in which a mixed population of patients with</seg>
<seg id="729">Under Rimonabant 20 mg has been seen an average waste of triglycerides of 6.9% (output value triglyceride 1.62 mmol / l) compared to a 5.8% increase.</seg>
<seg id="730">"" "" "" "in a second study in patients with obesity and previously untreated type 2- diabetes (serenade), the absolute change of HbA1c-value (with an initial value of 7.9% for Rimonabant 20 mg and -0.3 under Placebo I)" "" "" ""</seg>
<seg id="731">"" "" "" "the percentage of patients who reached a Hbale value of &lt; 7%, amounted to 51% in the Rimonseant group and 35% in the placebo group." "" "" ""</seg>
<seg id="732">The difference between the 20 mg- and the placebo group was 3.8 kg (CI95% -5.0, -2.6 p &lt; 0.001). LN</seg>
<seg id="733">Improvement of the HbA1c-value in patients suffering from Rimonabant 20 mg were declared by direct effects of Rimonabant and about 50% due to the weight reduction of Rimonabant. n EIM Arz</seg>
<seg id="734">2 hours have been reached after 13 days (Cmax = 196 ± 28,1 ng / ml; Ctp = 91.6 ± 14.1 ng / ml; AUC0-24 = 2960 ± 268 ng.h / ml).</seg>
<seg id="735">Influence of food: the subjects received that Rimonabant received either in deteriorating conditions or after a fat meal and increased by 67% increased Cmax and by 48% increased ng AUC.</seg>
<seg id="736">Patients with black skin color can produce up to 31% lower Cmax and a 43% lower AUC than patients of other ethnic populations.</seg>
<seg id="737">N popular macokinetic analyses (age range 18- 81 years) is estimated that a 75- year-old patient is an estimated 21% higher Cmax and a 27% higher AUC than a 40-year-old</seg>
<seg id="738">"" "" "" "5.3 The clinical data for the security of the following adverse effects, which were not observed in clinical trials, were considered potentially relevant for clinical use:" "" "" ""</seg>
<seg id="739">"" "" "" "in some cases, however, not in all cases, the beginning of the convulsions with process-related stress appears to be connected with the animals." "" "" ""</seg>
<seg id="740">Was Rimonemant allowed over a longer period before the mating (9 weeks) which allowed a recovery from the initial effects of Rimonabant so no unwanted effects were observed on fertility or cycle disorders.</seg>
<seg id="741">The influence of Rimonemant on the pre- and postnatal development was examined at the mat in dosages of up to 10 mg / kg / day.</seg>
<seg id="742">In a study of rats and postnatal development an exposition with Rimonabant in utero and by lactation will not cause any changes in learning behaviour or memory.</seg>
<seg id="743">Detailed information on this medicine can be found on the website of the European Medicines Agency (EMEA) http: / / www.emea.europa.eu / Serper.itte on EIM Arz</seg>
<seg id="744">"" "" "" "La On the packing site of the medicine, name and address of the manufacturers must be responsible for the release of the subject." "" "" ""</seg>
<seg id="745">"" "" "" "26 Grade psychiatric events such as depression or mood changes were reported by patients receiving oCOMPLIA, (see paragraph" Which NEBENWIRKUNGES "" "" "" "</seg>
<seg id="746">"" "" "" "if you occur in treating a depression (see below) during the treatment with ACOMPLIA, consult your doctor and break the treatment." "" "" ""</seg>
<seg id="747">"" "" "" "dizziness, diarrhea, anxiety, itching, excessive sweating, sore throat and pain, back pain, spinal pain, spinal pain, spinal pain, seizure, seizure, joint pain, seizure. EIM" "" "" ""</seg>
<seg id="748">"" "" "" "enter your doctor or pharmacist if one of the common side effects will affect you significantly, or you may notice any side effects listed in this manual information." "" "" ""</seg>
<seg id="749">"" "" "" "summary of the EPAR to the public The present document is an abstract of the European Public Fund (EPAR), in which explains how the Committee on Human Use (CHMP) has been evaluated to provide recommendations concerning the application of the medication." "" "" ""</seg>
<seg id="750">Actos is used to treat type 2 diabetes (also known as non-insulin-dependent diabetes). • It can be used alone (monotherapy) in patients with other diabetational treatment (duotherapy).</seg>
<seg id="751">"" "" "" "in addition to metformin in patients (especially overweight patients), which can be used with metformin alone in the highest tolerable dose cannot be satisfactory." "" "" ""</seg>
<seg id="752">"" "" "" "in combination with a sulphate resin or insulin, the existing dose of the sulphate agent can be sustained, except in patients with hypoglycemia (low blood sugar); it should be reduced to the dose of the Sulfonamide (low blood sugar)." "" "" ""</seg>
<seg id="753">"" "" "" "this means that the body-own insulin may be utilized better and the blood sugar level decreases, which makes type 2 diabetes better." "" "" ""</seg>
<seg id="754">"" "" "" "in more than 1 400 patients the effectiveness of Actos in tripleotherapy research was investigated, in addition, the patients received a combination of metformin with a Sulfonylharnstoff, in addition they received either Actos or placebo for up to 3.5 years." "" "" ""</seg>
<seg id="755">"" "" "" "in the studies the concentration of a substance in the blood (glycerylified hemoglobin, HbA1c) was measured, which shows how well the blood sugar is set." "" "" ""</seg>
<seg id="756">Actos lead to a lowering of the HbA1c-value that makes it possible to reduce blood sugar levels by using the dosing of 15 mg, 30 mg and 45 mg.</seg>
<seg id="757">At the end of the Tripleotherapy study the effect of an additional gift from Actos to existing treatment with metformin and a sulfonylharnance showed a reduction of 0.094% while the extra gift of placebo resulted in a reduction of 0.35%.</seg>
<seg id="758">"" "" "" "in a small study, in which the combination of Actos and insulin had been studied in addition to insulin, a reduction of HbA1c values of 0.69% after 6 months, compared with 0.14% in patients who received additional placebo." "" "" ""</seg>
<seg id="759">"" "" "" "the most common adverse events related to actos were vision disorders, infections of the upper respiratory tract (cold), weight gain and hypoethesia." "" "" ""</seg>
<seg id="760">Actos should not be applied to patients who may react to Pioglitazon or one of the other components in patients with liver problems or diabetic valve (high concentration levels - in blood).</seg>
<seg id="761">It has been decided that Actos should serve as an alternative to the standard treatment with metformin in patients with metformin which metformin is not displayed.</seg>
<seg id="762">"" "" "" "in October 2000, the European Commission issued the company Takeda Europe R & D Centre Limited, approved by Actos in the entire European Union." "" "" ""</seg>
<seg id="763">"" "" "" "the tablets are white to whitish, round, arched and wear on one side the markings" 15 "and on the other hand the wording" Actos "." "" "" ""</seg>
<seg id="764">Pioglitazon is also indicated for the combination with insulin for patients with type 2 diabetes mellitus, whose blood sugar is inadequate and the metformin is unsuitable for contraindications or incompatibility (see Section 4.4).</seg>
<seg id="765">"" "" "" "for the application of Pioglitazon in patients under 18 years of age, no data is available, therefore the application in this age group is not recommended." "" "" ""</seg>
<seg id="766">"" "" "" "in patients suffering at least one risk factor (e.g. early heart attack or symptomatic coronary heart disease), the doctor should start treatment with the lowest available dose and increase the dose." "" "" ""</seg>
<seg id="767">"" "" "" "patients should be observed in signs and symptoms of congestive heart failure, weight gain or ointment, especially those with reduced cardiac reserve." "" "" ""</seg>
<seg id="768">"" "" "" "patients should be observed in signs and symptoms of congestive heart failure, weight gain and ointment if Pioglitazon is applied in combination with insulin." "" "" ""</seg>
<seg id="769">A cardiovascular study with pioglitazon in patients under 75 years of diabetes mellitus and existing advanced macrovascular diseases was performed.</seg>
<seg id="770">"" "" "" "in this study, the increase of accounts of congestive heart failure stated that, however, did not lead to an increase in mortality in the study." "" "" ""</seg>
<seg id="771">Patients with increased output of liver enzyme (ALT &gt; 2.5 x upper limit of the norm) or with other signs of liver illness may not be used.</seg>
<seg id="772">"" "" "" "if the ALT mirrors are increased to 3 times the upper limit of the standard range, the liver enzyme could recontrol as soon as possible." "" "" ""</seg>
<seg id="773">"" "" "" "in case a patient symptoms are developed to investigate a hepatic dysfunction, such as unexplained nausea, vomiting, thelessness, fatigue, loss of appetite and / or darker Harn." "" "" ""</seg>
<seg id="774">The decision whether the treatment of patients with Pioglitazon should be continued until the anticipation of the laboratory parameters should be derived from clinical assessment.</seg>
<seg id="775">"" "" "" "in clinical trials with Pioglitazon, dosed weight gain has been proved that can mix of fat deposits and bound in some cases with a fluid retention." "" "" ""</seg>
<seg id="776">As a result of a hematelution in the therapy of Pioglitazon a minor reduction in the mean hemoglobination values (relative reduction of 4%) and hematokrits (relative reduction by 4.1%).</seg>
<seg id="777">Similar changes were observed in comparative controlled trials with Pioglitazon in patients under metformin (relative reduction of hemoglobin by 1-4% and hematokrits by 1-2% and hematokrits by 1-3.2%).</seg>
<seg id="778">As a result of increased insulin sensitivity in patients the Pioglitazone is obtained as oral or triple-combination therapy with insulin, the risk of a dosed hypoglycaemia.</seg>
<seg id="779">"" "" "" "after launch was reported under the treatment with thiazolidIndicons, including Pioglitazon, about an occurrence or deterioration of a diabetic macular hole." "" "" ""</seg>
<seg id="780">"" "" "" "it is unclear if there is a direct link between the intake of Pioglitazon and the occurrence of macular oedema if patients report on disturbances of visual acuity, an appropriate ophthalmological investigation should be considered." "" "" ""</seg>
<seg id="781">"" "" "" "in a summary analysis of messages, randomised, controlled, double-blind clinical trials over a period of up to 3.5 years with more than 8,100 patients receiving pioglitazon were treated." "" "" ""</seg>
<seg id="782">The analysis of the fracture was 1.9 million records per 100 patient years of patients treated with Pioglitazon for one 100 patient years in women who were treated with a comparison mediation.</seg>
<seg id="783">"" "" "" "in ProActive study, study over 3.5 years for study of cardiovascular events, the fractures were treated with 44 / 905 (2.5%; 0.5 fractures per 100 patient-years) in patients who were treated with a comparative medication." "" "" ""</seg>
<seg id="784">"" "" "" "patients should be aware of the possibility of pregnant women, and if one patient is pregnant or this entry, treating the treatment (see Section 4.6)." "" "" ""</seg>
<seg id="785">"" "" "" "studies on the examination of interactions, that Pioglitazon showed no relevant effects on pharmacokinetics or pharmaceutical dynamics of dioxin, warfarin, phenprocoumon and metformin." "" "" ""</seg>
<seg id="786">Interactions with medicines that are metabolized by these enzymes such as oral contraceptives, Cyclosporin, calciumkanalblocker and HMGCoA-reducer are not expected.</seg>
<seg id="787">Simultaneous application of Pioglitazon with gemfibrozil (a cytochrom P450 2C8- Inhibitor) resulted in an increase of AUC of Pioglitazon for 3 times.</seg>
<seg id="788">Simultaneous application of Pioglitazon with Rifampicin (a cytochrome P450 2C8-inductor) resulted in a reduction in AUC of Pioglitazon by 54%.</seg>
<seg id="789">"" "" "" "this is due to the treatment of hyperinsulinemia and increased insulin resistance of the mother's pregnancy, reducing the availability of the metabolic substrates for the fetal growth." "" "" ""</seg>
<seg id="790">Very often &gt; 1 / 10; common &gt; 1 / 100; occasional &gt; 1 / 1000; rare &gt; 1 / 10000; very rare &lt; 1 / 10000, individual cases: unknown (from present data not estimated).</seg>
<seg id="791">"" "" "" "this lead to a temporary change in the turf and refractive index, as well as other hypoglycaemic substances can be observed." "" "" ""</seg>
<seg id="792">"" "" "" "in clinical trials with Pioglitazon, ALT-Anstiege stood out equally frequently as under placebo, but rare than in comparison groups under metformin or sulfonchloride." "" "" ""</seg>
<seg id="793">"" "" "" "in a Outcome study in patients with existing advanced macular disease, the frequency of severe congestive heart failure was 1.6% higher than under placebo when Pioglitazon bzon." "" "" ""</seg>
<seg id="794">"" "" "" "since the market launch is rarely reported on congestive heart failure under Pioglitazon, more often when Pioglitazon was applied in combination with insulin or in patients with congestive heart failure in Anamnese." "" "" ""</seg>
<seg id="795">"" "" "" "it was randomised analysis of messages with randomised, controlled, double-blind clinical trials over a period of up to 3.5 years with more than 8,100 patients in the groups treated with comparative mediation." "" "" ""</seg>
<seg id="796">"" "" "" "over a period of 3.5 years of the ProActive study, fractures were treated with 44 / 870 (5.1%) of patients treated with Pioglitazon compared with 23 / 905 (2.5%) in patients that were treated with a comparative medication." "" "" ""</seg>
<seg id="797">"" "" "" "when taking the reported maximum dose of 120 mg / day, over four days, then 180 mg / day, over seven days there were no symptoms." "" "" ""</seg>
<seg id="798">Pioglitazon seems to have an activation of specific kernel receptors (peroxisome Proliferation) function in the animal model to an increased insulin sensitivity of liver, fat and skeleton muscle cells.</seg>
<seg id="799">It could be showed that Pioglitazon reduces the glucose production in the liver and the peripheral glucose level increases in the case of insulin resistance.</seg>
<seg id="800">A clinical study with Pioglitazon versus Gliclacion versus Gliclacion versus two years in order to examine the time until after the therapeutic effect (HbA1c ≥ 8.0% after the first 6 treatment months).</seg>
<seg id="801">At the time after two years after the start of the therapy a blood sugar control (defined as HbA1c &lt; 8.0%) was observed by Pioglitazon at 69% of the patients (compared to 50% of patients under the pathology).</seg>
<seg id="802">"" "" "" "in a placebo-controlled study of 12 months, patients whose blood sugar was randomized with insulin, in spite of three impregnated optimization, to Pioglitazon or placebo." "" "" ""</seg>
<seg id="803">In cases under the age of Pioglitazon the mean HbA1c reduced by 0.45% compared to the patients who were still receiving insulin; a reduction of the insulin injectors in the group treated with Pioglitazon was observed.</seg>
<seg id="804">In clinical trials over one year there was a statistically significant decrease in the albumine / creatinine quotian compared to the initial values.</seg>
<seg id="805">The effect of Pioglitazon (monotherapy with 45 mg versus Plazebo) was tested in a small and 18-week investigation of type 2 diabetics.</seg>
<seg id="806">"" "" "" "in most clinical trials, a reduction of the total plasma triglycerides and free fatty acids and the increase of HDL- Cholesterinspiegel and slightly significantly reduced LDL Cholesterinspiegel." "" "" ""</seg>
<seg id="807">"" "" "" "in clinical trials over a period of up to two years, Pioglitazon reduced the total plasmatriglyceride and the free fatty acids and increased the HDL Cholesterinspiegel." "" "" ""</seg>
<seg id="808">"" "" "" "in comparison with Plazebo, no statistically significant increase of LDL Cholesterinspiegel was observed while under Metformin and Gliclacidal reduced values were observed." "" "" ""</seg>
<seg id="809">"" "" "" "in a study of 20 weeks, Pioglitazon did not only diminished the sober-triglyceride, but also improved triglyceride absorption as well as on the triglyceride-synthesis and triglyceride synthesis." "" "" ""</seg>
<seg id="810">"" "" "" "in the ProActive study, a cardiovascular disease study, has randomised 5238 patients with type 2 diabetes mellitus, and existing advanced macular disease in groups of either Pioglitazon or placebo." "" "" ""</seg>
<seg id="811">"" "" "" "after oral application, Pioglitazon is absorbed quickly, with peak concentrations of unaltered Pioglitazon in the plasma generally 2 hours after application." "" "" ""</seg>
<seg id="812">"" "" "" "on this basis, the contribution of M-IV represents the effectiveness in about the three times the effectiveness of Pioglitazon, whereas the relative efficacy of M-II is minimal." "" "" ""</seg>
<seg id="813">"" "" "" "in interaction studies could be proven that Pioglitazon had no relevant effect on pharmacokinetics or pharmaceutical dynamics of dioxin, warfarin, phenprocoumon and metformin." "" "" ""</seg>
<seg id="814">The simultaneous application of Pioglitazon with gemfibrozil (a cytochrome P450 2C8-Inhibitor) or with belt concentration of Pioglitazon (see Section 4.5).</seg>
<seg id="815">After oral use of radioactive markedly Pioglitazon in humans the marker was found mainly in the barrel (55%) and a lower degree of urine (45%).</seg>
<seg id="816">The average plasma-elimination period of unchanging Pioglitazon is 5-6 hours in humans and the total active metabolites is 16 - 23 hours.</seg>
<seg id="817">"" "" "" "the plasma concentrations of Pioglitazon and its metabolites are lower in patients with reduced kidney function, whereas the ratios of oral Clearance of the breast are similar." "" "" ""</seg>
<seg id="818">"" "" "" "in a toxicological studies in mice, rats, dogs and monkeys matches after repeated Plasma-Volume enlargement with haemelution, anaemia and reversible environmental hypertrophie." "" "" ""</seg>
<seg id="819">"" "" "" "this is due to the treatment of hyperinsulinemia and increased insulin resistance of the mother, reducing the availability of the metabolic substrates for the fetal growth." "" "" ""</seg>
<seg id="820">Long-term studies (up to 2 years) have been induced by the rebate tendencies of hyperplasia (in male and female rats) and tumours (in male rats) of the bladder epithelium.</seg>
<seg id="821">In a animal model of the family monastatous polyposis (FAP) introduced the treatment with two other thiazolidIndians to an increased frequency of colontaneous diseases.</seg>
<seg id="822">"" "" "" "the tablets are white to whitish, round and flat and wear on one side the marking" 30 "and on the other hand the wording" Actos "." "" "" ""</seg>
<seg id="823">The analysis of the fracture was 1.9 million records per 100 patient years of patients treated with Pioglitazon for one 100 patient years in women who were treated with a comparison mediation.</seg>
<seg id="824">"" "" "" "in ProActive study, study over 3.5 years for study of cardiovascular events, the fractures were treated with 44 / 905 (2.5%; 0.5 fractures per 100 patient-years) in patients who were treated with a comparative medication." "" "" ""</seg>
<seg id="825">"" "" "" "in another study, over two years the effects of combination therapy of metformin each was investigated by Pioglitazon or Gliclacide." "" "" ""</seg>
<seg id="826">In clinical trials over 1 year there was a statistically significant decrease in the albumine / creatinine quotian compared to the initial values.</seg>
<seg id="827">"" "" "" "in a study of 20 weeks, Pioglitazon did not only diminished the sober-triglyceride, but increased beyond the effect on tryglyceride absorption as well as on the hectriglyceride-synthesis." "" "" ""</seg>
<seg id="828">"" "" "" "even though the study determined the goal concerning its primary endarisation, stroke, acute myocardial infarisation, stroke, acute myocardial infarisation and reascularisation of leg arteries that are not related to cardiovascular dysfunction." "" "" ""</seg>
<seg id="829">"" "" "" "the tablets are white to whitish, round and flat and wear on one side the marking" 45 "and on the other hand the wording" Actos "." "" "" ""</seg>
<seg id="830">"" "" "" "in a summary analysis of messages with randomised, controlled, double-blind clinical trials over a period of up to 3.5 years with more than 8,400 patients receiving ooglitazon, showed an increased inhibitor of fractures in women." "" "" ""</seg>
<seg id="831">"" "" "" "in ProActive study, study over 3.5 years for study of cardiovascular events, the fractures were treated with 44 / 905 (2.5%; 0.5 fractures per 100 patient-years) in patients who were treated with a comparative medication." "" "" ""</seg>
<seg id="832">"" "" "" "in a study of 20 weeks, Pioglitazon did not only diminished the sober-triglyceride, but also improved triglyceride absorption as well as on the triglyceride-synthesis and triglyceride synthesis." "" "" ""</seg>
<seg id="833">"" "" "" "at the packing site of the drug, name and address of the manufacturer, which is responsible for the release of the appropriate Charge." "" "" ""</seg>
<seg id="834">"" "" "" "in September 2005, the Pharmaceutical entrepreneur will submit an additional 6 month Perodic Safety Update Report (PSUR) and subsequent annual PSURs, until reaching a different decision of CHMP." "" "" ""</seg>
<seg id="835">A updated risk management plan must be submitted according to the CHMP Guideline on Risk Management System for Human Use.</seg>
<seg id="836">"" "" "" "if you are type 2 diabetes, Actos support 15 mg tablets that bring control of your blood sugar by giving a better devaluation of the body's own insulin." "" "" ""</seg>
<seg id="837">"" "" "" "if you know you are familiar with your sugar, please contact your doctor before taking Actos in 15mg tablets." "" "" ""</seg>
<seg id="838">"" "" "" "please inform your doctor or pharmacist if you have any other medicines or until recently taken, even if it is not prescription medicine." "" "" ""</seg>
<seg id="839">"" "" "" "if you take Actos 15 mg tablets in combination with other medicines for the treatment of diabetes (e.g. insulin, chloroamide, glibenclamide, calcium chloride, calcium chloride, calcium chloride), if you need to reduce the dose of your medicine." "" "" ""</seg>
<seg id="840">In some patients with longsuffering type 2 diabetes mellitus and heart disease or early stroke that were treated with Actos and insulin, congestive heart failure developed.</seg>
<seg id="841">"" "" "" "in clinical trials in which Pioglitazon was compared with other oral antidiabetics or placebo (but not in men), the Pioglitazon income, a higher number of fractures." "" "" ""</seg>
<seg id="842">"" "" "" "if you accidentally take too many tablets, or if any other or a child has taken your drug, you will get in touch with a doctor or pharmacist." "" "" ""</seg>
<seg id="843">"" "" "" "like Actos and content of the package Actos 15 mg tablets are white to whitish, round, curved tablets with the mark" 15 "on one page and the wording" Actos "on the other side." "" "" ""</seg>
<seg id="844">"" "" "" "if you are type 2 diabetes, Actos support 30 mg tablets that bring control of your blood sugar by giving a better devaluation of the body's own insulin." "" "" ""</seg>
<seg id="845">"" "" "" "if you know you are familiar with your sugar, please contact your doctor before taking Actos 30mg tablets." "" "" ""</seg>
<seg id="846">"" "" "" "if you take Actos 30 mg tablets in combination with other medicines for the treatment of diabetes (e.g. insulin, chloroamide, gliedclamide, calcium chloride, calcium chloride, calcium chloride, if you need to reduce the dose of your medicine." "" "" ""</seg>
<seg id="847">"" "" "" "61 Informing your doctor as soon as possible, if you determine signs of congestive heart failure to determine how unusual short trimness or rapid weight gain or local swelling (oil)." "" "" ""</seg>
<seg id="848">"" "" "" "in clinical trials in which Pioglitazon was compared with other oral antidiabetics or placebo (but not in men), the Pioglitazon income, a higher number of fractures." "" "" ""</seg>
<seg id="849">"" "" "" "like Actos and content of the package Actos 30 mg tablets are white to whitish, round, flat tablets with the marking" 30 "on one page and the wording" Actos "on the other side." "" "" ""</seg>
<seg id="850">"" "" "" "if you are type 2 diabetes, Actos support 45 mg tablets that bring control of your blood sugar by giving a better devaluation of the body's own insulin." "" "" ""</seg>
<seg id="851">"" "" "" "if you know it is known that you are suffering from sugar incompatibility, please contact your doctor before taking Actos 45mg tablets." "" "" ""</seg>
<seg id="852">"" "" "" "if you take Actos 45 mg tablets in combination with other medicines for the treatment of diabetes (e.g. insulin, chloroamide, glibenclamide, calcium chloride, calcium chloride, calcium chloride), if you need to reduce the dose of your medicine." "" "" ""</seg>
<seg id="853">"" "" "" "66 For some patients with longsuffering type 2 diabetes mellitus, heart disease or early stroke, treated with Actos and insulin, congestive heart failure developed." "" "" ""</seg>
<seg id="854">"" "" "" "as soon as possible, inform your doctor if you determine signs of congestive heart failure to determine how unusual short trimness or rapid weight gain or local swelling (oil)." "" "" ""</seg>
<seg id="855">"" "" "" "in clinical trials in which Pioglitazon was compared with other oral antidiabetics or placebo (but not in men), the Pioglitazon income, a higher number of fractures." "" "" ""</seg>
<seg id="856">"" "" "" "67 If any of the common side effects will affect you significantly, or you may notice any side effects listed in this manual information, please inform your doctor or pharmacist." "" "" ""</seg>
<seg id="857">"" "" "" "like Actos and content of the package Actos 45 mg tablets are white to whitish, round, flat tablets with the marking" 45 "on one page and the wording" Actos "on the other side." "" "" ""</seg>
<seg id="858">"" "" "" "the present document is a summary of the European Public Fund (EPAR), in which explains how the Committee on Human Use (CHMP) evaluates the studies to take recommendations concerning the application of the medication." "" "" ""</seg>
<seg id="859">If you need further information about your medical condition or treatment of your disease (which is also part of the EPAR) or contact a doctor or pharmacist.</seg>
<seg id="860">"" "" "" "if you wish further information about the recommendations of the CHMP, please read the scientific discussion (which is also part of the EPAR)." "" "" ""</seg>
<seg id="861">Actraphane 10: soluble insulin resistant to 100% Actraphane 20% Actraphane 30% Actraphane 30% Actraphane 30% Actraphane 50% Actraphane 50% Actraphane 50% Actraphane 50% Actuphane 50: soluble insulin-insulin-insulin-insulin-insulin-insulin-insulin-insulin resistance</seg>
<seg id="862">"" "" "" "Actraphane is usually used once or twice daily, when a rapid initial effect is desired together with a longer lasting effect." "" "" ""</seg>
<seg id="863">(44-20) 74 18 84 00 Fax (44-20) 74 18 86 68 E-mail: e-mail: e-mail: / / www.emea.eu.int © EMEA 2006 Reproduction and / or distribution of this document Authorised for non-specified medicine (rDNA) is produced with the method of so-called "recombinant technology."</seg>
<seg id="864">"" "" "" "Actraphane was not able to produce insulin for a total of 294 patients with type 1 diabetes, where the pancreas is not capable of using insulin." "" "" ""</seg>
<seg id="865">"" "" "" "in the study, after 12 weeks the concentration of a substance (glycerylified hemoglobin) was measured, which shows how well the blood sugar is set." "" "" ""</seg>
<seg id="866">Actraphane resulted in a decrease in the HbA1c mirror; which pointed out that the blood sugar levels were similar to much like with another human insulin.</seg>
<seg id="867">Actraphane should not be applied in patients who may react to human insulin (allergic) to human insulin (rDNA) or other components.</seg>
<seg id="868">"" "" "" "in addition, the doses of Actraphane may be adjusted if it is administered together with a number of other medicines that can affect the blood sugar (the full list is to extract the package directions)." "" "" ""</seg>
<seg id="869">"" "" "" "finally, the Committee on Human Use (CHMP) reached the end that the benefits of Actraphane weigh down to the risks of diabetes." "" "" ""</seg>
<seg id="870">"" "" "" "in October 2002, the European Commission approved the company Novo Nordisk A / S for placing on Actraphane in the entire European Union." "" "" ""</seg>
<seg id="871">"" "" "" "pre-mixed insulin products are usually used once or twice daily, if a fast initial effect is desired together with a longer lasting effect." "" "" ""</seg>
<seg id="872">"" "" "" "in order to ensure that the total dose is injected at least 6 seconds, to ensure that the total dose is injected." "" "" ""</seg>
<seg id="873">"" "" "" "for example, patients whose blood sugar may significantly improve due to intensified insulin therapy, hypoglycemia should be perceived and should be advised accordingly." "" "" ""</seg>
<seg id="874">"" "" "" "any change in terms of strength, trademark (manufacturer), insulin type (fast acting, biphastical) and / or production method (by recombinant DNA compared to insulin,) can result in a change of dosage." "" "" ""</seg>
<seg id="875">"" "" "" "in case of change to Actraphane in patients a dose adjustment is necessary, this can be necessary during the first dose or months after the conversion." "" "" ""</seg>
<seg id="876">"" "" "" "some patients suffering from hypoglycemic reactions after a change from animal on human insulin, reported that the early warning symptoms of a hypoglycemia were less pronounced than in their previous insulin." "" "" ""</seg>
<seg id="877">"" "" "" "before travelling, over several time zones, the patient should be advised to take the Council of his medical remedy because such trips can lead to other times that insulin and meals must be applied or taken." "" "" ""</seg>
<seg id="878">"" "" "" "the doctor needs to take possible interactions with the therapy, and all patients always ask themselves after other medicines." "" "" ""</seg>
<seg id="879">"" "" "" "4. hypoglycemia as well as hyperglycemia, which may occur in utero a sufficiently controlled diet therapy, increase the risk of abnormalities and fertility in utero." "" "" ""</seg>
<seg id="880">"" "" "" "severe Hypoglycasions can lead to awareness and / or seizures, and with temporary or lasting disturbances of brain function and even death." "" "" ""</seg>
<seg id="881">Diseases of the nervous system gels - peripheral new ropathy a rapid damage of blood sugar may be linked to complaints that are referred to as acute painful neuropathy and normally reversible.</seg>
<seg id="882">"" "" "" "5 An intensification of the insulin therapy with a abrupt improvement of blood sugar, however, may be associated with a temporary deterioration of diabetic retinopathy." "" "" ""</seg>
<seg id="883">Diseases of the skin and the lower tissue injury - Lipodocyrophy On the injection site can result in a lipodystrophy when it comes to switch inside the injection area.</seg>
<seg id="884">"" "" "" "general conditions and complaints at the meeting place - Local Attractive activities on the injection site While the insulin therapy can occur local hypersensitivity, itching, itching, pain and hematoma on the injection site)." "" "" ""</seg>
<seg id="885">Diseases of the immune system Gelegally - Urtikaria, Exanthem Very rarely - anaphylactic reactions including neutralised skin rash, fungal problems, respiratory diseases, low blood pressure and impotence / awareness.</seg>
<seg id="886">"" "" "" "however, a hypoglycaemia may develop gradually: • Easy hypoglycils can be handled by the oral sugars of glucose and glucose levels." "" "" ""</seg>
<seg id="887">"" "" "" "therefore, diabetics should always have grape variety, sweets, cookies, or sugar-sugars with an intramuscular or subcutaneous injection of the glucose or subcutaneous injection of gluten or by glucose to be given intravenously through the doctor." "" "" ""</seg>
<seg id="888">"" "" "" "the effect starts within half an hour, the maximum capacity is reached within 2 to 8 hours and the total amount of active duration is up to 24 hours." "" "" ""</seg>
<seg id="889">"" "" "" "the resorption profile is based on the product, that it is a mix of insulin products with faster or delayed resorption." "" "" ""</seg>
<seg id="890">A series of winding (hydrolysis) places on the Humaninsular molecule were observed in watering; none of the metabolites shown by the split is active.</seg>
<seg id="891">"" "" "" "based on conventional concepts for safety pharmacology, toxicity in repeated declaratory, genotoxicity, for reproductive potential and proreproduction, these preclinical data do not recognize any particular hazards for human beings." "" "" ""</seg>
<seg id="892">"" "" "" "it is recommended - after being taken out of the Actraphane seed bottle from the refrigerator - to increase the temperature of the insulin at room temperature (not above 25 ° C), before it is implemented for the first use." "" "" ""</seg>
<seg id="893">"" "" "" "some patients suffering from hypoglycemic reactions after a change from animal on human insulin, reported that the early warning symptoms of a hypoglycemia were less pronounced than in their previous insulin." "" "" ""</seg>
<seg id="894">"" "" "" "the doctor needs to take possible interactions with the therapy, and all patients always ask themselves after other medicines." "" "" ""</seg>
<seg id="895">12 Soviet hypoglycaemia as well as hyperglycemia which may occur in an unsufficient controlled diet therapy can increase the risk of abnormalities and fertility in utero.</seg>
<seg id="896">13. an intensification of the insulin therapy with a abrupt improvement of blood sugar settings may be associated with a temporary deterioration of diabetic retinopathy.</seg>
<seg id="897">The terminale half-life (t ½) is therefore a measure of the elimination than a measure of the elimination by the insulin form of the insulin (insulin has half a half from a few minutes).</seg>
<seg id="898">"" "" "" "it is recommended - after being taken out of the Actraphane seed bottle from the refrigerator - to increase the temperature of the insulin at room temperature (not above 25 ° C), before it is implemented for the first use." "" "" ""</seg>
<seg id="899">"" "" "" "some patients suffering from hypoglycemic reactions after a change from animal on human insulin, reported that the early warning symptoms of a hypoglycemia were less pronounced than in their previous insulin." "" "" ""</seg>
<seg id="900">20 "" "" "" "20. hypoglycemia as well as hyperglycemia, which may occur with a sufficiently controlled diet therapy, increase the risk of abnormalities and fertility in utero." "" "" ""</seg>
<seg id="901">"" "" "" "21. an intensification of the insulin therapy with a abrupt improvement of blood sugar, however, may be associated with a temporary deterioration of diabetic retinopathy." "" "" ""</seg>
<seg id="902">Diseases of the immune system Gelegally - Urtikaria, Exanthem Very rarely - anaphylactic reactions including neutralised skin rash, fungal problems, respiratory diseases, low blood pressure and impotence / awareness.</seg>
<seg id="903">Cartridges may only be used together with products that are compatible with them and ensure a safe and effective function of the cartridge.</seg>
<seg id="904">"" "" "" "it is recommended - after being taken out of Actraphane Penfill from the refrigerator - to increase the temperature of the insulin at room temperature (not above 25 ° C), before it is implemented for the first use." "" "" ""</seg>
<seg id="905">"" "" "" "some patients suffering from hypoglycemic reactions after a change from animal on human insulin, reported that the early warning symptoms of a hypoglycemia were less pronounced than in their previous insulin." "" "" ""</seg>
<seg id="906">"" "" "" "28 Incglycemia as well as hyperglycemia, which may occur in an unsufficient controlled diet therapy, increase the risk of abnormalities and fertility in utero." "" "" ""</seg>
<seg id="907">"" "" "" "29. an intensification of the insulin therapy with a abrupt improvement of blood sugar, however, may be associated with a temporary deterioration of diabetic retinopathy." "" "" ""</seg>
<seg id="908">"" "" "" "some patients suffering from hypoglycemic reactions after a change from animal on human insulin, reported that the early warning symptoms of a hypoglycemia were less pronounced than in their previous insulin." "" "" ""</seg>
<seg id="909">36 Soviet hypoglycaemia as well as hyperglycemia which may occur in an unsufficient controlled diet therapy can increase the risk of abnormalities and fertility in utero.</seg>
<seg id="910">37 "" "" "" "37 An intensification of the insulin therapy with a abrupt improvement of blood sugar, however, may be associated with a temporary deterioration of diabetic retinopathy." "" "" ""</seg>
<seg id="911">44. hypoglycaemia as well as hyperglycemia which can occur in a sufficiently controlled diet therapy and increase the risk of abnormalities and fertility in utero.</seg>
<seg id="912">"" "" "" "45. an intensification of the insulin therapy with a abrupt improvement of blood sugar, however, may be associated with a temporary deterioration of diabetic retinopathy." "" "" ""</seg>
<seg id="913">"" "" "" "some patients suffering from hypoglycemic reactions after a change from animal on human insulin, reported that the early warning symptoms of a hypoglycemia were less pronounced than in their previous insulin." "" "" ""</seg>
<seg id="914">52. hypoglycaemia as well as hyperglycemia that can occur in an unsufficient controlled diet therapy can increase the risk of abnormalities and fertility in utero.</seg>
<seg id="915">53 A intensity of insulin therapy with a abrupt improvement of blood sugar settings may be associated with a temporary deterioration of diabetic retinopathy.</seg>
<seg id="916">The injection units must be prepared before the injection that the tin control is driven to zero and does a insulin drops at the head of the injection nadel.</seg>
<seg id="917">"" "" "" "59 patients whose blood sugar may significantly improve due to intensified insulin therapy, the hypoglycaemia should be perceived and should be advised accordingly." "" "" ""</seg>
<seg id="918">"" "" "" "both hypoglycemia and hyperglycemia, which can occur in a sufficiently controlled diet therapy, increase the risk of abnormalities and fertility in utero." "" "" ""</seg>
<seg id="919">"" "" "" "however, an intensification of the insulin therapy with a abrupt improvement of blood sugar may be associated with a temporary deterioration of diabetic retinopathy." "" "" ""</seg>
<seg id="920">Diseases of the immune system Gelegally - Urtikaria, Exanthem Very rarely - anaphylactic reactions including neutralised skin rash, fungal problems, respiratory diseases, low blood pressure and impotence / awareness.</seg>
<seg id="921">"" "" "" "these manufacturing pens may only be used together with products, which are compatible with them and ensure a safe and effective functioning of the fabrication." "" "" ""</seg>
<seg id="922">"" "" "" "it is recommended - after taken out of Actraphane Novolet from the refrigerator - to increase the temperature of the insulin at room temperature (not above 25 ° C), before it is implemented for the first use." "" "" ""</seg>
<seg id="923">"" "" "" "67 patients whose blood sugar may significantly improve due to intensified insulin therapy, the hypoglycaemia should be perceived and should be advised accordingly." "" "" ""</seg>
<seg id="924">"" "" "" "75 patients whose blood sugar may significantly improve due to intensified insulin therapy, the hypoglycaemia should be perceived and should be advised accordingly." "" "" ""</seg>
<seg id="925">"" "" "" "83 patients whose blood sugar may significantly improve due to intensified insulin therapy, the hypoglycaemia should be perceived and should be advised accordingly." "" "" ""</seg>
<seg id="926">"" "" "" "for example, 91 patients whose blood sugar may significantly improve due to intensified insulin therapy, hypoglycemia should be perceived and should be advised accordingly." "" "" ""</seg>
<seg id="927">"" "" "" "99 patients whose blood sugar may significantly improve due to intensified insulin therapy, the hypoglycaemia should be perceived and should be advised accordingly." "" "" ""</seg>
<seg id="928">"" "" "" "any change in terms of strength, brand (manufacturer), insulin type (fast acting, bipolar) and / or production method (by recombinant DNA compared to insulin,) can result in a change of dosage." "" "" ""</seg>
<seg id="929">"" "" "" "it is recommended - after Actraphane Innolet is taken from the refrigerator - to increase the temperature of the insulin at room temperature (not above 25 ° C), before it is implemented for the first use." "" "" ""</seg>
<seg id="930">"" "" "" "it is recommended - after Actraphane FlexPen is taken from the refrigerator - to increase the temperature of the insulin at room temperature (not above 25 ° C), before it is implemented for the first use." "" "" ""</seg>
<seg id="931">"" "" "" "at the packing site of the drug, name and address of the manufacturer, which is responsible for the release of the appropriate Charge." "" "" ""</seg>
<seg id="932">Store in the refrigerator (2 ˚ C - 8 ˚ C) Not into the box in the box to protect the content from light After: not in the refrigerator or above 25 ° C</seg>
<seg id="933">Subcutaneous application Penfill cartridges are intended for use with insulin injections of Novo Nordisk and comply with the instructions for resussioning package age. Actraphane 10 Penfill may only be used by one person</seg>
<seg id="934">Store in the refrigerator (2 ˚ C - 8 ˚ C) Not to freeze the cylinder in the box to protect the content from light After: not in the refrigerator or above 30 ° C</seg>
<seg id="935">Subcutaneous application Penfill cartridges are intended for use with insulin injections of Novo Nordisk and comply with the instructions for resussioning package age. Actraphane 20 penfill may only be used by one person</seg>
<seg id="936">Subcutaneous application Penfill cartridges are intended for use with insulin injections of Novo Nordisk and comply with the instructions for resussioning package age. Actraphane 30 Penfill may only be used by one person</seg>
<seg id="937">Subcutaneous application Penfill cartridges are intended for use with insulin injections of Novo Nordisk. note the procedure for resussioning package age. Actraphane 40 Penfill may only be used by one person</seg>
<seg id="938">Subcutaneous application Penfill cartridges are intended for use with insulin injections of Novo Nordisk and comply with the instructions for resussioning package age. Actraphane 50 Penfill may only be used by one person</seg>
<seg id="939">Subcutaneous application For use with Actraphane 10 Novolet are intended for use with Actraphane 10 NovoLet's procedure of procedure for resussioning package age. Actraphane 10 Novolet may only be used by one person</seg>
<seg id="940">Store in the refrigerator (2 ˚ C - 8 ˚ C) Not to light in the fridge or at over 30 ° C</seg>
<seg id="941">Subcutaneous application For use with Actraphane 20 Novolet are intended for use with Actraphane 20 Novolet's procedure of procedure for resussioning package age. Actraphane 20 Novolet may only be used by one person</seg>
<seg id="942">Subcutaneous application For use with Actraphane 30 Novolet are intended for use with Actraphane 30 Novolet's procedure of procedure for resussioning package age. Actraphane 30 Novolet may only be used by one person</seg>
<seg id="943">Subcutaneous application For use with Actraphane 40 Novolet are intended to comply with Actraphane 40 NovoLet's procedure of procedure for resussioning package age. Actraphane 40 Novolet may only be used by one person</seg>
<seg id="944">Subcutaneous application For use with Actraphane 50 Novolet are intended to comply with Actraphane 50 NovoLet's procedure of procedure for compendency passes Actraphane 50 Novolet may only be used by one person</seg>
<seg id="945">Subcutaneous utilisation For use with Actraphane 30 Innolet are intended for use with Actraphane 30 Innolet. noodphane 30 Innolet shall only be used by one person</seg>
<seg id="946">"" "" "" "this means that around half an hour after you applied it, your blood sugar begins to decline and that the effect lasts approximately 24 hours." "" "" ""</seg>
<seg id="947">► If you are allergic to this isinproduct, metacresol or other components (see Section 7 Other information).</seg>
<seg id="948">"" "" "" "consider the symptoms of an allergy ► If you feel first signs of hypoglycemia, symptoms of an allergy." "" "" ""</seg>
<seg id="949">"" "" "" "if your doctor has caused a change from a insulin or brand to another, you may have to adjust the dose by your doctor." "" "" ""</seg>
<seg id="950">► You check if the rubber type is appealed to the correct insulin type. the rubber compound is detected with a medical tester.</seg>
<seg id="951">If this is not totally unhurt if you have been put through the barrel into your pharmacy. if it was not stored correctly in or frozen (see 6 How is Actraphane?) ► If it is not transparent after the resusement is not transparent and cloudy.</seg>
<seg id="952">Use the injection technology which recommended you your doctor or your Diabetesadviser ► If your skin has been injected at least 6 seconds under your skin to ensure that the total dose was injected.</seg>
<seg id="953">"" "" "" "suddenly the warning signs of a substitution can occur suddenly and can be: cold sweat, cold water, nausea, severe hunger, dizziness, anxiety, fearfulness, fearfulness, depression, concentration difficulties." "" "" ""</seg>
<seg id="954">"" "" "" "tell your relative, friends and close colleagues that you bring in the case of awareness into the stable lateral position and immediately have to communicate a doctor." "" "" ""</seg>
<seg id="955">"" "" "" "► If a severe substitution will not be treated to you or drink it, if you have not treated any serious accidental damage or even to death, if you had a subroutine with awareness or frequently appearing, look for your doctor." "" "" ""</seg>
<seg id="956">"" "" "" "you can regain your consciousness faster if the hormone is Glucagon, a person who is familiar with its gift." "" "" ""</seg>
<seg id="957">"" "" "" "this can happen: • If you are injected to much insulin, if you have too little eating or meal, if you need more than usual physically." "" "" ""</seg>
<seg id="958">Increased urinary bladder, thirst, loss of appetite, nausea or vomiting; dry skin and fruity (after acetone) rieching breath.</seg>
<seg id="959">• You have a insulin injunction • repeating less insulin when you need an infection or fever • more food than usual • less physical exercise than usual.</seg>
<seg id="960">"" "" "" "if you often have an injection on the same spot, this point can shrink to the skin fatty tissue (Lipatrophy) or increase (Lipohydrates trophie)." "" "" ""</seg>
<seg id="961">"" "" "" "if you notice Deeds or thickenings of your skin at the injection site, your doctor may affect your doctor or your diabetate advice if you have injected in such a place." "" "" ""</seg>
<seg id="962">"" "" "" "search a doctor if you immediately feel uncomfortable, or if you feel uncomfortable and you have sweat breaks, nausea (vomiting), respiratory sufferings or you have the impression you are unconscious." "" "" ""</seg>
<seg id="963">"" "" "" "you may possibly have a very rare allergic reaction to actraphane, or one of its constituents (a so-called systemic allergic reaction)." "" "" ""</seg>
<seg id="964">"" "" "" "if one of the common side effects are significantly impaired or you may notice any side effects listed in this manual information, please inform your doctor, your dietary advice or your pharmacist." "" "" ""</seg>
<seg id="965">What Actraphane 30 contains - The substance is produced by recombinant DNA technology produced insulin (30% as a soluble insulin and 70% as Isophan-insulin).</seg>
<seg id="966">Like Actraphane and content of the pack The injection suspension is delivered as cloudy, white and aqueous suspension into packs of 10 ml or 5 ml bottles of 5 ml bottles of 10 ml per 10 ml.</seg>
<seg id="967">Use the injection technology which recommended you your doctor or your Diabetesadviser ► If your skin has been injected at least 6 seconds under your skin to ensure that the total dose was injected.</seg>
<seg id="968">"" "" "" "it is recommended - after being taken out of the refrigerator - the temperature of the flow bottle to room temperature, before the insulin is compensated for the first use." "" "" ""</seg>
<seg id="969">Like Actraphane and content of the pack The injection suspension is delivered as cloudy, white and aqueous suspension into packs of 10 ml or 5 ml bottles of 5 ml bottles of 10 ml per 10 ml.</seg>
<seg id="970">► Read more about the label if it is about the right insulin type. check always the penetration of the pendulum including the elastic crust (Stopfen).</seg>
<seg id="971">Do not use it when any damage is visible or a gap between the rubber piston and the white bond of the label is visible.</seg>
<seg id="972">Further information can be taken from the operating instruction of your insulin injector. ► Use the rubber compound with a medical tupfer. ► You always use a new injections to avoid contamination.</seg>
<seg id="973">► Consular in insulin injections ► If the pendent or the unit contains if it has been dropped is damaged or broken down is the danger of the expiry of insulin (see 6 How is Actraphane?) ► If it is not transparent or clouded after the resustice.</seg>
<seg id="974">"" "" "" "if you are treated with Actraphane 10 Penfill and another insulin injector, you should use two insulin injections according to one for each insulin-type." "" "" ""</seg>
<seg id="975">Before using the cartridge to the insulin injections procedure you move at least 20 times between positions a and b and off (see figure) so that the glass spheres move from one end of the cartridge to the other.</seg>
<seg id="976">Use the injection system which has been recommended to help you your doctor or your Diabetesadviser for at least 6 seconds under your skin in order to remove and avoid the full dose and maintain Actraphane without being smoked injections.</seg>
<seg id="977">183 do you put your relative, friends and close colleagues that you bring in the case of awareness into the stable lateral position and have to be able to communicate a doctor immediately.</seg>
<seg id="978">• You have a insulin injunction • repeating less insulin when you need an infection or fever • more food than usual • less physical exercise than usual.</seg>
<seg id="979">"" "" "" "if one of the common side effects are significantly impaired or you may notice any side effects listed in this manual information, please inform your doctor, your dietary advice or your pharmacist." "" "" ""</seg>
<seg id="980">"" "" "" "it is recommended - after being taken out of the refrigerator - the temperature of the penetration on ambient temperature, before the insulin is compensated for the first use." "" "" ""</seg>
<seg id="981">"" "" "" "185 Preserve the cartridges always in the box, if you do not use them to protect them from light." "" "" ""</seg>
<seg id="982">What Actraphane 10 contains - The substance is produced by recombinant DNA technology produced insulin humane (10% as a soluble insulin and 90% as Isophan-insulin).</seg>
<seg id="983">Such as Actraphane and content of the pack The injection suspension is delivered as cloudy, white, aqueous suspension into packs of 1, 5 or 10 cartridges to 3 ml each.</seg>
<seg id="984">Further information can be taken from the operating instruction of your insulin injector. ► Use the rubber compound with a medical tupfer. ► You always use a new injections to avoid contamination.</seg>
<seg id="985">"" "" "" "in case you are treated with Actraphane 20 penfill and another insulin injector, you should use two insulin injections according to one for each insulin-type." "" "" ""</seg>
<seg id="986">"" "" "" "189 Give your relative, friends and close working workmates that they bring you in the case of awareness into the stable lateral position and immediately have to communicate a doctor." "" "" ""</seg>
<seg id="987">"" "" "" "if one of the common side effects are significantly impaired or you may notice any side effects listed in this manual information, please inform your doctor, your dietary advice or your pharmacist." "" "" ""</seg>
<seg id="988">"" "" "" "191 Maintaines the cartridges always in a box if you do not use them to protect them from light." "" "" ""</seg>
<seg id="989">What Actraphane 20 contains - The substance is produced by recombinant DNA technology produced insulin humane (20% as a soluble insulin and 80% as Isophan-insulin).</seg>
<seg id="990">Such as Actraphane and content of the pack The injection suspension is delivered as cloudy, white, aqueous suspension into packs of 1, 5 or 10 cartridges to 3 ml each.</seg>
<seg id="991">Further information can be taken from the operating instruction of your insulin injector. ► Use the rubber compound with a medical tupfer. ► You always use a new injections to avoid contamination.</seg>
<seg id="992">"" "" "" "if you are treated with Actraphane 30 Penfill and another insulin injector, you should use two insulin injections according to one for each insulin-type." "" "" ""</seg>
<seg id="993">"" "" "" "195 Sing your relative, friends and close colleagues that you bring in the case of awareness into the stable lateral position and immediately have to communicate a doctor." "" "" ""</seg>
<seg id="994">"" "" "" "if one of the common side effects are significantly impaired or you may notice any side effects listed in this manual information, please inform your doctor, your dietary advice or your pharmacist." "" "" ""</seg>
<seg id="995">197 Beware the cartridges always in a box if you don't use them to protect them from light.</seg>
<seg id="996">"" "" "" "manufacturers The manufacturer can be identified based on the batches marking, which is printed on the lid and printed on the label:" "" "" ""</seg>
<seg id="997">"" "" "" "if at the second and third place of the batches designation W5, S6, P5, K7 or ZF appears, the manufacturer Novo Nordisk A / S, Novo Allé, DK- 2880 Bagsvaerd, Denmark" "" "" ""</seg>
<seg id="998">"" "" "" "if at the second and third place of the batches designation H7 or T6, the manufacturer Novo Nordisk Production SAS, 45, Avenue d'Orléans, F-28002 Chartres, France." "" "" ""</seg>
<seg id="999">Further information can be taken from the operating instruction of your Insul Ininjects system. ► Use the rubber compound with a medical tupfer. ► You always use a new injections to avoid contamination.</seg>
<seg id="1000">"" "" "" "if you are treated with Actraphane 40 Penfill and another insulin injector, you should use two insulin injections according to one for each insulin-type." "" "" ""</seg>
<seg id="1001">"" "" "" "201 Sit at your relatives, friends and close colleagues that you bring in the case of awareness into the stable lateral position and immediately have to communicate a doctor." "" "" ""</seg>
<seg id="1002">"" "" "" "if one of the common side effects are significantly impaired or you may notice any side effects listed in this manual information, please inform your doctor, your dietary advice or your pharmacist." "" "" ""</seg>
<seg id="1003">"" "" "" "203 Maintaines the cartridges always in the box, if you do not use them to protect them from light." "" "" ""</seg>
<seg id="1004">What Actraphane 40 contains - The substance is produced by recombinant DNA technology produced insulin humane (40% as a soluble insulin and 60% as Isophan-insulin).</seg>
<seg id="1005">Further information can be taken from the operating instruction of your Insul Ininjects system. ► Use the rubber compound with a medical tupfer. ► You always use a new injections to avoid contamination.</seg>
<seg id="1006">"" "" "" "if you are treated with Actraphane 50 Penfill and another insulin injector, you should use two insulin injections according to one for each insulin-type." "" "" ""</seg>
<seg id="1007">Before using the penetration of the penetration into the insulin injections procedure you move at least 20 times between positions a and b (see figure) so that the glass spheres move from one end of the cartridge to the other.</seg>
<seg id="1008">"" "" "" "207 Give your relative, friends and narrow workmates that they bring you in the case of awareness into the stable lateral position and immediately have to communicate a doctor." "" "" ""</seg>
<seg id="1009">"" "" "" "if one of the common side effects are significantly impaired or you may notice any side effects listed in this manual information, please inform your doctor, your dietary advice or your pharmacist." "" "" ""</seg>
<seg id="1010">209 Keeps the cartridges always in the box if you don't use it to protect them from light.</seg>
<seg id="1011">What Actraphane 50 contains - The substance is produced by recombinant DNA technology produced insulin (50% as a soluble insulin and 50% as Isophan-insulin).</seg>
<seg id="1012">"" "" "" "oral antidiabetics (ACE) inhibitors, acetylsalicylic acid, anabolic steroids, sulfa drugs, sulfa drugs, growth hormone, Danazol, Octreotid or Lanoxy oxide." "" "" ""</seg>
<seg id="1013">► How to check if it is the correct insider type? please always use a new injections to avoid any injection of contamination.</seg>
<seg id="1014">► Enhance in insulin injections ► If the Novolet slip is left or wound is there is the danger of the expiry of insulin (see 6 How is Actraphane?) ► If it is not transparent and cloudy after the resultation process.</seg>
<seg id="1015">"" "" "" "suddenly the warning signs of a substitution can occur suddenly and can be: cold sweat, cold water, nausea, severe hunger, dizziness, anxiety, fearfulness, fearfulness, depression, concentration difficulties." "" "" ""</seg>
<seg id="1016">"" "" "" "214 When one of the common side effects are given significantly, or you may notice any side effects listed in this manual information, please inform your doctor, your dietary advice or your pharmacist." "" "" ""</seg>
<seg id="1017">"" "" "" "in use, Novoferro finished and those who are to be used shortly or as a substitute must not be kept in the refrigerator." "" "" ""</seg>
<seg id="1018">"" "" "" "it is recommended - after being taken out of the refrigerator - the temperature of Novolet's finished place to rise, before the insulin is compensated for the first use." "" "" ""</seg>
<seg id="1019">"" "" "" "don't miss the closing of your NovoLet skills, if Novolet is not in use to protect the insulin against light." "" "" ""</seg>
<seg id="1020">Such as Actraphane and content of the pack The injection suspension is delivered as cloudy, white, aqueous suspension in packs of 5 or 10 finished pens to 3 ml each.</seg>
<seg id="1021">"" "" "" "prior to each injection, check if there are still at least 12 units insulin for the cartridge that ensure a uniform mix." "" "" ""</seg>
<seg id="1022">"" "" "" "to avoid the injection of air, avoid the injection of air and avoid correct dosage: • Keep Actraphane 10 Novolet with the injection nadel up • knock a few times with the finger easily against the cartridge." "" "" ""</seg>
<seg id="1023">If air bubbles are present on the top of the cartridge (Figure C) · While you hold Actraphane 10 NovoLet the cartridge will continue in the direction of the arrow (Figure D) • Take a drop of insulin out of the tip of the injection pin (Figure D).</seg>
<seg id="1024">• Put the closing plate back so on the finishing line so that the number 0 is standing opposite the metering brand (Figure E) • Check it if the snap button is completely impregnable.</seg>
<seg id="1025">"" "" "" "if not, rotate the closing plate, until the print knob has been completely pressed • Keep your Actraphane 10 Novolet horizontally." "" "" ""</seg>
<seg id="1026">"" "" "" "when the print button does not move freely to the outside, insulin is pressed in the injection valve • The scale is shown on the seductus folder 0, 2, 4, 6, 8, 16, 16, 16 and 18 units." "" "" ""</seg>
<seg id="1027">"" "" "" "the print knob moves to the outside, while you turn the closing plate - the scale below is 20, 40 and 60 units." "" "" ""</seg>
<seg id="1028">"" "" "" "check the selected dose - note the number on the score mark • In case you can set the maximum number you set on the print knob, drop the sludge folder simply or backwards until you have set the right number to units." "" "" ""</seg>
<seg id="1029">"" "" "" "otherwise, insulin is removed from the injection and the stated dose will not be correct, if you have attempted to hire a dose of more than 78 units, perform the following steps:" "" "" ""</seg>
<seg id="1030">"" "" "" "then take the closing plate, and set it up so again that the 0 of the metering brand stands opposite." "" "" ""</seg>
<seg id="1031">"" "" "" "to press the button on the print button, wait for the injection on the print button until the injection is pulled out of the skin until the injection was removed." "" "" ""</seg>
<seg id="1032">"" "" "" "if not, turn the closing plate, until the print knob has been completely immined and then proceed as in front of the use • Possibly listen to a clickering sound when pressing the button." "" "" ""</seg>
<seg id="1033">"" "" "" "it may be unaccurate • You can do no dose, which is higher than the number of remaining numbers remaining in the cartridge, how much insulin is still left." "" "" ""</seg>
<seg id="1034">"" "" "" "oral antidiabetics (ACE) inhibitors, acetylsalicylic acid, anabolic steroids, sulfa drugs, sulfa drugs, growth hormone, Danazol, Octreotid or Lanoxy oxide." "" "" ""</seg>
<seg id="1035">"" "" "" "224 If any of the effects listed you have significantly impaired or you may notice any side effects listed in this manual information, please inform your doctor, your Diabetesadviser or your pharmacist." "" "" ""</seg>
<seg id="1036">226 "" "" "" 226 In front of any injection • Check if there are still at least 12 units insulin for the cartridge, ensuring a smooth mixture. "" "" "" "</seg>
<seg id="1037">"" "" "" "to avoid the injection of air, avoid the injection of air and avoid correct dosage: • Keep Actraphane 20 Novolet with the injection nadel up • knock a few times with the finger easily against the cartridge." "" "" ""</seg>
<seg id="1038">If air bubbles are present on the top of the cartridge (Figure C) · While you hold Actraphane 20 NovoLet the cartridge will continue in the direction of the arrow (Figure D) • Take a drop of insulin out of the tip of the injection pin (Figure D).</seg>
<seg id="1039">"" "" "" "if not, turn the closing plate, until the print knob has been completely pressed • Keep your Actraphane 20 Novolet horizontally." "" "" ""</seg>
<seg id="1040">"" "" "" "oral antidiabetics (ACE) inhibitors, acetylsalicylic acid, anabolic steroids, sulfa drugs, sulfa drugs, growth hormone, Danazol, Octreotid or Lanoxy oxide." "" "" ""</seg>
<seg id="1041">"" "" "" "234 If any of the common side effects have you significantly impaired or you may notice any side effects listed in this manual information, please inform your doctor, your Diabetesadviser or your pharmacist." "" "" ""</seg>
<seg id="1042">"" "" "" "236 In front of any injection • Check if there are still at least 12 units insulin for the cartridge, ensuring a smooth mixture." "" "" ""</seg>
<seg id="1043">"" "" "" "to avoid the injection of air, avoid the injection of air and avoid correct dosage: • Keep Actraphane 30 Novolet with the injection nadel up • knock a few times with the finger easily against the cartridge." "" "" ""</seg>
<seg id="1044">If air bubbles are present on the top of the cartridge (Figure C) · While you hold Actraphane 30 Novolet the cartridge will continue to look inside (Figure D) • Take a drop of insulin out of the tip of the injection pin (Figure D).</seg>
<seg id="1045">"" "" "" "if not, turn the closing plate, until the print knob has been completely pressed • Keep your Actraphane 30 Novolet horizontally." "" "" ""</seg>
<seg id="1046">"" "" "" "oral antidiabetics (ACE) inhibitors, acetylsalicylic acid, anabolic steroids, sulfa drugs, sulfa drugs, growth hormone, Danazol, Octreotid or Lanoxy oxide." "" "" ""</seg>
<seg id="1047">"" "" "" "244 If any of these effects listed you have significantly impaired or you may notice any side effects listed in this manual information, please inform your doctor, your dietary advice or your pharmacist." "" "" ""</seg>
<seg id="1048">"" "" "" "246 In front of any injection • Check if there are still at least 12 units insulin for the cartridge, ensuring a smooth mixture." "" "" ""</seg>
<seg id="1049">"" "" "" "to avoid the injection of air, avoid the injection of air and avoid correct dosage: • Keep Actraphane 40 Novolet with the injection nadel up • knock a few times with the finger easily against the cartridge." "" "" ""</seg>
<seg id="1050">If air bubbles are present on the top of the cartridge (Figure C) · While you hold Actraphane 40 NovoLet the cartridge will continue in the direction of the arrow (Figure D) • Take a drop of insulin out of the tip of the injection pin (Figure D).</seg>
<seg id="1051">"" "" "" "if not, turn the closing plate, until the print knob has been completely pressed • Keep your Actraphane 40 Novolet horizontally." "" "" ""</seg>
<seg id="1052">"" "" "" "oral antidiabetics (ACE) inhibitors, acetylsalicylic acid, anabolic steroids, sulfa drugs, sulfa drugs, growth hormone, Danazol, Octreotid or Lanoxy oxide." "" "" ""</seg>
<seg id="1053">"" "" "" "254 If any of the common side effects you have significantly impaired or you may notice any side effects listed in this manual information, please inform your doctor, your dietary advice or your pharmacist." "" "" ""</seg>
<seg id="1054">"" "" "" "it is recommended - after being taken out of the refrigerator - the temperature of Novolet's finished place to rise, before the insulin is compensated for the first use." "" "" ""</seg>
<seg id="1055">"" "" "" "256 Before the injection, check if there are still at least 12 units insulin for the cartridge that ensure an even mixture." "" "" ""</seg>
<seg id="1056">"" "" "" "to avoid the injection of air, avoid the injection of air and avoid correct dosage: • Keep Actraphane 50 Novolet with the injection nadel up • knock a few times with the finger easily against the cartridge." "" "" ""</seg>
<seg id="1057">If air bubbles are present on the top of the cartridge (Figure C) · While you hold Actraphane 50 NovoLet the cartridge will continue in the direction of the arrow (Figure D) • Take a drop of insulin out of the tip of the injection pin (Figure D).</seg>
<seg id="1058">"" "" "" "if not, rotate the closing plate, until the print knob has been completely pressed • Keep your Actraphane 50 Novolet horizontally." "" "" ""</seg>
<seg id="1059">"" "" "" "oral antidiabetics (ACE) inhibitors, acetylsalicylic acid, anabolic steroids, sulfa drugs, sulfa drugs, growth hormone, Danazol, Octreotid or Lanoxy oxide." "" "" ""</seg>
<seg id="1060">► How the inominfusion pumps ► If the inox is dropped if it was discarded or broken down is the danger of the expiry of insulin (see 6 How is Actraphane?) ► If it is not transparent and cloudy after the resultation process.</seg>
<seg id="1061">"" "" "" "suddenly the warning signs of a substitution can occur suddenly and can be: cold sweat, cold water, nausea, severe hunger, dizziness, anxiety, fearfulness, fearfulness, depression, concentration difficulties." "" "" ""</seg>
<seg id="1062">"" "" "" "264 If any of the common side effects have you significantly impaired or you may notice any side effects listed in this manual information, please inform your doctor, your dietary advice or your pharmacist." "" "" ""</seg>
<seg id="1063">"" "" "" "in use, Innolet finished and those who are used shortly or as a substitute must not be kept in the refrigerator." "" "" ""</seg>
<seg id="1064">"" "" "" "it is recommended - after being taken out of the refrigerator - the temperature of the inlet process to rise, before the insulin is compensated for the first use." "" "" ""</seg>
<seg id="1065">"" "" "" "don't miss the closing of your inlet skills, if Innolet is not in use to protect the insulin." "" "" ""</seg>
<seg id="1066">"" "" "" "like Actraphane and content of the pack The injection suspension is delivered as clouded, white, aqueous suspension into packs of 1, 5 or 10 finished pens to 3 ml each." "" "" ""</seg>
<seg id="1067">"" "" "" "the movement must be repeated until the liquid is evenly and cloudy, after ResusEncoding you perform all the following steps of injections without delay." "" "" ""</seg>
<seg id="1068">• Detect the rubber membrane with a medical tupfer • use the protective surface from a NovoFine S injections • screw the injections of a NovoFine S Innolet (Figure 1B) • Pull out the large outer injection valve and the internal injector switch.</seg>
<seg id="1069">"" "" "" "• always check if the snap is fully impregnated and the tin control is set to zero, adjust the number of units that you need to be injected by turning the tin control in clockwise (figure 2)." "" "" ""</seg>
<seg id="1070">Do not use the residues scale for measuring your insulin dose • You can hear a click noise for each single unit.</seg>
<seg id="1071">"" "" "" "lead the injections, which your doctor has shown to you • Enter your dosage, by pressing the push button in full press (Figure 3)." "" "" ""</seg>
<seg id="1072">"" "" "" "the Dosage regulator is set to zero, and you can not stall at least 6 seconds in order to ensure that the full insulin regulator must be reset when injection valve can be put down to zero if you are using the injection regulator." "" "" ""</seg>
<seg id="1073">Medical staff, family members and other staff must consider general precautions concerning removal and disposal of injections to avoid unintended stitches with the injection of inaction.</seg>
<seg id="1074">"" "" "" "oral antidiabetics (ACE) inhibitors, acetylsalicylic acid, anabolic steroids, sulfa drugs, sulfa drugs, growth hormone, Danazol, Octreotid or Lanoxy oxide." "" "" ""</seg>
<seg id="1075">► How the flexinfusion pumps ► if the Flexpen has been dropped out of damage or crushing it is made up of the expiry of insulin (see 6 How is Actraphane?) ► If it is not transparent and cloudy after the resultation process.</seg>
<seg id="1076">"" "" "" "if you notice Deeds or thickenings of your skin at the injection site, your doctor may affect your doctor or your diabetate advice if you have injected in such a place." "" "" ""</seg>
<seg id="1077">"" "" "" "274 If any of these effects listed you have significantly impaired or you may notice any side effects listed in this manual information, please inform your doctor, your dietary advice or your pharmacist." "" "" ""</seg>
<seg id="1078">"" "" "" "in use of flexpen manufacturing and those, which are used shortly or as a replacement, are not stored in the refrigerator." "" "" ""</seg>
<seg id="1079">"" "" "" "it is recommended - after being taken out of the refrigerator - the temperature of the fleece prepens to room temperature, before the insulin is compensated for the first use." "" "" ""</seg>
<seg id="1080">"" "" "" "don't set the closing plate of your fleece prepens, if fleece is not in use to protect the insulin against light." "" "" ""</seg>
<seg id="1081">"" "" "" "like Actraphane and content of the pack The injection suspension is delivered as clouded, white, aqueous suspension into packs of 1, 5 or 10 finished pens to 3 ml each." "" "" ""</seg>
<seg id="1082">"" "" "" "manufacturers The manufacturer can be identified based on the batches marking, which is printed on the lid and printed on the label:" "" "" ""</seg>
<seg id="1083">"" "" "" "275 • If the second and third place of the batches is called the combination of W5, S6, P5, K7 or ZF is the manufacturer Novo Nordisk Production SAS, 45, Avenue d'Orléans, F- 28002 Chartres, France." "" "" ""</seg>
<seg id="1084">B "" "" "" B "" "" "" "" B Beets the finished place between positions 1 and 2 twenty times, so that the glass spheres move from one end to the cylinder to the other. "" "" "" "</seg>
<seg id="1085">"" "" "" "move the finished bags at least 10 times between positions 1 and 2 and down, until the liquid appears alike and cloudy." "" "" ""</seg>
<seg id="1086">"" "" "" "• To reduce the risk of accidental needles, you never put the inner cover back to the injection, after you have taken it once." "" "" ""</seg>
<seg id="1087">"" "" "" "279 G Hold the flexpen with the injection nadel upward and knock a few times with the finger, to collect an existing air bubbles up in the cartridge." "" "" ""</seg>
<seg id="1088">"" "" "" "the dose can be corrected both upwards and downwards, by turning the desired dose into the appropriate direction until the correct dose is faced with the marking." "" "" ""</seg>
<seg id="1089">"" "" "" "the present document is a summary of the European Public Fund (EPAR), in which explains how the Committee for Human Use (CHMP) evaluates the studies with regard to recommendations concerning the application of the medication." "" "" ""</seg>
<seg id="1090">"" "" "" "the most attractive component in Actrapid, insulin, human (rDNA), is produced with the procedure of so-called" recombinant technology ":" "" "" ""</seg>
<seg id="1091">(44-20) 74 18 84 00 M. (44-20) 74 18 86 68 E-mail: mail @ emea.europa.eu © EMEA 2007 Reproduction and / or distribution of this document is Authorised for non business. only the EMEA is.</seg>
<seg id="1092">Actrapid may not be applied in patients who may possibly be sensitive to insulin (rDNA) or other components.</seg>
<seg id="1093">"" "" "" "in addition, the doses of Actrapid may be adapted, if it is administered together with a number of other medicines that can affect the blood sugar." "" "" ""</seg>
<seg id="1094">"" "" "" "in October 2002, the European Commission approved the company Novo Nordisk A / S for the placing of Actrapid throughout the European Union." "" "" ""</seg>
<seg id="1095">"" "" "" "when two types of insulin are mixed, first the amount of the fast acting insulin must be removed, then the amount of a long-effective insulin." "" "" ""</seg>
<seg id="1096">"" "" "" "3 If a dose adjustment is necessary when the patient is required, the dose may be necessary during the first dose or months after the conversion." "" "" ""</seg>
<seg id="1097">"" "" "" "before travelling, over several time zones, the patient should be advised to take the Council of his medical remedy because such trips can lead to other times that insulin and meals must be applied or taken." "" "" ""</seg>
<seg id="1098">"" "" "" "5 General disorders and complaints at the administration of vests in the injection site While the insulin therapy can occur local hypersensitivity, swelling, itching, pain and hematoma on the injection site)." "" "" ""</seg>
<seg id="1099">"" "" "" "therefore, diabetics should always have grape variety, sweets, cookies, or sugar-sugars with an intramuscular or subcutaneous injection of the glucose or subcutaneous injection of gluten or by glucose to be given intravenously through the doctor." "" "" ""</seg>
<seg id="1100">A clinical trial in an intensive care unit to treat hyperglycemia (blood sugar over 10 mmol / l) with 204 diabetic and 1344 non-diabetic patients (blood sugar) induced significantly by 42% (8% vs 4.6%).</seg>
<seg id="1101">"" "" "" "the effect starts within half an hour, the maximum amount is reached within 1.5 to 3.5 hours and the total amount of active duration is approximately 7 to 8 hours." "" "" ""</seg>
<seg id="1102">Children and adolescents The pharmacokinetic profile of Actrapid was examined at a smaller number (n = 18) diabetic children (aged between 6 and 12) and adolescence (aged between 13 and 17).</seg>
<seg id="1103">"" "" "" "the data is limited, however, however, make the adoption possible that the pharmacokinetic profile is similar in children and adolescents from adults." "" "" ""</seg>
<seg id="1104">Infusion systems with Actrapid in concentrations 0,05-E. / ml - 1.0 I.U. of sodium chloride, 5% D-glucose and 10% D- Glucose and 40% D- Glucose out of polypropylene at room temperature for 24 hours.</seg>
<seg id="1105">"" "" "" "11 If a dose adjustment to the patient is necessary, the dose may be necessary during the first dose or months after the conversion." "" "" ""</seg>
<seg id="1106">"" "" "" "before travelling, over several time zones, the patient should be advised to take the Council of his medical remedy because such trips can lead to other times that insulin and meals must be applied or taken." "" "" ""</seg>
<seg id="1107">"" "" "" "13 General disorders and complaints at the administration of vests in the injection site While the insulin therapy can occur local hypersensitivity, swelling, itching, pain and hematoma on the injection site)." "" "" ""</seg>
<seg id="1108">"" "" "" "therefore, diabetics should always have grape variety, sweets, cookies, or sugar-sugars with an intramuscular or subcutaneous injection of the glucose or subcutaneous injection of gluten or by glucose to be given intravenously through the doctor." "" "" ""</seg>
<seg id="1109">Children and adolescents The pharmacokinetic profile of Actrapid was examined at a smaller number (n = 18) diabetic children (aged between 6 and 12) and adolescence (aged between 13 and 17).</seg>
<seg id="1110">"" "" "" "intravenous application of acetpid or cartridges should be an exception, and only in situations where no chisels are available." "" "" ""</seg>
<seg id="1111">"" "" "" "in case of change to Actrapid during the patient a dose adjustment is necessary, this can be necessary during the first dose or months after the conversion." "" "" ""</seg>
<seg id="1112">21 Diseases of the skin and the lower tissue injury - Lipodocyrophy On the injection site may result in a lipodystrophy when it comes to switch inside the injection area.</seg>
<seg id="1113">Children and adolescents The pharmacokinetic profile of Actrapid was examined at a smaller number (n = 18) diabetic children (aged between 6 and 12) and adolescence (aged between 13 and 17).</seg>
<seg id="1114">29 Diseases of the skin and the lower tissue injury - Lipodocyrophy On the injection site may result in a lipodystrophy when it comes to switch inside the injection area.</seg>
<seg id="1115">Diseases of the immune system Gelegally - Urtikaria, Exanthem Very rarely - anaphylactic reactions including neutralised skin rash, fungal problems, respiratory diseases, low blood pressure and impotence / awareness.</seg>
<seg id="1116">Children and adolescents The pharmacokinetic profile of Actrapid was examined at a smaller number (n = 18) diabetic children (aged between 6 and 12) and adolescence (aged between 13 and 17).</seg>
<seg id="1117">Diseases of the immune system Gelegally - Urtikaria, Exanthem Very rarely - anaphylactic reactions including neutralised skin rash, fungal problems, respiratory diseases, low blood pressure and impotence / awareness.</seg>
<seg id="1118">38 A clinical trial in an intensive care unit to treat hyperglycemia (blood sugar over 10 mmol / l) with 204 diabetic and 1344 non-diabetic patients (blood sugar) induced significantly by 42% (8% vs 4.6%).</seg>
<seg id="1119">Diseases of the immune system Gelegally - Urtikaria, Exanthem Very rarely - anaphylactic reactions including neutralised skin rash, fungal problems, respiratory diseases, low blood pressure and impotence / awareness.</seg>
<seg id="1120">46 A clinical trial in an intensive care unit to treat hyperglycemia (blood sugar over 10 mmol / l) with 204 diabetic and 1344 non-diabetic patients (blood sugar) induced significantly by 42% (8% vs 4.6%).</seg>
<seg id="1121">Store in the fridge (2 ° C - 8 ° C) Not to freeze The bottle of the box in order to protect the content from light After: not in the refrigerator or above 25 ° C</seg>
<seg id="1122">Subcutaneous application Penfill cartridges are intended for use with Novo Nordisk insulin injector systems. please note Actrapid Penfill may only be used by a person</seg>
<seg id="1123">Store in the refrigerator (2 ° C - 8 ° C) Don't freeze the cylinder in the box to protect the contents from light after dawn: not in the refrigerator or above 30 ° C</seg>
<seg id="1124">Subcutaneous application For use with Actrapid Novolet NovoFine injection nappies foresees Actrapid Novolet may only be used by one person</seg>
<seg id="1125">Store in the fridge (2 ° C - 8 ° C) Not to freeze light after freezing: do not store in the refrigerator or above 30 ° C</seg>
<seg id="1126">Subcutaneous application For use with Actrapid Innolet are intended for use with Actrapid Innolet Amtrapid Innolet may only be used by one person</seg>
<seg id="1127">"" "" "" "this means that around half an hour after you applied it, your blood sugar begins to sink and that the effect lasts approximately 8 hours." "" "" ""</seg>
<seg id="1128">► You check if you are using the correct insulin type. ► How to disinfect the rubber membrane with a medical tester.</seg>
<seg id="1129">If this is not totally unhurt if you have the cold bottle back to your pharmacy. if it was not stored properly or frozen (see 6 How is Actrapid to retain?) ► If it does not look like water and colourless.</seg>
<seg id="1130">Use the injection technology which recommended you your doctor or your Diabetesadviser ► If your skin has been injected at least 6 seconds under your skin to ensure that the total dose was injected.</seg>
<seg id="1131">83 "" "" "" "83 Give your relative, friends and close working workmates that they bring you into the case of awareness into the stable lateral position and immediately have to communicate a doctor." "" "" ""</seg>
<seg id="1132">"" "" "" "you may possibly have a very rare allergic reaction to acetpid, or any of its components (an so-called systemic allergic reaction)." "" "" ""</seg>
<seg id="1133">The injection solution is supplied as clear and colorless, aqueous solution in packs of 1 or 5 continuous bottles of 10 ml or a bundle pack of 5 ml bottles each 10 ml.</seg>
<seg id="1134">"" "" "" "89 Sing your relative, friends and close colleagues that you bring in the case of awareness into the stable lateral position and immediately have to communicate a doctor." "" "" ""</seg>
<seg id="1135">► Read more about the label if it is about the right insulin type. check the cartridge including the gumshield including the elasticity.</seg>
<seg id="1136">► Enhance in insulin injections ► If the pendent or the unit contains if it has been dropped is damaged or broken; it is made up of the expiry of insulin.) ► If it is not clear like water and colourless.</seg>
<seg id="1137">"" "" "" "in case you are treated with Actrapid Penfill and another insulin injector, you should use two insulin injections according to one for each insulin-type." "" "" ""</seg>
<seg id="1138">Use the injection system which has been recommended to help you your doctor or your Diabetesadviser for at least 6 seconds under your skin in order to ensure that the total dose is injected by using it and to entate and maintain Actrapid without being smoked injections.</seg>
<seg id="1139">"" "" "" "• If the second and third place of the batches are called the combination of W5, S6, P5, K7 or ZF is the manufacturer Novo Nordisk A / S, Novo Allé, DK-2880 Bagsvaerd, Denmark" "" "" ""</seg>
<seg id="1140">"" "" "" "• If the second and third place of the batches are called the character combination H7 or T6, the manufacturer Novo Nordisk Production SAS, 45, Avenue d'Orléans, F- 28002 Chartres, France." "" "" ""</seg>
<seg id="1141">"" "" "" "oral antidiabetics (ACE) inhibitors, acetylsalicylic acid, anabolic steroids, sulfa drugs, sulfa drugs, growth hormone, Danazol, Octreotid or Lanoxy oxide." "" "" ""</seg>
<seg id="1142">► You check if you are using the correct insulin type. ► You always use a new injections to avoid any injection of contamination.</seg>
<seg id="1143">► Enhance in insulin injections ► If the Novolet slip is left or wound up; it is made up of the expiry of insulin (see 6 How is Actrapid to retain?) ► If it is not clear how water and colourless.</seg>
<seg id="1144">"" "" "" "this can happen: • If you are injected to much insulin, if you have too little eating or meal, if you want to use more than usual" "" "" ""</seg>
<seg id="1145">"" "" "" "don't miss the closing of your NovoLet skills, if it is not in use to protect it from light." "" "" ""</seg>
<seg id="1146">"" "" "" "• Take out the rubber compound with a medical tester, using a new injections of a NovoFine injection system (Figure A) • Apply the large outer cap with the injection nadel and the inner cap of the injection nadel." "" "" ""</seg>
<seg id="1147">"" "" "" "to avoid the injection of air, avoid the injection of air and avoid correct dosage: • Stay Actrapid Novolet with the injection nadel upward • knock a few times with the finger easily against the cartridge." "" "" ""</seg>
<seg id="1148">"" "" "" "when air bubbles are present, these changes will continue to accumulate in the cartridge (Figure B) • While the injection line indicates the arrow (Figure C) • Apply a drop of insulin." "" "" ""</seg>
<seg id="1149">• Put the closing plate back so on the finishing line so that the number 0 is standing opposite the metering brand (Figure D) • Check it if the snap button is completely impregnable.</seg>
<seg id="1150">"" "" "" "when the print button does not move freely, insulin is pressed in the injection valve • The scale on the seductus folder shows 0, 2, 4, 6, 8, 12, 16, 16 and 18 units." "" "" ""</seg>
<seg id="1151">"" "" "" "the print knob moves to the outside, while you turn the closing plate - the scale below the print knob (print knob) shows 20, 40 and 60 units." "" "" ""</seg>
<seg id="1152">"" "" "" "107 • Notice the highest number you can see on the printed quantity • In case you have set up a wrong dose, turn the closing tag simply or backwards until you have set the right number to units." "" "" ""</seg>
<seg id="1153">"" "" "" "turn it down until the print knob is down and you feel the dashing out, and place it so again that the 0 of the metering brand stands opposite." "" "" ""</seg>
<seg id="1154">"" "" "" "to press the button on the ink by injection, pay attention to the pressure button, until the injection die was pulled out of the skin until the injection head has been drawn." "" "" ""</seg>
<seg id="1155">"" "" "" "it may be unaccurate • You can use no dose, which is higher than the number of remaining in the cartridge that is higher, but you can't use it to stop or select your dose." "" "" ""</seg>
<seg id="1156">"" "" "" "oral antidiabetics (ACE) inhibitors, acetylsalicylic acid, anabolic steroids, sulfa drugs, sulfa drugs, growth hormone, Danazol, Octreotid or Lanoxy oxide." "" "" ""</seg>
<seg id="1157">► How the inominfusion pumps ► if the inlet let fall has been loosed or broken; it is made up of the expiry of insulin (see 6 How is Actrapid to retain?) ► If it is not clear how water and colourless.</seg>
<seg id="1158">"" "" "" "don't miss the closing of your inlet skills, if it is not in use to protect it from light." "" "" ""</seg>
<seg id="1159">• Detect the rubber membrane with a medical tupfer • use the protective surface from a NovoFine S injector. • Carrying out the protective tube straight and firmly on Actrapid Innolet (Figure 1A) • toes the large outer cap of the injection nadel and the inner cap of the injection nadel.</seg>
<seg id="1160">"" "" "" "the Dosage regulator is set to zero, and you can not stall at least 6 seconds in order to ensure that the full insulin control must be injected under the skin when using the injection valve • remove the injection adjustment according to any injection." "" "" ""</seg>
<seg id="1161">"" "" "" "oral antidiabetics (ACE) inhibitors, acetylsalicylic acid, anabolic steroids, sulfa drugs, sulfa drugs, growth hormone, Danazol, Octreotid or Lanoxy oxide." "" "" ""</seg>
<seg id="1162">"" "" "" "121 ► If it was not kept correctly, or frozen (see 6 How is Actrapid retained?) ► If it looks not clear how water and colourless." "" "" ""</seg>
<seg id="1163">"" "" "" "if one of the common side effects are significantly impaired or you may notice any side effects listed in this manual information, please inform your doctor, your dietary advice or your pharmacist." "" "" ""</seg>
<seg id="1164">"" "" "" "don't miss the closing of your flexo flaws whenever it is not in use, to protect it from light." "" "" ""</seg>
<seg id="1165">"" "" "" "F Keep the Flexpen with the injection nadel upward and knock a few times with the finger, to collect an existing air bubbles up in the cartridge." "" "" ""</seg>
<seg id="1166">"" "" "" "the dose can be corrected both upwards and downwards, by turning the desired dose into the appropriate direction until the correct dose is on the mark of the dose indicator." "" "" ""</seg>
<seg id="1167">Adenisic is used in patients who have already used signs of crystalline rock including arthritis (pain and inflammation in joints) or ginal nodes ("stones" i.e. bigger primitive crystalliances that can lead to joint and bone damage).</seg>
<seg id="1168">"" "" "" "if the uric acid level is still over 6 mg per month, the dose may be increased to 120 mg once a day." "" "" ""</seg>
<seg id="1169">"" "" "" "during the first therapy months, still ginal attacks may occur; therefore, patients are recommended for at least during the first six months of treatment with Adenosic drugs." "" "" ""</seg>
<seg id="1170">"" "" "" "the medicine is not recommended in children and in patients who had an organ transplant, because it was not studied for those groups." "" "" ""</seg>
<seg id="1171">In the first study on which 1 072 patients participated in the effectiveness of three Adenosic doses (once daily 80, 120 and 240 mg) compared to a placebo (pseudovein) and from Allopurinol (a different drug for treatment of hyperurant).</seg>
<seg id="1172">"" "" "" "in the second study, two doses of adenuric (once daily 80 and 120 mg) were compared to 762 patients with Allopurinol each year." "" "" ""</seg>
<seg id="1173">"" "" "" "in both trials, Allopurinol was applied in a dose of 300 mg once daily; patients with kidney problems received only 100 mg per day." "" "" ""</seg>
<seg id="1174">"" "" "" "the main indicator for efficacy was the number of patients whose uric acid was under 6 mg / dl in the last three measurements." "" "" ""</seg>
<seg id="1175">"" "" "" "in the first study 48% (126 of 262) of patients, Adenosic in a dose of once daily 80 mg of patients, administered at once daily 120 mg, with the last three measurements of the blood of under 6 mg / l." "" "" ""</seg>
<seg id="1176">"" "" "" "in comparison, this was at 22% (60 of 268) of patients under Allopurinol and in no one of the 134 patients under Placebo." "" "" ""</seg>
<seg id="1177">The most common adverse events of adenabic (observed at 1 to 10 of 100 patients) are headaches, diarrhea and nausea. nausea and normal liver values.</seg>
<seg id="1178">"" "" "" "especially in patients with cardiovascular problems in prehistory, possibly a higher risk of certain side effects that affect the heart and blood vessels." "" "" ""</seg>
<seg id="1179">"" "" "" "finally, the Committee on Human Use (CHMP) reached the conclusion that Adenosic acid was more effective than alompurinol, but also a higher risk of side effects in connection with the heart and blood vessels." "" "" ""</seg>
<seg id="1180">Treatment of chronic hypertension in diseases that have already led to urine deposits (including one from the patient's history known or present prescription and / or arthritis).</seg>
<seg id="1181">If the serum acid is still under 2-4 weeks even more &gt; 6 mg / dl (357 µnl / l) can be considered as an increase of a dose of dose to ADENURIC 120 mg once daily.</seg>
<seg id="1182">"" "" "" "in patients with severe kidney failure, efficacy and safety were not fully examined until now (Kreatinine Clearance &lt; 30 ml / min, see Section 5.2)." "" "" ""</seg>
<seg id="1183">"" "" "" "children and adolescents, since there are no experiences with children and youths, the use of Febuxostat is not recommended in this patient group." "" "" ""</seg>
<seg id="1184">Organ transplantation Since there is no experiences with organ transplants when the application of Febuxostat in this patient group is not recommended (see section 5.1).</seg>
<seg id="1185">"" "" "" "in patients with ischemia heart disease, cardiovascular disease, the treatment with Febuxostat is not recommended (see Section 4.8)." "" "" ""</seg>
<seg id="1186">"" "" "" "as with other harnleic acid remedies, it can be mobilized during the treatment beginning, because the lowering of the serum acid level may initially be mobilized in the tissue." "" "" ""</seg>
<seg id="1187">B. in malignant diseases and their treatment, Lesh- Nyhan-syndrome) the absolute concentration of Xanthin in rare cases is to increase so far that it comes to a relocation in the urine tract.</seg>
<seg id="1188">"" "" "" "during clinical trials during Phase 3, slight upligible assets were observed in patients treated with Febuxostat (3.5%)." "" "" ""</seg>
<seg id="1189">It is therefore recommended to carry out before the beginning of the Febuxostatine and in subsequent course of clinical trials (see Section 5.1).</seg>
<seg id="1190">"" "" "" "theophylline Twas not performed intrinsic studies on Febuxostat, but it is known that XO inhibiting can lead to a rise in theophylline spike (a inhibiting of theophylline) is also reported to other XO inhibitors)." "" "" ""</seg>
<seg id="1191">Subjects were associated with Febuxostat and Naproxen 250 mg 2 times a day with an increase of the Febuxostatams (Cmax 28% and AUC 41% and t1 / 2 26%).</seg>
<seg id="1192">"" "" "" "in clinical trials, the use of naproxen or other NSAR / Cox-2 inhibitors did not stand in connection with a clinically significant increase of adverse events." "" "" ""</seg>
<seg id="1193">Colchicin / hydrochlorthiazide / Warfarin Febuxostat can be applied together with colchicin or Indometacin. without that a dose adjustment for febuxostat or at the same time applied other active substance is required.</seg>
<seg id="1194">In a study with subjects subjects 120 mg ADENURIC 1 x a daily 22% increase in AUC of Desipramin, a CYP2D6 substrate which indicates the CYP2D6-enzyme within vivo.</seg>
<seg id="1195">Antazida It could be shown that the simultaneous intake of an antacids containing magnesium hydroxide and aluminium hydroxide (about 1 hour) and caused a reduction of the Cmax. 32%, but no significant change in AUC causes.</seg>
<seg id="1196">Pregnancy data on a very limited number of exposed pregnancies can not be excluded from side effects of Febuxostat upon the pregnancy or the health of the fetus / newborns.</seg>
<seg id="1197">"" "" "" "experimental studies can not include direct or indirect harmful effects on pregnancy, embryonic / fetal development or birth (see paragraph 5.3)." "" "" ""</seg>
<seg id="1198">"" "" "" "patients should be careful at the control of a vehicle, serve machines or in the exercise of dangerous activities, until they can not be certain that ADENURIC is not affected your performance." "" "" ""</seg>
<seg id="1199">In comparison with the Allopurinol Group in comparison with the Allopurinol Group in comparison with the Allopurinol Group in the Pivotal study (1,4 vs. 0,7 events per 100 patient period) and in long term renewal studies were found and no significant correlation with Febuxostat could be found.</seg>
<seg id="1200">The risk factors associated with these patients were an arterial erotic disease and / or a myocardial infarction or a decompensated heart failure in the patient story.</seg>
<seg id="1201">Common (≥ 1 / 100 to &lt; 1 / 100) and rare (≥ 1 / 10.000 to &lt; 1 / 100) and rare (≥ 1 / 1000 mg Febuxostat) and that were reported in all Febuxostat treatment groups more than once reported there are listed below.</seg>
<seg id="1202">Diarrhoea, nausea and vomiting are more common in patients who are simultaneously treated with colchicine. * * In clinical trials were observed no severe skin reactions or heavy impact actions.</seg>
<seg id="1203">7 Offering long-term renewal studies in the open long-term renewal studies ranged from 906 patients up to 1 year long and 53 patients up to 3 years long and 53 patients treated with Febuxostat 80 mg / 120 mg.</seg>
<seg id="1204">"" "" "" "the events related during the long-term renewal studies were similar to those related to phase 3 studies (see table 1)." "" "" ""</seg>
<seg id="1205">The following treatment-related events were reported in all Febuxo stat- treatment groups in a total of more than once and appeared in patients who received febuxostat 80 mg / 120 mg with exposure time of &gt; 1.900 patient years) according to the study.</seg>
<seg id="1206">"" "" "" "the following treatment options were reported in the Pivotal Studies of Phase 3, either at all or with a lower frequency:" "" "" ""</seg>
<seg id="1207">"" "" "" "type of diabetes, hyperlipidemia, insomnia, cerebinsufficiency, heart disease, kidney disease, increase in potassium concentration in blood, increase in lymphocytes, decline in the number of white blood cells." "" "" ""</seg>
<seg id="1208">Active mechanism of uric acid is the final product of the Purintoxicism and is formed within the framework of the reaction line Hypoxanthin → Xanthin → Xanthin →</seg>
<seg id="1209">Febuxostat is a powerful, not Purin-selective inhibitor of the XO (NP-SIxO) with an Ki-value for in vitro inhibition.</seg>
<seg id="1210">Clinical study results The efficacy of ADENURIC was described in two pivotal studies phase 3 (APEX study and FACT study as described below) that were performed using 1.832 patients with hyperurikaemia and poison.</seg>
<seg id="1211">"" "" "" "primary efficacy endpoint was in every study of patients, where the last three month sales of serum under 6.0 mg / l (357 µnl / l) were included." "" "" ""</seg>
<seg id="1212">Placebo (n = 134); ADENURIC 80 mg 1 x daily (n = 269), ADENURIC 240 mg 1 x daily (n = 269) for patients with serum increment of study of &gt; 1.5 mg / l and ≤ 2.0 mg / l.</seg>
<seg id="1213">The APEX study showed that the statistically significant superiority of less than 6 mg / l (357 µnl / l) (see table 2 and Figure 1) proved the statistically significant difference in the treatment with conventional doses of Allopurinol 300 mg (n = 258) / 100 mg (n = 10).</seg>
<seg id="1214">"" "" "" "with regard to the lasting lowering of the metabolism of serum acid levels below 6 mg / l (357 µmol / l), the statistically significant lesuperiority as well as with ADENURIC 120 mg 1 x daily compared to the treatment with the conventional used dose Allopurinol 300 mg." "" "" ""</seg>
<seg id="1215">Patients with serum cancer values &gt; 1.5 and ≤ 2.0 mg / dl) or 300 mg 1 x daily (n = 509) received samples for analyses. * p &lt; 0.0001 versus Allopurinol, # p &lt; 0.0001 versus 80 mg</seg>
<seg id="1216">The lowering of the serum acid level at &lt; 6.0 mg / l (357 µnl / l) was observed at the physician attendance in week 2 and maintain permanently over the entire treatment.</seg>
<seg id="1217">509 patients received alabpurinol 300 mg 1 x daily; 10 patients with serum increment &gt; 1.5 and &lt; 2.0 mg / dl received 100 mg 1 x daily.</seg>
<seg id="1218">Primary endpoint in the subgroup of patients with kidney function restriction The APEX study evaluated the efficacy of 40 patients with kidney failure (d.).</seg>
<seg id="1219">With ADENURIC the primary efficacy endpoint was achieved at 44% (80 mg 1 x daily) and 60% (120 mg 1 x daily) and 60% (240 mg 1 x daily) of patients achieved.</seg>
<seg id="1220">There were no clinically significant differences regarding the percentage of serum harmacular acid concentrations in the group (58% in the group with normal kidney function and 55% in the group with severe kidney disorders).</seg>
<seg id="1221">The primary endpoint in the subgroup of patients with serum harassular congestion ≥ 10 mg / dl) about 40% of patients (APEX- and FACT study) had a serum concentration of ≥ 10 mg / l.</seg>
<seg id="1222">The data collected in two years of the open renewal study during phase 3 showed that less than 3% of patients resulting in the incidence of disease (i.e. more than 97% of patients had taken no treatment for a contamination).</seg>
<seg id="1223">This was associated with a reduction of the toxicity file resulting in 54% of patients a complete disappearance of the toxin notes up to the month 24.</seg>
<seg id="1224">Increased TSH- Values (&gt; 5.5 µW / ml) were observed in patients who received a long-term treatment with Febuxostat (5.0%) and received in the open long-term renewal studies (see Section 4.4).</seg>
<seg id="1225">The maximum plasma concentrations of Plasmasturostat (Cmax) and the area under the Plasmakonzentration time curve (AUC) from Febuxostat to administration was simpler and multiple doses ranging from 10 mg to 120 mg dosistically.</seg>
<seg id="1226">"" "" "" "for doses of 120 mg and 300 mg is observed for febuxostat an increase in AUC, which is larger than the dosed increase." "" "" ""</seg>
<seg id="1227">"" "" "" "after taking a simpler or multiple oral dosages of 80 and 120 mg, the Cmax is 2.8-3.2 µg / ml and 5,0-5.3 µg / ml." "" "" ""</seg>
<seg id="1228">"" "" "" "however, no clinically significant change in the percentage reduction of serum harmacular concentration was observed (multiple doses of 80 mg)." "" "" ""</seg>
<seg id="1229">Distribution The apparent Steady state distribution volume (Vss / F) from Febuxostat lies in the range from 29 to 75 l after taking part of doses of 10-300 mg.</seg>
<seg id="1230">"" "" "" "the plasma selection of Febuxostat amounts to around 99.2% (primary binding to Albumin) and is reached over the concentration width, with doses of 80 and 120 mg is constant." "" "" ""</seg>
<seg id="1231">In vitro studies in human liver microsomes showed that these oxidative metabolites are formed primarily by CYP1A1, CYP1A2 and CYP2C9, 1A8 and 1A9.</seg>
<seg id="1232">After taking an 80 mg dose of 14C-markedly Febuxostat (3%) the dose in the urine is found (30%) and acetabulostat of the active substance (30%) and its known metabolism (13%) as well as further unknown metabolites (3%).</seg>
<seg id="1233">In addition to the excretion of urine over the urine is also about 45% of the dose in the chair known as unchanging Febuxostat (12%) and acetylene metabolism (25%) and known metal metabolism (7%) as well as further unknown metabolites (7%).</seg>
<seg id="1234">Special patient groups kidney failure after taking multiple doses of 80 mg ADENURIC in patients with slight, moderate or severe congenital heart failure the Cmax of Febuxostat did not change in proportion to subjects with normal kidney function.</seg>
<seg id="1235">The mean overall AUC from Febuxostat increased about 1,8 m / ml in the group with normal kidney function to 13,2 μ g / ml in the group with severe kidney function.</seg>
<seg id="1236">12 liver damage after taking multipler doses of 80 mg ADENURIC in patients with lighter (Child- Pugh-classification B) of liver damage changed the Cmax and AUC of Febuxostat and its metabolites not significantly change significantly compared to subjects with normal liver function.</seg>
<seg id="1237">Age There were no significant changes regarding AUC from Febuxostat or its metabolites after taking multidimensional doses of ADENURIC in older patients compared to younger subjects.</seg>
<seg id="1238">"" "" "" "carcinogenesis, mutagenesis, impairment of fertilization. a statistically significant increase in urea bladder and carcinomas increased only in connection with Xanthin-stones in the highly dosed group, with about 11 times exposure to human exposure." "" "" ""</seg>
<seg id="1239">These findings are seen as a result of a specific Purinmetabolization and urine composition and considered not relevant for clinical use.</seg>
<seg id="1240">It has been noted that Febuxostat has no effect on fertility and reproduction capacity of male and female rats.</seg>
<seg id="1241">"" "" "" "at high doses, which were about 4,3-times of the human therapeutic exposure, the maternal toxicity occurred, resulting in lowering the performance and development delay in rats." "" "" ""</seg>
<seg id="1242">"" "" "" "Teratological studies with tracing rats with expositions, which approximately the 4.3 times and in supporting rabbits with expositions indicated about the 13-times of human-therapeutic exposure, resulted in no teratogenic properties." "" "" ""</seg>
<seg id="1243">Colchicin / hydrochlorthiazide / Warfarin Febuxostat can be applied together with colchicin or Indometacin. without that a dose adjustment for febuxostat or at the same time applied other active substance is required.</seg>
<seg id="1244">Diarrhoea, nausea and vomiting are more common in patients who are simultaneously treated with colchicine. * * In clinical trials were observed no severe skin reactions or heavy impact actions.</seg>
<seg id="1245">"" "" "" "21 patients with Febuxostat 80 mg / 120 mg were treated with Febuxostat 80 mg / 120 mg for up to 2 years in the open long-term renewal studies." "" "" ""</seg>
<seg id="1246">"" "" "" "primary efficacy endpoint was in every study of patients, where the last three month sales of serum under 6.0 mg / l (357 µnl / l) were included." "" "" ""</seg>
<seg id="1247">The data collected in two years of the open renewal study during phase 3 showed that less than 3% of patients resulting in the incidence of disease (i.e. more than 97% of patients had taken no treatment for a contamination).</seg>
<seg id="1248">26 as unchanging Febuxostat (3%), Acylo curonid of active substance (30%) known as well known antioxidant metabolites and their jugate (13%) as well as further unknown metabolites (3%).</seg>
<seg id="1249">Liver function restriction After taking multiple doses of 80 mg ADENURIC in patients with lighter (Child- Pugh-classification B) or moderate (Child-Pugh-classification B) of liver damage changed the Cmax and AUC of Febuxostat and its metabolites not significantly significantly compared to subjects with normal liver function.</seg>
<seg id="1250">"" "" "" "carcinogenesis, mutagenesis, impairment of fertilization. a statistically significant increase in urea bladder and carcinomas increased only in connection with Xanthin-stones in the highly dosed group, with about 11 times exposure to human exposure." "" "" ""</seg>
<seg id="1251">"" "" "" "the holder of approval for the vehicle has been described for sure that a pharmacovigilance system is described as described in version 2.0 module 1.8.1, before the drug is placed in traffic, and so long is the medicine placed in traffic." "" "" ""</seg>
<seg id="1252">A updated RMP is to be submitted to risk management systems according to CHMP Guideline using the next Periodic Safety Update Report (PSUR).</seg>
<seg id="1253">"" "" "" "in addition, an update of the RMP is required if new information exists which have an influence on the safety data, pharmacovigilance or activity for risk reduction (Pharmacovigilance or risk assessment) • on request of the EMEA." "" "" ""</seg>
<seg id="1254">"" "" "" "in some people, the uric acid accumulates in blood and can reach concentrations that are so high that uric acid is insoluble." "" "" ""</seg>
<seg id="1255">"" "" "" "if you keep the uric acid low by using the 1 x daily intake of ADENURIC, the deformation is prevented and in this way a reduction of complaints achieved." "" "" ""</seg>
<seg id="1256">ADENURIC may not be taken when you are hypersensitive (allergic) against the active ingredient Febuxostat or any of the other ingredients of ADENURIC.</seg>
<seg id="1257">"" "" "" "inform your doctor before taking this medicine by taking a heartweakness, or suffering from a high blood problem." "" "" "" • If you suffer from a high urinary disease, or the Lesch Nyhan-syndroms (a rare inborn disorder in the blood). "" "" "" "</seg>
<seg id="1258">"" "" "" "if you have a failure in the moment (sudden occurrence of severe pain, pressure sensitivity, redness, thermal sense and joint swelling), before you start treatment with ADENURIC." "" "" ""</seg>
<seg id="1259">"" "" "" "this doesn't have to be with everyone, but also with you, especially during the first treatment weeks or months, if you are taking ADENURIC." "" "" ""</seg>
<seg id="1260">"" "" "" "your doctor will prescribe other medicines if necessary, to prevent losing sight or to treat the associated symptoms (such as pain and joint swelling)." "" "" ""</seg>
<seg id="1261">"" "" "" "please inform your doctor or pharmacist if you use other medicines consuming / apply / apply recently, even if it is not prescription medicine." "" "" ""</seg>
<seg id="1262">"" "" "" "it is particularly important that you may use your doctor or pharmacist if you use drugs, as interactions with ADENURIC (for treating asthma) • Warranioprine (for treating asthma) • Warfarin (for blood thinner in heart disease)" "" "" ""</seg>
<seg id="1263">"" "" "" "there were no studies on the effects of ADENURIC on the road, and the ability to serve machines." "" "" ""</seg>
<seg id="1264">"" "" "" "therefore, use ADENURIC for consultation with your doctor if you are aware that you suffer from incompatibility to certain sugars." "" "" ""</seg>
<seg id="1265">"" "" "" "on the back of the blister packs, the individual weekdays are printed so that you may check if you have taken a tablet every day and be taken with or without food." "" "" ""</seg>
<seg id="1266">"" "" "" "in case you are intentional taken an overdose, apply to your doctor or to the nearest hospital." "" "" ""</seg>
<seg id="1267">"" "" "" "if you have forgotten the dosage of ADENURIC, get this as soon as possible, unless the next ingestion is shortly before." "" "" ""</seg>
<seg id="1268">"" "" "" "when you break the intake of ADENURIC, your urinary bladder can increase again and your complaints may be worsen because new urine smell can be found in your joints and kidneys as well as their surroundings." "" "" ""</seg>
<seg id="1269">Frequent side effects (more than 1 out of 100 treated but less than 1 out of 10 treated): • obtrusive liver tests • diarrhea • headache • nausea</seg>
<seg id="1270">"" "" "" "rare side effects (more than 1 out of 10,000 treated, but less than 1 out of 1,000 treated): • weakness • Duration • Durtiness" "" "" ""</seg>
<seg id="1271">"" "" "" "please inform your doctor or pharmacist if one of the listed side effects will affect you significantly, or you may notice any side effects listed in this manual information." "" "" ""</seg>
<seg id="1272">ADENURIC is available in 2 blister packages each with 14 tablets (pack of 28 tablets) or in 6 blister packages each with 14 tablets (Pack of 84 tablets).</seg>
<seg id="1273">Pioneers in relationships Ipsen Pharma 24 rue Erlanger F-75781 Paris Cedex 16 France Tél: + 33 - 1 - 44 96 13 13</seg>
<seg id="1274">Danmark, Norge, Suomi / Finland, Sverige, Ísland Institute of production synthèse (IPSEN) AB Kista Sverige / Ruotsi / Ruotsi / Puh / Puh / Puh / Puh / Sími / + 46 8 588 370 70</seg>
<seg id="1275">ADROVANCE is used for the treatment of osteoporosis (a disorder in which the bones are fragile) in women after menopause - in which a risk for a low vitamin D mirror exists.</seg>
<seg id="1276">The patient must take the tablet with a full glass of water (no mineral water) at least 30 minutes before eating, drinking or use other medicines (including Antazida, calcium and vitamin supplements).</seg>
<seg id="1277">"" "" "" "to avoid irritation of the esophagus, the patient must not lie down until after the first dietary intake of the day, which should occur at the earliest 30 minutes after taking the tablet." "" "" ""</seg>
<seg id="1278">"" "" "" "since Alendronate and vitamin D3 are already being separated from other medicines that are approved in the European Union, the company presented data from previous studies and published literature." "" "" ""</seg>
<seg id="1279">"" "" "" "in addition, the company also conducted a study involving 35 men and 682 postmenopausal women with osteoporosis to prove the efficacy of ADROVANCE relating to increasing vitamin D levels." "" "" ""</seg>
<seg id="1280">"" "" "" "after a 15 week treatment, the proportion of patients with low vitamin D levels were treated with ADROVANCE, lower (11%) than those who only have Alendronate revenues (32%)." "" "" ""</seg>
<seg id="1281">"" "" "" "the company also presented data on the Alendronate dose contained in ADROVANCE, which is needed for preventing a bone loss." "" "" ""</seg>
<seg id="1282">The most common adverse events (observed at 1 to 10 of 100 patients) are headaches, pain or joints and symptoms of digestive tract (indigestion), ulcosis (ulcera) of esophagus (ulcereal) as well as suction cups.</seg>
<seg id="1283">ADROVANCE must not be used in patients with any hypersensitivity (allergy) against alendronate, vitamin D3 or other ingredients.</seg>
<seg id="1284">"" "" "" "it must not be applied for diseases of the esophagus, in patients with hypocalcemia (low calcium levels) or patients who can't stand or sit for at least 30 minutes." "" "" ""</seg>
<seg id="1285">"" "" "" "in January 2007, the European Commission granted the company Merck Sharp & Dohme Ltd. it has approval for the shipping of ADROVANCE throughout the European Union." "" "" ""</seg>
<seg id="1286">"" "" "" "capsule form, white to broken white tablets, marked with the outline of a bone on one side and" 710 "on the other side." "" "" ""</seg>
<seg id="1287">ADROVANCE is only with water (not with mineral water) at least 30 minutes before the first meal, beverage or intake of medicines (including Antazida, calcium and vitamin supplements) for the day to take.</seg>
<seg id="1288">The following critics are to be followed exactly to reduce the risk of malophageal irritation and associated side effects (see Section 4.4):</seg>
<seg id="1289">• ADROVANCE is expected to be lured after the end of the day with a full glass of water (at least 200 ml) or the pill is not to be cut off before the first half of the day that should occur at the earliest 30 minutes after taking the tablet.</seg>
<seg id="1290">B. peptic ulcer, active gastrointestinal bleeding or surgical intervention in the upper Gastrointestinal trades except pylorioplasty but only subject to special caution (see Section 4.3).</seg>
<seg id="1291">"" "" "" "initial hagetic reactions, such as Esophagitis, ösophageal Ulzera and malophageal erosions, rarely followed by malophagetic Strictures (sometimes this severe and required a hospital reference) were reported." "" "" ""</seg>
<seg id="1292">"" "" "" "the doctor should therefore respect all signs and symptoms appearing on possible malophageal reactions, such as dysphagie, pain in swallowing or retroferning heartburn and prescribe medical advice (see Section 4.8)." "" "" ""</seg>
<seg id="1293">"" "" "" "3 The risk of serious adverse events seems to be increased in patients who do not take the medicine correctly, and / or after the occurrence of symptoms that refer to a malophageal irritation." "" "" ""</seg>
<seg id="1294">"" "" "" "it is very important that all dosage instructions are passed on to the patient, and can be understood by the patient (see section 4.2)." "" "" ""</seg>
<seg id="1295">"" "" "" "while in large clinical trials with alendronate no increased risk was observed, some severe and Duodenalulcera, among them some severe and with complications, are reported (see Section 4.8)." "" "" ""</seg>
<seg id="1296">"" "" "" "osteoneksis of the jaw, usually in connection with a tooth extraction and / or a local infection (including osteopathy), was reported in cancer patients, containing bisphosphonate." "" "" ""</seg>
<seg id="1297">There are no data available to give notice of whether the Abuse of bisphosphonatotherapy in patients receiving a surgical surgical procedure reduces the risk of osteonecsis of the jaw.</seg>
<seg id="1298">"" "" "" "the clinical assessment by the treated physician is authoritative for therapy planning for each patient based on an individual benefit-risk assessment." "" "" ""</seg>
<seg id="1299">"" "" "" "patients should be dependent on the intake of taking a dose ADROVANCE the tablet in the next morning, after being noticed." "" "" ""</seg>
<seg id="1300">"" "" "" "you should not take two tablets a day, but the intake of one tablet a week, as originally planned at the planned weekday." "" "" ""</seg>
<seg id="1301">Other diseases affecting the mineral metabolism (such as vitamin D deficiency and hypoparathyreoidism) should also be treated adequate before the therapy with ADROVANCE.</seg>
<seg id="1302">"" "" "" "Alendronate food and beverages (including mineral water), calcium supplements, antacids and some oral drugs can affect the absorption of alendronate if they are taken at the same time." "" "" ""</seg>
<seg id="1303">"" "" "" "therefore, patients after taking Alendronate must wait at least 30 minutes before taking other medicines (see sections 4.2 and 5.2)." "" "" ""</seg>
<seg id="1304">"" "" "" "although specific interaction studies were not performed, Alendronate was taken in clinical trials together with a variety of commonly prescribed medicines, without clinically relevant interaction." "" "" ""</seg>
<seg id="1305">ADROVANCE is intended only for application with postmenopausal women and therefore ought to be either avoided by pregnant women or pregnant women.</seg>
<seg id="1306">Animal studies with Alendronate don't allow any clue to recognize directly harmful effects regarding the pregnancy, the embryonic / fetal or postnatal development.</seg>
<seg id="1307">Osteoneksis of the jaw was reported in patients under bisphosphonates; most reports originate from cancer patients but also reported to osteoporosis.</seg>
<seg id="1308">Nevertheless deviations from the serum-calcium to &lt; 8.0 mg / l (2.0 mmol / l) and of the power phosphats up to ≤ 2.0 mg / l (0.65 mmol / l) were observed in both treatment groups with a similar frequency.</seg>
<seg id="1309">"" "" "" "Alendronate as a result of an oral overdose may occur with hypocalcemia, hypophthalatemia and side effects in the upper Gastrointestinal tract, sodonitis, gastritis or ulcera." "" "" ""</seg>
<seg id="1310">Colecalciferol (vitamin D3) is produced in the skin by UV light over the conversion of 7-density levels to vitamin D3.</seg>
<seg id="1311">The main effect of 1.25-Dihydroxygen D3 is the increase of the intestinal absorption of calcium and phosphate as well as the regulation of calcium calcium and the renal excretion of calcium and phosphate.</seg>
<seg id="1312">"" "" "" "in severe cases, a deficiency could lead to secondary hyperparathyreoidism, hypophonist, weaknesses of the proximal musculature and osteomalazie and thus further increased risk for apron and bone quarries in osteoporosis persons." "" "" ""</seg>
<seg id="1313">Bone mineral density) of spinal column or hips equivalent to 2.5 standard deviations under the average value for a normal and young population or irregardless of the density of the present pathological Fraktur formed.</seg>
<seg id="1314">The patients received ADROVANCE in lower thickness (70 mg / 2.800 I.U.) (n = 350) or FOSAMAX (n = 332) once a week (n = 332); additional vitamin D supplements were prohibited.</seg>
<seg id="1315">After 15-week treatment the mean serum level of 25-hydroxygen D was significantly higher (26%) in the group under the ADROVANCE (70% / 2.800 I.U.) in the group under Alendronate alone (46 nmol / l [18,2 ng / ml]).</seg>
<seg id="1316">ADROVANCE (70 mg / 2.800 I.U.) significantly reduced the percentage of patients with vitamin D insufficiency (serum of 25-hydroxygen D &lt; 37,5 nmol / l [&lt; 15 ng / ml]) compared to Alendronate alone (12% vs.</seg>
<seg id="1317">Studies with Alendronate once a week 70 mg (n = 519) and Alendronate 10 mg daily (n = 519) and Alendronate 10 mg daily (n = 370) was demonstrated in a one-year multi-multicenter study of postmenopausal women with osteoporosis.</seg>
<seg id="1318">The effects of Alendronate on bone mass and freading incidence of postmenopausal women were studied in two phase III studies of identical design (n = 944) and in the Fraktur-Intervenation Study (FIT: n = 6.459).</seg>
<seg id="1319">In Phase III studies of the middle income of the BMD with Alendronate 10 mg / day in relation to placebo 3 years of 8% to the spinal column; 5.9% at the Femurhas and 7.8% at the upper changer.</seg>
<seg id="1320">"" "" "" "in the group treated with Alendronate, a reduction of 48% (Alendronate 3.2% compared to Plazebo 6.2%) in the proportion of patients experienced one or several spinal cord." "" "" ""</seg>
<seg id="1321">"" "" "" "in the two-year extension of these studies, the BMD of the spinal column and the Trochanter continued to keep the BMD of the Female and the entire body was maintained." "" "" ""</seg>
<seg id="1322">"" "" "" "fit consisted of two placebo-controlled trials per day (5 mg daily for 2 years and then 10 mg daily, either over 1 or 2 years) was taken:" "" "" ""</seg>
<seg id="1323">In this study the daily gift of Alendronate reduced the occurrence of at least 47% (Alendronate 7.9% compared to Plazebo 15.0%).</seg>
<seg id="1324">Resorption was transferred to an intravenous reference dose of alendronate at women 0.64% for doses ranging from 5 to 70 mg after nocturnal Fasting and two hours before enrolment.</seg>
<seg id="1325">The bioavailability adopted in accordance with approximately 0.46% and 0.39% if alendronate had taken one or half an hour before a standardised breakfast.</seg>
<seg id="1326">"" "" "" "in osteoporosis studies, alendronate was effective if at least 30 minutes before the first meal or drinking of the day was taken." "" "" ""</seg>
<seg id="1327">"" "" "" "in healthy subjects, the gift of oral Prednisone (20 mg three times a day) was not a clinically significant change in the oral bioavailability( increase in range from 20% to 44%)." "" "" ""</seg>
<seg id="1328">9 distribution studies in rats have resulted that alendronate is temporarily distributed in turnout tissue by intravenous gift of 1 mg / kg and then divided into the bones or eliminated with urine.</seg>
<seg id="1329">Excretion According to intravenous gift of a single dose of 14C-Alendronate were eliminated about 50% of the radioactive substance within 72 hours with urine and little or no radioactivity was found in the threads.</seg>
<seg id="1330">"" "" "" "after intravenous gift of a single dose of 10 mg, the renal Clearance of Alendronate 71 ml / min and the systemic clearing not exceeded 200 ml / min." "" "" ""</seg>
<seg id="1331">"" "" "" "Alendronate is not excreted over the acid or basic transport system of the kidneys, and therefore it is not assumed that it is influenced by humans the excretion of other medicines." "" "" ""</seg>
<seg id="1332">Resorption In patients with healthy adult volunteers (women and men) after a meal the middle area under the serum concentration curve (AUC0-120 h) for vitamin D3 296.4 ng • h / ml (without considering comogenous vitamin D3-mirror).</seg>
<seg id="1333">The average maximum concentration in serum (Cmax) of vitamin D3 was 5.9 ng / ml and the mediation time until reaching the maximum serum concentration (Tmax) 12 hours.</seg>
<seg id="1334">"" "" "" "Biotransformation vitamin D3 is processed in the liver quickly to 25-hydroxygen D3 hydroxycycline D3, which metabolized organically active form, metabolized." "" "" ""</seg>
<seg id="1335">Excretion of radioactivity-active vitamin D3 in healthy volunteers was the average removal of radioactivity in the urine according to 48 hours 2.4% in the barrels after 4 days 4.9%.</seg>
<seg id="1336">"" "" "" "characteristika with patient preclinical trials have shown that the proportion of alendronate that is not stored in bone, quickly excreted over the urine." "" "" ""</seg>
<seg id="1337">"" "" "" "although there is no clinical data about it, nevertheless the renal elimination of alendronate as in the animal experiments should be reduced in patients with reduced kidney function." "" "" ""</seg>
<seg id="1338">"" "" "" "therefore, in patients with reduced kidney function a slightly increased pain of alendronate in the bone can be expected (see paragraph 4.2)." "" "" ""</seg>
<seg id="1339">"" "" "" "Alendronate Non-clinical data on conventional studies on safety pharmacology, to chronic toxicity, for genotoxicity and for seduced potential, do not recognize any particular hazards for human beings." "" "" ""</seg>
<seg id="1340">"" "" "" "studies in rats showed that the gift of Alendronate was caused by pregnant rats with the appearance of Dystokie, due to the motherhood, was attributable to a hypocalcemia." "" "" ""</seg>
<seg id="1341">Microcrystalline cellulose (E 460) Lactose triglyceride gelatine crooke sodium hydroxyumstearate (E 572) Butylhydroxytoluine (E 572) (E 572) aluminum (E 554)</seg>
<seg id="1342">Etui with sealed aluminum / aluminum blister packs in cartons to 2 (1 Etuis with 2 tablets) and 6 (3 Etuis with 4 tablets) or 40 (10 Etuis with 4 tablets) or 40 (10 Etuis with 4 tablets) tablets.</seg>
<seg id="1343">EU / 1 / 06 / 364 / 002 - 2 tablets of EU / 1 / 06 / 364 / 003 - 6 tablets EU / 1 / 06 / 364 / 004 - 12 pills EU / 1 / 06 / 364 / 004 - 40 tablets</seg>
<seg id="1344">"" "" "" "square-like, white to broken white tablets, marked with the outline of a bone on one side and" 270 "on the other side." "" "" ""</seg>
<seg id="1345">13 • The patients should not lie down after taking part of the ADROVANCE at least 30 minutes. • ADROVANCE should not be taken before bedtime or before the first stop of the day.</seg>
<seg id="1346">"" "" "" "the risk of serious adverse events seems to be increased in patients who do not take the medicine correctly, and / or after the occurrence of symptoms that refer to a malophageal irritation." "" "" ""</seg>
<seg id="1347">"" "" "" "while in large clinical trials with alendronate no increased risk was observed, some severe and Duodenalulcera, among them some severe and with complications, are reported (see Section 4.8)." "" "" ""</seg>
<seg id="1348">18 Colecalciferol (vitamin D3) is produced in the skin by UV light over the conversion of 7-density levels to vitamin D3.</seg>
<seg id="1349">The patients received ADROVANCE in lower thickness (70 mg / 2.800 I.U.) (n = 350) or FOSAMAX (n = 332) once a week (n = 332); additional vitamin D supplements were prohibited.</seg>
<seg id="1350">Vitamin D3 (the amount of vitamin D3 in the higher dose of ADROVANCE) once per week is equal to a 24-week extension study with 619 postmenopausal women with osteoporosis.</seg>
<seg id="1351">After 24-week treatment the mean serum level of 25-hydroxygen D was significantly higher in the 5.600-I.G.I. Group (69 nmol / l [27,6 ng / ml]) than in the 2.800-I.E.-vitamin D3-group (25,5 ng / ml]).</seg>
<seg id="1352">There was no statistically significant difference between treatment groups in patients with hypercalciurie at the end of the 24-week extension.</seg>
<seg id="1353">"" "" "" "- 3.1% on the hips of the hips, take 70 mg once a week or 10 mg daily." "" "" ""</seg>
<seg id="1354">In this study the daily gift of Alendronate reduced the occurrence of at least 47% (Alendronate 7.9% compared to Plazebo 15.0%).</seg>
<seg id="1355">The bioavailability decreased to about 0.46% and 0.39% compared to alendronate one or half an hour before a standardised breakfast</seg>
<seg id="1356">"" "" "" "distribution studies in rats have resulted that alendronate is temporarily distributed in turnout tissue by intravenous gift of 1 mg / kg, but then rapidly disperse in bone or with the urine." "" "" ""</seg>
<seg id="1357">Resorption of healthy adult volunteers (women and men) after nightly fasting and two hours prior to taking a meal the middle area under the serum concentration curve (AUC0-80 h) for vitamin D3 490.2 ng • h / ml (without considering comogenous vitamin D3-mirror).</seg>
<seg id="1358">The average maximum concentration in serum (Cmax) of vitamin D3 was 12.2 ng / ml and the mediation time until reaching the maximum serum concentration (Tmax) 10.6 hours.</seg>
<seg id="1359">"" "" "" "smaller amounts spread in fat and muscle tissue, and are stored as vitamin D3 in order to be emitted later into the cycle." "" "" ""</seg>
<seg id="1360">"" "" "" "vitamin D3 is quickly hydroxycycline and then processed in the kidney to 1,25-Dihydroxygen D3, which metabolized organically active form." "" "" ""</seg>
<seg id="1361">No clues were found on saturation of the capacity of the bone after long-term dose of cumulative intravenous doses of up to 35 mg / kg of animals.</seg>
<seg id="1362">Etui with sealed aluminum / aluminum blister packs in cartons to 2 (1 Etui with 2 tablets), 4 (1 Etuis with 4 tablets) or 40 (10 Etuis with 4 tablets) tablets.</seg>
<seg id="1363">"" "" "" "pharmacovigilance-system The holder of approval for the vehicle has been described certain that a pharmacovigilance system is described as described in Version 2 module 1.8.1, before the drug is placed in traffic, and so long it is distributed in traffic." "" "" ""</seg>
<seg id="1364">Risk management plan The holder of approval for the transaction is committed to conduct studies and further pharmacovigilance activities in the risk management plan (RMP) and its corresponding upgrades in accordance with version 1 module 1.8.2 of the approval document.</seg>
<seg id="1365">A updated RMP is to be submitted to risk management systems according to CHMP Guideline using the next peril Safetey update report (PSUR).</seg>
<seg id="1366">"" "" "" "in addition, an update of the RMP is required - when new information exists which have an influence on safety data, pharmacovigilance or risk activity to achieve important milestones (Pharmacovigilance or minimization) − to the requirements of the EMEA." "" "" ""</seg>
<seg id="1367">"" "" "" "take on the weekday a ADROVANCE tablet as well as before the first meal and drink, and prior to the first food and drink, take the tablet with a full glass of water (not chewing and not noise)." "" "" ""</seg>
<seg id="1368">"" "" "" "maybe you would like to read these later again. • If you have any further questions, please contact your doctor or pharmacist. • This medicine was personally prescribed to you." "" "" ""</seg>
<seg id="1369">"" "" "" "in the following years, the ovaries produce no female hormones, oestrogen, more who help the skeleton of women health." "" "" ""</seg>
<seg id="1370">"" "" "" "the brooks usually arise at the hip, spinal column or the wrist and cannot cause considerable problems as well as bent attitude (" Witwenbuckel.) and a loss of flexibility. "" "" "" "</seg>
<seg id="1371">"" "" "" "ADROVANCE is not only avoids loss of bone mass, but also contributes to reduce bone loss and reduce the risk of spinal and hip breaks." "" "" ""</seg>
<seg id="1372">Stopping the esophagus or swallowing disorders (3) if it is not possible to sit or stand at least 30 minutes if your doctor has noticed that your calcium content is decreased in the blood.</seg>
<seg id="1373">"" "" "" "40 • If you have problems when swallowing or with digestion, • If you have cancer, • if you have chemotherapy or radiation treatment, if you are not routinely used to care." "" "" ""</seg>
<seg id="1374">"" "" "" "these complaints can occur in particular if the patients take the ADROVANCE tablet with a full glass of water, and / or take it again from the expiry of 30 minutes after taking it." "" "" ""</seg>
<seg id="1375">Taking ADROVANCE with other medicines of calcium supplements, antacids and some other medicines to take the effectiveness of ADROVANCE can be disabled at the same time.</seg>
<seg id="1376">"" "" "" "certain medicines or food additives can be hindered the intake of vitamin D contained in the body, including artificial fish fillers, mineral oils, orlistat and cholesterinsensory medicines Cholestyramin and Collowpol." "" "" ""</seg>
<seg id="1377">"" "" "" "please inform your doctor or pharmacist if you use other medicines consuming / apply / apply recently, even if it is not prescription medicine." "" "" ""</seg>
<seg id="1378">"" "" "" "please take this medicine after consultation with your physician, if you know it is known that you suffer from incompatibility to certain sugars." "" "" ""</seg>
<seg id="1379">Please follow the clues 2) (3) and 5) to facilitate the transport of the ADROVANCE tablet in the stomach and to reduce the possible irritation of the esophagus (esophagus - which connects your mouth with the stomach).</seg>
<seg id="1380">(2) Take the ADROVANCE tablet after the first appearance and take it before the intake of any food or beverages as well as prior to taking any other medicines (with or without carbonic acid). • Do not take with mineral water (with or without carbonic acid).</seg>
<seg id="1381">"" "" "" "(3) Do not worry - stay completely upright (sitting, standing or going) - at least 30 minutes after taking the tablet." "" "" ""</seg>
<seg id="1382">"" "" "" "(5) If in case of having trouble or pain when swallowing, pain behind the chest, reuse or deteriorating heartburn, put ADROVANCE and look for your doctor." "" "" ""</seg>
<seg id="1383">(6) Wait after the swallowing of your ADROVANCE tablet for at least 30 minutes before you take your first food, beverages or other medicines such as Antazida (magenta or vitamin) on that day.</seg>
<seg id="1384">"" "" "" "should you accidentally take too many tablets at once, drink a full glass of milk and consult your doctor immediately." "" "" ""</seg>
<seg id="1385">"" "" "" "if you have missed the intake of a tablet, just take one tablet in the next morning, after you noticed your inheritance." "" "" ""</seg>
<seg id="1386">"" "" "" "frequently: • Saures refill; swallowing pains; pain in the breastplate, bleeding or pain or discomfort when swallowing your mouth. digestive problems; diarrhea; diarrhea; diarrhea; deficiency, or headache." "" "" ""</seg>
<seg id="1387">Occasionally: • nausea; vomiting; • irritation and infections of the esophagus (oesophagus) or the mucous membrane; • black or tedious chair; • skin rash; itch's skin.</seg>
<seg id="1388">"" "" "" "after launch the following side effects have been reported (frequency not known): • (rotational) swelling, • fatigue, • jaw problems (osteoneksis) in combination with delayed wound healing and infections, often after pulling the teeth, • swelling of hands or legs." "" "" ""</seg>
<seg id="1389">"" "" "" "43 Again, if you record, what ailments they did when they began, and as long as they did." "" "" ""</seg>
<seg id="1390">"" "" "" "the other components are micro-crystalline cellulose (E 460), lactose, middle-triglyceride, ocrosis, high dispersion silicon, magnesium chloride (corn), and aluminium oxide (E 554)." "" "" ""</seg>
<seg id="1391">The tablets are available in tutuis with sealed aluminium / aluminum blister packs in one of the following packs (1 Etuis with 2 tablets per aluminum blister packs) • 12 tablets (10 Etuis with 4 tablets per aluminum blister packs) • 40 tablets (10 Etuis with 4 tablets per aluminum blister packs).</seg>
<seg id="1392">"" "" "" "in the following years, the ovaries produce no female hormones, oestrogen, more who help the skeleton of women health." "" "" ""</seg>
<seg id="1393">"" "" "" "48 • If you have any allergies if you have problems when swallowing or with digestion, • if you have chemotherapy or radiation treatment, if you are not routinely used to care." "" "" ""</seg>
<seg id="1394">Taking ADROVANCE with other medicines of calcium supplements, antacids and some other medicines to take the effectiveness of ADROVANCE can be disabled at the same time.</seg>
<seg id="1395">"" "" "" "2) Take the ADROVANCE tablet after taking any food or beverages, as well as taking any other medicines with mineral water (with or without carbonic acid). • Do not take with mineral water (with or without carbonic acid)." "" "" ""</seg>
<seg id="1396">"" "" "" "3) Do not lie down - stay completely upright (sitting, standing or going) - at least 30 minutes after taking the tablet." "" "" ""</seg>
<seg id="1397">5) If in case of having trouble or pain when swallowing the pain behind the chest pain or reuse or deteriorating heartburn, use ADROVANCE and look for your doctor.</seg>
<seg id="1398">6) Wait after the swallowing of your ADROVANCE tablet for at least 30 minutes before you take your first food, beverages or other medicines such as Antazida (magenta or vitamin) on that day.</seg>
<seg id="1399">"" "" "" "• (rotary) swingle, • money swelling, • fatigue, • fatigue, • jaw problems (osteoneksis) in combination with delayed wound healing and infections, often after pulling the teeth, • swelling of hands or legs." "" "" ""</seg>
<seg id="1400">"" "" "" "tablets are available in a rectangular, white to broken white tablets, marked with the outline of a bone on one side and" 270 "on the other side." "" "" ""</seg>
<seg id="1401">"" "" "" "advances is given to adult patients, to which a kidney or liver was transplanted to prevent a loss of transplanted organ by the immune system." "" "" ""</seg>
<seg id="1402">"" "" "" "since Tacrolimus and Prograf / Programmer is already used in the EU, the company has presented the results from previously carried out studies using Prograf / Programmer, as well as data from published literature." "" "" ""</seg>
<seg id="1403">"" "" "" "furthermore, the results of a clinical study of 668 patients were presented with kidney transplantation which was compared with Prograf / Prograf or Ciclosporin." "" "" ""</seg>
<seg id="1404">"" "" "" "the main indicative of the efficacy was the number of patients with which the transplant was crashed after a treatment duration of one year (by example, a re-transplant transplant or a reacting of dialysis was necessary)." "" "" ""</seg>
<seg id="1405">"" "" "" "in addition, more recent studies of 119 patients with kidney transplantation and 129 patients were performed with liver transplantation and examined as Advantf in comparison to Prograf / Prograft from the body." "" "" ""</seg>
<seg id="1406">"" "" "" "tremor (cittern), headaches, nausea / vomiting, diarrhea (hyperglycaemia), diabetes, increased potassium content of blood (hypertension) and insomnia (Insomnia)." "" "" ""</seg>
<seg id="1407">"" "" "" "in patients with fat sensitivity (allergy) against tacrolimus, macrolid antibiotics (such as erythromycin) or one of the other ingredients may not be applied." "" "" ""</seg>
<seg id="1408">"" "" "" "patients and doctors will be careful when others (especially several herbal) medicines are taken at the same time with advances, since the advent dose may be adapted accordingly." "" "" ""</seg>
<seg id="1409">"" "" "" "hard capsules, retardly yellow-orange gelatine capsules, printed in red ink on the light yellow capsule part with" 4,647 "; they contain white powder." "" "" ""</seg>
<seg id="1410">"" "" "" "only physicians who are familiar with the immunosursive therapy and treatment of transplantation patients, should prescribe medicine or make changes in immunossuppressive therapy." "" "" ""</seg>
<seg id="1411">"" "" "" "due to clinically relevant differences of the systemic exposure of tacrolimus, this may lead to graft shocks or to an increased incidence of side effects, including under- or overimmune system." "" "" ""</seg>
<seg id="1412">Patients should always keep the same tacrolimus formulation and appropriate daily dosage; rendition of the formulation or regime should only be performed under the narrowful control of a medical doctor's transplantation (see sections 4.4 and 4.8).</seg>
<seg id="1413">"" "" "" "in a result of conversion to an alternative formulation, a therapeutic pharmaceutical surveillance and appropriate dose adjustment must be carried out to ensure that the systemic exposure of tacrolimus can remain." "" "" ""</seg>
<seg id="1414">"" "" "" "advances should be primarily based on clinical assessment of impouring and tolerability in individual cases, and on blood levels (see below" Recommendations "" "" "" "</seg>
<seg id="1415">"" "" "" "after conversion from Prograf to Advagraf, the Tacrolimus talents should be controlled before switching and over two weeks after conversion." "" "" ""</seg>
<seg id="1416">"" "" "" "on Day 4 the systemic exposure was measured with both formulations, with both formulls and leopted patients." "" "" ""</seg>
<seg id="1417">Careful and repeated checks of the Tacrolimus Talmud are recommended during the first two weeks after transplantation in advance according to correct substance exposition in the immediate aftercare phase.</seg>
<seg id="1418">"" "" "" "because tacrolimus is a substance with lower Clearance, an adaptation of the advance can take several days until the Steady State can be reached." "" "" ""</seg>
<seg id="1419">"" "" "" "in case the patient does not allow patients in the first postoperative phase, the Tacrolimus therapy can be administered intravenously (Prograf 5 mg / ml concentrate on the production of infusion solution) with a dose of ca." "" "" ""</seg>
<seg id="1420">Duration of the use In the suppression of transplantation ensues must not be specified. consequently a maximum duration of oral therapy cannot be specified.</seg>
<seg id="1421">Dose visits - kidney transplantation and prophylaxis of transplants. oral Advantment therapy should start at 0.20 - 0.30 mg / kg / day as once daily gift in the morning.</seg>
<seg id="1422">Further dose adjustment can be later necessary because the pharmacokinetic of tacrolimus can change in the course of stabilisation of the patient after transplantation.</seg>
<seg id="1423">Dose recommendations - liver transplantation of prophylaxis The oral Advantment therapy should start at 0.10 - 0.20 mg / kg / day as once daily gift in the morning.</seg>
<seg id="1424">"" "" "" "Dosage recommendation - switch from Prograf on Advantf is a transplants made of twice daily dose of Prograf capsules to once daily taking daily intake, thus to take place on the entire daily dose." "" "" ""</seg>
<seg id="1425">Kidney and liver transplantation After a changeover from other immunossuppressants to advances once daily must begin the treatment with each dose of kidney transplantation recommended for prophylaxis of transplantation.</seg>
<seg id="1426">"" "" "" "heart transplantation In cases of adult patients, aimed at advances, is an oral Initial dose of 0.15 mg / kg / day daily." "" "" ""</seg>
<seg id="1427">Other transplants received no clinical experience with advances in lung and pancreta treatment in an oral initial dose of 0.2 mg / kg / day and in an oral initiate dose of 0.2 mg / kg / day and in an oral initiate dose of 0.3 mg / kg / day.</seg>
<seg id="1428">"" "" "" "Dosisadaptations in special patient groups patients with reduced liver function In the targeted field, can be required in patients with severe liver failure to minimise the dose." "" "" ""</seg>
<seg id="1429">"" "" "" "patients with reduced kidney function, when the kidney function had no influence on the pharmacokinetic of tacrolimus, can be assumed that a dose adjustment is not required." "" "" ""</seg>
<seg id="1430">"" "" "" "however, due to the nephrotoxic potentials of tacrolimus, a careful monitoring of the kidneys (including a regular determination of the serum-inoids, and monitoring of the urine volume) is recommended." "" "" ""</seg>
<seg id="1431">Change of Ciclosporin on Advantment At the changeover from a Ciclosporin to a Tacrolimus-based therapy is careful (see sections 4.4 and 4.5).</seg>
<seg id="1432">"" "" "" "the dose should be taken primarily on the clinical assessment of impouring and tolerability in the individual case under substrapping of whole blood-tacrolimus talents." "" "" ""</seg>
<seg id="1433">"" "" "" "it is recommended to perform frequent controls of the Tacrolimus talents during the first two weeks after transplantation, followed by periodic inspections during maintenance therapy." "" "" ""</seg>
<seg id="1434">"" "" "" "the blood levels of tacrolimus should also change according to transition from Prograf to Advagraf, Dosage adjustments, changes in the tacrolimus can change blood sugar (see Section 4.5)." "" "" ""</seg>
<seg id="1435">"" "" "" "since Advent is a medicine with a low Clearance, the dose may take several days until the Steady State can occur." "" "" ""</seg>
<seg id="1436">"" "" "" "the data in clinical trials allow that a successful treatment is possible in most cases, if the tallow should not exceed 20 ng / ml." "" "" ""</seg>
<seg id="1437">In clinical practice the topical mirror of tacrolimus are usually found in the first time according to liver transplantation in the range of 5 - 20 ng / ml and transplant patients at 10 - 20 ng / ml.</seg>
<seg id="1438">During the subsequent maintenance therapy of liver, kidney and heart transplant were usually used in the range of blood pressure concentrations in the range of 5 - 15 ng / ml.</seg>
<seg id="1439">"" "" "" "this has led to severe adverse events, including grafts, or any other side effects that occur in sequence of tacrolimus or overexposure." "" "" ""</seg>
<seg id="1440">Patients should always keep the same tacrolimus formulation and appropriate daily dosage; rendition of the formulation or regime should only be performed under the narrowful control of a medical doctor's transplantation (see sections 4.2 and 4.8).</seg>
<seg id="1441">"" "" "" "5 For the treatment of adult patients with transplants, which proved to be treated with other immunossuppressants, are still no clinical data for retardating formulation Advagraf." "" "" ""</seg>
<seg id="1442">For prophylaxis of grafts in adult heart transplants and grafts in the Kindesage are not yet any clinical data for retardant formulation Advagraf.</seg>
<seg id="1443">"" "" "" "due to possible interactions that can lead to a reduction of the tacrolimuscle levels in the blood and a shortening of the clinical effect of tacrointestinal (hypericum perforatum), or other plant ingredients during treatment with advances (see Section 4.5)." "" "" ""</seg>
<seg id="1444">In patients with diarrhoea a particularly careful monitoring of the tacrolimus- concentrations in the blood has been offered because the tacrolimus blood levels can be subjected to considerable variation in such circumstances.</seg>
<seg id="1445">In rare cases the chamber or Septumhypertrophie referred to as a cardiomyopathy was observed that therefore may also occur below advances.</seg>
<seg id="1446">"" "" "" "further factors that increase the risk of such clinical disorders, are an already existing heart disease, high blood pressure, kidney or liver failure, infections, fluid transfer and oder." "" "" ""</seg>
<seg id="1447">"" "" "" "like other immunossuppressants, exposure to sunlight or UV light should be restricted by suitable clothing or use of a sun protection using a high protection factor." "" "" ""</seg>
<seg id="1448">"" "" "" "if patients who capture tacrolimus, symptoms of res like headache, changed unit of consciousness, cramps and sintering, should be a radiological examination (e.g." "" "" ""</seg>
<seg id="1449">"" "" "" "because advent hard capsules, retardants, lactose, is in patients with the rare hereditary galactose intolerance, lactase deficiency, or glucose-galactose malignation special caution." "" "" ""</seg>
<seg id="1450">"" "" "" "the simultaneous application of medicines or herbal remedies, which are known as inhibitors or induction of CYP3A4, can increase or decrease the metabolism of tacrolimus." "" "" ""</seg>
<seg id="1451">"" "" "" "therefore, it is advisable to change the Tacrolimuscle blood levels at the same gift of substances that allow the CYP3A metabolism to maintain and adjust the tacrolimus dosage to maintaining uniform levels (see sections 4.2 and 4.4)." "" "" ""</seg>
<seg id="1452">A strong effect was made with antifungal agents like Ketoconazole, Itraconazole and Voriconazole as well as with the Macroid antibiotic erythromycin and HIV Protease Inhibitors (z).</seg>
<seg id="1453">Pharmacokinetic studies found that the increase of blood levels resulted from the increased oral bioavailability of tacrolimus, caused by the inhibition of gastrointestinal injection.</seg>
<seg id="1454">High-dose prednisolone or methylprednisolone how to increase or decrease the concentration of tacrolimus in the blood.</seg>
<seg id="1455">"" "" "" "the effect of tacrolimus on the metabolism of other medicines Tacrolimus is known as CYP3A4. therefore, the simultaneous use of tacrolimus can be metabolized by CYP3A4, which metabolism may interfere." "" "" ""</seg>
<seg id="1456">"" "" "" "since Tacrolimus disguise the Clearance of steroid-contraceptives, and thus increasing the hormone exposure, is particularly careful to deal with emptive measures." "" "" ""</seg>
<seg id="1457">The results of animal experiments have shown that tacrolimus can reduce the clearing of pentobarbital and phenazon and can extend their half-time.</seg>
<seg id="1458">"" "" "" "the results of a low number of examinations in transplantation patients do not provide evidence that under tacrolimus an increased risk of unwanted events, with regard to the course and result of pregnancy." "" "" ""</seg>
<seg id="1459">In utero exposition a monitoring of the newborns on possible harmful effects of tacrolimus (especially regarding its effect on kidneys) is recommended.</seg>
<seg id="1460">There is a risk of early birth (&lt; Week 37) and an hyperinfant of newborns (incidence 8 of 111 newborns):</seg>
<seg id="1461">The profile-effective profile of immunossuppressants can often be found exactly because of the undergoing disease of the patient and the simultaneous treatment with a variety of other medicines.</seg>
<seg id="1462">"" "" "" "below, the side effects are performed after their frequency in descending order: very frequently (≥ 1 / 100, ≤ 1 / $), very rare (≥ 1 / $10,000, ≤ 1 / 10,000), very rare (frequency on the basis of available data not invaluable)." "" "" ""</seg>
<seg id="1463">"" "" "" "intoxin disorders of coronary heart disease, tachykarmic arrhythmia, cardiac disease, myocardiac disease, supreventricular arrhythmia, palpitatio, anomalies in the ECG, abnormal heart rate and pulse rate." "" "" ""</seg>
<seg id="1464">"" "" "" "diarrhoea, nausea gastrointestinal disorders, gastrointestinal signs and symptoms, obstipation, flatulence, bloatiness, bloating, signs and symptoms in the stomach cross- area" "" "" ""</seg>
<seg id="1465">"" "" "" "infections and parasitic conditions as well known in other highly effective immunosulressants may be treated with tacrolimus, susceptibility to infections (viral, bacterial, mycotic, protozoale)." "" "" ""</seg>
<seg id="1466">Cases of BK-Virus-associated nephropathy and JC virus-associated Progressive multifunctional leukoencephalopathy (PML) reported in patients with immunosodression therapy, including therapy with advances.</seg>
<seg id="1467">It was reported on benign or malignant neoplasmen including EBV- associated lymphoproliferative disorders and skin tumors related with tacrolimus.</seg>
<seg id="1468">"" "" "" "due to its high molecular weight, its low water solubility and a high binding of erythrocytes and plasma samples, the tacrolimus can not dialyzed." "" "" ""</seg>
<seg id="1469">The effects of action and pharmacodynamic effects on molecular levels can be conveyed by its ties to a cytosolical protein (FKBP12) which is responsible for enriching the connection in the nucleus.</seg>
<seg id="1470">"" "" "" "this leads to a calciumdependent inhibiting of signals in the T cell, thereby preventing the transcription of a certain number of lymphocytes." "" "" ""</seg>
<seg id="1471">"" "" "" "tacrolimus suppresses the T-cells activation and the formation of lymphokines (such as interleukin-2, interleukin-3, and g -interferon) and expression of interleukin-2 receptors." "" "" ""</seg>
<seg id="1472">"" "" "" "12 Permanent abortions amounted to 29.3% within the first 24 weeks in the Advantf Group (N = 237), 32.6% and in the Prograf Group (N = 234)." "" "" ""</seg>
<seg id="1473">"" "" "" "patients and survival rates after 12 months were made up at 89,2% for Advagraf and 90.8% for Prograf; in the Advantf arm 25 (14 women, 11 men) and in the Prograf arm 24 (5 women, 19 men) deaths." "" "" ""</seg>
<seg id="1474">Kidney transplantation The efficacy and safety of lawyers and Prograf was compared in combination with Mycophenolatmofetil (MMF) and corticosteroids during 667 de Novo kidney transplantation.</seg>
<seg id="1475">Patients and survival rates after 12 months were 96.9% for advances and 97.5% for Prograf; in the Advantf arm appeared 10 (3 women, 7 men) and in the Prograf arm 8 (3 women, 5 men) deaths.</seg>
<seg id="1476">The effectiveness and safety of Prograf, Ciclosporin and Advagraf became compared in combination with Basiliximab-antibody detection, MMF and corticosteroids, at 638 de Novo kidney transplantation.</seg>
<seg id="1477">Incidence of therapy operations after 12 months (defined as death, transplants loss or missing follow-up data) was 14.0% in the Advantf Group (N = 212) and 17.0% in the Ciclosporin group (N = 212).</seg>
<seg id="1478">The treatment difference was -3.0% (Advagraphs Ciclosporin) (95.2%]) for Advagrams vs Ciclosporin and -1.9% (Prograf Ciclosporin) (95.2%) for Prograf vs Ciclosporin.</seg>
<seg id="1479">"" "" "" "in the Advantment Arm 3 (men), in the Prograf arm 10 (3 women, 7 men) and at Ciclosporin arm 6 (3 women, 3 men) deaths." "" "" ""</seg>
<seg id="1480">Published results of the primary immunosuppression with tacrolimus in the form of twice daily applied Prograf after other primary organ transplantation Prograf has developed into a recognized primary immunossuppressful according to pancreas-, lung and rectal transplants.</seg>
<seg id="1481">"" "" "" "175 traffic transplant surgery, in 475 patients who had subjected to a pancreatic transplant and in 630 patients, as a primary immune supple therapy." "" "" ""</seg>
<seg id="1482">"" "" "" "overall, the safety profile of oral Prograf in these published studies observed the observations in the large studies where Prograf with liver, kidney and heart transplant were responsive to primary immunosuppression." "" "" ""</seg>
<seg id="1483">An intermediate analysis in an intermediate analysis over a recently conducted multi-centric study with oral Prograf has been reported over 110 patients who received either tacrolimus or Ciclosporin during a 1: 1 Randomization.</seg>
<seg id="1484">A chronic grafts of the bronchiolitis obliterate syndrome was also less frequently observed in the first year after transplantation (2.86% versus 8,57%).</seg>
<seg id="1485">The survival rate after a year was 80,8% in the tacrolimus- and 83% in the Ciclosporin Group (Treede et al., 3rd ICI San Diego, USA, 2004; Abstract 22).</seg>
<seg id="1486">"" "" "" "in cases of patients treated with tacrolimus, there came to 21.7% of cases coming to the emergence of a bronchiolitis obliterine compared to 38.0% under Ciclosporin (p = 0,025)." "" "" ""</seg>
<seg id="1487">The number of cases where Ciclosporin had to be changed on tacrolimus (n = 0.02) as the number of patients who have been converted by tacrolimus on Ciclosporin (n = 2) (Keenan et al., Ann Thoracic Surg 1995; 60: 580).</seg>
<seg id="1488">The number of cases observed in which there was not an acclaimed transplants after 6 months (57.7% versus 45.8%) and after 1 year (50% versus 33.3%) in response transplant patients of the Tacrolimus group 2001; 20: 511).</seg>
<seg id="1489">In one study the frequency of a bronchiolitis obliterine disease was significantly lower in patients with tacrolimus patients.</seg>
<seg id="1490">Pancreatic transplantation A multi-centric study with oral Prograf was carried out in 205 patients who were treated at the same time with a randomised procedure Tacrolimus (n = 103) or Ciclosporin (n = 102).</seg>
<seg id="1491">The oral Initial Initial (by protocol) from Tacrolimus was 0.2 mg / kg / day and thereafter was reached after reaching the targeted talents of 8 to 15 ng / ml per day.</seg>
<seg id="1492">The published clinical results from a monocentric study with oral Prograf with oral Prograf showed in 155 patients (65 only intestines and colorectal transplants) below Tacrolimus and 25 multivisceral transplants) under tacrolimus and 25% after 5 years and 42% after 10 years.</seg>
<seg id="1493">Methods for the early detection of Epstein-Barr (EBV) - and CMV infections, addition to talents between 10 and 15 ng / ml and the beginning graft graft radiation (Abu-Elmagd et al.; Ann Surg 2001; 234: 404).</seg>
<seg id="1494">Factors such as a low hematocytes and low protein group concentrations lead to an increase in the found faction of tacrolimus or an increase of metastasis was responsible for transplantation observed after transplantation observed.</seg>
<seg id="1495">"" "" "" "this suggests that tacrolimus is almost completely metabolized almost entirely, with excretion above all occurs." "" "" ""</seg>
<seg id="1496">"" "" "" "in case of stable patients, offered by Prograf (twice daily) in relation to the overall daily dose, the systemic exposure of tacrolimus (AUC0-24) was nearly 10% lower than before Prograf." "" "" ""</seg>
<seg id="1497">"" "" "" "it is recommended to perform frequent controls of the Tacrolimus talents during the first two weeks after transplantation, followed by periodic inspections during maintenance therapy." "" "" ""</seg>
<seg id="1498">"" "" "" "21 For the treatment of adult patients with transplants, which proved to be treated with other immunossuppressants, are still no clinical data to retardant formulation Advagraf." "" "" ""</seg>
<seg id="1499">"" "" "" "further factors that increase the risk of such clinical disorders, are an already existing heart disease, high blood pressure, kidney or liver failure, infections, fluid transfer and oder." "" "" ""</seg>
<seg id="1500">"" "" "" "28 confirmed abortions amounted to 29.3% within the first 24 weeks in the Advantf Group (N = 237), 32.6% and in the Prograf Group (N = 234)." "" "" ""</seg>
<seg id="1501">The effectiveness and safety of Prograf, Ciclosporin and Advagraf became compared in combination with Basiliximab-antibody detection, MMF and corticosteroids, at 638 de Novo kidney transplantation.</seg>
<seg id="1502">"" "" "" "hard capsules, retardly glowing red-orange gelatine capsules, printed in red ink with" 5 mg "and orange capsling part with" H687, "they contain white powder." "" "" ""</seg>
<seg id="1503">"" "" "" "it is recommended to perform frequent controls of the Tacrolimus talents during the first two weeks after transplantation, followed by periodic inspections during maintenance therapy." "" "" ""</seg>
<seg id="1504">"" "" "" "37 In the treatment of adult patients with transplants, which proved to be treated with other immunossuppressants, there are still no clinical data to retardant formulation Advagraf." "" "" ""</seg>
<seg id="1505">"" "" "" "further factors that increase the risk of such clinical disorders, are an already existing heart disease, high blood pressure, kidney or liver failure, infections, fluid transfer and oder." "" "" ""</seg>
<seg id="1506">44 confirmed reproduction amounted to 32.6% within the first 24 weeks in the Advantf Group (N = 237) and in the Prograf Group (N = 234) 29.3%.</seg>
<seg id="1507">The effectiveness and safety of Prograf, Ciclosporin and Advagraf became compared in combination with Basiliximab-antibody detection, MMF and corticosteroids, at 638 de Novo kidney transplantation.</seg>
<seg id="1508">A total of 34 patients received from Ciclosporin on Tacrolimus during only 6 Tacrolimus patients need another therapy (Bechstein et al., transplantation 2004; 77: 1221).</seg>
<seg id="1509">The published clinical results from a monocentric study with oral Prograf with oral Prograf showed in 155 patients (65 only intestines and colorectal transplants) below Tacrolimus and 25 multivisceral transplants) under tacrolimus and 25% after 5 years and 42% after 10 years.</seg>
<seg id="1510">"" "" "" "this suggests that tacrolimus is almost completely metabolized almost entirely, with excretion above all occurs." "" "" ""</seg>
<seg id="1511">"" "" "" "risk management plan The holder of the Commission's risk management is obligated to perform the studies described in the pharmacovigilance plan described in version 3.2 of the risk management plan (RMP) and all subsequent updates of the RMP, which are approved by CHMP." "" "" ""</seg>
<seg id="1512">"" "" "" "according to CHMP control systems for pharmaceuticals for application on humans, the updated RMP must be submitted simultaneously to the next periodic safety report (periodiodic Safety Update Report, PSUR)." "" "" ""</seg>
<seg id="1513">"" "" "" "you may also get Advantf to the treatment of its liver, kidney or heart transplantation or of other transplanted organs, or because immune response of your body could not be ruled by a predicted treatment." "" "" ""</seg>
<seg id="1514">"" "" "" "when taking with advances with other medicines, please inform your doctor or pharmacist if you have taken other medicines or if it is not prescription medicine or remedy herbal origin." "" "" ""</seg>
<seg id="1515">"" "" "" "Amiloride, Triamteren or Spironolacton), certain medicines (known non-steroid antiphlogistika like ibuprofen), anticoagulants or drugs to treat diabetes mellitus." "" "" ""</seg>
<seg id="1516">"" "" "" "pregnancy and breastfeeding, If a pregnancy is planned or is already exists, ask your doctor or pharmacist before taking any medicine." "" "" ""</seg>
<seg id="1517">"" "" "" "if you sit or look at the wheel of a vehicle, or use tools or machines if you feel lazy or sleepy during taking up of advances." "" "" ""</seg>
<seg id="1518">"" "" "" "important information on certain other components of Advantment Please take advances in consultation with your physician, if you know that you suffer from incompatibility to certain sugars." "" "" ""</seg>
<seg id="1519">Make sure you get the same tacrolimus medicine when you redeem your prescription unless your specialist has been agreed to a change of the Tacrolimus preparations.</seg>
<seg id="1520">"" "" "" "if you receive a medicine whose appearance does not differ from the usual or the sampling process, please feel as fast as possible with your doctor or pharmacist that you have the right drug." "" "" ""</seg>
<seg id="1521">"" "" "" "to determine your doctor's correct dose and adjust time to time, it must subsequently be carried out regularly." "" "" ""</seg>
<seg id="1522">"" "" "" "if you have taken a larger amount of advances than you should accidentally have a bigger amount of advances, search your doctor or the emergency department of the nearest hospital." "" "" ""</seg>
<seg id="1523">"" "" "" "if you have forgotten the intake of advances, if you have forgotten to take the capsules, take the same day at the earliest possible time." "" "" ""</seg>
<seg id="1524">"" "" "" "when you break the intake of advances in the ending of the treatment with advances, the risk of raising your transplantation can increase." "" "" ""</seg>
<seg id="1525">"" "" "" "advances 0,5 mg of hard capsules, retardants, are hard yellow inekels, whose light yellow upper part with" 0.5 mg "and their oranges subparts are printed in red powder and filled with white powder." "" "" ""</seg>
<seg id="1526">"" "" "" "advances 1 mg of hard capsules, retardants, are cemented oil capsules, whose white upper part with" 1 mg "and their oranges subparts are printed both with white powder and white powder." "" "" ""</seg>
<seg id="1527">"" "" "" "advances 5 mg of hard capsules, retardants, are hard-gelatine capsules, whose graspas low part with" 687 "are printed both red and which are filled with white powder." "" "" ""</seg>
<seg id="1528">România Astellas Pharma Internav - Internaivu de contact pentru România Parks 42-44, Clerdire 1, Parter, 013696-Bucureş ti Tel: + 40 (0) 21 361 0495</seg>
<seg id="1529">Slovenska Repubka Astellas Pharma s.r.o., organizač ná clož ka Galvániho 15 / C SK821 04 Bratislava 2 Tel: + 421 2 4444 2157</seg>
<seg id="1530">Advances is used for the treatment and prevention of bleeding associated with haemophilia A (one by the lack of factor VIII.</seg>
<seg id="1531">"" "" "" "depending on the dose and frequency of the application, Advance is employed for the treatment of bleeding or prevention of blood vessels during surgical intervention." "" "" ""</seg>
<seg id="1532">Patients with hemophilia A suffer from a factor VIII deficiency, which caused blood clotation problems such as bleeding in joints, muscles or internal organs.</seg>
<seg id="1533">Octocog alfa is not extracted from human plasma but is produced using a method called "recombinant DNA technology":</seg>
<seg id="1534">"" "" "" "it is produced by a cell, into which a gene (DNA) was brought to the formation of the human scent factor VIII." "" "" ""</seg>
<seg id="1535">Advance is a different medicine approved in the European Union called Recombinate, but it does not contain proteins of human or animal origin.</seg>
<seg id="1536">"" "" "" "in three additional studies of patients with severe to moderate hemophilia A, including a study of 53 children under six years, the application of the drug was investigated for prevention of bleeding and with surgical intervention." "" "" ""</seg>
<seg id="1537">In the main study the effectiveness of Advances in the prevention of bleeding was awarded with "excellent" or "excellent" with the prevention of bleeding in 86%.</seg>
<seg id="1538">The most common adverse events (observed at 1 to 10 of 100 patients) are dizziness, headaches, pyrexia (fever) and the formation of antibodies against factor VIII.</seg>
<seg id="1539">"" "" "" "Advance may not be applied in patients who may possibly be sensitive (allergic) against the human scent factor VIII, Mausoleum or Hamsterprotein or any of the other ingredients." "" "" ""</seg>
<seg id="1540">"" "" "" "in March 2004, the European Commission approved the company Baxter AG for the placing of interest in the entire European Union." "" "" ""</seg>
<seg id="1541">"" "" "" "dosage: dose and duration of the substitution step is according to the severity of the factor VIII, according to the place and the degree of bleeding and the clinical condition of the patient." "" "" ""</seg>
<seg id="1542">"" "" "" "for the following trophirhagic events, the factor VIII activity in the corresponding period is not likely to fall under the indicated plasma level of plastic (in% of the standard or in I.U. / l)." "" "" ""</seg>
<seg id="1543">Injection every 12-24 hours (8-24 hours for patients under 6 years) for 3-4 days or for longer repeated until the pain and acute attacks are removed.</seg>
<seg id="1544">Injection every 8-24 hours (6-12 hours for patients under 6 years) are repeated until the risk is over.</seg>
<seg id="1545">"" "" "" "during the treatment, it is recommended to control the dose of injections and the frequency of the injections of VIII." "" "" ""</seg>
<seg id="1546">"" "" "" "individual patients can differ in their response to factor VIII, varying in vivo recovery and have different half times." "" "" ""</seg>
<seg id="1547">3 prophylaxis For long-term prophylaxis of bleeding in patients with severe hemophilia A should be given doses between 20 and 40 I.U. of factor VIII per kilogram of body weight within 2-3 days.</seg>
<seg id="1548">"" "" "" "if the expected factor VIII can not be achieved, or if the bleeding is uncontrolled with an appropriate dose, a test must be performed to prove to an inhibitor." "" "" ""</seg>
<seg id="1549">"" "" "" "in patients with high inhibitors, it is possible that the factor VIII therapy is not effective that other therapeutic interventions must be considered." "" "" ""</seg>
<seg id="1550">"" "" "" "appointment should be set by the patient, whereby a maximum injection rate of 10 ml / min should not be exceeded." "" "" ""</seg>
<seg id="1551">The formation of neutralizing antibodies against factor VIII is a well-known complication in the treatment of patients with haemophilia A.</seg>
<seg id="1552">These inhibitors are always directed against the procoagulatory activity of factor VIII by IgG Immaclobuline that were quantified in Bethesda units (B.E.) per ml plasma using the modified Bethesda Assay.</seg>
<seg id="1553">"" "" "" "the risk, inhibitors to develop, correlates with the extent of exposure to the factor VIII, whereby the risk depends on the greatest and other factors within the first 20 Expressive days." "" "" ""</seg>
<seg id="1554">In pre-treated patients (PTPs) with more than 100 expositions and anamnestically well known Inhibitory development was observed after the changeover from a recombinant factor VIII to another that reoccur (lowtitrigen) inhibitors.</seg>
<seg id="1555">"" "" "" "due to the rare occurrence of the haemophilia A in women, no experiences are required during pregnancy and lactation period." "" "" ""</seg>
<seg id="1556">"" "" "" "in the greatest number of patients occurring ADRs were inhibitors against factor VIII (5 patients) which have treated previously untreated patients, headaches (5 patients), fever, and dizziness (in each case 3 patients)." "" "" ""</seg>
<seg id="1557">"" "" "" "very common (≥ 1 / 100), often (≥ 1 / 1000 to &lt; 1 / 10,000), very rare (≥ 1 / 10.000), very rare &lt; 1 / 10,000), very rare (frequency on the basis of available data not invaluable)." "" "" ""</seg>
<seg id="1558">A) The percentage of patients was calculated using the sum of individual patients (234). the unexpected waste of blood coagulation factor VIII-Spiegels occurred within a patient with continuous ADVATE infusion.</seg>
<seg id="1559">The bleeding was maintained throughout the whole period and both the factor VIII- mirror in the plasma and the Clearance Rate showed sufficient values on 15 post operative day.</seg>
<seg id="1560">For clinical trials with ADVATE to 145 children and adults with prior exposure to factor VIII- concentrates (≥ 150 days) only one patient in 26 expositions with ADVATE showed a low inhibitory (2.4 B.E. in the modified Bethesda approach).</seg>
<seg id="1561">In addition to no of the 53 paediatric patients with an age of under 6 years and diagnosed with moderate to moderate hemophilia A (FVIII ≤ 2%) after previous exposure to factor VIII- concentrates (≥ 50 days) an FVIII-inhibitor was established.</seg>
<seg id="1562">"" "" "" "in previously untreated patients from a continuous clinical trial, 5 out of 25 (20%) with ADVATE are treated Inhibitors against factor VIII." "" "" ""</seg>
<seg id="1563">The immune response of patients to traces of contamination protein was analysed by the investigation of antibodies against these proteins, laboratory parameters and reported side effects.</seg>
<seg id="1564">"" "" "" "one patient had a statistically significant upward trend for anti-Cho cell membranes, otherwise there were no signs or symptoms related to an allergic reaction or hypersensitivity." "" "" ""</seg>
<seg id="1565">"" "" "" "in four patients the occurrence of Urtikaria, Pruritus, rash and increased number of eosinophiles Granulotes reported on several repetitive product expositions in the study." "" "" ""</seg>
<seg id="1566">"" "" "" "7 As with other intravenous products, ADVATE has been reported on hypersensitive type, including anaphylactic / anaphylactoider reactions (frequency not known)." "" "" ""</seg>
<seg id="1567">The activated factor VIII acts as a factor for the activated Factor IX and accelerates the formation of activated carbon X from factor X.</seg>
<seg id="1568">All pharmacokinetics studies with ADVATE were performed in previously treated patients with severe or moderate hemophilia A (base value of the Factor VIII-Activity ≤ 2%).</seg>
<seg id="1569">The pharmacokinetic parameters come from a cross-over study with ADVATE in 100 previously treated patients or &gt; 10 years and are listed in the table below 3.</seg>
<seg id="1570">Table 3 Summary of the pharmacokinetic parameter of ADVATE for 100 patients with heavy to moderate hemophilia A (factor VIII &lt; 2%) PK Parameters (Pharmacokinetics)</seg>
<seg id="1571">"" "" "" "non-clinical data based on security pharmacology, to acute, repeated and local toxicity and to genotoxicity, show no special risk for human beings." "" "" ""</seg>
<seg id="1572">Each single pack consists of a water bottle with powder, a piercing tank with 5 ml liquid (both glass Type I with chlorobutyl rubber stamps) and a device for reconstruction (BAXJECT II).</seg>
<seg id="1573">"" "" "" "if the product is still stored in the refrigerator, remove both jumper bottles with ADVATE powder and solvents from the refrigerator and warm up at room temperature (between 15 and 25 ° C)." "" "" ""</seg>
<seg id="1574">"" "" "" "a significant increase in pulse rate can be slowed down, or temporarily down the injection of injections (see sections 4.4 and 4.8)." "" "" ""</seg>
<seg id="1575">14 prophylaxis For long-term prophylaxis of bleeding in patients with severe hemophilia A should be given doses between 20 and 40 I.U. of factor VIII per kilogram of body weight within 2-3 days.</seg>
<seg id="1576">"" "" "" "due to the rare occurrence of the haemophilia A in women, no experiences are required during pregnancy and lactation period." "" "" ""</seg>
<seg id="1577">3 newborn infants (aged 0-1 month) with infants (aged 1 month - 2 years) children (aged 2-12 years) and children (aged 12-16); adults (over 16 years old)</seg>
<seg id="1578">For clinical trials with ADVATE to 145 children and adults 4 with diagnosed heavy to moderate hemophilia A (≥ 150 days) only one patient in 26 expositions with ADVATE showed a low inhibitory (2.4 B.E. in the modified Bethesda approach).</seg>
<seg id="1579">"" "" "" "18 As with other intravenous products, ADVATE has been reported on hypersensitive type, including anaphylactic / anaphylactoider reactions (frequency not known)." "" "" ""</seg>
<seg id="1580">Table 3 Summary of the pharmacokinetic parameter of ADVATE for 100 patients with heavy to moderate hemophilia A (factor VIII &lt; 2%) PK Parameters (Pharmacokinetics)</seg>
<seg id="1581">"" "" "" "non-clinical data based on security pharmacology, to acute, repeated and local toxicity and to genotoxicity, show no special risk for human beings." "" "" ""</seg>
<seg id="1582">25 prophylaxis For long-term prophylaxis of bleeding in patients with severe hemophilia A should be given doses between 20 and 40 I.U. of factor VIII per kilogram of body weight within 2-3 days.</seg>
<seg id="1583">5 newborn infants (aged 0-1 month) for infants (aged 1 month - 2 years) children (aged 2-12 years) and children (aged 12-16); adults (over 16 years old)</seg>
<seg id="1584">For clinical trials with ADVATE to 145 children and adults 6 with diagnosed heavy to moderate hemophilia A (≥ 150 days) only one patient in 26 expositions with ADVATE showed a low inhibitory (2.4 B.E. in the modified Bethesda approach).</seg>
<seg id="1585">"" "" "" "29 As with other intravenous products, ADVATE has been reported on hypersensitive type, including anaphylactic / anaphylactoider reactions (frequency not known)." "" "" ""</seg>
<seg id="1586">"" "" "" "non-clinical data based on security pharmacology, to acute, repeated and local toxicity and to genotoxicity, show no special risk for human beings." "" "" ""</seg>
<seg id="1587">36 prophylaxis For long-term prophylaxis of bleeding in patients with severe hemophilia A should be given doses between 20 and 40 I.U. of factor VIII per kilogram of body weight within 2-3 days.</seg>
<seg id="1588">7 newborn infants (aged 0-1 month) for infants (aged 1 month - 2 years old) children (aged 2-12 years) and children (aged 12-16) and adults (over 16 years old).</seg>
<seg id="1589">For clinical trials with ADVATE to 145 children and adults 8 with diagnosed heavy to moderate hemophilia A (≥ 150 days) only one patient in 26 expositions with ADVATE showed a low inhibitory (2.4 B.E. in the modified Bethesda approach).</seg>
<seg id="1590">"" "" "" "40 As with other intravenous products, ADVATE has been reported on hypersensitive type, including anaphylactic / anaphylactoider reactions (frequency not known)." "" "" ""</seg>
<seg id="1591">"" "" "" "non-clinical data based on security pharmacology, to acute, repeated and local toxicity and to genotoxicity, show no special risk for human beings." "" "" ""</seg>
<seg id="1592">47 prophylaxis For long-term prophylaxis of bleeding in patients with severe hemophilia A should be given doses between 20 and 40 I.U. of factor VIII per kilogram of body weight within 2-3 days.</seg>
<seg id="1593">"" "" "" "9 newborn infants (aged 0-1 month), infants (aged 1 month - 2 years), children (aged 2-12 years), children (aged 12-16), adults (over 16 years old)" "" "" ""</seg>
<seg id="1594">For clinical trials with ADVATE to 145 children and adults 10 with diagnosed heavy to moderate hemophilia A (≥ 150 days) only one patient in 26 expositions with ADVATE showed a low inhibitory (2.4 B.E. in the modified Bethesda approach).</seg>
<seg id="1595">"" "" "" "51 As with other intravenous products, ADVATE has been reported on hypersensitive type, including anaphylactic / anaphylactoider reactions (frequency not known)." "" "" ""</seg>
<seg id="1596">"" "" "" "non-clinical data based on security pharmacology, to acute, repeated and local toxicity and to genotoxicity, show no special risk for human beings." "" "" ""</seg>
<seg id="1597">58 prophylaxis For long-term prophylaxis of bleeding in patients with severe hemophilia A should be given doses between 20 and 40 I.U. of factor VIII per kilogram of body weight within 2-3 days.</seg>
<seg id="1598">11 new children (aged 0-1 month) with infants (aged 1 month - 2 years) children (aged 2-12 years) and children (aged 12-16) and adults (over 16 years old).</seg>
<seg id="1599">For clinical trials with ADVATE to 145 children and adults 12 with diagnosed heavy to moderate hemophilia A (≥ 150 days) only one patient in 26 expositions with ADVATE showed a low inhibitory (2.4 B.E. in the modified Bethesda approach).</seg>
<seg id="1600">62 How to be reported on other intravenous products regarding the types of hypersensitive type, including anaphylactic / anaphylactoider reactions (frequency not known).</seg>
<seg id="1601">"" "" "" "non-clinical data based on security pharmacology, to acute, repeated and local toxicity and to genotoxicity, show no special risk for human beings." "" "" ""</seg>
<seg id="1602">"" "" "" "Pharmacovigilance System The authorisation holder has to ensure that a pharmacovigilance system is described, as described in paragraph 1.1 of the section 1.8.1 in the drug approval process, and that this system is in force in which the product remains on the market." "" "" ""</seg>
<seg id="1603">"" "" "" "as defined in the CHMP Directive on the Risk-Managment Plan for Human-Medicines, these updates are simultaneously filed with the next Periodic Safety Update Report (PSUR)." "" "" ""</seg>
<seg id="1604">"" "" "" "• If new information is available, the pharmacovigilance plan or the measures to minimise the risk minimization, within 60 days of an important event (with regard to the pharmacovigilance or regarding a measure to risk minimization)" "" "" ""</seg>
<seg id="1605">1 bottle bottle with ADVATE 500 i.e Octocog alfa, 1 average bottle with 5 ml sterilised water for injection purposes, 1 BAXJECT II medical device.</seg>
<seg id="1606">1 bottle bottle with ADVATE 1000 i.e Octocog alfa, 1 average bottle with 5 ml sterilised water for injection purposes, 1 BAXJECT II medicine product</seg>
<seg id="1607">"" "" "" "special caution when applying ADVATE is required, if you were treated recently with Factor VIII's products, especially if you have developed Inhibitors." "" "" ""</seg>
<seg id="1608">These symptoms can display early signs of anaphylactic shocks which can include the following symptoms: extreme zziness, consciousness loss and extreme respiratory sufferings.</seg>
<seg id="1609">"" "" "" "with other medicines, please inform your doctor if you have taken other medicines or if it is not prescribed for non-prescription medicine." "" "" ""</seg>
<seg id="1610">"" "" "" "your doctor will calculate your dose ADVATE (in international units or i.E.) depending on your body weight and body weight, and whether it is used for prevention or treatment of bleeding." "" "" ""</seg>
<seg id="1611">"" "" "" "patients suffering from factor VIII ininhibitors If the expected factor VIII should not be achieved in your plasma using ADVATE, or blood flow could not be controlled, this could be the development of factor VIII-" "" "" ""</seg>
<seg id="1612">"" "" "" "in combination with operations catheter infections, lower number of red blood cells, swelling of limbs and joints, extended bleeding after the removal of drainage, decreased factor VIII-Spiegel and postoperative hematoma." "" "" ""</seg>
<seg id="1613">"" "" "" "rare side effects since the introduction of the drug on the market has been amidated over heavy and potentially life-threatening reactions (anaphylaxis), and other allergic reactions (see above)." "" "" ""</seg>
<seg id="1614">Inform your doctor if one of the listed side effects will affect you significantly or if you notice any side effects that are not listed in this package age.</seg>
<seg id="1615">Portugal Baxter Médico Farmacêutica LDA Sintra Business Park Zona Industrial da Abrunheira, Edifício 10 P-2710-089 Sintra Tel: + 351 21 925 25 00</seg>
<seg id="1616">"" "" "" "do not use hints for the manufacture of the solution • Do not use after the holding tank and the boxes given on in force, if his sterile barrier is broken or signs of manipulation has damaged or signs of manipulation, such as in the symbol" "" "" ""</seg>
<seg id="1617">"" "" "" "important note: • Do not agree, before you have received special training from your doctor or your nurse. • Check the product on suspended particles or discoloration." "" "" ""</seg>
<seg id="1618">"" "" "" "the solution should be slow with an infusion speed, which can be applied to patients and exceeds 10 ml per minute." "" "" ""</seg>
<seg id="1619">"" "" "" "106 In case of blood outcomes, the factor VIII should not fall within the corresponding period of time (in% or in I.U. / ml)." "" "" ""</seg>
<seg id="1620">These symptoms can display early signs of anaphylactic shocks which can include the following symptoms: extreme zziness, consciousness loss and extreme respiratory sufferings.</seg>
<seg id="1621">"" "" "" "patients suffering from factor VIII ininhibitors If the expected factor VIII should not be achieved in your plasma using ADVATE, or blood flow could not be controlled, this could be the development of factor VIII-" "" "" ""</seg>
<seg id="1622">"" "" "" "occasional side effects Juitching, reinforced diarrhoea, diarrhoea, diarrhoea, diarrhoea, severe disease, inflammations, skin rash, extreme sweating, extreme sweating," "" "" ""</seg>
<seg id="1623">116 "" "" "" "116 Used in the case of blood outcomes, the factor VIII should not fall within the corresponding period of time (in% or in I.U. / ml)." "" "" ""</seg>
<seg id="1624">These symptoms can display early signs of anaphylactic shocks which can include the following symptoms: extreme zziness, consciousness loss and extreme respiratory sufferings.</seg>
<seg id="1625">"" "" "" "patients suffering from factor VIII ininhibitors If the expected factor VIII should not be achieved in your plasma using ADVATE, or blood flow could not be controlled, this could be the development of factor VIII-" "" "" ""</seg>
<seg id="1626">126 "" "" "" "126 In case of haemaking results, the factor VIII should not fall within the corresponding period of time (in% or in I.U. / ml)." "" "" ""</seg>
<seg id="1627">These symptoms can display early signs of anaphylactic shocks which can include the following symptoms: extreme zziness, consciousness loss and extreme respiratory sufferings.</seg>
<seg id="1628">"" "" "" "patients suffering from factor VIII ininhibitors If the expected factor VIII should not be achieved in your plasma using ADVATE, or blood flow could not be controlled, this could be the development of factor VIII-" "" "" ""</seg>
<seg id="1629">"" "" "" "136 In case of blood outcomes, the factor VIII should not fall within the corresponding period of time (in% or in I.U. / ml)." "" "" ""</seg>
<seg id="1630">These symptoms can display early signs of anaphylactic shocks which can include the following symptoms: extreme zziness, consciousness loss and extreme respiratory sufferings.</seg>
<seg id="1631">"" "" "" "patients suffering from factor VIII ininhibitors If the expected factor VIII should not be achieved in your plasma using ADVATE, or blood flow could not be controlled, this could be the development of factor VIII-" "" "" ""</seg>
<seg id="1632">146 In case of incidence of blood the factor VIII should not fall within the corresponding period of time (in% or in I.U. / ml).</seg>
<seg id="1633">These symptoms can display early signs of anaphylactic shocks which can include the following symptoms: extreme zziness, consciousness loss and extreme respiratory sufferings.</seg>
<seg id="1634">"" "" "" "patients suffering from factor VIII ininhibitors If the expected factor VIII should not be achieved in your plasma using ADVATE, or blood flow could not be controlled, this could be the development of factor VIII-" "" "" ""</seg>
<seg id="1635">"" "" "" "occasional side effects Juitching, reinforced diarrhoea, diarrhoea, diarrhoea, diarrhoea, severe disease, inflammations, skin rash, extreme sweating, extreme sweating," "" "" ""</seg>
<seg id="1636">"" "" "" "rare side effects since the introduction of the drug on the market has been amidated over heavy and potentially life-threatening reactions (anaphylaxis), and other allergic reactions (see above)." "" "" ""</seg>
<seg id="1637">"" "" "" "156 In case of haemaking results, the factor VIII should not fall within the corresponding period of time (in% or in I.U. / ml)." "" "" ""</seg>
<seg id="1638">"" "" "" "based on the data available since the first application, the CHMP has remained positively evaluated than positive, but also considered the safety profile of the following reasons must be closely monitored:" "" "" ""</seg>
<seg id="1639">"" "" "" "therefore, CHMP has thus made a further extension procedure on the basis of the security profile of ADVATE, which is required for filing an additional extension procedure in 5 years." "" "" ""</seg>
<seg id="1640">"" "" "" "nevertheless, Gendux Molecular Limited, the Committee for Human Use (CHMP) officially accepted the company's request to permit for the treatment of Advexin for the treatment of Li-Fraumeni cancer." "" "" ""</seg>
<seg id="1641">"" "" "" "however, the breast, the bones, bone or soft parts (tissue that combines other structures in the body, and relies on) it is affected." "" "" ""</seg>
<seg id="1642">"" "" "" "this is a type of virus, which was genetically modified that it can carry a gene into the cells of the body." "" "" ""</seg>
<seg id="1643">"" "" "" "in the virus in Advexin, it is a Adenovirus, which has been changed so that there are no copies of itself, and therefore no infections can resolve in humans." "" "" ""</seg>
<seg id="1644">"" "" "" "Advexin would have injected directly into the tumors, and to enable the cancer cells to form the normal p53 protein." "" "" ""</seg>
<seg id="1645">"" "" "" "the p53 gene, which is formed from the non-defective body of existing p53 gene, usually contributes to restoration damaged DNA and to kill cells when DNA can not be recovered." "" "" ""</seg>
<seg id="1646">"" "" "" "with Li-Fraumeni cancer, with which the p53 gene is defective, the p53 protein is not working properly, and the cancer cells may grow further and share." "" "" ""</seg>
<seg id="1647">"" "" "" "the company placed data from a study involving thousands of patients with Li-Fraumeni cancer in the area of subbuilding, in the bones and in the brain." "" "" ""</seg>
<seg id="1648">"" "" "" "after the CHMP has examined the questions posed on the questions, there were still some issues unsolved." "" "" ""</seg>
<seg id="1649">"" "" "" "based on the initial documents, the CHMP grants a list of questions which will be sent to the company by day 120." "" "" ""</seg>
<seg id="1650">"" "" "" "according to the CHMP, the injection of Advantage in Li-Fraumeni tumors has proved benefits to patients." "" "" ""</seg>
<seg id="1651">"" "" "" "furthermore, the committee had concerns regarding the processing of drugs in the body, type of administration and safety of medicine." "" "" ""</seg>
<seg id="1652">"" "" "" "in addition, the company had not yet proven that Advexin can be made in reliable manner and that there is neither the environment nor for people who come in close contact with the patient." "" "" ""</seg>
<seg id="1653">"" "" "" "the CHMP is not having knowledge of whether the withdrawal of patients has currently taking part in clinical trials or" Compassionate Use "programs with Advexin." "" "" ""</seg>
<seg id="1654">"" "" "" "" changed mode release, means that the tablets are so composed that one of the effective components are immediately released and the other slowly is released over a few hours. "" "" "" "</seg>
<seg id="1655">"" "" "" "Aerinaze is used to treat symptoms of seasonal allergic rhinitis (hay fever, by allergy to pollen) in patients with nose syndrome (clogged nose)." "" "" ""</seg>
<seg id="1656">"" "" "" "for adults and adolescents 12 years the recommended dose of aaaze is twice daily, which should be taken with a glass of water with or without food." "" "" ""</seg>
<seg id="1657">"" "" "" "the duration of the treatment should be as short as possible and end as soon as symptoms, especially the swelling of the nasal mucosa (clogged nose)." "" "" ""</seg>
<seg id="1658">Treatment duration of more than 10 days is not recommended because the effects of the medication can be redirected to constipation of the nose.</seg>
<seg id="1659">"" "" "" "the main dimensions of the severity were the changes in the severity of hypocrushing symptoms, which were reported by the patients before the beginning of treatment and during 15-day treatment." "" "" ""</seg>
<seg id="1660">"" "" "" "during the study, patients showed their symptoms every 12 hours in a journal and valuate the symptoms in the last 12 hours." "" "" ""</seg>
<seg id="1661">"" "" "" "in consideration of all hay fever symptoms, except the constipation of the nose the patients reported an increase in symptoms of 46.0%, compared with 35.9% in patients receiving pseudoephedrine alone." "" "" ""</seg>
<seg id="1662">"" "" "" "if only the swelling of the nasal mucosa was considered, the patients showed under Aerinaze showed a reduction of symptoms of 37.4% compared to 26.7% in patients suffering from the desloratadine alone." "" "" ""</seg>
<seg id="1663">"" "" "" "the most common side effects of Aerinaze (observed at 1 to 10 of 100 patients) are tachykarma (appetite, headache, fatigue, insomnia), somnolence, sleep disorders, and nervousness." "" "" ""</seg>
<seg id="1664">"" "" "" "for patients who may possibly be sensitive (allergic) against desloratadine, pseudoephedrine or one of the other ingredients, against adrenerous compounds or lauatadine (another medicine for the treatment of allergies), cannot be applied." "" "" ""</seg>
<seg id="1665">"" "" "" "aeroinaze may also not be applied to patients who suffer from a Engangle glaucoma (hypertension), cervical or vascular diseases (hypertension) or have a reduction of hemorrhagic stroke." "" "" ""</seg>
<seg id="1666">"" "" "" "on 30 July 2007, the European Commission issued an approval for the shipping of aerinaze in the entire European Union." "" "" ""</seg>
<seg id="1667">"" "" "" "the tablet can be taken with a glass of water, however, is to swallow whole (i.e. without bite to break or chew)." "" "" ""</seg>
<seg id="1668">Aerinaze should not be used by the lack of data on harmlessness and effectiveness (see Section 5.1) for children under 12 years of age.</seg>
<seg id="1669">"" "" "" "the duration of the application is as short as possible, and should not continue after the sound of the symptoms." "" "" ""</seg>
<seg id="1670">It is recommended to limit the application time to 10 days as with long-term application the activity of pseudoephedrine can take time.</seg>
<seg id="1671">"" "" "" "after a decline in swelling of the mucous membranes in the upper respiratory tract, treatment can be continued with desloratadin as monotherapy." "" "" ""</seg>
<seg id="1672">"" "" "" "as Aerinaze pseudoephedrine contains, the medicine is also contraindicated in patients who are treated with monocaminase (MAO) or within 2 weeks after completion of such therapy." "" "" ""</seg>
<seg id="1673">This is attributable to the alphamimetic activity in the combined application of pseudoephedrine with other vasoconstrictors such as bromocripitin, phenylephrine, phenylephrine, ephedrine, oximeta etc.).</seg>
<seg id="1674">"" "" "" "the safety and efficacy of these combination therapy were not auditory, and the data do not suffice to supply appropriate recommendations for the dosage." "" "" ""</seg>
<seg id="1675">"" "" "" "the safety and efficacy of aerinaze were not checked in patients with kidney or liver failure, and the data are not sufficient to supply appropriate recommendations for dosage." "" "" ""</seg>
<seg id="1676">"" "" "" "patients need to be informed that treatment in the occurrence of hypertension or tachykarate or of palpitations, arrhythmic disorders, nausea, or any eventual other neurological symptoms (such as headache or a amplification of the headache) must be stopped." "" "" ""</seg>
<seg id="1677">In the treatment of the following patient groups we will be approached with caution: • Patients with heart rhythm disorders • Patients with a myocardial infarction in Anamnese, diabetes mellitus, bladder construction or bronchiospasm in Anamnese.</seg>
<seg id="1678">"" "" "" "Aerinaze has at least 48 hours before serving the matological tests, as antihistamines can prevent positive reactions to indicators for skin actions or reduce their extent." "" "" ""</seg>
<seg id="1679">"" "" "" "however, in the context of clinical trials involving Trifiatadin where erythromycin or Ketoconazole were additionally given, no clinically relevant interactions or changes of plasma concentration have been observed." "" "" ""</seg>
<seg id="1680">"" "" "" "with the results of psychomotor testing, no significant differences between the patients treated with the disintegatadin and the placebo treated with placebo have been taken alone or with alcohol." "" "" ""</seg>
<seg id="1681">"" "" "" "this enzyme has not yet been identified for the metabolism of loratadine, so that interactions with other medicines may not be excluded entirely." "" "" ""</seg>
<seg id="1682">"" "" "" "deserters in vivo CYP3A4 not inhibit, and in-vitro studies have shown that the medicine CYP2D6 does not inhibits and does not inhibit the inhibitor of the P-glycoproteins." "" "" ""</seg>
<seg id="1683">"" "" "" "the inconsistency of the application of Aerinaze during pregnancy is not secured, experience from a large number of affected pregnancies, however, no increase in frequency of abnormalities compared to frequency in normal population." "" "" ""</seg>
<seg id="1684">"" "" "" "because territory studies of animals are not always transferred to humans, and for the vasoconstrictor properties of pseudoephedrine should not be used in pregnancy." "" "" ""</seg>
<seg id="1685">"" "" "" "the patients should be clarified, however, that in very rare cases it can come to a dizziness, which can lead to a drawback of machines." "" "" ""</seg>
<seg id="1686">"" "" "" "symptoms vary between a CNS-depression (dation, apnee, reduced mental attention, cyanosis, coma, cardiovascular collagen, tremor, convulsions) with possible leases." "" "" ""</seg>
<seg id="1687">"" "" "" "headache, anxiety, diffusion, failure, muscular weakness, arrhythmic disorders, aract, respiratory disorders, dizziness, tinnitus, ataxia, vision and hypertension or hypotony." "" "" ""</seg>
<seg id="1688">"" "" "" "a CNS stimulation is particularly probable with children, as well as Atropin-typical symptoms (mouth drying, pupil size, hyperthermia, hyperthermia, gastrointestinal symptoms)." "" "" ""</seg>
<seg id="1689">These include both the inhibiting of inflammatory cytokines such as IL-4, IL-6, IL-8 and IL-13 from human macular cells / basophils and expression of the expression of expression of the hemiodine molecule P selecule on endothelial cells.</seg>
<seg id="1690">"" "" "" "in an individual dose study of adults, desloratadine showed no effect on standard measuring values, including the amplification of subjective sleepiness or the tasks that are connected to the bow." "" "" ""</seg>
<seg id="1691">"" "" "" "in controlled clinical trials, a daily dosage of 5 mg daily increased no increased frequency of drowsiness in comparison to placebo." "" "" ""</seg>
<seg id="1692">"" "" "" "the oral application of pseudoephedrine in the recommended dosage can produce more sympathomimetic effects, such as an increase of blood pressure, a tachykarate or manifestation of a CNS arousal." "" "" ""</seg>
<seg id="1693">"" "" "" "it took 1.248 patients aged between 12 and 78, with seasonal allergic rhinitis, with 414 patients aerobaze tablets." "" "" ""</seg>
<seg id="1694">"" "" "" "in both trials, the histamantagonistic efficacy of aeroinaze tablets determined significantly higher than under a monotherapy with pseudoephedrine with pseudoephedrine over the 2 weeks treatment time." "" "" ""</seg>
<seg id="1695">"" "" "" "the effectiveness of aeroinaze tablets with regard to the fluctuating effect, determines from the nose-breaking effect, was significantly higher than under a monotherapy with a loratadin over the 2 weeks treatment time." "" "" ""</seg>
<seg id="1696">"" "" "" "the effectiveness of aerobaze tablets showed no significant differences in terms of gender, age or ethnic origin." "" "" ""</seg>
<seg id="1697">"" "" "" "as part of a single-dose study for pharmacokinetics of aerobaze, the loratadine is verifiable within 30 minutes after administration in the plasma." "" "" ""</seg>
<seg id="1698">"" "" "" "after the peroral application of aeroinaze in healthy subjects over 14 days, the flowed balance of loratadine, 3-hydroxydesloratadine and pseudoephedrine was reached on day 10." "" "" ""</seg>
<seg id="1699">"" "" "" "as part of a pharmacokinetic multi-doscope study, which was conducted with formulation as a tablet of healthy adult volunteers, was found that four subjects were disintegrating badly." "" "" ""</seg>
<seg id="1700">A component interaction study shows that the exposure (Cmax and AUC) from pseudoephedrine based on the sole gift of pseudoephedrine was made of exposure to the gift of an Aerinaze tablet.</seg>
<seg id="1701">"" "" "" "based on conventional concepts for safety pharmacology, to toxicity, on the toxicity of redox toxicity and for reproduction, the preclinical data with the dichloratadin does not recognize any hazards for human beings." "" "" ""</seg>
<seg id="1702">"" "" "" "the combination had no greater toxicity than its individual components, and the observed effects were generally related to the ingredients Pseudoephedrine." "" "" ""</seg>
<seg id="1703">In reproductive neuroological studies the combination of bay adin / pseudoephedrine was not termed up to 120 mg / kg / day and per rabbit in a dose of up to 120 mg / kg / day.</seg>
<seg id="1704">"" "" "" "March 2007 and in Module 1.8.1 of the application application is established, and works before and while the product is on the market." "" "" ""</seg>
<seg id="1705">"" "" "" "antihistamines contribute to the relieving of allergic symptoms, by preventing histamine that can unfold its own substance." "" "" ""</seg>
<seg id="1706">"" "" "" "aerobaze tablets include symptoms that occur in connection with seasonal allergic rhinitis (hay fever), such as niesen, current or justling eyes, while constiffing or justly eyes." "" "" ""</seg>
<seg id="1707">"" "" "" "20 In certain circumstances, they may be particularly sensitive to the mucuous membrane pseudoephedrine, which is contained in this medicine." "" "" ""</seg>
<seg id="1708">(disease disease) an stenounding gastric ulcer (ulcer that leads to a constriction of gastric acid or of the lumber collars) which have prostate symptoms or problems with the liver, kidneys or bladder problems.</seg>
<seg id="1709">"" "" "" "inform your doctor if you are doing or diagnosed with the following symptoms or diseases: • hypertension, cardiac beat, heart rhythmia • nausea and headache or a reinforcement of existing headache." "" "" ""</seg>
<seg id="1710">Taking Aerinaze with other medicines Please inform your doctor or pharmacist if you have taken other medicines or if it is not prescribed for prescription medicine.</seg>
<seg id="1711">"" "" "" "with the recommended dosage, the recommended dosage means that Aerinaze leads to dizziness or dispose of attention." "" "" ""</seg>
<seg id="1712">"" "" "" "if you have taken a larger amount of Aerinaze, you should immediately use your doctor or pharmacist if you should have taken a bigger amount of Aerinaze than you should." "" "" ""</seg>
<seg id="1713">"" "" "" "if you have forgotten the intake of Aerinaze If you have forgotten to take a dose in time, get your application as soon as possible and turn the next dose at the required moment." "" "" ""</seg>
<seg id="1714">"" "" "" "please inform your doctor or pharmacist if one of the listed side effects will affect you significantly, or you may notice any side effects listed in this manual information." "" "" ""</seg>
<seg id="1715">"" "" "" "heart chase, elessness with increased physical activity, mouth-drying, distiffness, stipation, sugar in urine, increased blood sugar levels, thirst, fatigue, sleep disorders, nervousness and dizziness." "" "" ""</seg>
<seg id="1716">"" "" "" "palpitations or heart rhythmia, increased physical activity, skin dripping, nasal irritations, nasal irritations, nasal denies, nasal denies, distortion of odor disease, obstructing liver values, restlessness, anxiety and irritability." "" "" ""</seg>
<seg id="1717">"" "" "" "after the launch of loratadin very rarely were reported in cases of severe allergic reactions (breathing not, whitching breathing, hives, hives and swelling) or skin proposals." "" "" ""</seg>
<seg id="1718">"" "" "" "about cases of palpitations, pain chase, abdominal pain, nausea, vomiting, hallucinations, diarrheel, diarrhoea, diarrhoea, diarrhoea, chronic liver harm has also been reported very rarely." "" "" ""</seg>
<seg id="1719">It is available as a 5 mg tray, 5 mg- and 5 mg- and 5 mg fusion tablets (tablets that dissolve in the mouth) and 0,5 mg / ml-syrup and as per 0.5 mg / ml solution.</seg>
<seg id="1720">"" "" "" "for children aged one to five years, the dose is 1.25 mg once a day, in the form of 2.5 ml of syrup or respectively." "" "" ""</seg>
<seg id="1721">"" "" "" "for children aged six to eleven years, the dose is 2.5 mg once a day, either in the form of 5 ml syrup or respectively." "" "" ""</seg>
<seg id="1722">"" "" "" "Aerius was examined in eight studies of about 4 800 adults and adolescents with allergic rhinitis (among which four studies with seasonal allergic rhinitis and two studies of patients, which had also asthma)." "" "" ""</seg>
<seg id="1723">"" "" "" "efficacy was measured by the change of symptoms (itching, count and size of squares, impairment of sleep and performance on days) before and after six weeks of treatment." "" "" ""</seg>
<seg id="1724">"" "" "" "there were further studies submitted to prove that the body uses the syrup, the solution to capture and the hot tablets in the same manner, as the tablets and the application of children is harmless." "" "" ""</seg>
<seg id="1725">"" "" "" "in case of allergic rhinitis, if the results of all studies were taken with 5 mg Aerius to an average decrease of the symptom (symptoms score) by 25 to 26% compared to the patients who received a placebo." "" "" ""</seg>
<seg id="1726">"" "" "" "in the two trials at Urtikaria, the decrease of the symptoms after six weeks of treatment with Aerius 58 and 67% compared to 40 and 33% compared to placebo-treated patients." "" "" ""</seg>
<seg id="1727">Aerius may not be applied in patients who may possibly be sensitive (allergic) against desloratadin or loratadine or one of the other ingredients.</seg>
<seg id="1728">"" "" "" "in January 2001, the European Commission issued an approval for the inclusion of Aerius in the entire European Union." "" "" ""</seg>
<seg id="1729">"" "" "" "one tablet once daily, with one or without a meal, to relieving symptoms of allergic rhinitis (including intermittent and persistic rhinitis) and urticaria (see section 5.1)." "" "" ""</seg>
<seg id="1730">There are limited experience from clinical trials on effectiveness in the application of deserters from 12 to 17 years (see sections 4.8 and 5.1).</seg>
<seg id="1731">"" "" "" "the treatment of intermittances allergic rhinitis (symptoms of symptoms for less than 4 days a week or less than 4 weeks) should be terminated according to the end of the disease, and after their return the symptoms can be resumed." "" "" ""</seg>
<seg id="1732">"" "" "" "in case of persistent allergic rhinitis (symptoms of symptoms of 4 or more days a week and over 4 weeks), patients can be recommended during the worse period." "" "" ""</seg>
<seg id="1733">Clinically relevant interactions were reported in the framework of clinical trials involving dichloratadin tablets at which Erythromycin or Ketoconazole were additionally given (see section 5.1).</seg>
<seg id="1734">"" "" "" "in a clinical pharmacological study, associated ingestion of alcohol and alcohol was not enhanced (see section 5.1)." "" "" ""</seg>
<seg id="1735">"" "" "" "however, patients should be clarified in the fact that in very rare cases it can lead to an impairment or the ability to serve machines." "" "" ""</seg>
<seg id="1736">"" "" "" "in clinical trials in different indications, including allergic rhinitis and chronic idiopathic Urtikaria, were reported at the recommended dose of 5 mg daily 3% more side effects in patients with Aerius than patients who were treated with placebo." "" "" ""</seg>
<seg id="1737">"" "" "" "the most common adverse events that were reported more often than in placebo, fatigue (1.2%), mouth-dried (0.8%) and headache (0.6%)." "" "" ""</seg>
<seg id="1738">"" "" "" "in a clinical study with 578 young young patients from 12 to 17 years, the most frequent adverse headaches, who were treated with desloratadin, were treated with 6,9% of patients who were treated with placebo." "" "" ""</seg>
<seg id="1739">"" "" "" "in a multiple-dose study, which were administered up to 45 mg of desloratadine (Neunfold clinical dose) were observed not clinically relevant effects." "" "" ""</seg>
<seg id="1740">This includes both the inhibition of inflammatory cytokines such as IL-4, IL-6, IL-8 and IL-13 from human macular cells / basophies as well as the expression of the expression of the hemiodine molecule P selecule on endothelial cells.</seg>
<seg id="1741">"" "" "" "as part of a clinical study with multiple outlets, administered during a dose of up to 20 mg daily for 14 days, no statistical or clinically relevant cardiovascular effect was described." "" "" ""</seg>
<seg id="1742">"" "" "" "in a clinical pharmacological study, which has been given a dose of 45 mg daily (the Neunfold of the clinical dose) over ten days, there was no extension of the QTc interval." "" "" ""</seg>
<seg id="1743">"" "" "" "with an individual dose- study of adults, desloratadine showed no effect on standard measuring values, including the amplification of subjective sleepiness or the tasks that are connected to the bow." "" "" ""</seg>
<seg id="1744">"" "" "" "in patients with allergic rhinitis, Aerius was effective in relieving symptoms such as Niesen, nasal secretion and itching of the nose, itching and redness of the eyes and itching on the palate." "" "" ""</seg>
<seg id="1745">"" "" "" "in addition to the established classification in seasonal and perennial, allergic rhinitis may be divided into intermittent allergic rhinitis, or in intermittent allergic rhinitis." "" "" ""</seg>
<seg id="1746">Intermittent allergic rhinitis is defined as the occurrence of symptoms for less than 4 days a week or less than 4 weeks.</seg>
<seg id="1747">"" "" "" "an unusual or allergic rhinitis is defined as the symptoms of 4 or more days a week, more than 4 weeks." "" "" ""</seg>
<seg id="1748">"" "" "" "as shown on the overall quality of life at rhino junctivitis, Aerius effectively reduces diseases caused by seasonal allergic rhinitis." "" "" ""</seg>
<seg id="1749">"" "" "" "the chronically idiopathic Urtikaria was inquired for further forms of the Urtikaria, since the underlying pathology is irrespective of the different forms and chronic patients can be recruited." "" "" ""</seg>
<seg id="1750">"" "" "" "since the histamorphanism is a causal factor in all pretikarial diseases, that desloratadin is also expected to improve symptoms in other forms of the symptoms; this is confirmed by the recommendations of clinical guidelines." "" "" ""</seg>
<seg id="1751">In two placebo-controlled trials over 6 weeks in patients with chronically idiopathic Scotikaria Aerius was effective in the improvement of Pruritus and the reduction of size and number of squares at the end of the first dose-gap.</seg>
<seg id="1752">"" "" "" "as in other studies with antihistamines at the chronic idiopathic Scotikaria, the minority of patients who did not react to antihistamines from the study." "" "" ""</seg>
<seg id="1753">An improvement in the target of more than 50% was observed at 55% of patients treated with the desloratadin treated patients compared to 19% of patients treated with placebo.</seg>
<seg id="1754">"" "" "" "treatment with Aerius reduced the disturbance of sleep and growth, as measured by a 4-point scale for evaluating these variables." "" "" ""</seg>
<seg id="1755">"" "" "" "in a pharmacokinetic study, in which patients were comparable with the general seasonal allergic rhinitis of population, was achieved in 4% of patients a higher concentration of loratadine." "" "" ""</seg>
<seg id="1756">There are no clues for a clinically relevant Kumulation after a daily use of loratadin (5- 20 mg) for 14 days.</seg>
<seg id="1757">"" "" "" "however, the enzyme responsible for the metabolism of deserters was not yet identified so that interactions with other medicines are not completely excluded." "" "" ""</seg>
<seg id="1758">"" "" "" "disintegatadin inhibits no CYP3A4 and in-vitro studies have shown that the medicine CYP2D6 does not inhibits, neither a substrate yet another inhibitor of the P-glycoproteins." "" "" ""</seg>
<seg id="1759">"" "" "" "in a single dosshadine with a distillate in a dosage of 7.5 mg, meals (greasy, rich breakfast) does not affect the availability of loratadine." "" "" ""</seg>
<seg id="1760">"" "" "" "with a comparable degree of exposition of the disinteratadine and loratadine, there were no qualitative or quantitative differences regarding the toxicity profile of loratadin and of Loratadin." "" "" ""</seg>
<seg id="1761">"" "" "" "based on conventional concepts for safety pharmacology, toxicity in repeated declaratory, genotoxicity and for reproduction, the preclinical data with the disinteratadin does not recognize any hazards for human beings." "" "" ""</seg>
<seg id="1762">"" "" "" "colorless film (contains lactose monohydrate, Hypromless, titanium dioxide, Macrogol 400, Indigocarmin (E 132)), carnaubagel, soft wax." "" "" ""</seg>
<seg id="1763">Aerius can be taken regardless of meals, to prevent symptoms of allergic rhinitis (including intermittent and persistic rhinitis) and Urtikaria (see section 5.1).</seg>
<seg id="1764">"" "" "" "the missing doctor should be aware that most cases of rhinitis in children under 2 years are caused by an infection (see Section 4.4) and that no data is available, which support a treatment of infantile rhinitis with Aerius." "" "" ""</seg>
<seg id="1765">"" "" "" "in addition to the exclusion of upper respiratory infections or anatomic anomalies should play a role in diagnosis, physical research and appropriate laboratory and skin tests." "" "" ""</seg>
<seg id="1766">About 6% of adults and children between 2 and 11 years of metabolize is reduced to a higher substress (see section 5.2).</seg>
<seg id="1767">"" "" "" "the safety of Aerius Sirup in children between the ages of 2 and 11 have limited to metabolized, is identical with the children that metabolize normally." "" "" ""</seg>
<seg id="1768">This medicine contains saccharose and Sorbitol; therefore patients with hereditary problems of fructose intolerance, glucose-galactose deficiency may not be taken.</seg>
<seg id="1769">Clinically relevant interactions were not found in clinical trials involving Aerius tablets at which Erythromycin or Ketoconazole were additionally given (see section 5.1).</seg>
<seg id="1770">"" "" "" "in a clinical pharmacological study, associated with intake of Aerius tablets and alcohol was not enhanced (see section 5.1)." "" "" ""</seg>
<seg id="1771">"" "" "" "the Aerius Sirup Group was similar to the Aerius Sirup Group, similar to the placebo group." "" "" ""</seg>
<seg id="1772">"" "" "" "in clinical trials involving adults and adolescents in different indications, including allergic rhinitis and chronic idiopathic Urtikaria, were reported at the recommended dose 3% more side effects in patients with Aerius than patients who were treated with placebo." "" "" ""</seg>
<seg id="1773">"" "" "" "in a multiple dose study of adults and adolescents, at which up to 45 mg of desloratadin (Neunfold clinical dose) were observed, no clinically relevant effects were observed." "" "" ""</seg>
<seg id="1774">"" "" "" "children aged between 1 and 11 years, received a daily disinformation dose of 1.25 mg (aged between 1 and 5 years) or 2.5 mg (aged between 6 and 11)." "" "" ""</seg>
<seg id="1775">Because the evolution of allergic rhinitis / chronically idiopathic Scotikaria and the profile of desloratadin in adults and children can be extrapolated by the absorption data of loratadin in adults on the children's population.</seg>
<seg id="1776">"" "" "" "as part of a clinical study with multiple outlets in adults and teenagers, employed in a dose of up to 20 mg daily, no statistical or clinically relevant cardiovascular effect was described." "" "" ""</seg>
<seg id="1777">"" "" "" "in a clinical pharmacological study on adults and adolescents, having been used in a dose of 45 mg daily (Neunfold the clinical dose) over ten days in adults, there was no extension of the QTc interval." "" "" ""</seg>
<seg id="1778">"" "" "" "in controlled clinical trials, a recommended dosage of 5 mg daily for adults and adolescents has no increased frequency of drowsiness in comparison to placebo." "" "" ""</seg>
<seg id="1779">"" "" "" "in an individual daily dose of 7.5 mg, Aerius tablets led in adults and adolescents to no impairment of psychomotors." "" "" ""</seg>
<seg id="1780">"" "" "" "in clinical pharmacological studies of adults, it was not affected by the simultaneous intake of alcohol to an increase of alcohol insurgents nor an increase of drowsiness." "" "" ""</seg>
<seg id="1781">"" "" "" "in adult and youthful patients with allergic rhinitis, Aerius tablets were effective in relieving symptoms like stheses, nasal secretion, tear and redness of the eyes and itching on the palate." "" "" ""</seg>
<seg id="1782">"" "" "" "as shown on the overall quality of quality of life at rhino junctivitis, Aserius tablets are effective that caused by seasonal allergic rhinitis." "" "" ""</seg>
<seg id="1783">In two placebo-controlled trials over 6 weeks in patients with chronically idiopathic Scotikaria Aerius was effective in the improvement of Pruritus and the reduction of size and number of squares at the end of the first dose-gap.</seg>
<seg id="1784">The spread of this natural metabolizing phenotype was comparable in adults (6%) and children between 2 and 11 years (6% adults + 16% children) than with Caucasia (2% adults + 3% children).</seg>
<seg id="1785">Similar pharmacokinetic parameters were observed in a pharmacokinetic multi-dose study with the syrup formulation of children between 2 and 11 years of allergic rhinitis which have limited to metabolition.</seg>
<seg id="1786">The load (AUC) by desloratadin was approximately 6mal higher after 3 to 6 hours and the Cmax is about 3 to 4 times higher with a season half-time of approximately 120 hours.</seg>
<seg id="1787">There are no clues for a clinically relevant drug compulation after a daily use of loratadin (5- 20 mg) for 14 days in adults and adolescents.</seg>
<seg id="1788">12 In various individual dose studies reported that AUC- and Cmax values of desloratadin showed at the recommended doses were comparable with those of adults who received the desloratadin syrup in a dose of 5 mg.</seg>
<seg id="1789">"" "" "" "however, the enzyme responsible for the metabolism of deserters was not yet identified so that interactions with other medicines may not be excluded entirely." "" "" ""</seg>
<seg id="1790">"" "" "" "Aerius Sirup is available in type III colours with a child-safe polypropylene seal cap with 30, 50, 60, 100, 120, 150, 225 and 300 ml." "" "" ""</seg>
<seg id="1791">"" "" "" "equipped with rigid, transparent polystyrene, measuring spoon, calibrated with 2.5 ml and 5 ml or with a application-injection for preparations for intake of 2.5 ml and 5 ml (only for the 150 ml bottle)." "" "" ""</seg>
<seg id="1792">To put an dose of Aerius Lyophilisat once a day in the mouth to alleviate symptoms of allergic rhinitis (including intermittent and persistic rhinitis) and Urtikaria (see section 5.1).</seg>
<seg id="1793">"" "" "" "immediately before the application, the blister must be carefully opened and the dose of the lyophilariats must be taken out without damaging them." "" "" ""</seg>
<seg id="1794">Clinically relevant interactions were not found in clinical trials with Aerius tablets at which Erythromycin or Ketoconazole were additionally used (see section 5.1).</seg>
<seg id="1795">"" "" "" "in clinical trials in different indications, including allergic rhinitis and chronic idiopathic Urtikaria, were reported at the recommended dose of 5 mg daily 3% more side effects in patients with Aerius tablets that were treated with placebo." "" "" ""</seg>
<seg id="1796">"" "" "" "in a multiple-dose study, which were used up to 45 mg of desloratadin (Neunfold clinical dose), no clinically relevant effects were observed." "" "" ""</seg>
<seg id="1797">"" "" "" "in two individual dose studies, Aerius Lyophilisat was well tolerated and documented by clinical laboratory results, medical examinations, vital signs and ECG interval data." "" "" ""</seg>
<seg id="1798">"" "" "" "as part of a clinical study with multiple sockets, measured in a dose of up to 20 mg daily, no statistical or clinically relevant cardiovascular effect was described." "" "" ""</seg>
<seg id="1799">"" "" "" "in a clinical pharmacological study, which has been applied to a dose of 45 mg daily (the Neunfold of the clinical dose) over ten days, there was no extension of the QTc interval." "" "" ""</seg>
<seg id="1800">"" "" "" "in controlled clinical trials, a daily dosage of 5 mg daily increased no increased frequency of drowsiness in comparison to placebo." "" "" ""</seg>
<seg id="1801">"" "" "" "in a 17 single dose study of adults, desloratadine showed no effect on standard values of the flow of fluids including the amplification of subjective sleepiness or the tasks that are connected to the bow." "" "" ""</seg>
<seg id="1802">"" "" "" "in patients with allergic rhinitis, Aerius tablets were effective in relieving symptoms such as Niesen, nasal secretion and itching of the nose, itching and redness of the eyes and itching on the palate." "" "" ""</seg>
<seg id="1803">"" "" "" "as shown on the overall quality of life at rhino junctivitis, Aerius effectively reduces diseases caused by seasonal allergic rhinitis." "" "" ""</seg>
<seg id="1804">"" "" "" "18 In a pharmacokinetic study, where patients were comparable with the general seasonal allergic rhinitis of population, was achieved in 4% of patients a higher concentration of loratadine." "" "" ""</seg>
<seg id="1805">Food has no significant effect on AUC and Cmax von Aerius Lyophilisat for intake that extends from 2.5 to 4 hours and a maximum of 3-OH-desloratadin from 4 to 6 hours.</seg>
<seg id="1806">Gelatine Mannitol aspartame (E 951) Polacrilin potassium dye opatint red (contains iron (III) -oxide (E 464) and Hypromless (E 464)) - Tutti-frutti water-free Citric acid</seg>
<seg id="1807">Add an Aerius 2.5 mg fusion tray once a day in the mouth to alleviate symptoms of allergic rhinitis (including intermittent and persistic rhinitis) and Urtikaria (see section 5.1).</seg>
<seg id="1808">Two Aerius 2.5 mg melt tablets once a day in the mouth add to the relieving symptoms of allergic rhinitis (including intermittent and persistic rhinitis) and Urtikaria (see section 5.1).</seg>
<seg id="1809">There are limited experience from clinical trials on effectiveness in the application of deserters from 12 to 17 years (see sections 4.8 and 5.1)</seg>
<seg id="1810">"" "" "" "immediately before application, the blister must be carefully opened and the dose of hot tablets are taken out without damaging them." "" "" ""</seg>
<seg id="1811">The efficacy and integrity of Aerius 2.5 mg has not been detected in the treatment of children under 6 years of age.</seg>
<seg id="1812">"" "" "" "the overall stability of the side effects between the loratadine syrup and the placebral group was equal, and departed not significantly from the safety profile." "" "" ""</seg>
<seg id="1813">"" "" "" "at the recommended dose, Aerius fusion tablets proved to be organic equivalent to the Aerius 5 mg conventional tablets formulation and the Aerius 5 mg of lyophilisate formulation." "" "" ""</seg>
<seg id="1814">"" "" "" "as part of a clinical study with multiple outlets, measured in a dose of up to 20 mg daily, no statistical or clinically significant was observed." "" "" ""</seg>
<seg id="1815">"" "" "" "in an individual dose study of adults, desloratadine showed no effect on standard values of the flow of fluids including the amplification of subjective sleepiness or the tasks that are connected to the bow." "" "" ""</seg>
<seg id="1816">The spread of this badly metabolized phenotype was comparable for adult (6%) and pediatric patients aged between 2 and 11 years (adult children 3%) and the safety profile of these patients was not different from that of the general population.</seg>
<seg id="1817">"" "" "" "in single dose-crossover studies of Aerius melting tray with Aerius 5 mg conventional tablets or Aerius 5 mg of lyophilisat, formulations were bioequivalent." "" "" ""</seg>
<seg id="1818">"" "" "" "Aerius 2.5 mg tablets were not investigated in pediatric patients, however, in combination with the dose of dose, however, the pharmacokinetic data for Aerius melting tablets can be used for children from 6 to 11 years." "" "" ""</seg>
<seg id="1819">Food has no significant effect on AUC and Cmax from Aerius Aerius Aerius Lyophilisat for intake that extends from 2.5 to 4 hours and Tmax from 3-OH- desloratadin from 4 to 6 hours.</seg>
<seg id="1820">"" "" "" "analysis of the predefined clinical and clinical trials for the fusion tablets showed that this formulation is an unlikely risk for local irritation, to clinical use." "" "" ""</seg>
<seg id="1821">Mikrocoine Cellulose manufactured strength Carboxymethyl-sodium citric carbonate citric carbonate citric acid citric carbonate citric carbonate Opitol Aspartame (E951) aroma Tutti Frutti</seg>
<seg id="1822">The cold forming sheet is made of polyvinyl chloride (PVC) laminated for a related polyamide (OPA) film and laminated onto an aluminum foil and laminated for a polyvinyl chloride (PVC) film.</seg>
<seg id="1823">"" "" "" "put an Aerius 5 mg melting tray once a day, to prevent symptoms of allergic rhinitis (including intermittent and persistic rhinitis) and urticaria (see section 5.1)." "" "" ""</seg>
<seg id="1824">The recommended dose proved 5 mg of conventional tablets as organic equivalent to the Aerius 5 mg conventional tablets formulation and the Aerius 5 mg of lyophilisate formulation.</seg>
<seg id="1825">"" "" "" "as part of a clinical study with multiple sockets, measured in a dose of up to 20 mg daily, no statistical or clinically relevant cardiovascular effect was described." "" "" ""</seg>
<seg id="1826">"" "" "" "in a 30 single dose study of adults, desloratadine showed no effect on standard values of the flow of fluids including the amplification of subjective sleepiness or the tasks that are connected to the bow." "" "" ""</seg>
<seg id="1827">"" "" "" "in patients with allergic rhinitis, Aerius tablets were effective in relieving symptoms such as Niesen, nasal secretion and itching of the nose, itching and redness of the eyes and itching on the palate." "" "" ""</seg>
<seg id="1828">"" "" "" "in single dose-crossover studies of Aerius 5 mg of conventional tablets or Aerius 5 mg of lyophilisat, formulations were bioequivalent." "" "" ""</seg>
<seg id="1829">"" "" "" "analysis of the predefined clinical and clinical trials for the fusion tablets showed that this formulation is an unlikely risk for local irritation, to clinical use." "" "" ""</seg>
<seg id="1830">The safety of loratadine in children between the ages of 2 and 11 have limited to metabolized is identical with the children that metabolize normally.</seg>
<seg id="1831">This medicine contains Sorbitol; therefore patients with hereditary problems of fructose- intolerance, glucose-galactose absorption or a saccharase isomonase insuffsufficiency is not taken.</seg>
<seg id="1832">"" "" "" "the overall stability of the side effects in children between the ages of 2 and 11 was similar to the disintegatadin group, similar to the placebo group." "" "" ""</seg>
<seg id="1833">"" "" "" "for infants between 6 and 23 months the most common adverse events were reported, more than the common than in placebo, diarrhoe (3,7%), fever (2.3%) and sleeplessness (2.3%)." "" "" ""</seg>
<seg id="1834">"" "" "" "in an additional study, 2.5 mg of the loratadine solution were observed at an immersive dose of patients at the age of 6 and 11." "" "" ""</seg>
<seg id="1835">At the recommended doses the plasma concentrations of desloratadin (see section 5.2) were comparable in the kindergarten and adult population.</seg>
<seg id="1836">"" "" "" "in controlled clinical trials, a recommended dosage of 5 mg daily for adults and adolescents has no increased frequency of drowsiness in comparison to placebo." "" "" ""</seg>
<seg id="1837">"" "" "" "in addition to the established classification in seasonal and perennial, allergic rhinitis may vary depending on the duration of the symptoms, or in intermittent allergic rhinitis." "" "" ""</seg>
<seg id="1838">"" "" "" "as shown on the overall quality of life at rhino junctivitis, Aerius tablets was effectively diminished with seasonal allergic rhinitis." "" "" ""</seg>
<seg id="1839">The spread of this natural metabolizing phenotype was comparable in adults (6%) and children between 2 and 11 years (6% adults + 16% children) than with Caucasia (2% adults + 3% children).</seg>
<seg id="1840">"" "" "" "since Aerius solution to import the same concentration of the loratadine, no bioequivalent study was necessary and it is expected to meet the syrup and the tablets." "" "" ""</seg>
<seg id="1841">"" "" "" "in various individual dose studies, AUC- and Cmax values of desloratadin showed at the recommended doses were comparable with those of adults who received the desloratadin syrup in a dose of 5 mg." "" "" ""</seg>
<seg id="1842">Sorbitol, Propylglycol, Sucralose E 955, Hypromless E 2910, sodium citrate 2 H2O, natural and artificial flavouric acid (Bubble Gum), water-free Citric acid, sodium edetate (Ph.D.). cleaned water.</seg>
<seg id="1843">"" "" "" "Aerius solution for inclusion is offered with 30, 50, 60, 100, 120, 150, 225 and 300 ml bottles with a child safe screw cap with multi-layer polyethylene overcoated use." "" "" ""</seg>
<seg id="1844">All packagings except 150 ml of pack size are offered with a measuring spoon containing markers for dosing of 2.5 ml and 5 ml.</seg>
<seg id="1845">The 150 ml package size is a measuring spoon or application-injection for preparations for fixing with scalability of 2.5 ml and 5 ml.</seg>
<seg id="1846">"" "" "" "subsequent to the extension of approval, the authorisation holder will submit regularly updated reports about the inconceivable account of a drug every two years, unless something else is decided by CHMP." "" "" ""</seg>
<seg id="1847">1 slide tabletten 3 film tray for 3 film tablets at 9 film tablets to total 30 film tray for 30 film tray 30 film tray 90 film tray 90 filmballs for 30 film tablets.</seg>
<seg id="1848">1 slide tabletten 3 film tray for 3 film tablets at 9 film tablets to total 30 film tray for 30 film tray 30 film tray 90 film tray 90 filmballs for 30 film tablets.</seg>
<seg id="1849">Sirup 30 ml with 1 measuring spoon of 50 ml with 1 measuring spoon 100 ml with 1 measuring spoon 150 ml with 1 measuring spoon 150 ml with 1 measuring spoon and 1 measuring spoon of 300 ml with 1 measuring spoon</seg>
<seg id="1850">30 ml. with 1 measuring spoon of 50 ml with 1 measuring spoon 100 ml with 1 measuring spoon 150 ml with 1 measuring spoon 150 ml with 1 measuring spoon and 1 measuring spoon with 1 measuring spoon of 300 ml with 1 measuring spoon</seg>
<seg id="1851">1 doses Lyophilisat for insertion 3 doses Lyophilisat for insertion 80 cans Lyophilisat for insertion 80 cans Lyophilisat for insertion 50 doses Lyophilisat to capture 100 doses Lyophilisat to capture 100 doses Lyophilisat to capture 100 doses Lyophilisat to capture 100 doses Lyophilisat to capture 100 doses Lyophilisat to capture 100 doses Lyophilisat to capture 100 doses Lyophilisat to capture 100 doses Lyophilisat to capture 100 doses Lyophilisat to capture 100 doses Lyophilisat to capture 100 doses Lyophilisat to capture 100 doses Lyophilisat to capture 100 doses Lyophilisat to capture 100 doses Lyophilisat to capture 100 doses Lyophilisat to capture 100 doses Lyophilisat to capture 100 doses Lyophilisat to capture 100 doses Lyophilisat to capture 100 doses Lyophilisat to capture 100 doses Lyophilisat to capture 100 doses Lyophilisat to capture 100 doses Lyophilisat to capture 100 doses Lyophilisat to capture 100 doses Lyophilisat to capture 100 doses Lyophilisat to capture 100 doses Lyophilisat to capture 100 doses Lyophilisat to capture 100 doses Lyophilisat to capture 100 doses Lyophilisat to capture 100 doses Lyophilisat to capture 100 doses Lyophilisat to capture 100 doses Lyophilisat to capture 100 doses Lyophilisat to capture 100 doses Lyophilisat to capture 100 doses Lyophilisat to capture 100 doses Lyophilisat to capture 100 doses Lyophilisat to capture 100 doses Lyophilisat to capture 100 doses</seg>
<seg id="1852">5 hot tablets 6 melting tray for 30 melting tablets per hot tablets to 60 hot tablets to 60 hot tablets to 60 hot tablets to 60 hot tablets.</seg>
<seg id="1853">Solution to immerse 30 ml with 1 measuring spoon 100 ml with 1 measuring spoon 100 ml with 1 measuring spoon 150 ml with 1 measuring spoon 150 ml with 1 measuring spoon and 1 measuring spoon of 300 ml with 1 measuring spoon</seg>
<seg id="1854">Pregnancy and breastfeeding should ask for advice during pregnancy and lactation period before taking any medicine or pharmacist for advice.</seg>
<seg id="1855">"" "" "" "if using machines in the recommended dosage, dosage means that Aerius leads to dizziness or dispose of attention." "" "" ""</seg>
<seg id="1856">"" "" "" "if you have said about your doctor, you may have an intolerance against certain sugars, ask your doctor before taking this medicine." "" "" ""</seg>
<seg id="1857">"" "" "" "regarding the treatment duration, your doctor will determine the type of allergic rhinitis under which you suffer, and will determine how long you should use Aerius." "" "" ""</seg>
<seg id="1858">If your allergic rhinitis is intermittent (symptoms occur less than 4 days a week or less than 4 weeks), your doctor will recommend you with a treatment scheme.</seg>
<seg id="1859">"" "" "" "if your allergic rhinitis is persist (symptoms indicate 4 or more days per week, and more than 4 weeks), your doctor may recommend you a longer lasting treatment." "" "" ""</seg>
<seg id="1860">"" "" "" "if you have forgotten the intake of Aerius If you have forgotten your dose in time, take it as soon as possible and then follow the normal treatment plan." "" "" ""</seg>
<seg id="1861">71 In the market launch of Aerius very rarely was reported on cases of severe allergic reactions (difficulty breathing, whistle attack and swelling and swelling) and skin rash.</seg>
<seg id="1862">"" "" "" "about cases of palpitations, pain chase, abdominal pain, nausea, vomiting, sleeplessness, sleeplessness, restlessness with increased physical activity, liver ignant and unusual liver function has also been reported very seldom." "" "" ""</seg>
<seg id="1863">"" "" "" "tablet coating consists of coloured film (contains lactose monohydrate, titanium dioxide, Macrogol 400, Indigocarmin (E 132)), Carnaubagel, bleached wax." "" "" ""</seg>
<seg id="1864">"" "" "" "Aerius 5 mg film tablets are packed individually in blister packages with 1, 2, 3, 5, 15, 30, 30, 30, 90, 90 or 100 tablets." "" "" ""</seg>
<seg id="1865">"" "" "" "Aerius Sirup is displayed for children between the ages of 1 and 11, young people (12 years and older) and adults, elderly people included." "" "" ""</seg>
<seg id="1866">Important information on certain other components of Aerius you should not take Aerius Sirup if you are allergic to the dye E 110.</seg>
<seg id="1867">"" "" "" "if you know your doctor, you may have an incompatibility to some sugar types, contact your doctor before taking this medicine." "" "" ""</seg>
<seg id="1868">"" "" "" "if the syrup has a application-bubbly to use with scaling, you can use this alternatively in order to take the appropriate amount of syrup." "" "" ""</seg>
<seg id="1869">"" "" "" "regarding the treatment duration, your doctor will determine the type of allergic rhinitis under which you suffer, and will determine how long you should use Aerius syrup." "" "" ""</seg>
<seg id="1870">"" "" "" "however, in children under 2 years of diarrhoea, fever and sleeplessness frequent side effects, while adults were often tiredness, mouth-drying and headache often than placebo were reported." "" "" ""</seg>
<seg id="1871">"" "" "" "after the launch of Aerius very rarely about cases of allergic reactions (difficulty breathing, whaling, hives, hives and swelling) and skin rash." "" "" ""</seg>
<seg id="1872">"" "" "" "77 Aerius Sirup is available in bottles with childproof glazing with 30, 50, 60, 100, 120, 150, 225 and 300 ml." "" "" ""</seg>
<seg id="1873">Aerius Lyophilisat for importation improves symptoms of allergic rhinitis (caused by allergy to the nasal infection or dust-dust allergy).</seg>
<seg id="1874">Intake of Aerius Lyophilisat together with foods and beverages Aerius Lyophilisat must not be taken with water or any other liquid.</seg>
<seg id="1875">"" "" "" "regarding the treatment duration, your doctor will determine the type of allergic rhinitis under which you suffer, and will determine how long you should use Aerius Lyophilisat." "" "" ""</seg>
<seg id="1876">"" "" "" "81 If you have forgotten taking Aerius Lyophilisat, if you have forgotten your dose in time, take it as soon as possible and then follow the normal treatment plan." "" "" ""</seg>
<seg id="1877">"" "" "" "after the launch of Aerius very rarely about cases of allergic reactions (difficulty breathing, whaling, hives, hives and swelling) and skin rash." "" "" ""</seg>
<seg id="1878">"" "" "" "Aerius Lyophilisat for insertion is individually wrapped in blister packages with 1, 2, 3, 14, 30, 30, 30, 30, 50, 30, 30, 50 or 100 doses." "" "" ""</seg>
<seg id="1879">Aerius fusion tray improves the symptoms of allergic rhinitis (caused by allergy to inflammatory inflammation or dust-dust allergy).</seg>
<seg id="1880">"" "" "" "when taking Aerius hot tablets together with foods and beverages, Aerius melting tray does not need to be taken with water or any other liquid." "" "" ""</seg>
<seg id="1881">"" "" "" "regarding the treatment duration, your doctor will determine the type of allergic rhinitis under which you suffer, and will determine how long you should take Aerius melting tablets." "" "" ""</seg>
<seg id="1882">"" "" "" "86 If you have forgotten the intake of Aerius fusion tablets if you have forgotten your dose in time, take it as soon as possible and then follow the normal treatment plan." "" "" ""</seg>
<seg id="1883">"" "" "" "Aerius melting tray is packed individually in blister packages with 5, 6, 10, 12, 30, 50, 60, 90 and 100 doses of melting tray." "" "" ""</seg>
<seg id="1884">"" "" "" "when taking Aerius hot tablets together with foods and beverages, Aerius melting tray does not need to be taken with water or any other liquid." "" "" ""</seg>
<seg id="1885">"" "" "" "if you have forgotten the intake of Aerius melting tray If you forget to take your dose in time, take it as soon as possible and then follow the normal treatment plan." "" "" ""</seg>
<seg id="1886">"" "" "" "after the launch of Aerius very rarely about cases of allergic reactions (difficulty breathing, whaling, hives, hives and swelling) and skin rash." "" "" ""</seg>
<seg id="1887">"" "" "" "Aerius solution to take is indicated for children between the ages of 1 and 11, young people (12 years and older) and adults, elderly people included." "" "" ""</seg>
<seg id="1888">"" "" "" "when the solution to import a application-injection for preparations for use with scalators, you can use this alternatively in order to take the appropriate amount solution." "" "" ""</seg>
<seg id="1889">"" "" "" "regarding the treatment duration, your doctor will determine the type of allergic rhinitis under which you suffer, and will determine how long you should take Aerius solution to capture." "" "" ""</seg>
<seg id="1890">"" "" "" "however, in children under 2 years diarrhoea, fever and sleeplessness frequent adverse events during adults were often tiredness, mouth drying and headache often than placebo were reported." "" "" ""</seg>
<seg id="1891">"" "" "" "97 Aerius solution for inclusion is available in bottles with a child-safe screw cap with 30, 50, 60, 100, 120, 150, 225 and 300 ml." "" "" ""</seg>
<seg id="1892">The 150 ml package size is a measuring spoon or application spills for use with scalating of 2.5 MLC and 5 ml doses.</seg>
<seg id="1893">"" "" "" "in June 2008, Novartis Vaccines and Diagnostics S.r.l. officially accepted the committee for Human Use of Aflunov to the prevention of aviar H5N1 influenza in adults and elderly people." "" "" ""</seg>
<seg id="1894">"" "" "" "Aflunov should be applied in adults and elderly people against flu, which is caused by the strain (type) H5N1 of influenza-A virus." "" "" ""</seg>
<seg id="1895">"" "" "" "this is a special kind of vaccine which might cause a future pandemic to protect a future pandemic." "" "" ""</seg>
<seg id="1896">"" "" "" "a influenza pandemic breaks out when a new strain of the Grippevirus appears, which can easily spread from man to person, because people still have no immunity (no protection) against it." "" "" ""</seg>
<seg id="1897">"" "" "" "in addition, the vaccine identifies the immune system contained in the vaccine contained in the vaccine as" physical alien "and prevents antibodies against it." "" "" ""</seg>
<seg id="1898">"" "" "" "this makes the immune system later, in a contact with an influenza of that pedims to form rapid antibody." "" "" ""</seg>
<seg id="1899">"" "" "" "afterwards, the diaphragm of the virus with the" surface antigens "(proteins on the membrane surface) separated, purified, purified and used as a component of the vaccine." "" "" ""</seg>
<seg id="1900">An inspection of some of the study sites prove that the study was not carried out according to the "good clinical practice" (GCP).</seg>
<seg id="1901">"" "" "" "thereby, the extent of clinical data base for evaluating the safety of the vaccine is not sufficient to satisfy the requirements of the guidelines of the EMEA (EMEA) vaccines." "" "" ""</seg>
<seg id="1902">"" "" "" "should you take part in clinical testing and need further information about your treatment, please contact your doctor." "" "" ""</seg>
<seg id="1903">"" "" "" "if you wish further information regarding the recommendations of the CHMP, please read the scientific discussion (also part of EPAR)." "" "" ""</seg>
<seg id="1904">"" "" "" "it is used in combination with other antiviral drugs for the treatment of adults and children over four years, which are infected with the Human Immunodeficiency syndrome (HIV), which are infected with the acquired immunodeficiency syndrome (AIDS)." "" "" ""</seg>
<seg id="1905">"" "" "" "for patients who cannot swallow the capsules, agase is indeed available as a solution for use, but this cannot be taken together with Ritonavir since the safety of this combination was not examined." "" "" ""</seg>
<seg id="1906">"" "" "" "agase should only be prescribed then if the doctor has taken, which has taken up the antiviral medicines in the patient, and the likelihood is judged that the virus is contested against the medicine." "" "" ""</seg>
<seg id="1907">"" "" "" "the recommended dose for patients over twelve years is 600 mg twice daily, taken together with twice daily 100 mg of Ritonavir and other antiviral drugs." "" "" ""</seg>
<seg id="1908">"" "" "" "in children between four and twelve years and in patients with a body weight of less than 50 kg, the recommended dose of asoil is based on body weight." "" "" ""</seg>
<seg id="1909">"" "" "" "in combination with other antiviral drugs, Ahaase reduces the HIV content in blood and holds it on a low level." "" "" ""</seg>
<seg id="1910">"" "" "" "AIDS is not to cure, however, the damage of the immune system can thus far go beyond the development of AIDS associated infections and diseases." "" "" ""</seg>
<seg id="1911">"" "" "" "in combination with other antiviral drugs, however, without Ritonavir, performed in two main studies with 736 HIV-infected adults who were previously untreated with Protease Inhibitors." "" "" ""</seg>
<seg id="1912">"" "" "" "the drug regimonavir reinforced drug asgenerators was compared at 206 adults who had used previously Proteasehemitions, compared with other Protease Inhibitors." "" "" ""</seg>
<seg id="1913">"" "" "" "the main indicator for efficacy was the proportion of patients with non-verifiable concentrations of HIV in the blood (Viruslast), or the change in viral load according to the treatment." "" "" ""</seg>
<seg id="1914">"" "" "" "in the study involving patients who had taken no proteasehema had taken a viral load under 400 copies / ml as under placebo, but asgenerators were less effective than Injavir." "" "" ""</seg>
<seg id="1915">"" "" "" "in children, Alaase also reduced the virus, but of the children who were treated earlier with Proteasehemiah, were very few on the treatment." "" "" ""</seg>
<seg id="1916">"" "" "" "in the study of adults who were treated earlier with Proteashibitors, dealing with Ritonavir reinforced medicines Ahaase after 16-week treatment as effective as other Protease of Protease:" "" "" ""</seg>
<seg id="1917">"" "" "" "in patients with HIV, which was resistant to four other proteins, it came together with Ritonavir to a stronger waste of viral load after four weeks as in the patients whose previous Protease of hibitors continued to:" "" "" ""</seg>
<seg id="1918">The most common side effects of Ahaase (observed in more than 1 out of 10 patients) are headaches, diarrhoea (diarrhea), sea sea (nausea). vomiting, skin rash and Fatigue (fatigue).</seg>
<seg id="1919">2 / 3 Alaase must not be applied in patients who may possibly be insensitive (allergic) against amboar or any of the other ingredients.</seg>
<seg id="1920">Agasy may also not be applied in patients who are degraded to currants (an herbal supplement for the treatment of depression) or drugs that are equally affected as Alaase and are taken in high concentrations in the blood health.</seg>
<seg id="1921">"" "" "" "like with other medicines against HIV, the risk of a body fat (changes in the distribution of the body fat), an osteonectomy (symptoms of infection, caused by the restful immune system)." "" "" ""</seg>
<seg id="1922">"" "" "" "in combination with other antiretroviral drugs, the Committee for Human Diagnosis in combination with other antiretroviral drugs to treat HIV-1 infected adults and children over four years compared to the risks." "" "" ""</seg>
<seg id="1923">"" "" "" "agase is usually taken together with the pharmacokinetic amplifier Ritonavir, but the Committee established that the benefits of asticase is taken in combination with Ritonavir in patients who had never been captured as a protector." "" "" ""</seg>
<seg id="1924">"" "" "" "Ahaase was originally registered under" extraordinary circumstances, "at the time the approval of scientific reasons only limited information." "" "" ""</seg>
<seg id="1925">"" "" "" "in October 2000, the European Commission issued Glaxo Group Limited for placing the transport of ads in the entire European Union." "" "" ""</seg>
<seg id="1926">"" "" "" "in combination with other antiretroviral drugs for the treatment of HIV-1- infected, Protease of adults and children aged 4 years and older." "" "" ""</seg>
<seg id="1927">"" "" "" "usually, Ahaase capsules should be administered to the pharmacokinetic feat of Amonavir together with low doses of Ritonavir (see sections 4.2 and 4.5)." "" "" ""</seg>
<seg id="1928">The use of amphybr should take place under consideration of the individual viral resistance and treatment of the patient (see section 5.1).</seg>
<seg id="1929">The bioavailability of Ambleavir as a solution to take up is 14% less than capsule; therefore Agenerating capsules and solution are not interchangeable to one milligrams per milligrams (see section 5.2).</seg>
<seg id="1930">The recommended dose for asgenerators capsules is 600 mg of Ammelavir twice daily with 100 mg Ritonavir twice daily in combination with other antiretroviral drugs.</seg>
<seg id="1931">"" "" "" "2 If Ahaase capsules are applied without the amplified addition of Ritonavir (boosted), higher doses of agase (1200 mg twice daily) must be applied." "" "" ""</seg>
<seg id="1932">The recommended dose for agase capsules is 20 mg Ambleavir / kg body weight twice daily in combination with other antiretroviral drugs up to a daily total dose of 2400 mg Amosavir which should not be exceeded (see section 5.1).</seg>
<seg id="1933">"" "" "" "the pharmacokinetics, efficacy and safety of agase in combination with low doses of Ritonavir or other Protease Inhibitors were not studied for children." "" "" ""</seg>
<seg id="1934">Agase is not recommended for the use with children under 4 years of age due to the lack of data for the inconsistency and effectiveness (see section 5.2).</seg>
<seg id="1935">"" "" "" "based on pharmacokinetic data, the dose should be reduced to 450 mg twice daily and in patients with heavy liver failure to 300 mg twice daily." "" "" ""</seg>
<seg id="1936">"" "" "" "the simultaneous application is to be contraindicated in patients with light or excessive liver failure when patients with severe liver function, it is contraindicated (see Section 4.3)." "" "" ""</seg>
<seg id="1937">Agase may not be given at the same time with medicines which have a low therapeutic width and also represent substrates of the cytochrom P450-Isoenzyme 3A4 (CYP3A4).</seg>
<seg id="1938">Vegetable preparations containing currants (hypericum perforatum) may not be used because of the risk of reduced plasma concentrations and a diminished therapeutic effect of amphybr (see Section 4.5).</seg>
<seg id="1939">"" "" "" "patients should be advised that atriase or any other antiretroviral therapy cannot lead to an infection of HIV infection, and that they may continue to develop opportunistic infections or other complications of an HIV infection." "" "" ""</seg>
<seg id="1940">"" "" "" "the current antiretroviral therapy including treatment with agase prevents the risk of transmission of HIV on others by sexual contact, or contamination with blood." "" "" ""</seg>
<seg id="1941">"" "" "" "usually, Ahaase capsules are used together with low doses of Ritonavir and in combination with other antiretroviral drugs (see section 4.2)." "" "" ""</seg>
<seg id="1942">Patients who suffer from chronic hepatitis B or C and treated with an antiretroviral combination therapy have increased risk of severe liver damage with potentially fatal course.</seg>
<seg id="1943">"" "" "" "for the case of simultaneous treatment of hepatitis B or C, please read the relevant information about this medicine." "" "" ""</seg>
<seg id="1944">Patients with existing restricted liver function including a chronic-active Hepatitis show increased incidence of liver function disturbances under an antiretroviral combination therapy and should be monitored according to clinical practice.</seg>
<seg id="1945">The simultaneous use of asticase and ritonavir with fluticular or other glucocorticoids that are not recommended by CYP3A4 (see Section 4.5) for the possible treatment of the risk of corticosteroid effects (see Section 4.5).</seg>
<seg id="1946">Since the formation change of the HMG-Coa-reductase inhibitor of bevastatin is strongly recommended by CYP3A4 because of elevated risk of risk of Lovastatin and Simvastatin which is not recommended.</seg>
<seg id="1947">"" "" "" "4 For some medicines that cause serious or life-threatening side effects, like carbamazepine, phenytoin, phenytoin, tricyclic antidepressants and warfarin, are available methods for determining the substance concentration." "" "" ""</seg>
<seg id="1948">"" "" "" "for patients who take these drugs at the same time, Alaase may be less effective due to reduced plasma level of amphyper cent (see Section 4.5)." "" "" ""</seg>
<seg id="1949">"" "" "" "due to the possibility of metabolic exchange with Amberavir, the effectiveness of hormonal contraceptives may be changed, however the information is not sufficient to estimate the type of interactions." "" "" ""</seg>
<seg id="1950">"" "" "" "when methadon is given at the same time with Amberjr, patients should therefore be monitored in opatentaries symptoms, especially if there are still low doses of Ritonavir." "" "" ""</seg>
<seg id="1951">"" "" "" "due to the potential risk of a toxicity, this Darreichase solution is contraindicated for children under one age of four years, should be applied with caution at certain other patient groups." "" "" ""</seg>
<seg id="1952">Agase should be set in duration 5 when a rash of systemic or allergic symptoms is accompanied or the mucous membranes are involved (see Section 4.8).</seg>
<seg id="1953">"" "" "" "patients receiving antiretroviral therapy including proteasehemiah, was reported using the occurrence of diabetes mellitus, hyperglycaemia or an exazheration of an existing diabetes mellitus." "" "" ""</seg>
<seg id="1954">"" "" "" "many of the patients had other diseases associated with their therapy medications, associated with the development of diabetes mellitus or hyperglycemia." "" "" ""</seg>
<seg id="1955">B. "" "" "" B. higher age, and with drug addicts, such as a longer lasting antiretroviral treatment and associated metabolic disorders. "" "" "" "</seg>
<seg id="1956">"" "" "" "with haemhibitors (type A and B), which were treated with Proteashibitors, reports on an increase of bleeding including spontaneous cutaneous hematomas and hemerthrosis." "" "" ""</seg>
<seg id="1957">"" "" "" "in the introduction of an antiretroviral combination therapy (ART), an antiretroviral combination therapy (ART) can develop an inflammatous reaction to asymptomatic or remodal opportunistic infections, which lead to severe clinical states or deterioration of symptoms." "" "" ""</seg>
<seg id="1958">"" "" "" "although a multifactorial etiology is adopted (among them the use of corticosteroids, alcohol use, severe immunoscope, higher body mass index), were reported in patients with advanced HIV disease and / or long-term application of antiretroviral combination therapy (ART)." "" "" ""</seg>
<seg id="1959">CYP3A4 Substrate with low therapeutic lavisors may not be given at the same time with medicines which have a low therapeutic width and also represent substrates of the cytochrom P450-Isoenzyme 3A4 (CYP3A4).</seg>
<seg id="1960">CYP2D6 substrates with a low therapeutic width of asonavir must not be joined together with medicines that are primarily connected to CYP2D6 and are linked to increased plasma torch with severe and / or life-threatening side effects.</seg>
<seg id="1961">"" "" "" "it was shown that Rifampicin causes a 82% decrease in AUC of Ambleavir, which can lead to a virological understanding and a resistance of resistance." "" "" ""</seg>
<seg id="1962">"" "" "" "in attempting to compensate the humbled plasma torch in combination with Ritoravir, often unwanted effects were observed at the liver." "" "" ""</seg>
<seg id="1963">Hypericum (Hypericum perforatum) The serum level of Ammelavir can be decreased by the simultaneous application of plant preparations with currants (hypericum perforatum).</seg>
<seg id="1964">"" "" "" "when a patient is already incorporated at Johannisweed, the amuses are blown up and when possible to validate the virus and vaporize." "" "" ""</seg>
<seg id="1965">A dose adjustment for any of the medicine is not required if nelfinavir is administered together with Amberavir (see also efavirenz below).</seg>
<seg id="1966">508% increase; for Cmax it is reduced by 30% if Ritonavir (100 mg twice daily) is given in combination with Amberavir capsules (600 mg twice daily).</seg>
<seg id="1967">"" "" "" "in clinical trials, doses of 600 mg of Amonavir were used twice daily and also administered oronavir 100 mg twice daily, with efficacy and harmlessness of this matriematography." "" "" ""</seg>
<seg id="1968">52% degraded when Ammelavir (750 mg twice daily) in combination with caletra (400 mg Lopinavir + 100 mg of Ritonavir twice daily) was administered.</seg>
<seg id="1969">"" "" "" "the Cmin values of Ammelavir (600 mg. twice daily) with calorra (600 mg. of Lopinavir twice daily) were reached, are approximately 40 to 50% lower than if amhyloavir is administered twice daily in combination with 100 mg of Ritonavir twice daily." "" "" ""</seg>
<seg id="1970">"" "" "" "a dosing system for the simultaneous administration of Ambleavir and Kaletra may not be given, however, a close monitoring is recommended as the effectiveness and imperfection of this combination is not known." "" "" ""</seg>
<seg id="1971">"" "" "" "no pharmacokinetic study conducted for the application of asrease in combination with Didanosin, however, is recommended for at least one hour due to the antageous component of Didanosin." "" "" ""</seg>
<seg id="1972">This is why in combination with amavirenz in combination with Amberavir (600 mg twice daily) and Ritonavir (100 mg twice daily) no dose adjustment is required.</seg>
<seg id="1973">The treatment with efavirenz in combination with Amberavir and Saquinavir is not recommended because the exposure of both Proteasehemmer would suffice.</seg>
<seg id="1974">The effect of Nevirapin on other proteins of this and existing limited data suggest that Nevirapin may reduce serum concentration of Ammelavir.</seg>
<seg id="1975">"" "" "" "if these drugs should be used simultaneously, caution is advisable because Delavirdin could be less effective because of the reduced and possibly subtherapeutic plasma level." "" "" ""</seg>
<seg id="1976">"" "" "" "when these drugs are used together, caution is advisable; a thorough clinical and virological supervision should be undertaken as an accurate prediction of the effect of Amberavir and Ritonavir's combination is difficult." "" "" ""</seg>
<seg id="1977">The simultaneous administration of Ammelavir and Rifabutin resulted in a rise in the plasma concentration of 193% and thus resulted in a rise in the side effects associated with Rifabutin.</seg>
<seg id="1978">"" "" "" "if it is necessary for clinical reasons, Rifabutin will be taken along with agase in at least half of the recommended dose, though there are no clinical data available for this." "" "" ""</seg>
<seg id="1979">Pharmacokinetic studies with oases in combination with erythromycin have not been carried out however the plasma level of both drugs could be increased in the case of simultaneous administration.</seg>
<seg id="1980">The simultaneous use of twice daily 700 mg Fosamphazole once daily led to an increase of the Cmax of Ketoconazole a day which was observed after 200 mg of Ketoconazole a day without the simultaneous use of Fosamphazole by Ritoravir once daily.</seg>
<seg id="1981">"" "" "" "other medicines that are listed below are also listed below, including substrates, inhibitor or inductors of CYP3A4, if they are used together with agase, may lead to interactions." "" "" ""</seg>
<seg id="1982">"" "" "" "patients should therefore be applied to toxic reactions which are linked to these medicines, if they are applied in combination with agase." "" "" ""</seg>
<seg id="1983">"" "" "" "based on the data of other proteins, it is recommended that Antazida is not used at the same time as ads, as it can occur to resorption disorders." "" "" ""</seg>
<seg id="1984">"" "" "" "the simultaneous use of anticonvulcanines which are known as enzymes (phenytoin, phenobarbital, carbamazepine), with Ambassavir, can lead to a decrease of the plasma torch of Amberavir." "" "" ""</seg>
<seg id="1985">"" "" "" "the serum concentrations of calcium channel-blockers such as Amlodipine, diodipine, diodipine," "" "" ""</seg>
<seg id="1986">"" "" "" "increasing intake with asteroid can increase their blood concentrations in combination with PDE5 inhibitors, including hypotension, vision disorders and priapism (see Section 4.4)." "" "" ""</seg>
<seg id="1987">"" "" "" "in a clinical study, in the Ritonavir 100 mg capsules twice daily along with 50 µg fluticasonpropionate (4 times daily) over 7 days were decreased, while endogenous cortisol decreased by approximately 86% (90% turntable interval 82 to 89%)." "" "" ""</seg>
<seg id="1988">"" "" "" "as a result, the simultaneous administration of asonavir together with these glucocorticoids is not recommended that the potential benefit of treatment exceeds the risk of systemic corticosteroid effects (see Section 4.4)." "" "" ""</seg>
<seg id="1989">"" "" "" "with HMG-CoA-reductase inhibitors such as Lovastatin and Simvastatin, whose infection changes greatly increased from CYP3A4, are expected to expect to increase influx of orders at the same time." "" "" ""</seg>
<seg id="1990">"" "" "" "since plasma level increases in these HMG-CoA reductase inhibitors, including a habdomyolysis, the combined application of this medicine is not recommended with Amberjr." "" "" ""</seg>
<seg id="1991">"" "" "" "there is a common monitoring of therapeutic concentrations as well as stabilization of the mirror, since the plasma concentrations of Cyclosporin, Rapamycin and tacrolimus can be increased with the current gift of amphybr (see Section 4.4)." "" "" ""</seg>
<seg id="1992">"" "" "" "therefore, Ahaase must not be used together with oral incorporated midazolam (see Section 4.3), while using Agenerase with parenteral Midazolam caution is advisable." "" "" ""</seg>
<seg id="1993">Data for simultaneous use of parenteral midazolam with other proteaseinhibitors refer to a possible increase in the plasma level of Midazolam to 3- or 4-times.</seg>
<seg id="1994">"" "" "" "if methadon is administered together with Amberavir, the patients should therefore be monitored in opatentaries symptoms, especially if there are still low doses of Ritonavir." "" "" ""</seg>
<seg id="1995">"" "" "" "due to the reduced reliability of historic Verdes, no recommendation can be made, as Amberavir is administered at the same time with methadon." "" "" ""</seg>
<seg id="1996">"" "" "" "with an associated gift of warfarin or other oral anticoagulants along with agase, an increased control of INR (International standardization) is strongly recommended (see Section 4.4)." "" "" ""</seg>
<seg id="1997">"" "" "" "the effect of an additional administration of Ritonavir on hormonal contraceptives is not predictable, therefore alternative methods of contraception are recommended." "" "" ""</seg>
<seg id="1998">Careful monitoring of the therapeutic effects and side effects of tricyclical anti-depressants (for example desipramin and Nortryptilin) is recommended for the current gift of aging (see Section 4.4).</seg>
<seg id="1999">"" "" "" "during pregnancy, this medicine may only be applied after careful consideration of the possible use of the potential for the mother in comparison to the potential risks for the fetus." "" "" ""</seg>
<seg id="2000">"" "" "" "in the milk of lactic rats, Ambleavir-related substances were not known, however, it is not known whether Amberavir overrides his breast milk." "" "" ""</seg>
<seg id="2001">A reproduction study on pregnant rats who was administered to the Uterus by the end of the lactation period till the end of the lactation period showed a decreased increase in the 12 body weight.</seg>
<seg id="2002">"" "" "" "further development of the traceability, including Fertilisation and Reproduction capacity was not impaired by the addition of Amberavir to the dam." "" "" ""</seg>
<seg id="2003">The harmlessness of agase has been studied in adults and in children under 4 years in controlled clinical trials in combination with various other antiretroviral drugs.</seg>
<seg id="2004">"" "" "" "most of the side-related side-effects associated with agase treatment were slightly up to unduly pronounced, and resulted rarely to treatment." "" "" ""</seg>
<seg id="2005">"" "" "" "in many of these events, it is not clear whether they are used in connection with the intake of asgenerators or another at the same time to the HIV treatment." "" "" ""</seg>
<seg id="2006">"" "" "" "most of the side-mentioned events originate from two clinical trials (PRODU3001, PROAB3006) in which patients were not treated twice daily with Protease Inhibitors." "" "" ""</seg>
<seg id="2007">Events (Grade 2 to 4) which were standing by the investigators in connection with the study medicine and performed more than 1% of the patients as well as in the treatment of occurring lab changes (Grade 3 to 4).</seg>
<seg id="2008">"" "" "" "antiretroviral combination therapy is associated with a redistribution of the body fat, including a loss of peripheral and fskin fatty tissue, increases intraocular and visceral fat tissue, hypertrophie of breasts and dorsal fat collection (pens)." "" "" ""</seg>
<seg id="2009">Among 113 antiretroviral treatment with lamivudr in combination with lamivudine / Zidovudin had been treated for a medium term of 36 weeks and was observed (&lt; 1%).</seg>
<seg id="2010">In the study PROAB 3006 presented at 245 NRTI- in previously treated patients under Amberavir 7 cases (3%) in comparison to 27 cases (11%) in combination with different NRTIs over a medium term of 56 weeks (p &lt; 0.0001).</seg>
<seg id="2011">"" "" "" "skin rash were usually slightly pronounced, erythematry or makulopapal nature, with or without itching and disappeared during the second treatment week and disappeared during the second treatment week, without the treatment with Amberavir had to be aborted." "" "" ""</seg>
<seg id="2012">Cases of osteoneksis were reported particularly in patients with general known risk factors, advanced HIV disease or long-term application of a antiretroviral combination therapy (ART).</seg>
<seg id="2013">"" "" "" "in the introduction of an antiretroviral combination therapy (ART), an antiretroviral combination therapy (ART) can develop an inflammatory response to asymptomatic or remodal opportunistic infections (see Section 4.4)." "" "" ""</seg>
<seg id="2014">"" "" "" "patients with PI pre-treated patients who were observed twice daily with low dose of treatment (degrees 2 to 4) and laboratory changes (degree 2 to 4) and laboratory changes (degree 2 to 4) and of patients, which were treated with low dose ritonavir, were very frequently played." "" "" ""</seg>
<seg id="2015">"" "" "" "in case of overdosage the patient is observable to observe a toxication (see Section 4.8), if necessary, necessary support measures are necessary." "" "" ""</seg>
<seg id="2016">Ammelavir binds to the active centre of the HIV-1 protease and thereby prevents the process of viral gag- and fermentation polyprofiled markings with the result of an education unmature, non-infectious viral particles.</seg>
<seg id="2017">Antiviral activity of Ammelavir in vitro on HIV-1 IIIB has been investigated by acute lymphoblastic cell lines (MT-4, CEM-CCRF and H9) as well as peripheral blood lymphocytes.</seg>
<seg id="2018">The 50% inhibitors (IC50) of Ammelavir is in the range from 0.012 to 0.08 µM of acute cells and amounts to 0.41 µM in chronically infected cells</seg>
<seg id="2019">The connection between the activity of Ambleavir against HIV-1 in vitro and the inhibition of HIV-1 replication in humans is not yet defined.</seg>
<seg id="2020">In the treatment of antiretroviral patients with the currently approved Fosamprenavir / Ritonavir-Dosidings were observed - as with other ritonavir bleoored treatment schemas with proteasephores - the described mutations rarely observed.</seg>
<seg id="2021">"" "" "" "in sixteen of 434 antiretroviral patients receiving 100mg of Fosonavir twice daily in the study ESS100732, a virological procedure occurred within 14 days, with 14 isolates could be studied." "" "" ""</seg>
<seg id="2022">A genotypic analysis of the Isolate of 13 out of 14 children where a virological failure occurred within the 59 days with proteasehemants showed non-treated patients who were similar to those with adults.</seg>
<seg id="2023">"" "" "" "L10F / I / V, V11R, E32I, E32V, E71V, E71V, I62V, I62V, I62V, I62V, I36V, I85V, L90M and I93L / M." "" "" ""</seg>
<seg id="2024">In the study APV30003 and its extension APV30005 (700 mg Fosamprenavir twice daily: n = 107) in patients with virological verses of over 96 weeks in patients with Vietnamese failure to occur:</seg>
<seg id="2025">Based on genotypic resistance setting analyses genotypic interpreter systems can be applied to the assessment of the activity of Amberavir / Ritoravir / Ritoravir / Ritoravir and Fosamprenavir / Ritoravir when patients with Proteasehemmer-resistant isolates can be applied.</seg>
<seg id="2026">The current (July 2006) ANRS-AC algorithm for Fosamprenavir / Ritoravir defines resistance than the presence of the mutations V32I + 1472A / C / F / F / V / F / F / V / F / F / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V / V.</seg>
<seg id="2027">"" "" "" "conclusions regarding the relevance of specific mutations or mutation samples can be subject to changes due to additional data, and it is recommended always to determine the current interpreter systems analysis of the results of resistance tests." "" "" ""</seg>
<seg id="2028">Phenotypic resistance of the phenotype based phenotypic interpreter systems can be applied in combination with the genotypical data for the assessment of the activity of Amlaavir / Ritoravir / Ritoravir / Ritoravir and Fosamprenavir / Ritoravir when patients with Proteasehemmer-resistant isolates can be applied.</seg>
<seg id="2029">Companies that distribute diagnostic resistance tests have been developed clinically-phenotypic Cut-offs (Interface points) for FPV / RTV which can be used to interpret results of a resistance tests.</seg>
<seg id="2030">"" "" "" "each of these four with a reduced sensitivity of amponavir associated genetic patterns creates a certain cross-resistant against Ritonavir, the sensitivity to Injavir, nelfinavir and Saquinavir." "" "" ""</seg>
<seg id="2031">"" "" "" "there are currently data on the cross-resistance between Amberavir and other Protease Inhibitors for all 4 Fosamprenavir resistance, either alone or in combination with other mutations." "" "" ""</seg>
<seg id="2032">On the basis of twenty-five antiretroviral attacks (one of them denied a resistance against Lopinavir / Ritoravir (three of 25 Isolate), Injavir / Ritonavir (three of 24 isolates) and Tipranavir / Ritonavir (three of 24 isolates) and Tipranavir / Ritonavir (four out of 24 isolates).</seg>
<seg id="2033">"" "" "" "vice versa, Amonavir retains its activity against some other Protease-resistant isolates; obtaining these activity seems depending on the number and type of resistance mutations in the isolate." "" "" ""</seg>
<seg id="2034">Early departure of a failed therapy is recommended to keep the acquisition of a wide range of mutations in the limits that can affect the subsequent treatment of nocturnal effects.</seg>
<seg id="2035">"" "" "" "in combination with Ritonavir 100 mg twice daily, with a randomised study (600 mg twice daily) and Nustiflare (600 mg twice daily) and Nustiflare aloga (NRTI) or standard therapy (standard of care, Soc) with a PI, predominantly with low-dosed knonavir." "" "" ""</seg>
<seg id="2036">One hundred threescore three (n = 163) patients with proven virus sensitivity to asoil and at least another PI and at least one NRTI were included in the partial-study A of PRO30017.</seg>
<seg id="2037">"" "" "" "the primary analysis presented the non-superiority of APV / Ritonavir compared to the adoption of time (AAUCMB) in the viral load (HIV-1 RNA) compared to 16 weeks, with a non-sub-wave of 0,4 log10 copies / ml." "" "" ""</seg>
<seg id="2038">"" "" "" "the evidence of the efficacy of ungeboosterous ads is based on two uncontrolled studies with a total of 288 HIV-infected children aged 2 to 18, of which 152 were treated with PI." "" "" ""</seg>
<seg id="2039">"" "" "" "in the studies, Agenerate solution for intake and capsules of 15 mg / kg has three times daily, 20 mg / kg twice daily, 20 mg / kg twice daily, whereas the majority of patients received 20 mg / kg twice daily." "" "" ""</seg>
<seg id="2040">There was no low dose of doonavir at the same time; the majority of the patients treated with PI had previously given at least one (78%) or two (42%) of the NRTIs.</seg>
<seg id="2041">"" "" "" "after 48 weeks, about 25% of patients included in the study a plasma-1 RNA concentration of &lt; 10,000 copies / ml and 9% &lt; 400 copies / ml in a median increase in CD4 cell number of 26 cells / mm ³ (n = 74)." "" "" ""</seg>
<seg id="2042">19 Based on this data should be considered with the treatment of treatment optimisation using PI in the expected benefits of "ungeboosterated" agase. "</seg>
<seg id="2043">"" "" "" "following oral administration, the average duration (Tmax) to the maximum serum concentration of Ambleavir approximately 1 to 2 hours for the capsule and approximately 0.5 to 1 hour for solution." "" "" ""</seg>
<seg id="2044">508% increase then reduced by 30% for Cmax. when Ritonavir (100 mg twice daily) was administered together with Amberavir (600 mg twice daily).</seg>
<seg id="2045">The administration of Ambleavir with a meal leads to a 25% decrease in AUC but has no effect on the concentration of Ambleavir 12 hours after dosage (C12).</seg>
<seg id="2046">"" "" "" "therefore, the minimum concentration in the Steady State (Cmin, ss) remained unaffected by the food intake, although the simultaneous food intake decreased and the rate of resorption was influenced." "" "" ""</seg>
<seg id="2047">The apparent distribution volume is approximately 430 liters (6 l / kg with a body weight of 70 kg) and it is possible to close a large distribution volume and an unhindered penitration of Ammelavir from the bloodstream into the tissue.</seg>
<seg id="2048">"" "" "" "this change leads to a decrease in the total concentration of active substance in the plasma, with the amount of unused amboar that remains the active part, probably remains unchanged." "" "" ""</seg>
<seg id="2049">"" "" "" "while the absolute concentration of imperative amhybaboo remains constant, the percentage of free active ingredients during the total drug concentration in the Steady State can vary across the range from Cmax, ss to Cmin, ss." "" "" ""</seg>
<seg id="2050">"" "" "" "therefore, medicines that CYP3A4 should be induced or inhibit a medium of CYP3A4 if they are given with caution (see sections 4.3, 4.4 and 4.5)." "" "" ""</seg>
<seg id="2051">"" "" "" "the gift of veins capsules, either 20 mg / kg twice or 15 mg / kg three times daily, leads to a similar daily Amberavir exposition like in adults with a dosage of 1200 mg twice daily." "" "" ""</seg>
<seg id="2052">Amber cavir is made from the solution 14% less bioavailable than from capsules; therefore Agenerate solution and asgenerators capsules are not exchangeable to a billionset.</seg>
<seg id="2053">"" "" "" "also, the renal Clearance of Ritonavir is negligibly neglected, therefore, the effect of a renal functioning on the elimination of Amberavir and Ritonavir is likely to be low." "" "" ""</seg>
<seg id="2054">These treatments lead to Ammelavir plasma mirrors comparable to those that are achieved at healthy volunteers according to a dose of 1200 mg Ambleavir twice daily without a simultaneous administration of knonavir.</seg>
<seg id="2055">"" "" "" "in long-term studies on cranogenicity with Amberavir in mice and rats, in cases of male animals, Adenepatobiliary Adenosae on humans, after two daily gift of 1200 mg Amberavir, promised." "" "" ""</seg>
<seg id="2056">"" "" "" "the 21 underlying mechanisms for the formation of hepatocellular civilians and carcinomas have not yet been solved, and the relevance of these observed effects for human beings is unclear." "" "" ""</seg>
<seg id="2057">"" "" "" "however, from the current exposure data on humans, both clinical studies as well as from the therapeutic application, fluctuates little evidence of the adoption of a clinical relevance of these findings." "" "" ""</seg>
<seg id="2058">"" "" "" "in a standard battery of In-vivo- and in-vitro genotoxicity testing, microkernel test for rats and chromosome analysis, Amberavir was neither mutations nor genotoxic." "" "" ""</seg>
<seg id="2059">"" "" "" "these liver toxicity can be monitored and demonstrated in clinical everyday life by measuring AST, ALT and the activity of alkaline phosphatase." "" "" ""</seg>
<seg id="2060">"" "" "" "in clinical trials, no significant metastasis was observed in patients, either during the treatment of Ahaase or after the end of the treatment." "" "" ""</seg>
<seg id="2061">"" "" "" "studies on the toxicity of young animals, which were treated from 4 days at the age of 4, showed high mortality in the control of the animals and those with Amberavir." "" "" ""</seg>
<seg id="2062">"" "" "" "in a systemic plasma exposure, which was significantly higher (rabbits) or not significantly higher (rats) than the expected exposition of minor changes including thymuselongation and minor skeleton changes, which indicate a delayed development." "" "" ""</seg>
<seg id="2063">24 If Ahaase capsules are applied without the increased addition of Ritonavir (boosted) higher doses of asthenase (1200 mg twice daily) must be applied.</seg>
<seg id="2064">The recommended dose for agase capsules is 20 mg Ambleavir / kg body weight twice daily in combination with other antiretroviral drugs up to a daily total dose of 2400 mg Amosavir which should not be exceeded (see section 5.1).</seg>
<seg id="2065">"" "" "" "the simultaneous application is to be contraindicated in patients with low or light liver failure when patients with severe liver function, it is contraindicated (see Section 4.3)." "" "" ""</seg>
<seg id="2066">"" "" "" "26 For some medicines that cause serious or life-threatening side effects, like carbamazepine, phenytoin, phenytoin, tricyclic antidepressants and warfarin, are available methods for determining the substance concentration." "" "" ""</seg>
<seg id="2067">Agase should be set in duration 27 if a rash of systemic or allergic symptoms is accompanied or the mucous membranes are involved (see Section 4.8).</seg>
<seg id="2068">"" "" "" "an increased risk of a lipodocytic was associated with individual factors such as older age, and with drugs-related factors such as a longer lasting antiretroviral treatment and related metabolic disorders." "" "" ""</seg>
<seg id="2069">"" "" "" "it was shown that Rifampicin causes a 82% decrease in AUC of Ambleavir, which can lead to a virological understanding and a resistance of resistance." "" "" ""</seg>
<seg id="2070">508% increase; for Cmax it is reduced by 30% if Ritonavir (100 mg twice daily) is given in combination with Amberavir capsules (600 mg twice daily).</seg>
<seg id="2071">"" "" "" "the Cmin values of Ammelavir (600 mg. twice daily) with calorra (600 mg. of Lopinavir twice daily) were reached, are approximately 40 to 50% lower than if amhyloavir is administered twice daily in combination with 100 mg of Ritonavir twice daily." "" "" ""</seg>
<seg id="2072">"" "" "" "a dosing system for the simultaneous administration of Ambleavir and Kaletra may not be given, however, a close monitoring is recommended as the effectiveness and imperfection of this combination is not known." "" "" ""</seg>
<seg id="2073">The treatment with efavirenz in combination with Amberavir and Saquinavir is not recommended because the exposure of both Proteasehemmer would suffice.</seg>
<seg id="2074">"" "" "" "when these drugs are used together, caution is advisable; a thorough clinical and virological supervision should be undertaken as an accurate prediction of the effect of Amberavir and Ritonavir's combination is difficult." "" "" ""</seg>
<seg id="2075">"" "" "" "if it is necessary for clinical reasons, Rifabutin will be taken along with agase in at least half of the recommended dose 31, though there are no clinical data available for this." "" "" ""</seg>
<seg id="2076">"" "" "" "the serum concentrations of calcium channel-blockers such as Amlodipine, diodipine, diodipine," "" "" ""</seg>
<seg id="2077">"" "" "" "in a clinical study, in the Ritonavir 100 mg capsules twice daily along with 50 µg fluticasonpropionate (4 times daily) over 7 days were decreased, while endogenous cortisol decreased by approximately 86% (90% turntable interval 82 to 89%)." "" "" ""</seg>
<seg id="2078">"" "" "" "with an associated gift of warfarin or other oral anticoagulants along with agase, an increased control of INR (International standardization) is strongly recommended (see Section 4.4)." "" "" ""</seg>
<seg id="2079">The simultaneous administration of Ortho-Novum 1 / 35 (0.035 mg of ethinylestradiol plus 1.0 mg Norethindrone) resulted in a decrease in AUC and Cmin from Amberavir by 22% respectively.</seg>
<seg id="2080">"" "" "" "during pregnancy, this medicine may only be applied after careful consideration of the possible use of the potential for the mother in comparison to the possible risks for the fetus." "" "" ""</seg>
<seg id="2081">A reproduction study on pregnant rats that was administered by the armor in the uterus until the end of the lactation period Ammelavir was still a decreased increase in body weight during the lactation period.</seg>
<seg id="2082">The harmlessness of agase has been studied in adults and in children under 4 years in controlled clinical trials in combination with various other antiretroviral drugs.</seg>
<seg id="2083">"" "" "" "in case of overdosage the patient is observable to observe a toxication (see Section 4.8), if necessary, necessary support measures are necessary." "" "" ""</seg>
<seg id="2084">Antiviral activity of Ammelavir in vitro on HIV-1 IIIB has been investigated by acute lymphoblastic cell lines (MT-4, CEM-CCRF and H9) as well as peripheral blood lymphocytes.</seg>
<seg id="2085">The 50% inhibitors (IC50) of Ammelavir is in the range from 0.012 to 0.08 µM with acute infected cells (1 µM = 0.50 µg / ml).</seg>
<seg id="2086">"" "" "" "vice versa, Amonavir retains its activity against some other Protease-resistant isolates; obtaining these activity seems depending on the number and type of resistance mutations in the isolate." "" "" ""</seg>
<seg id="2087">"" "" "" "based on this data, treatment optimization was taken into account with PI pre-treated children of the expected benefits of" ungeboosterated "agase." "" "" ""</seg>
<seg id="2088">"" "" "" "while the absolute concentration of imperative amhybaboo remains constant, the percentage of free active ingredients during the total drug concentration in the Steady State can vary across the range from Cmax, ss to Cmin, ss.." "" "" ""</seg>
<seg id="2089">"" "" "" "therefore, medicines that CYP3A4 should be induced or inhibit a medium of CYP3A4 if they are given with caution (see sections 4.3, 4.4 and 4.5)." "" "" ""</seg>
<seg id="2090">"" "" "" "also, the renal Clearance of Ritonavir is negligibly neglected. therefore, the effect of a renal functioning on the elimination of amponavir and Ritonavir is likely to be low." "" "" ""</seg>
<seg id="2091">"" "" "" "in long-term studies on the lumberogenicity with Amberavir in mice and rats, Adenosatocytes Adenosporous Adenosporous Adenosae on men after two hours of daily gift of 1200 mg of Amberavir." "" "" ""</seg>
<seg id="2092">The underlying mechanism for the formation of hepatocytes Adenosome and carcinomas have not yet been solved and the relevance of these observed effects for human beings is unclear.</seg>
<seg id="2093">"" "" "" "however, from the current exposure data on humans, from clinical studies as well as from the therapeutic application, however little indications for the adoption of a clinical relevance of these findings." "" "" ""</seg>
<seg id="2094">"" "" "" "in a standard battery of In-vivo- and in-vitro genotoxicity testing, microkernel test for rats and chromosome analysis, Amberavir neither mutations nor darotoxic." "" "" ""</seg>
<seg id="2095">"" "" "" "studies on the toxicity of young animals, which were treated from 4 days at the age of 4, showed high mortality in the control of the animals and those with Amberavir." "" "" ""</seg>
<seg id="2096">"" "" "" "these results let us make, that in young they are not fully mature, Amberavir, or other critical components of the formulation." "" "" ""</seg>
<seg id="2097">"" "" "" "in combination with other antiretroviral drugs to treat HIV-1 infected, Proteasehemently (PI) -pre-treated adults and children aged 4 years." "" "" ""</seg>
<seg id="2098">"" "" "" "the benefits of using Ritonavir," asmodic "solution to capture, has not been treated with PI previously treated patients in PI." "" "" ""</seg>
<seg id="2099">The bioavailability of Ambleavir as a solution to take up is 14% less than capsule; therefore Agenerating capsules and solution are not interchangeable to one milligrams per milligrams (see section 5.2).</seg>
<seg id="2100">"" "" "" "patients should be able to swallow capsules, if they are able to swallow capsules, use the solution to redeem (see Section 4.4)." "" "" ""</seg>
<seg id="2101">The recommended dose for agase solution is 17 mg (1.1 ml) Ambleavir / kg body weight three times daily in combination with other antiretroviral drugs that should not be exceeded every day (see Section 5.1).</seg>
<seg id="2102">"" "" "" "in addition, no dose recommendation for the simultaneous application of asoil solution to capture and low dosified kavir can be avoided this combination with these patient groups can be avoided." "" "" ""</seg>
<seg id="2103">"" "" "" "although a dose adjustment for Amlaavir is not considered to be necessary, an application of astoase solution is contraindicated in patients with kidney failure (see section 4.3)." "" "" ""</seg>
<seg id="2104">Due to the potential risk of a toxic reaction as a result of high prooethylene glycobalances in patients with reduced liver function or liver failure and in patients with kidney failure contraindicated in patients with kidney failure.</seg>
<seg id="2105">The simultaneous administration can lead to a Competitive inhibiting of this medicine and may cause severe and / or life-threatening side effects such as heart rhythmia (z).</seg>
<seg id="2106">"" "" "" "patients should be advised that atriase or any other antiretroviral therapy cannot lead to an infection of HIV infection, and that they also continue to develop opportunistic infections or other complications of an HIV infection." "" "" ""</seg>
<seg id="2107">"" "" "" "the current antiretroviral therapy including treatment with agase avoids risk 47 of infection of HIV on others by sexual contact, or contamination with blood." "" "" ""</seg>
<seg id="2108">"" "" "" "for some medicines that cause serious or life-threatening side effects, like carbamazepine, phenytoin, tricyclic antidepressants, and warfarin, are available methods for determining the substance concentration." "" "" ""</seg>
<seg id="2109">Agase should be dropped in duration if a rash occurs on systemic or allergic symptoms, or the mucous membranes are involved (see Section 4.8).</seg>
<seg id="2110">"" "" "" "an increased risk of a lipodocytic was associated with individual factors such as older age, and with drugs-49 dependent factors, such as a longer lasting antiretroviral treatment and associated metabolic disorders." "" "" ""</seg>
<seg id="2111">"" "" "" "with haemhibitors (type A and B), which were treated with Proteashibitors, reports on an increase of bleeding including spontaneous cutaneous hematomas and hemerthrosis." "" "" ""</seg>
<seg id="2112">"" "" "" "it was shown that Rifampicin causes a 82% decrease in AUC of Ambleavir, which can lead to a virological understanding and a resistance of resistance." "" "" ""</seg>
<seg id="2113">508% increase; for Cmax it is reduced by 30% if Ritonavir (100 mg twice daily) is given in combination with Amberavir capsules (600 mg twice daily).</seg>
<seg id="2114">"" "" "" "increasing intake with asteroid can considerably increase their plasma concentrations in combination with PDE5 inhibitors, including hypotension, disruptions and priapism (see Section 4.4)." "" "" ""</seg>
<seg id="2115">"" "" "" "based on data 54 different CYP3A4 inhibitors, Midazolam significantly increased significantly higher plasma concentrations from Midazolam." "" "" ""</seg>
<seg id="2116">The potential risk of human beings is not known as the result of possible toxic reactions from the fetus to the contained propylene glycol mixture (see Section 4.3).</seg>
<seg id="2117">"" "" "" "in the milk of lactic rats, Ambleavir-related substances were not known, however, it is not known whether Amberavir overrides his breast milk." "" "" ""</seg>
<seg id="2118">A reproduction study on pregnant rats who was administered to the Uterus by the end of the lactation period till the end of the lactation period showed a decreased increase in 55 body weight.</seg>
<seg id="2119">The harmlessness of agase has been studied in adults and in children under 4 years in controlled clinical trials in combination with various other antiretroviral drugs.</seg>
<seg id="2120">"" "" "" "in many of these events, it is not clear whether they are used in connection with the intake of asgenerators or another at the same time to the HIV treatment." "" "" ""</seg>
<seg id="2121">In the treatment of antiretroviral patients with the currently approved Fosamprenavir / Ritonavir-Dosidings were observed - as with other ritonavir bleoored treatment schemas with proteasephores - the described mutations rarely observed.</seg>
<seg id="2122">Early departure of a failed 60 therapy is recommended to keep the acquisition of a wide range of mutations in the limits that can affect the subsequent treatment of nocturnal effects.</seg>
<seg id="2123">62 Based on this data should be considered with the treatment of treatment optimisation using PI in the expected benefits of "ungeboosterated" agase. "</seg>
<seg id="2124">The apparent distribution volume is approximately 430 liters (6 l / kg with a body weight of 70 kg) and it is possible to close up a large couturf volume and an unhindered penitration of Ammelavir from the bloodstream into the tissue.</seg>
<seg id="2125">The underlying mechanism for the formation of hepatocellular civilians and carcinomas have not yet been solved and the relevance of these observed effects for human beings is unclear.</seg>
<seg id="2126">"" "" "" "in a systemic plasma exposure, which was significantly higher (rabbits) or not significantly higher (rats) than the expected exposition of minor changes including thymuselongation and minor skeleton changes, which indicate a delayed development." "" "" ""</seg>
<seg id="2127">Perhaps you would like to read this later again. − If you have any further questions please contact your doctor or pharmacist. − This medicine was personally prescribed to you.</seg>
<seg id="2128">"" "" "" "it can harm other people if they have the same complaints as you. − If any of these effects are noted, please inform your doctor or pharmacist." "" "" ""</seg>
<seg id="2129">"" "" "" "your doctor will normally advise you to apply Ahaase capsules along with low doses of Ritonavir, to increase the effect of agase." "" "" ""</seg>
<seg id="2130">The use of asgenerators will be based on that of your doctor for you the individual viral resistance test and your treatment story.</seg>
<seg id="2131">"" "" "" "inform your doctor if you suffer from one of the above mentioned diseases, or take any of the drugs mentioned above." "" "" ""</seg>
<seg id="2132">If your doctor has recommended that you take Ahaase capsules along with low doses of Ritonavir to reinforce the effect (boosters) before starting treatment the instruction information on Ritonavir carefully read.</seg>
<seg id="2133">"" "" "" "likewise, no adequate information can be found in order to recommend the application of Ahaase capsules, together with Ritonavir at age 4 to 12 years or generally in patients under 50 kg of body weight." "" "" ""</seg>
<seg id="2134">"" "" "" "therefore, it is important that you start the section" With taking advantage of asgenerators with other medicines before taking off with the intake of ads. "" "" "" "</seg>
<seg id="2135">"" "" "" "you may need additional factor VIII to control blood pressure. − With patients receiving a antiretroviral combination therapy, a redistribution, accumulation or loss of body fat can occur." "" "" ""</seg>
<seg id="2136">"" "" "" "if you are certain medicines that lead to severe side effects, like carbamazepine, phenytoin, tacamycin, cyclamycin, cyclamycin, cyclamycin, cyclamycin, cyclamycin, tricyclic antidepressants, tried to minimize additional blood tests in order to minimize potential problems." "" "" ""</seg>
<seg id="2137">"" "" "" "it is recommended that HIV positive women are to keep their children under any circumstances, to avoid HIV." "" "" ""</seg>
<seg id="2138">"" "" "" "no studies have been performed to the impact of Alaase, or the ability to serve machines." "" "" ""</seg>
<seg id="2139">"" "" "" "please take this medicine after consultation with your physician, if you know it is known that you suffer from incompatibility to certain sugars." "" "" ""</seg>
<seg id="2140">"" "" "" "if you are using Didanosin, it is advisable to take this more than one hour before or after ahaase, otherwise the effects of ads can be reduced." "" "" ""</seg>
<seg id="2141">Dose of agase capsules is 600 mg twice daily with 100 mg of Ritonavir twice daily in combination with other antiretroviral drugs.</seg>
<seg id="2142">"" "" "" "if your doctor decides that taking rite of Ritonavir is not suitable for you, you will need to take higher doses (1200 mg of Amberavir twice daily)." "" "" ""</seg>
<seg id="2143">"" "" "" "85" "" "" "" "85" It is very important to take advantage of the entire daily dose, which your doctor is prescribed to you. "" "" "" "</seg>
<seg id="2144">"" "" "" "if you have taken a larger amount of asgenerators than you should have taken more than the cancelled dose of asgenerators, you should immediately contact your doctor or pharmacist contact." "" "" ""</seg>
<seg id="2145">"" "" "" "if you have forgotten the intake of asgenerators if you have forgotten the intake of asgenerators, take it as soon as you think it and continue the intake as before." "" "" ""</seg>
<seg id="2146">"" "" "" "in treating a HIV infection, it is not always possible to say if occurring side effects are taken by agase, caused by other medicines that can be taken at the same time or caused by the HIV disease." "" "" ""</seg>
<seg id="2147">Headache, lack of being diarrhoea, illness, vomiting, bloating skin rash (redness, blister or itching) - occasionally the rash can be severe and you to break this medication.</seg>
<seg id="2148">"" "" "" "irritation, depression, sleep disorders, loss of appetite in lips and mouth, soft chairs, increase of certain liver enzymes, called transaminases, the increase of an enzyme called pancreas named Amylase." "" "" ""</seg>
<seg id="2149">Increased blood levels for sugar or cholesterol (a certain blood fat) increases blood levels of a substance called Bilirubin sponge of face; lips and tongue (angioedema).</seg>
<seg id="2150">"" "" "" "this can include fat loss of legs, arms, and face, fetching on the abdomen and in other inner organs, breast augmentation and fatty breast purses in the neck." "" "" ""</seg>
<seg id="2151">"" "" "" "please inform your doctor or pharmacist if one of the listed side effects will affect you significantly, or you may notice any side effects listed in this manual information." "" "" ""</seg>
<seg id="2152">"" "" "" "therefore, it is important that you start the section" With taking advantage of asgenerators with other medicines before taking off with the intake of ads. "" "" "" "</seg>
<seg id="2153">In some patients who received a antiretroviral combined treatment can develop as osteoneksis (death of bone tissue as a result of inadequate blood supply of the bone).</seg>
<seg id="2154">"" "" "" "if you are using Didanosin, it is advisable to take this more than one hour before or after ahaase, otherwise the effects of ads can be reduced." "" "" ""</seg>
<seg id="2155">"" "" "" "94 It is very important to make sure you use the entire daily dose, which your doctor is prescribed to you." "" "" ""</seg>
<seg id="2156">"" "" "" "if you have forgotten the intake of asgenerators if you have forgotten the intake of asgenerators, take it as soon as you think it and then apply it as before." "" "" ""</seg>
<seg id="2157">Headache, lack of being diarrhoea, illness, vomiting, bloating skin rash (redness, blister or itching) - occasionally the rash can be severe and you to break this medication.</seg>
<seg id="2158">"" "" "" "please inform your doctor or pharmacist if one of the listed side effects will affect you significantly, or you may notice any side effects listed in this manual information." "" "" ""</seg>
<seg id="2159">Dose of agase capsules is 600 mg twice daily with 100 mg of Ritonavir twice daily in combination with other antiretroviral drugs.</seg>
<seg id="2160">"" "" "" "to avoid asgenerators as possible as possible, it is very important that you prescribed the entire daily dose that your doctor is prescribed to you." "" "" ""</seg>
<seg id="2161">"" "" "" "if you have taken larger amounts of asoil as you should have taken more than the cancelled dose of asgenerators, you should immediately contact your doctor or pharmacist contact." "" "" ""</seg>
<seg id="2162">"" "" "" "the benefits of using Ritonavir," aspious solution to capture, was not assigned to patients previously treated with Protease Inhibitors. "" "" "" "</seg>
<seg id="2163">For use lower doses of Ritonavir (usually used to strengthen the effect [booching] of asgenerators capsules) together with asgenerating solution to take-out can be given no dosing recommendations.</seg>
<seg id="2164">"" "" "" "Ritonavir solution for capture, or in addition feed propylene glycol during the intake of intake of intake (see also Agenerative intake may not be taken)." "" "" ""</seg>
<seg id="2165">"" "" "" "your doctor may possibly take you to side effects that are linked with the propylene glycol mixture, in particular if you have a kidney or liver disease." "" "" ""</seg>
<seg id="2166">111 "" "" "" "111 When you may cause certain medicines that lead to severe side effects, like carbamazepine, phenytoin, tacamycin, cyclamycin, cyclamycin, tricyclic antidepressants, tacamycin, tricyclic antidepressants, tried to minimize additional blood tests." "" "" ""</seg>
<seg id="2167">"" "" "" "Ritonavir solution, used for intake) or an additional proxyglycol, not to be taken during intake of asgenerators (see asgenerators cannot be taken)." "" "" ""</seg>
<seg id="2168">Important information on certain other components of asoil solution to capture The solution to intake contains propylene glycol mixture which can result in high doses to side effects.</seg>
<seg id="2169">Propylglycol can cause a number of side effects including occlusion, dizziness and reduction of red blood cells (see also agase may not be taken when taking asgenerators is necessary precautions).</seg>
<seg id="2170">"" "" "" "if you have forgotten the intake of asgenerators if you have forgotten the intake of asgenerators, take it as soon as you think it and continue the intake as before." "" "" ""</seg>
<seg id="2171">Headache, lack of being diarrhoea, illness, vomiting, bloating skin rash (redness, blister or itching) - occasionally the rash can be severe and you to break this medication.</seg>
<seg id="2172">"" "" "" "this can include fat loss of legs, arms, and face, fetching on the abdomen and in other inner organs, breast augmentation and fatty breast purses in the neck." "" "" ""</seg>
<seg id="2173">"" "" "" "the other ingredients are propylene glycol, azigol 400 (poly ethylene glycol, saccharin sodium, sodium chloride, citric acid, citric acid, citric citrate, purified water." "" "" ""</seg>
<seg id="2174">"" "" "" "• For six weeks of treatment in the genital area, Aldara can carry up to a maximum of 16 weeks per week. • In case of case single basal cell carcinomas it is up to a maximum of 16 weeks, with four weeks break between the treatment cycles, three times a week." "" "" ""</seg>
<seg id="2175">"" "" "" "before bedtime, the cream is spread on the affected skin areas because it remains sufficient for long (about eight hours) on the skin before it is washed." "" "" ""</seg>
<seg id="2176">In all studies Aldara was compared with a placebo (the same cream but without the active substance). • Aldara was tested in four main studies at 923 patients with warts in the genital area for 16 weeks.</seg>
<seg id="2177">The main indicative index for efficacy was the number of patients with complete demolition of the treated warts. • Aldara was examined at 724 patients with small basal cell carcinoma in two studies where patients were treated for six weeks or placebo either every day or five times a week.</seg>
<seg id="2178">"" "" "" "the main indicative index for efficacy was the number of patients with complete healing of the tumors after twelve weeks. • Aldara was also tested in two trials in total 505 patients with actinine guys." "" "" ""</seg>
<seg id="2179">In all studies Aldara was more effective than the placebo. • In the treatment of warts in the genital area the total healing rate was taken from 66% to 80% in the patients treated with Aldara patients compared to 0% to 3% in the placebo group.</seg>
<seg id="2180">The most common adverse events of Aldara (observed in more than 1 out of 10 patients) are reactions to the use of cream (pain or itching).</seg>
<seg id="2181">"" "" "" "clinically typical, non-hyperkeratopic, not hypertrophysical Keratosis (AKS) in the face or the number of lesions limit the efficacy and / or acceptance of a cryotherapy and other topical treatment options are contraindicated or less suitable." "" "" ""</seg>
<seg id="2182">"" "" "" "Monday, Wednesday and Friday or Tuesday, Thursday and Saturday) carry out the skin for 6 to 10 hours." "" "" ""</seg>
<seg id="2183">The treatment with imiquimod-cream is so long fortzut until all visible inclination in the genital or percidal zone has disappeared or up to a maximum of 16 weeks per treatment time.</seg>
<seg id="2184">An interruption in the treatment process should be considered if intensive local infections occur (see Section 4.4) or when in the treatment sector is observed.</seg>
<seg id="2185">"" "" "" "if the follow-up examination 4 to 8 weeks after the second treatment period the lesions were completely healed, another therapy should be started (see Section 4.4)." "" "" ""</seg>
<seg id="2186">"" "" "" "when a dose was left out, the patient should apply the cream as soon as he / she noticed this and then proceed with the usual therapy plan." "" "" ""</seg>
<seg id="2187">"" "" "" "Imiquimod crème is applied in a thin layer and rub in a thin, dried skin zone, until the cream is completely moved." "" "" ""</seg>
<seg id="2188">"" "" "" "it should be effected in these patients, between the benefits of an treatment with Imiquimod and associated with a possible intensification of its autoimmune disease." "" "" ""</seg>
<seg id="2189">"" "" "" "it should be effected in these patients, between the benefits of an treatment with Imiquimod and the risk associated with a possible organ reduction or graft versus host- reaction." "" "" ""</seg>
<seg id="2190">"" "" "" "in other trials in which no daily intimacy was performed, two cases of severe phimose and a case were observed with a circumcising leading strike." "" "" ""</seg>
<seg id="2191">In an application of Imiquimod-cream in higher than the recommended cans there is an increased risk of severe local irritation (see section 4.2.) In rare cases where severe local irritation were observed and / or caused a temporary physical injury.</seg>
<seg id="2192">"" "" "" "in cases where such reactions appeared at the outcome of the urethra, some women had trouble passing urine and treatment of the affected area were required." "" "" ""</seg>
<seg id="2193">"" "" "" "to use Imiquimod-cream directly in connection to treatment with other cutaneous applications, they have no clinical experiences so far." "" "" ""</seg>
<seg id="2194">"" "" "" "limited data suggest an enhanced rate of tilting reductions in HIV positive patients, Imiquimod crème has shown a lower effectiveness in this patient group." "" "" ""</seg>
<seg id="2195">"" "" "" "the treatment of basal cell carcinoma with Imiquimod within 1 cm to the eyelids, the nose, the lips or hairline was not studied." "" "" ""</seg>
<seg id="2196">"" "" "" "local skin reactions are frequent, but the intensity of these reactions take back in general during therapy or reactions take back after the treatment with Imiquimod crème." "" "" ""</seg>
<seg id="2197">"" "" "" "if it is necessary due to the patient's complaints or due to the severity of the local skin reaction, a treatment room can be made of several days." "" "" ""</seg>
<seg id="2198">The clinical result of therapy can be assessed after the regeneration of the treated skin for 12 weeks after the treatment.</seg>
<seg id="2199">"" "" "" "since there are currently no data available for long-term healing rates of more than 36 months after the treatment, some suitable therapy forms should be taken into consideration." "" "" ""</seg>
<seg id="2200">"" "" "" "in patients with recurrent and previously treated BCCs there are no clinical experiences, therefore the application is not recommended in previously treated Tumors." "" "" ""</seg>
<seg id="2201">Data from an open clinical study point out that with large tumours (&gt; 7.25 cm2) a lower probability of response to the Imiquimod therapy.</seg>
<seg id="2202">"" "" "" "Imiquimod was not examined for the treatment of acute attacks on eyelids, inside the nose or ears or in the lip area within the lip." "" "" ""</seg>
<seg id="2203">"" "" "" "there are only very limited data on the application of Imiquimod for the treatment of actinine keratosis, anatomical areas outside the face and scalp." "" "" ""</seg>
<seg id="2204">"" "" "" "the available data on the actinical notatosis in arms and hands will not support the effectiveness in this use purpose, therefore such application is not recommended." "" "" ""</seg>
<seg id="2205">"" "" "" "local skin reaction often occur, but these reactions normally take back to intensity during the therapy or go back after putting the therapy with Imiquimod crème." "" "" ""</seg>
<seg id="2206">"" "" "" "if the local skin reactions to patients would cause great discomfort or are very strong, treatment can be exposed for several days." "" "" ""</seg>
<seg id="2207">"" "" "" "out of the data of an open clinical study, patients with more than 8 acons lesions has a lower degree of healing than patients with less than 8 lesions." "" "" ""</seg>
<seg id="2208">Due to the immune stimulating properties Imiquimod can be applied with caution in patients who receive immunodensive treatment (see 4.4).</seg>
<seg id="2209">"" "" "" "no direct or indirect effects on the pregnancy, embryonic / ffetal development, debinding or postnatal development (see 5.3)." "" "" ""</seg>
<seg id="2210">"" "" "" "although neither inely after repeated optical use (&gt; 5ng / ml), no recommendation can be given to the application during lactation period." "" "" ""</seg>
<seg id="2211">The patients with imiquimod-cream in connection with the application of Imiquimod-cream in connection with three-week treatment were local reactions in the treatment of the treatment of the event (33.7% of patients treated with Imiquimod patients).</seg>
<seg id="2212">"" "" "" "most often reported, and possibly using the application of Imiquimod crème in relation to side-effects include complaints to application area with a frequency of 28,1%." "" "" ""</seg>
<seg id="2213">"" "" "" "the study of 185 with Imiquimod from a placebo-controlled clinical study of Phase III reported side effects are shown below." "" "" ""</seg>
<seg id="2214">The most frequent occurrence as probably or possibly with the application of Imiquimod-cream in connection between these studies were a reaction to the application area (22% of patients treated with Imiquimod patients).</seg>
<seg id="2215">"" "" "" "the adverse events, which were treated by 252 in placebo-controlled clinical trials with imiquimod to patients with actinical keratosis, are listed below." "" "" ""</seg>
<seg id="2216">According to a study determined review of clinical signs that there is often observed in these placebo-controlled clinical trials including Erythem (61%) and erosion / bottling (23%) and odem (14%) and odem (see Section 4.4).</seg>
<seg id="2217">"" "" "" "this noisy evaluation of clinical signs indicate that there were five times a weekly treatment with Imiquimod (31%), severe seizure of seizure (13%), and heavy seizure and marching (19%)." "" "" ""</seg>
<seg id="2218">"" "" "" "in clinical trials to study the application of Imiquimod for the treatment of actincine keratosis, alopecia was found at the treatment location or in the surrounding area." "" "" ""</seg>
<seg id="2219">"" "" "" "the accidentally unique oral uptake of 200 mg Imiquimod which corresponds to the content of about 16 bags, could result nausea, vomiting, headache, myalgies and fever." "" "" ""</seg>
<seg id="2220">"" "" "" "the clinically most severe side effect, normalized after several oral doses of &gt; 200 mg, normalized after oral or intravenous hydration." "" "" ""</seg>
<seg id="2221">In a pharmacokinetic study an increasing systemic concentration of alpha interferon and other cytokines were detected after the topical application of Imiquimod.</seg>
<seg id="2222">In 3 sound-relevant phase 3 efficacy studies could be shown that the effectiveness in regards to a complete alimod treatment is superior to an Imiquimod treatment over 16 weeks of a placebo treatment.</seg>
<seg id="2223">"" "" "" "at 60% of patients with Imiquimod treated patients the failures were completely healed, with 20% of the 105 patients with placebo-treated patients (95%):" "" "" ""</seg>
<seg id="2224">A complete execution could be achieved at 23% from 157 with Imiquimod treated male patients over 5% of 161 with placebo-treated male patients (95% CI):</seg>
<seg id="2225">"" "" "" "Imiquimod's effectiveness in five times per week over 6 weeks has been investigated in two double-blind, placebo-controlled clinical studies." "" "" ""</seg>
<seg id="2226">The target tumors were histologically confirmed by single primary superfizitional basal cell carcinoma with a minimum size of 0.5 cm2 and a maximum diameter of 2 cm.</seg>
<seg id="2227">The study from an open and uncontrolled long-term study after four years of this data show that roughly 79.3% [95%] (74.9%)] of all treated patients were clinically cured and this also remained for 48 months.</seg>
<seg id="2228">"" "" "" "Imiquimod's effectiveness in one or two treatment sessions of 4 weeks, interrupted by a four-week, treatment-free time period, was examined in two double-blind, placebo-controlled clinical studies." "" "" ""</seg>
<seg id="2229">"" "" "" "the patients had clinically typical, visible, discrete, non-hyperakatotical, non-hypertropic lesions within a related 25 cm2 area than on the hairless scalp or in the face." "" "" ""</seg>
<seg id="2230">The one-year data from two combined observation studies show patients with clinical healing after one or two treatment rooms a real rate of 27% (35 / 128 patients).</seg>
<seg id="2231">"" "" "" "the licensed indications, actincosis and super fibrillary basal cell carcinoma usually occur in paediatric patients, and were therefore not examined." "" "" ""</seg>
<seg id="2232">Alima cream has been examined in four randomised and double-blind placebo-controlled studies in children from 2 to 15 years with molluscum contagiosum (Imiquimod n = 576, placebo n = 313).</seg>
<seg id="2233">"" "" "" "in these studies, the effectiveness of Imiquimod was not shown in these studies (3x / week for a period of ≤ 16 weeks)." "" "" ""</seg>
<seg id="2234">A minimal systemic absorption of the 5% Imiquimod crème through the skin of 58 patients with akine keratosis was observed in the three times weekly application during 16 weeks.</seg>
<seg id="2235">The highest drug concentrations in the serum at the end of the week 16 were observed between 9 and 12 hours and betrugen 0.1, 0.2 and 1.6 ng / ml in the application in the face (25mg, 2 bags) and on the hands / arms (75 mg, 6 bags).</seg>
<seg id="2236">"" "" "" "the calculated half-life time was about 10times higher than the 2 hourly half-time after the subcutaneous application in a former study, which indicates an extended retention of medication in the skin." "" "" ""</seg>
<seg id="2237">The data on the systemic exposure showed that the resorption of Imiquimod according to topical application was low in patients at the age of 6-12 years and comparable to patients suffering from healthy adults and adults with aktinical notatosis or superfiziontal basal cell carcinoma.</seg>
<seg id="2238">"" "" "" "in a four month study on which weighed toxicity at the rat ratios of 0.5 and 2.5 mg / kg, kg regulates significantly reduced body weight and higher milk weight; an appropriate study for four months showed no similar effects in the mouse." "" "" ""</seg>
<seg id="2239">"" "" "" "a two-year study on carcinogenicity in mice near three days per week, no tumours ininduced towards the application." "" "" ""</seg>
<seg id="2240">"" "" "" "the corresponding mechanism is not known, but since Imiquimod has only a low systemic absorption from the human skin and does not mutagen, is a risk to see people based on the systemic exposure." "" "" ""</seg>
<seg id="2241">"" "" "" "the tumors appeared in the mice, which was treated with the impact-free cream, used earlier and in greater numbers than in the control group with low UVR." "" "" ""</seg>
<seg id="2242">"" "" "" "it can harm other people, even if these same symptoms seem to affect you. − If any of these effects are noted, please inform your doctor or pharmacist." "" "" ""</seg>
<seg id="2243">● Feignizen (Condylomata acuminata) formed in the skin in the range of genitals (genital organs) and the anus (after) is a frequently encountered, slow growing shape of the skin cancer with very low probability of the spread to other parts of the body.</seg>
<seg id="2244">When it is treated untreated it may result in particular in the face - therefore a early detection and treatment is important.</seg>
<seg id="2245">"" "" "" "actinical cherries are harsh areas of the skin that occur with people, which were exposed to sunlight during their previous life." "" "" ""</seg>
<seg id="2246">Aldara should only be applied with flat-tincosis in the face and on the scalp in patients with a healthy immune system where your doctor has decided that Aldara is the best suitable treatment.</seg>
<seg id="2247">"" "" "" "Aldara cream supports your body's own immune system with the production of natural substances that help your body to combat the superficial bloatoma, the aktincosis or the infection with the warnings." "" "" ""</seg>
<seg id="2248">"" "" "" "O if you used to apply alima cream or other, similar preparations before you start with the treatment. o Do not use aldara cream until you get problems with your previous medication or surgical treatment. o Avoid the contact with eyes, lips and rendometrium." "" "" ""</seg>
<seg id="2249">"" "" "" "in accidental contact the cream rinse through rinse with water. o Do not use cream as your doctor. o if reactions to the treated position arise, wash the cream with a mild soap and water." "" "" ""</seg>
<seg id="2250">"" "" "" "once the reactions are delayed, you can continue the treatment. o Informing your doctor if they have no normal blood picture." "" "" ""</seg>
<seg id="2251">"" "" "" "when this daily cleaning is not performed under the foreskin, the skin or difficulty may be effected by the skin or difficulty passing the foreskin." "" "" ""</seg>
<seg id="2252">Do not apply alima cream into urethra (urethra) to the vagina (vagina), cervix (cervix) or within the anus (after).</seg>
<seg id="2253">"" "" "" "taking other medicines having serious problems with your immune system, you should not use this medication for no more than one treatment cycle." "" "" ""</seg>
<seg id="2254">"" "" "" "if you have sexual intercourse during the infection in the genital area, treatment with Albena cream is done after sexual intercourse (not before)." "" "" ""</seg>
<seg id="2255">"" "" "" "please inform your doctor or pharmacist if you apply other medicines or are recently applied, even if it is not prescription medicine." "" "" ""</seg>
<seg id="2256">"" "" "" "breastfeeding your infant during treatment with Aldara cream, since not known whether Imiquimod enters the breast milk." "" "" ""</seg>
<seg id="2257">"" "" "" "the frequency and duration of the treatment are different in case warts, basal cell carcinoma and aktinical notatosis (see specific instructions for each application area)." "" "" ""</seg>
<seg id="2258">"" "" "" "wear a thin layer of Aldara cream on the clean, dry skin place with the pincts and rub the cream gently on the skin until the cream is completely moved." "" "" ""</seg>
<seg id="2259">Men with peignitions under the foreskin must remove the foreskin each day and wash the skin area among them (see section 2) What do you have to consider before applying Albena cream? ").</seg>
<seg id="2260">"" "" "" "please contact your doctor or pharmacist if you have the impression that the effect of Aldara is too strong or weak." "" "" ""</seg>
<seg id="2261">"" "" "" "for 6 weeks, 5 days per week apply a sufficient amount of Aldara cream to cover the affected area and 1 cm around this area." "" "" ""</seg>
<seg id="2262">"" "" "" "very common adverse events (expected more than 1 out of 10 patients) occasionally expect side effects (in less than 1 out of 100 patients) Very rare side effects (less than 1 out of 10,000 patients)" "" "" ""</seg>
<seg id="2263">"" "" "" "tell your doctor / your doctor or your pharmacist / your pharmacist immediately, if you feel uncomfortable during the use of Aldara cream." "" "" ""</seg>
<seg id="2264">"" "" "" "in case your skin reacts strongly to the treatment with alima cream, you should not continue using the affected skin area with water and mild soap and communicate your doctor or your pharmacist." "" "" ""</seg>
<seg id="2265">"" "" "" "a inherited number of blood cells may cause you to susceptible to infections, and it can cause you a blue stain, or she can cause fatigue." "" "" ""</seg>
<seg id="2266">Inform your doctor or pharmacist if one of the listed side effects you significantly impaired or you have noticed effects that are not indicated in this user information.</seg>
<seg id="2267">"" "" "" "in addition, you can feel itching (32% of patients), burning (26% of patients) or pain in the fields that you have applied Aldara cream (8% of patients)." "" "" ""</seg>
<seg id="2268">"" "" "" "mostly, it is a lighter skin reaction which sound within about 2 weeks after decompose the treatment." "" "" ""</seg>
<seg id="2269">"" "" "" "occasionally, some patients notice changes in application place (wound secretion, inflammation, indignation, dermatitis, nausea, dry mouth, flu-like symptoms and fatigue." "" "" ""</seg>
<seg id="2270">"" "" "" "occasionally, some patients suffer from changes in the application area (bloody, inflammation, wound diseases, cervical or discomfort, depression, facial pain, ulcpain, fever, weakness, fever, or chills)." "" "" ""</seg>
<seg id="2271">Aldurazyma is used in patients with reliable diagnosis of a mudysaccharitin I (MPS I; α -L-Iduronidase deficiency) in order to treat the non-neurological manifestations of the disease (symptoms which are not linked to the brain or brain disorders).</seg>
<seg id="2272">"" "" "" "this means that certain substances (glycaminites, gags) are not to be dismantled and can therefore accumulate in most organs in the body and damage them." "" "" ""</seg>
<seg id="2273">"" "" "" "the following non-neurological symptoms of MPS I can occur: enlarged liver, stiff joints, complicate movements, decreased cancers, heart and eye disease." "" "" ""</seg>
<seg id="2274">Treatment with Aldurazyma should be supervised by a physician who has experience in the treatment of patients with MPS I or other hereditary metabolic diseases.</seg>
<seg id="2275">"" "" "" "administration of Aldurazyme should take place in a hospital or hospital with resissing devices, and patients need appropriate drugs to prevent an allergic reaction." "" "" ""</seg>
<seg id="2276">(44-20) 74 18 84 00 M. (44-20) 74 18 86 68 E-mail: mail @ emea.europa.eu © EMEA 2007 Reproduction and / or distribution of this document is Authorised for non business. only. the EMEA is.</seg>
<seg id="2277">"" "" "" "in the study, mainly the safety of the drug was investigated (by reducing its effect on the reduction of the concentration of concentrations in the urine and in relation to the size of the liver)." "" "" ""</seg>
<seg id="2278">"" "" "" "in children under five years alone, Aldurazyme showed up the concentrations in the urine by about 60%, and half of the treated children showed a normal high liver at the end of the study." "" "" ""</seg>
<seg id="2279">"" "" "" "the most common adverse events in patients at age over five years (observed in more than 1 of 10 patients) are headaches, nausea, abdominal pain, skin rash, pain in limbs, fever and reactions to the infusion center." "" "" ""</seg>
<seg id="2280">Very frequent side effects in patients under five years of age are increased blood pressure and reduced oxygen saturation (a measuring size of lung function), tachykarmic (accelerated heart rate), fever and chills.</seg>
<seg id="2281">Aldurazyme may not be very sensitive to patients who react possibly strongly (allergic) to laronidase or one of the other components (anaphylactic reaction).</seg>
<seg id="2282">"" "" "" "every year, the European Medicines Agency (EMEA) will test all new information that may be known, check, and update this summary." "" "" ""</seg>
<seg id="2283">The manufacturer of Aldurazyme will receive patients who are aldurazyme to observe the reactions to the infusion and the development of antibodies.</seg>
<seg id="2284">"" "" "" "in June 2003, the European Commission issued the company Genzyme Europe B.V., approved for the transport of Aldurazyme throughout the European Union." "" "" ""</seg>
<seg id="2285">Laronidase is a recombinant form of human α-L-Iduronidase and is produced by recombinant DNA technology using Cho-mammal-cell cultures (Chinese Hamster Ovary, derived from the Chinese Hamsters).</seg>
<seg id="2286">Aldurazyma is indicated for long-time enzymes in patients with reliable diagnosis of a mudysaccharitin I (MPS I, α -L-Iduronidase deficiency) to treat non-neurological manifestations of the disease (see Section 5.1).</seg>
<seg id="2287">Treatment with Aldurazyma should be done by a physician who has experience in the treatment of patients with MPS I or other hereditary metabolic diseases.</seg>
<seg id="2288">"" "" "" "if the patient can be increased from 2 E / kg / h, every 15 minutes in individual steps a maximum dose of 43 E / kg / h can be increased." "" "" ""</seg>
<seg id="2289">The safety and effectiveness of Aldurazyme in adults over 65 years was not determined and for these patients no sampling scheme can be recommended.</seg>
<seg id="2290">"" "" "" "the safety and efficacy of alarazyma in patients with kidney or liver failure was not determined, and no sampling scheme can be recommended for those patients." "" "" ""</seg>
<seg id="2291">"" "" "" "patients with Aldurazyme treated patients may develop infusion-related reactions, which are defined as each related side effect that occurs during infusion or until the end of the infusion of life (see Section 4.8)." "" "" ""</seg>
<seg id="2292">"" "" "" "for this reason, specially these patients should continue to be monitored and the infusion of Aldurazyme should be provided only in an appropriate clinical manner where medical emergencies are immediately available." "" "" ""</seg>
<seg id="2293">"" "" "" "due to the clinical phase 3 study, it is expected that almost all patients of IgG antibodies against laronidase are normally formed within 3 months." "" "" ""</seg>
<seg id="2294">"" "" "" "to develop patients, antibodies, or symptoms of infusion-related reaction, must be treated with caution (see sections 4.3 and 4.8)." "" "" ""</seg>
<seg id="2295">"" "" "" "as little experience concerning the recovery of treatment after a longer break, has to be careful with the theoretically increased risk reaction after an interruption of treatment." "" "" ""</seg>
<seg id="2296">60 minutes before the beginning of infusion with medication (antihistamine and / or antipyretika) to treat the potential occurance of infusion reactions.</seg>
<seg id="2297">"" "" "" "in case of light or moderate infusion-related reaction, treatment with antihistamines and paracetamol / ibuprofen should be considered and / or a reduction of the infusion rate in which the reaction has occurred." "" "" ""</seg>
<seg id="2298">"" "" "" "in case of a single, severe infusion-related reaction, the infusion has to be stopped until symptoms are reduced to investigate a treatment with antihistamines and paracetamol / ibuprofen." "" "" ""</seg>
<seg id="2299">"" "" "" "the infusion can be re-recorded with an increment rate of 1 / 2 - 1 / 4 of the infusion rate, in which the reaction has occurred." "" "" ""</seg>
<seg id="2300">3 (antihistamine and paracetamol / ibuprofen and / or corticosteroids) as well as a reduction of the infusion rate at 1 / 2 - 1 / 4 of the infusion rate occurred in which the reaction has occurred.</seg>
<seg id="2301">Aldurazyme should not be used simultaneously with chloroquin or Procain because a potential risk of interference with the intracellular absorption of Laronidase exists.</seg>
<seg id="2302">"" "" "" "experimental studies can not be concluded on direct or indirect harmful effects on pregnancy, embryonic / fetal development, birth and postnatal development (see paragraph 5.3)." "" "" ""</seg>
<seg id="2303">"" "" "" "since no data on newborns, which were exponates from laronidase over the breast milk, is suggested, during the treatment with Aldurazyme." "" "" ""</seg>
<seg id="2304">Adverse reactions in clinical trials were mainly filed as infusion-related reactions that were observed in the phase 3 study (duration of treatment up to 4 years) and 35% of patients in the study with participants under 5 years (duration of treatment up to 1 year) were observed.</seg>
<seg id="2305">Adverse reactions in connection with Aldurazyme who were observed during the phase-3 study and their extension for a total of 45 years in the age of 5 years or older in a duration of up to 4 years (≥ 1 / 10); often (≥ 1 / 100 to &lt; 1 / 10).</seg>
<seg id="2306">"" "" "" "in some patients with heavy MPS I-conditional participation of the upper respiratory tract and lungs in prehistory, bronchiospasmus, breathing and facial expressions (see Section 4.4)." "" "" ""</seg>
<seg id="2307">"" "" "" "children Disposal drug risks associated with Aldurazyme, associated with a total of 20 patients under the age of 5, including a period of heavy duty and duration of up to 12 months, have been reported in the table." "" "" ""</seg>
<seg id="2308">Intravenously every 2 weeks or 300 E / kg intravenously every 2 weeks or 300 E / kg intravenously every 2 weeks or 300 E / kg intravenously every 2 weeks.</seg>
<seg id="2309">"" "" "" "in most patients it came to a serocondiversion within 3 months following the treatment of an serocontention period (an average age of 5 years compared to 45 days in patients at the age of 5 years and older)." "" "" ""</seg>
<seg id="2310">"" "" "" "until the end of the Phase 3 study (or up to premature exploiting from the study) assorted bodies were observed in 13 / 45 patients, including 3 patients, including 3 patients, where there was never too Serocontra." "" "" ""</seg>
<seg id="2311">Patients with lack of low-low-antibody levels had a robust reduction of the gag-mirror in the harp while patients with high antibody titres was an variable reduction of Gag in the Harn.</seg>
<seg id="2312">"" "" "" "four patients (three in the phase 3 study and one in phase 2 study) showed a marginal to low neutralizing clinical effect on enzymatic laronidal activity in vitro, which seemed not to affect clinical effectiveness and / or reduction of gag in the harn." "" "" ""</seg>
<seg id="2313">"" "" "" "the presence of antibodies seemed not to stand in connection with the incidence of undesired medicines, which coincide with the formation of IgG-antibodies." "" "" ""</seg>
<seg id="2314">"" "" "" "the reasoning method is sufficient for the hydrolysis of the accumulated substrates, and the displacement of an accumulation of sufficient accumulation." "" "" ""</seg>
<seg id="2315">"" "" "" "after intravenous infusion, Laronidase is rapidly absorbed from the circulation and cells into the lysosomes, most likely over manosis-6 phosphate receptors." "" "" ""</seg>
<seg id="2316">"" "" "" "the safety and effectiveness of Aldurazyma were examined in a randomised, double-blind, placebo-controlled Phase 3 study from 6 to 43 years." "" "" ""</seg>
<seg id="2317">"" "" "" "although patients were recruited for the study, the majority of patients from the central phenotype was the phenotype in the central phenotype and only one patient contained the heavy phenotype." "" "" ""</seg>
<seg id="2318">"" "" "" "patients have been recruited, if they had a driving exponical value (FEV) of less than 80% of the expected value, and they had to be able to stand 6 minutes and walk 5 feet." "" "" ""</seg>
<seg id="2319">The primary endpoints for the efficacy were the percentage of the expected FEV and the absolute passage in the 6 minute walk.</seg>
<seg id="2320">"" "" "" "all patients were recruited for an open-label extension study, where they received 100 E / kg Aldurazyme every week (182 weeks)." "" "" ""</seg>
<seg id="2321">"" "" "" "after 26 weeks of therapy, the patients treated with Aldurazyma joined the placebral group to improve lung function and the ability to be displayed in the following table." "" "" ""</seg>
<seg id="2322">In an open extension study the improvement and / or maintenance of these effects of up to 208 weeks showed in the Aldurazyme / Aldurazyme group and of 182 weeks in the placebo / Aldurazyme group as seen from the following table.</seg>
<seg id="2323">The decrease in the expected percentage of FEV is not significant above that period clinically significant and the absolute lung volumes increased further proportionally to the height of growing children.</seg>
<seg id="2324">"" "" "" "of the 26 patients with a hepatoma in front of the treatment, 22 (85%) had a normal liver size until the end of the study." "" "" ""</seg>
<seg id="2325">"" "" "" "within the first 4 weeks, a significant decrease in the fermentation mirror in the harn (µg / mg of creatinine) was observed until the end of the study remained constant." "" "" ""</seg>
<seg id="2326">"" "" "" "in regard to the heterogeneous statistical presentation of patients, the clinically significant changes of cross-point AHI and visual acuity (58%) was generally consistent with 10 patients (22%) and a deterioration in 9 patients (20%)." "" "" ""</seg>
<seg id="2327">One-year-old Phase 2 study was conducted in which mainly the safety and pharmacokinetics of Aldurazyma was examined in 20 patients (16 patients with severe displacement form and 4 with the middle cutter shape).</seg>
<seg id="2328">"" "" "" "for four patients, the dosage was increased because of increased GAG- mirror in the Harn in week 22 in the last 26 weeks to 200 E / kg." "" "" ""</seg>
<seg id="2329">In several patients an increase of weight growth (n = 7) and a weight gain (n = 3) and a weight gain (n = 3) showed a normal mental development velocity (&lt; 2.5 years) and all 4 patients with moderate reduction form only limited or even no progress in cognitive development.</seg>
<seg id="2330">"" "" "" "in a Phase 4 study, studies on pharmacodynamic effects of various alkaloids are performed on the gag-mirror in the harn, the liver volume and the 6-minute walking test." "" "" ""</seg>
<seg id="2331">Intravenously every 2 weeks or 300 E / kg intravenously every 2 weeks or 300 E / kg intravenously every 2 weeks or 300 E / kg intravenously every 2 weeks.</seg>
<seg id="2332">"" "" "" "dosing scheme with 200 E / kg intravenously every 2 weeks can be present in patients who have difficulty with weekly infusions, however, is not proven that the long-term clinical effectiveness of these two sampling schemas is equivalent." "" "" ""</seg>
<seg id="2333">"" "" "" "the European Medicines Agency (EMEA) will provide any new information available, rate annually, and if necessary, the summary of the characteristics of the medication will be updated." "" "" ""</seg>
<seg id="2334">"" "" "" "the pharmacokinetic profile of patients at the age of 5 was similar to that of older and less affected patients." "" "" ""</seg>
<seg id="2335">"" "" "" "based on conventional concepts for safety pharmacology, toxicity in exceptional gift, toxicity in repeated declaratory and reproduction of reproduction, the preclinical data won no particular hazards for human beings." "" "" ""</seg>
<seg id="2336">"" "" "" "since no offense studies have been carried out, this medicine may not be mixed with other medicines except those listed below 6.6." "" "" ""</seg>
<seg id="2337">"" "" "" "if the ready made preparation is not used immediately, it is no longer stored for 24 hours at 2 ° C - 8º C, if the dilution under controlled and validated aseptic conditions." "" "" ""</seg>
<seg id="2338">5 ml concentrate on producing a solution in water bottle (Typical I-glass) with stoppers (silicone-chlorobyl rubber) and sealer (aluminium) with tearing cap (polypropylene).</seg>
<seg id="2339">10 preparation of the Aldurazyme infusion (using aseptic technology) • Je after body weight of individual patients first determine the number of thinner bottles.</seg>
<seg id="2340">"" "" "" "within the given time, the owner has completed the following study program to form the basis for the annual evaluation report as the benefit ratio." "" "" ""</seg>
<seg id="2341">This tab will lead long-term security and efficacy information about patients who were treated with Aldurazyme as well as data on the natural pro greasy of the disease in patients without treatment.</seg>
<seg id="2342">"" "" "" "in patients suffering from MPS I, there is an enzyme called Fα -L-Iduronidase, which has certain substances in the body (glycosaminoglycite), either in small quantity before or this enzyme is completely different." "" "" ""</seg>
<seg id="2343">"" "" "" "if you are allergic to one of the ingredients of Aldurazyme, or if an allergic reaction to larvidase occur." "" "" ""</seg>
<seg id="2344">An infusion-conditional reaction is a side effect that occurs during infusion or until the end of the infusion of life (see section 4 "What side effects are possible).</seg>
<seg id="2345">"" "" "" "when using Aldurazyma with other medicines, please inform your doctor if you use medicines, chloroquin or procaine, because a possible risk of diminished effect of aldurazyme." "" "" ""</seg>
<seg id="2346">"" "" "" "please inform your doctor or pharmacist if you have other medicines or have recently taken, including non-prescription drugs." "" "" ""</seg>
<seg id="2347">Indications of use - dilution and application The concentrate for the production of infusion solution must be diluted in front of the application and is intended for intravenous application (see information for doctors or medical professionals).</seg>
<seg id="2348">"" "" "" "the initial inclusion rate of 2 E / kg / h can be increased, if the patient is tolerated, every 15 minutes gradually increased to a maximum dose of 43 E / kg / h." "" "" ""</seg>
<seg id="2349">"" "" "" "in some patients with heavy MPS-I- unconditional participation of the upper respiratory tract and lungs in prehistory, but bronchiospasm, breath and facial surgery." "" "" ""</seg>
<seg id="2350">"" "" "" "very frequently (occurrence by more than 1 of 10 patients): • headache • nausea pain, joint pain, back pain, pain in arms and legs • Low oxygen • hypertension • less oxygen in the blood • Response to the infusion center" "" "" ""</seg>
<seg id="2351">"" "" "" "the European Medicines Agency (EMEA) will provide any new information that will be available, rate annually, and if necessary, the package directions will be updated." "" "" ""</seg>
<seg id="2352">"" "" "" "if the ready made preparation is not used immediately, it is no longer stored for 24 hours at 2 ° C - 8º C, if the dilution under controlled and validated aseptic conditions." "" "" ""</seg>
<seg id="2353">Preparation of the Aldurazyme infusion (using aseptic technology) • Je according to body weight of individual patients first determine the number of thinner bottles.</seg>
<seg id="2354">"" "" "" "Alimta is applied together with Cisplatin which does not have any chemotherapy (drugs against cancer) which has not yet been removed (or any other parts of the body), or is spread to other parts of the body." "" "" "" "• advanced or metastatic" lung cancer, which does not attack the epithelial cells. "" "" "" "</seg>
<seg id="2355">"" "" "" "Alimta is treated with patients who were previously untreated previously, in combination with cisplatin and in patients who had previously been given other chemotherapy regimens." "" "" ""</seg>
<seg id="2356">"" "" "" "to reduce side effects, patients during treatment with Alimta should take a corticosteroid as well as folic acid (vitamin) and obtain injections of vitamin B12." "" "" ""</seg>
<seg id="2357">"" "" "" "when Alimta is given together with Cisplatin, which should be given prior to or after the gift of Cisplatin which should be prevented before or after the gift of cisplatin." "" "" ""</seg>
<seg id="2358">"" "" "" "in patients whose blood pattern changes or with which certain other side effects occur, the treatment should be worn down or the dose should be reduced." "" "" ""</seg>
<seg id="2359">"" "" "" "thus, the active form of Pemetreed slows down the formation of DNA and RNA, and prevents the cells." "" "" ""</seg>
<seg id="2360">"" "" "" "the conversion of Pemetremixed in its active form is lighter than in healthy cells, leading to higher concentrations of active form of medication and a longer active duration in cancer cells." "" "" ""</seg>
<seg id="2361">"" "" "" "in a major study of 456 patients, Alimta was examined in a major study of 456 patients who had previously received chemotherapy against their illness." "" "" ""</seg>
<seg id="2362">"" "" "" "in the treatment of non-cell lung cancer, the effects of Alimta were compared to 571 patients with local advanced or metastatic disease, previously compared to chemotherapy with the effects of docetaxel (a different drug against cancer)." "" "" ""</seg>
<seg id="2363">"" "" "" "Alimta also compared with gemcitabine (a further drug against cancer), both in combination with cisplatin in a study of 1 725 patients who had previously obtained chemotherapy for lung cancer." "" "" ""</seg>
<seg id="2364">"" "" "" "patients who were treated with Alimta and Cisplatin, survived an average of 12.1 months, compared to 9.6 months at the sole meeting of Cisplatin." "" "" ""</seg>
<seg id="2365">"" "" "" "in patients who had previously received chemotherapy, the average survival time was with Alimta 8,3 months, compared with 7.9 months at docetaxel." "" "" ""</seg>
<seg id="2366">"" "" "" "in both trials, patients with cancer did not attack the cSCC attack, during the administration of Alimta prolonged survival compared to the comparative potential." "" "" ""</seg>
<seg id="2367">"" "" "" "in September 2004, the European Commission issued the company Eli Lilly Nederland B.V. for placing the transport of Alimta in the entire European Union." "" "" ""</seg>
<seg id="2368">"" "" "" "each water bottle must be absorbed by 4.2 ml 0,9% sodium chloride injections (9 mg / ml), which results in a solution of 25 mg / ml." "" "" ""</seg>
<seg id="2369">The corresponding volume of the necessary Do- SIS is taken from the water bottle and diluted with a sodium chloride injector solution (9 mg / ml) to 100 ml (see Section 6.6).</seg>
<seg id="2370">ALIMTA is displayed in combination with Cisplatin shown for first-line treatment of patients with locally advanced or metastatic breast cancer (see section 5.1).</seg>
<seg id="2371">ALIMTA in monotherapy is indicated for the treatment in second-line treatment of patients with Lo- Kal advanced or metastatic bronchial carcinoma except for overactive plate of epithelial histology (see section 5.1).</seg>
<seg id="2372">The recommended dose of ALIMTA 500 mg / m ² body surface (KOF) administered as an intravenous infusion over a period of 10 minutes on the first day of every 21 day treatment cycle.</seg>
<seg id="2373">The recommended dose of Cisplatin is 75 mg / m ² KOF as an infusion over a period of 2 hours approx. 30 minutes after conclusion of the pemetrexed- infusion the first day of every 21 day treatment cycle.</seg>
<seg id="2374">In patients with non-single bronchial carcinoma after previous chemotherapy the recommended dose of ALIMTA 500 mg / m ² KOF is administered as an intravenous infusion over a period of 10 minutes on the first day of every 21 day treatment cycle.</seg>
<seg id="2375">"" "" "" "to reduce the frequency and severity of skin reaction, a day before and after the treatment a corticosteroid had to be given a day after the treatment." "" "" ""</seg>
<seg id="2376">"" "" "" "during the seven days before the first dose Pemetry must be taken at least 5 doses of folic acid, and the intake must be continued during the entire duration of therapy and for further 21 days after the last phemetrexed- dose." "" "" ""</seg>
<seg id="2377">Patients must also receive an intramuscular injection of vitamin B12 (1000 micrograms) in week before the first Pemetry supplement and after every third eclipse cycle.</seg>
<seg id="2378">"" "" "" "in patients receiving pacemetry, in front of every gift a complete blood picture should be created, including a differentiation of the leukocytes and a Thrombocyte." "" "" ""</seg>
<seg id="2379">Alkaline phosphatase (AP), aspartame transaminase (AST or SGOT) and Alanin transaminase (ALT or SGPT) should be &lt; 3 times the upper limit value.</seg>
<seg id="2380">In the beginning of a new treatment course a dose of doscope must take place under the end of the blood bilrs of blood flow or the maximum non-haematological toxicity.</seg>
<seg id="2381">"" "" "" "after recovery the patients must be treated in accordance with the indications in tables 1, 2 and 3, which are used for ALIMTA than monotherapy or in combination with Cisplatin." "" "" ""</seg>
<seg id="2382">These criteria conform to the definition of the National Cancer Institute Common Toxicity Criteria (CTC v2.0; NCI 1998) ≥ CTC level 2 bleeding.</seg>
<seg id="2383">"" "" "" "should patients not develop non-haematological toxicity 1 to 3 (except neurotoxicity), the treatment with ALIMTA must be interrupted by the patient." "" "" ""</seg>
<seg id="2384">Treatment with ALIMTA must be canceled if in patients after 2 doses of dose or non-haematological toxicity or non-haematological toxicity 3 or 4 or 4 or 4 neurotoxicity.</seg>
<seg id="2385">"" "" "" "clinical trials have no notice that in patients aged 65 years or in comparison to those aged 65 years, clinical trials undertook an increased adjuni- ko." "" "" ""</seg>
<seg id="2386">ALIMTA is not recommended for the application in children under 18 years due to sufficient data on harmlessness and effectiveness.</seg>
<seg id="2387">"" "" "" "in clinical trials, patients with a Kreatinine-Clearance of ≥ 45 ml / min were not necessary to outpace the dose adjustment recommended for all patients." "" "" ""</seg>
<seg id="2388">The data situation in patients with a Kreatinine-Clearance of under 45 ml / min was not sufficient; therefore the application is not recommended (see Section 4.4).</seg>
<seg id="2389">However patients with a liver function limit of &gt; to 1.5 times in the upper limit value (for the presence of liver metastases) or &gt; 5.3-times of the upper limit (for the presence of liver metastases) is not specifically investigated in studies.</seg>
<seg id="2390">"" "" "" "patients must not be administered to patients with respect to the bone marital regulation, before their absolute neutrophils may not be administered at a value of ≥ 400 cells / mm ³ and the Thrombo- number once again reached a value of ≥ 100.000 cells / mm ³." "" "" ""</seg>
<seg id="2391">A dose-reduction for further cycles is based on the Nadir of absolute neutrophilarious number and maximum non-haematological toxicity as they were observed in the preceding treatment cycles (see paragraph 4.2).</seg>
<seg id="2392">A lower toxicity and a reduction of grade 3 / 4 haematological toxicity such as neutropenia and infection with degree 3 / 4 Neutropenie and infection with grade 3 / 4 Neutropenie was examined for a pre-treatment with folic acid and vitamin B12.</seg>
<seg id="2393">"" "" "" "therefore, all patients with pemetry must be dependent on acid and vitamin B12 to prevent harmful toxicity (see section 4.2)." "" "" ""</seg>
<seg id="2394">Patients with mild to medium kidney failure (CSAIDs) such as ibuprofen and acetylsali- cylic acid (&gt; 1.3 g daily) must be paid for at least 2 days before therapy and after therapy with pemetry (see Section 4.5).</seg>
<seg id="2395">"" "" "" "all patients, for treatment with Pemetry must be expected, intake of NSAIDs must be paid for at least 5 days before therapy, on the day of therapy and at least 2 days after therapy with paremetry (see Section 4.5)." "" "" ""</seg>
<seg id="2396">"" "" "" "many patients, where these events occur, had corresponding risk factors for the occurrence of renal events, including dehydration, existing high blood pressure or diabetes." "" "" ""</seg>
<seg id="2397">"" "" "" "therefore, in patients with clinically significant hydration accumulation in transcellular space a drainage of the result should be considered before the mixed treatment." "" "" ""</seg>
<seg id="2398">"" "" "" "5 most severe cardiovascular events, including myocardial infarction, and cerebrovascular events were reported in clinical trials of Pemetry." "" "" ""</seg>
<seg id="2399">"" "" "" "for this reason, the use of attenuated fuel prices (except yellow fever; this vaccination is contraindicated) not recommended (see section 4.3 and 4.5)." "" "" ""</seg>
<seg id="2400">"" "" "" "as the possibility of an irreversible injury is made for reproductive capacity due to Pemetry, men should be advised in prior to treatment, advice regarding semasturdity." "" "" ""</seg>
<seg id="2401">In patients with normal kidney function (CSAIDs) such as Ibuprofen &gt; 1600 mg / day) and acetylsalicylic acid in high doses (≥ 1.3 g daily) and acetylsalicylic acid in high doses (≥ 1.3 g daily) to a diminished breakdown of side effects.</seg>
<seg id="2402">Therefore caution is advisable if in patients with normal kidney function (Kreatinine-Clearance ≥ 80 ml / min) high doses of NSAIDs or Ace- tylsalicylic acid.</seg>
<seg id="2403">Ibuprofen) or acetylsalicylic acid in high dose for at least 2 days before the therapy, a day of therapy and reduction of 2 days after therapy with paremetry should be avoided (see Section 4.4).</seg>
<seg id="2404">"" "" "" "since no data are received with regard to interaction with NSAIDs, such as Piro- xicam or Rofecoxib, the simultaneous application must be mixed with pemetry at least 2 days after therapy." "" "" ""</seg>
<seg id="2405">The great intra-individual variability of tinness status during the disease and the possibility of interactions between oral anticoagulants and antineoplastic chemotherapy is an increased monitoring frequency of INR (International standardization). when the decision was taken to treat the patient with oral anticoagulants.</seg>
<seg id="2406">"" "" "" "there are no data for the use of Pemetremixed in pregnant women, but as in ande- antimetabolites are expected to be severe during pregnancy." "" "" ""</seg>
<seg id="2407">"" "" "" "parrot should not be applied during pregnancy, except if unnecessarily and after careful consideration of the use for the mother and risk for the fetus (see Section 4.4)." "" "" ""</seg>
<seg id="2408">"" "" "" "as the possibility of an irreversible injury to reproductive capacity is made possible, men should be advised before the treatment begins to obstruct advice regarding the locking system." "" "" ""</seg>
<seg id="2409">"" "" "" "it is not known whether pemetry exceeds the breast milk, and unwanted effects with the infant infant cannot be excluded." "" "" ""</seg>
<seg id="2410">"" "" "" "the following table shows the frequency and severity of adverse effects that were reported in &gt; 5% of 168 patients with Mesendotheliom, which were randomized Cisplatin which were randomized cisplatin as a monotherapy." "" "" ""</seg>
<seg id="2411">Side effects (≥ 1 / 100 and &lt; 1 / 10) and sometimes (≥ 1 / 1000 and &lt; 1 / 1000). very rare (≥ 1 / 10.000) and is very rare (≥ 1 / 10.000) and not (&lt; 1 / 10.000) and is not invaluable on the basis of available data from spontaneasements.</seg>
<seg id="2412">* CTC Version 2 (* * *) concerning National Cancer Institute CTC Version 2 for each toxicity degree is excluded from the term "Creatinine-Clearance Other." * * * Beching on National Cancer Institute CTC (v2.0; NCI 1998) should be reported to taste and hair loss only as degrees 1 or 2.</seg>
<seg id="2413">"" "" "" "for this table, a threshold of 5% was laid down regarding the absorption of all events, where the reporting doctor held a connection with Pemetry and Cisplatin which was possible." "" "" ""</seg>
<seg id="2414">"" "" "" "clinically relevant CTC toxicity, which were reported at &lt; 1% (occasionally) of patients, were randomized cisplatin and poemetry, encepitated arrhythmia and motor reapathy." "" "" ""</seg>
<seg id="2415">"" "" "" "the following table shows the frequency and severity of adverse effects that were reported in &gt; 5% of 265 patients, randomized pemetry. and 276 patients were randomized docetaxel as a monotherapy." "" "" ""</seg>
<seg id="2416">* CTC Version 2 regarding the National Cancer Institute CTC Version 2 for each toxicity. * * Beching on National Cancer Institute CTC (v2.0; NCI 1998) shall not only be reported as degree 1 or 2.</seg>
<seg id="2417">"" "" "" "for this table, a threshold of 5% was determined concerning the acceptance of all events, where the reporting doctor held a connection with Pemetry." "" "" ""</seg>
<seg id="2418">"" "" "" "clinically relevant CTC toxicity, which were reported at &lt; 1% (occasionally) of patients, were randomized Pemetry to participate, included supragventricular arrhythmia." "" "" ""</seg>
<seg id="2419">The clinically relevant laboratory toxicity 3 and 4 was similar to the combined results of three single Pemetry mixed monotherapiaries (n = 164) of the phase 2 (compared with 5.3% compared to 5.3%) and an increase of Alanintransaminase (15.2% compared to 1.9%).</seg>
<seg id="2420">These differences are likely to lead to differences in patient population since the Pha- se 2 studies both chemonaive and / or abnormal breast cancer patients with existing liver metastases and / or abnormal case values of liver function.</seg>
<seg id="2421">"" "" "" "the following table shows the frequency and severity of adverse effects associated with NSCLC, randomized Cisplatin and Pemetry received and 830 patients with NSCLC, randomized Cisplatin and gemcitabine." "" "" ""</seg>
<seg id="2422">11 * P values &lt; 0,05 Comparison of Pemetry signposted / Cisplatin and Gemini (v2.0; NCI 1998) for each toxicity. * * * Beching on National Cancer Institute CTC (v2.0; NCI 1998) should be reported to taste and hair loss only as degrees 1 or 2.</seg>
<seg id="2423">"" "" "" "for this table, a threshold of 5% was laid for the recording of all events in which the reporting doctor held a link of 5%." "" "" ""</seg>
<seg id="2424">"" "" "" "clinically relevant toxicity, which were reported at ≥ 1% and ≤ 5% (often) of patients, were randomized cisplatin and Pemetrexed:" "" "" ""</seg>
<seg id="2425">"" "" "" "clinically relevant toxicity, which were reported at &lt; 1% (occasionally) of the patients, associated to cisplatin and ponemetry, included:" "" "" ""</seg>
<seg id="2426">"" "" "" "adverse events, including myocardial infarction, including myocardial infarction, angina pectoris, cerebrovascular examinations, usually administered in combination with another cytotoxic substance, occasionally reported." "" "" ""</seg>
<seg id="2427">"" "" "" "clinical trials were reported in patients with pemetreed treatment occasionally cases of Coli- tis, including intestinal and rectals, intestinal performers, intestinal necrosis and typhlitis." "" "" ""</seg>
<seg id="2428">"" "" "" "clinical trials were occasionally reported in patients with pemetry, occasionally deadly interstical pneumonitis with respiratory failure." "" "" ""</seg>
<seg id="2429">"" "" "" "in case of cases of acute kidney failure, monotherapy or combination with other chemotherapy was reported (see Section 4.4)." "" "" ""</seg>
<seg id="2430">"" "" "" "these were reported cases of radienpneumonitis in patients who were used before, during or after their pimparted therapy (see Section 4.4)." "" "" ""</seg>
<seg id="2431">ALIMTA (Pemetry xed) is an antinedioplasty Antifolate that breaks its effect by consuming a weight-dependent metabolic processes that are necessary for cell replication.</seg>
<seg id="2432">In vitro studies showed that Pemetry has been blocked as an antifolate with multiple attaching (DHFR) and Glycamidrivesucleotidase (DHFR) and glycoamidrivesucleotidase (DHFR) and the thymidine bacteria from thymidine and Purinnucleotids.</seg>
<seg id="2433">"" "" "" "EMPHACIS, a multi-centric, randomised, straightforward-blind phase 3 study from ALIMTA plus cisplatin treated patients suffering from ALIMTA and cisplatin which were collected only with Cisplatin which had only been installed with Cisplatin." "" "" ""</seg>
<seg id="2434">"" "" "" "the primary analysis of this study was carried out in the population of all patients, randomized and treated in the treatment arm." "" "" ""</seg>
<seg id="2435">A statistically significant improvement of clinical symptoms (pain and dyspnoe) in connection with the malignant pleurbendotheliom was shown in the ALIMTA / Cisplatin arm (212 patients) compared to the sole Cisplatin Tin arm (218 patients).</seg>
<seg id="2436">The differences between the two treatment arms showed an improvement of lung function parameters in the ALIMTA / Cisplatin arm and a poorer of lung function during the time of control.</seg>
<seg id="2437">A multi-centric, randomised and open Phase III study with ALIMTA to docetaxel in patients with locally advanced or metastatic breast cancer (Intent to Treat Population n = 283) and 7.9 months treated with docetaxel treated patients (ITT n = 288).</seg>
<seg id="2438">An analysis of the influence of histology on the treatment effect on the overall survival compared HR = 0.99; 95% CI = 0.61-1.00, p = 0.56; 95% CI = 1.56; 95% CI = 1.08-2.26, p = 0.018).</seg>
<seg id="2439">Limited data from a separately randomised controlled Phase 3 study shows that efficacy data (survival and progression-free survival) for paremetry between patients with (n = 41) and without (n = 540) previous treatment by docetaxel similar.</seg>
<seg id="2440">The efficacy analysis of the PQ population are consistent with the analyses of the ITT population and support the non-underperiority of the ALIMTA cisplatin combination opposite the gemcitabine Cisplatin combination.</seg>
<seg id="2441">"" "" "" "11.5 months for the combination of gemcitabine Cisplatin (adjusted HR = 1.04; 95% CI = 0,0 - 31.4), the overall response rate reached 30.6% (95% CI = 25.0 - 31.4) for the combination of gemcitabine Cisplatin." "" "" ""</seg>
<seg id="2442">Analysis of the impact of the NSCLC histology on survival showed clinically relevant differences in the history of histology. see table below.</seg>
<seg id="2443">CI = Unfair-to-Treat; N = size of the entire population of statistically Significant for non-undersuperiority as well as a total consistent interval for HR (= Hazard ratio) significantly below the non-underline gap of 1.17645 (p &lt; 0.0001).</seg>
<seg id="2444">Patients that were treated with ALIMTA and Cisplatin which were treated with ALIMTA versus 28.9% versus 28.9% versus 11.3% (p &lt; 0.001) and Thrombocytfusions (1.8% versus 4.5%, p = 0.0002).</seg>
<seg id="2445">"" "" "" "furthermore, patients suffering from Erythropoetin / Darbopoetin (3.1% versus 6.1%, p = 0.01%, p = 0.004), and iron prepared (4,3% versus 7.0%, p = 0.021)." "" "" ""</seg>
<seg id="2446">The pharmacokinetic properties of Pemetreed according to gift as monotherapists were investigated in 426 cancer patients with various solid tumors in doses ranging from 0.2 to 838 mg / m ² in infusion areas over a period of 10 minutes.</seg>
<seg id="2447">Pemetry reportedly remains unchanged in the urine and 70% to 90% of the desired dose will be found unchanged within 24 hours after use in the urine.</seg>
<seg id="2448">Pemetry has a total of 91.8 ml / min and the half-time in the plasma is 3.5 hours in patients with normal kidney funtion (creatinine-Clearance 90 ml / min).</seg>
<seg id="2449">In a study with Beagle-dogs who had received intravenous Bolus injections that were observed for 9 months (Degene- ration / necrosis of the seminiferous epithelial-tissue).</seg>
<seg id="2450">Unless unused less applied is the storage times and conditions after preparing and should not be shout normally 24 hours at 2 to 8 ° C (unless the preparation / dilution has occurred under controlled and validated aseptic conditions).</seg>
<seg id="2451">Dissolve the contents of 100 mg / ml of sodium chloride (9 mg / ml) without preservative added to this result in a solution having a concentration of approximately 25 mg / ml Pemetry.</seg>
<seg id="2452">"" "" "" "the resulting solution is clear and the coloring is ranging from colourless to yellow or greenish, without the product quality is impaired." "" "" ""</seg>
<seg id="2453">"" "" "" "each water bottle must be dissolved with 20 ml 0,9% sodium chloride injections (9 mg / ml), which results in a solution of 25 mg / ml." "" "" ""</seg>
<seg id="2454">"" "" "" "23 serious kardioval events, including myocardial infarction, and cerebrovascular events were reported in clinical trials with Pemetry. when this active substance was usually administered in combination with another cytotoxic substance." "" "" ""</seg>
<seg id="2455">* CTC Version 2 (* * *) concerning National Cancer Institute CTC Version 2 for each toxicity degree is excluded from the term "Creatinine-Clearance Other." * * * Beching on National Cancer Institute CTC (v2.0; NCI 1998) should be reported to taste and hair loss only as degrees 1 or 2.</seg>
<seg id="2456">"" "" "" "for this table, a threshold of 5% is defined regarding the absorption of all events, during which the correct doctor held a connection with pemetry and cisplatin which was possible." "" "" ""</seg>
<seg id="2457">* CTC Version 2 regarding the National Cancer Institute CTC Version 2 for each toxicity. * * Beching on National Cancer Institute CTC (v2.0; NCI 1998) shall not only be reported as degree 1 or 2.</seg>
<seg id="2458">29 * P values &lt; 0,05 Comparison of Pemetry signposted / Cisplatin and Gemini (v2.0; NCI 1998) for each toxicity. * * * Beching on National Cancer Institute CTC (v2.0; NCI 1998) should be reported to taste and hair loss only as degrees 1 or 2.</seg>
<seg id="2459">"" "" "" "clinically relevant toxicity, which were reported at &lt; 1% (occasionally) of the patients, associated to cisplatin and ponemetry, included:" "" "" ""</seg>
<seg id="2460">An analysis of the influence of histology on the treatment effect on the overall survival compared HR = 0.99; 95% CI = 0.61-1.00, p = 0.56; 95% CI = 1.56; 95% CI = 1.08-2.26, p = 0.018).</seg>
<seg id="2461">Solve the content of 500 mg per cent of sodium chloride (9 mg / ml) without preservative added to this result in a solution having a concentration of approximately 25 mg / ml Pemetry.</seg>
<seg id="2462">The resulting solution is clear and the dye is ranging from colourless to yellow or greenish without the product quality is impaired.</seg>
<seg id="2463">"" "" "" "Pharmakovigilance System The holder of approval for the transaction has approved for this, as described in version 2.0 included in module 1.8.1. the approval for the transport, ready and ready for use and while the product is placed in the market." "" "" ""</seg>
<seg id="2464">Risk Management plan The holder of approval for the inclusion of pharmacovigilance-activities according to Pharmakovigilanz activities such as agreed in Version 1.2 of the Risk Management Plan (RMP) provided in Module 1.8.2. the approval for placing and all subsequent updates of the RMP provided by CHMP.</seg>
<seg id="2465">"" "" "" "according to CHMP Guideline on Risk Management Systems for HighStep for Human use, an updated RMP must be submitted simultaneously with the next" Periodic Safety Update Report "(PSUR)." "" "" ""</seg>
<seg id="2466">"" "" "" "in addition, an updated RMP must be submitted • If new information might have a effect on current security specifications, the Pharmacovigilance plan or the risk of risk assessment (Pharmacovigilance or risk assessment) • Overrequest by the EMEA." "" "" ""</seg>
<seg id="2467">ALIMTA 100 mg is based on the fabrication of a concentrates in the ALIMTA 500 mg of powder for the production of a concentrates solution for the production of infusion.</seg>
<seg id="2468">ALIMTA is used in patients who have received no previous chemotherapy; in combination with Cisplatin, a combination with cisplatin and a different drug for treatment of cancers.</seg>
<seg id="2469">"" "" "" "if you have a kidney or one of a kidney, please discuss it with your doctor or Hospital pharmacy, as you may not get ALIMTA." "" "" ""</seg>
<seg id="2470">"" "" "" "in case of any infusion blood tests, one will examine whether your kidney and liver function will be sufficient, and if you have enough blood cells to get ALIMTA to 49." "" "" ""</seg>
<seg id="2471">"" "" "" "your doctor may change the dose or break the treatment, if your general condition requires and if your blood levels are too low." "" "" ""</seg>
<seg id="2472">"" "" "" "if you also received Cisplatin, your doctor will ensure that your body contains sufficient water and you will receive the necessary medicine to break the vomiting before and after the cisplatin gift." "" "" ""</seg>
<seg id="2473">"" "" "" "should there be a fluid buildup around the lungs around the lungs, your doctor may decide to eliminate such liquid before you receive ALIMTA." "" "" ""</seg>
<seg id="2474">"" "" "" "if you would like to bear a child during the treatment or during the first 6 months of treatment, please contact your doctor or pharmacist." "" "" ""</seg>
<seg id="2475">Interactions with other medicines Please tell your doctor if you are medicine against pain or infections (swellae) such as medicines that are non-prescription drugs (like ibuprofen).</seg>
<seg id="2476">Depending on the planned release of your ALIMTA infusion and / or the extent of your renal function your doctor will tell you what other drugs you can take it and when.</seg>
<seg id="2477">"" "" "" "please inform your doctor or pharmacist if you take other medicines or have recently taken it, even if there is no prescription drug." "" "" ""</seg>
<seg id="2478">An Hospital holder where nursing staff or a doctor will mix the ALIMTA powder with sterile 0.9% sodium chloride injections (9 mg / ml) before being applied to you.</seg>
<seg id="2479">"" "" "" "your doctor will prescribe cortisone tablets (according to 4 mg dexamines two times daily), which you have to take on the day before, during and day after the application of ALIMTA." "" "" ""</seg>
<seg id="2480">"" "" "" "your doctor will give you folic acid (a vitamin) for intake or multivitamins, which contain folic acid (350 to 1000 micrograms), which you need to use ALIMTA within a daily basis." "" "" ""</seg>
<seg id="2481">In the week before the application of ALIMTA and approximately every 9 weeks (according to 3 cycles of treatment with ALIMTA) you will also obtain an injection of Vi- tamin B12 (1000 micrograms).</seg>
<seg id="2482">"" "" "" "in this manual formation, a side effect is described as" very frequently, "means that it was reported by at least 1 out of 10 patients." "" "" ""</seg>
<seg id="2483">"" "" "" "a side effect is described as" frequently, "means that it reported at least 1 of 100 patients, but reported less than 1 of 10 patients." "" "" ""</seg>
<seg id="2484">"" "" "" "in a side effect as" occasionally, "it indicates that it has been reported by at least 1 of 1,000 but less than 1 of 100 patients, it means that they have reported less than 1 out of 10,000 patients." "" "" ""</seg>
<seg id="2485">Fever or infection (often): if you have a body temperature of 38 ° C or above, sweating or other signs of infection (because you may have less white blood cells than normally what is very common).</seg>
<seg id="2486">"" "" "" "if you feel tired or weak, swiftly in breath needs or look (because you might have less hemoglobin than normal, which is very common)." "" "" ""</seg>
<seg id="2487">"" "" "" "if you find a bluff of the gum or the mouth of the mouth or any other hemorality that does not come to a halt, or a reddish or pink pristine or unexpected bluepzets have (normal, which is very common)." "" "" ""</seg>
<seg id="2488">"" "" "" "occasionally (occurs at least 1 out of 1,000 patients, but less than 1 of 100 patients) increased pulsation of colon (inflammation of the intestine and endgut) eyelash (leaving of water into the body tissue, which leads to swelling)." "" "" ""</seg>
<seg id="2489">"" "" "" "rare (more than 1 out of 10,000 patients, but less than 1 of 1,000 patients)" Radiation Recall "(an rash similar to a heavy sunburn), appearance on the skin that was exposed to radiation therapy (a few days until years)." "" "" ""</seg>
<seg id="2490">"" "" "" "occasionally in patients receiving ALIMTA, usually in combination with other cancer members, a stroke, or stroke, had a loss of damage." "" "" ""</seg>
<seg id="2491">"" "" "" "in patients who received a radiation treatment before, during or after their ALIMTA treatment, can occur through radiation resulting inflammation of the lung tissue (or the radiation treatment in relation)." "" "" ""</seg>
<seg id="2492">52 Informing your doctor or pharmacist if one of the listed side effects you have to affect or if you notice any side effects that are not routed in this package age.</seg>
<seg id="2493">"" "" "" "provided as prescribed, the chemical and physical stability of the diluted and the infusion solution for storage in the refrigerator or at 25 ° C was proved for a period of 24 hours." "" "" ""</seg>
<seg id="2494">"" "" "" "Tél / Tel: + 32- (0) 2 548 84 84 children's première-sconvulsone. + 359 2 491 41 40 Č eská Republika ELI LILLY TRR, s.r.o." "" "" ""</seg>
<seg id="2495">"" "" "" "Tel: + 420 234 664 111 Danmark Eli Lilly Danmark A / S Tlf: + 45 45 26 6100 Germany Lilly Germany GmbH. Tel: + 45 45 26 6100 Germany Lilly Germany GmbH." "" "" "" "+ 45 45 26 6100 Germany Lilly Germany GmbH." "" "" "" "+ 3726441100" "" "" ""</seg>
<seg id="2496">Tel: + 34-91-623-1732 France Lilly France SAS Tél: + 33- (0) 1 55 49 34 34 Ireland Eli Lilly and Company (Ireland) Limited Tel: + 353- (0) 1 661 4377 Ísland Icephalma hf.</seg>
<seg id="2497">Sensory measures: + 357 22 715000 Latvija Eli Lilly Holdings Limited recently taken: + 371 67364000 Lietuva Eli Lilly Holdings Limited atstovybdas Tel. + 370 (5) 2649600</seg>
<seg id="2498">Tel.: + 48 (0) 22 440 33 00 Portugal Lilly Portugal - Produtos Farmacêuticos, LDA Tel: + 351-21-4126600 România S.R.L.</seg>
<seg id="2499">Tel: + 421 220 663 111 Suomi / Finland Oy Eli Lilly Finland: + 358- (0) 9 85 45 250 Sverige Eli Lilly and Company Limited Call: + 46- (0) 8 7378800 United Kingdom Eli Lilly and Company Limited Tel: + 44- (0) 1256 315999</seg>
<seg id="2500">Solve the content of 100 mg per cent of sodium chloride (9 mg / ml) without preservative added to what a solution with a concentration of about 25 mg / ml Pemetry is due.</seg>
<seg id="2501">Solve the content of 500 mg per cent of sodium chloride (9 mg / ml) without preservative added to what a solution with a concentration of about 25 mg / ml Pemetry is due.</seg>
<seg id="2502">"" "" "" "the resulting solution is clear and the coloring varies from color to yellow or greenish, without impacting the reproduction." "" "" ""</seg>
<seg id="2503">It is used in overweight adults with a body mass index (Body Mass Index - BMI) from ≥ 28 kg per square meter in combination with a low-calorie-rich diet.</seg>
<seg id="2504">"" "" "" "patients receiving weight loss after 12 weeks, should consult a doctor or pharmacist." "" "" ""</seg>
<seg id="2505">"" "" "" "if these enzymes are inhibited, they can't dismantle some fats in the diet, causing a quarter of the fats led to the intestines." "" "" ""</seg>
<seg id="2506">"" "" "" "in a third study, alli was compared with a BMI between 25 and 28 kg / m2 with a placebo between 25 and 28 kg / m2." "" "" ""</seg>
<seg id="2507">"" "" "" "in the two studies on patients with a BMI of ≥ 28 kg / m2, patients who had an average weight loss of 4.8 kg, compared to 2.3 kg when taking placebo." "" "" ""</seg>
<seg id="2508">"" "" "" "in the study with alli in patients with a BMI between 25 and 28 kg / m2, no weight loss could be observed for patients." "" "" ""</seg>
<seg id="2509">"" "" "" "the most common adverse events of alli (observed in more than 1 of 10 patients) are sociable stains at after, Flatus (winch) with a bowel movement, fetal / oily chair, wearching and softened sections (winch) and soft chairs." "" "" ""</seg>
<seg id="2510">It must not be applied in patients who are treated with Ciclosporin (to prevent organ reduction in transplants) or medicines such as warfarin to prevent blood clots.</seg>
<seg id="2511">It may not be applied to patients who suffer from a long-term malignant syndrome (where not enough nutrients from digestive tract) or to chase of liver (liver disease) or during pregnancy or with lactating mothers.</seg>
<seg id="2512">"" "" "" "in July 2007, the European Commission issued Glaxo Group Limited for placing the transport of Orlistat GSK throughout the European Union." "" "" ""</seg>
<seg id="2513">Alli is indexed to weight reduction of adults with obesity (Body Mass Index BMI ≥ 28 kg / m2) and should be used in combination with an easily hypokalorical and greasy treatment.</seg>
<seg id="2514">Alli must not be applied by children and adolescents under 18 because there are no sufficient data for efficacy and safety.</seg>
<seg id="2515">"" "" "" "since Orlistat is not only minimally absorbed, with elderly and / or kidney function, no adjustment of the dosage is necessary." "" "" ""</seg>
<seg id="2516">• hypersensitivity to the active ingredient or one of the other ingredients • Equal treatment with Ciclosporin (see Section 4.6) • Time treatment with warfarin or other oral anticoagulants (see sections 4.5 and 4.8)</seg>
<seg id="2517">"" "" "" "the probability of occurrence of gastrointestinal symptoms (see Section 4.8) can increase, if alli is taken together with a fat-free meal or obesity diet." "" "" ""</seg>
<seg id="2518">"" "" "" "as the weight reduction in diabetes can occur with improved metabolic control, patients who can consult a medicine or pharmacist in the beginning of a therapy with alli a doctor or pharmacist." "" "" ""</seg>
<seg id="2519">"" "" "" "patients suffering from alli as well as medicines for high blood pressure or increased cholesterol, should consult a doctor or pharmacist if the dosage needs to be adjusted." "" "" ""</seg>
<seg id="2520">"" "" "" "it is recommended to take additional fluctuation vulnerable measures to prevent the oral contraceptive failure (see Section 4.5), in case of severe diarrhoea." "" "" ""</seg>
<seg id="2521">"" "" "" "in a study on interactions of pharmaceuticals, as well as in several cases, using orlistat and Ciclosporin has been observed a reduction of Ciclosporin plasma devices." "" "" ""</seg>
<seg id="2522">"" "" "" "in combination with oral or other oral anticoagulants in combination with orlistat, the quick values (globally standardisratio, INR) could be affected (see Section 4.8)." "" "" ""</seg>
<seg id="2523">"" "" "" "in most patients who were treated in clinical trials up to 4 full years with orlistat, concentrations of vitamins A, D, E and K and the beta-carotenters into the norm." "" "" ""</seg>
<seg id="2524">"" "" "" "however, patients should be recommended to take a supplement of multivitamin before bedtime to ensure adequate vitamin intake (see Section 4.4)." "" "" ""</seg>
<seg id="2525">"" "" "" "according to the gift of an injection dose Amiodaron, a limited number of healthy volunteers received at the same time Orlistat, a minor decrease in the Amiodaron plasma concentration." "" "" ""</seg>
<seg id="2526">"" "" "" "experimental studies showed no direct or indirect harmful effects on pregnancy, embryonic / fetal development, birth or postnatal development (see paragraph 5.3)." "" "" ""</seg>
<seg id="2527">"" "" "" "the effects of orlistat mainly are gastrointestinal nature and are associated with the pharmacological effects of the medication, since the absorption of incorporated fat is prevented." "" "" ""</seg>
<seg id="2528">Gastrointestinal effects were obtained from clinical trials with Orlistat 60 mg over a period of 18 months to 2 years and were generally light and temporary.</seg>
<seg id="2529">"" "" "" "the Frequencies are defined as follows: very frequently (≥ 1 / 100, &lt; 1 / $), rare (≥ 1 / 10,000, &lt; 1 / 10,000) and very rare (incidence based on the data available)." "" "" ""</seg>
<seg id="2530">"" "" "" "the incidence of previously known side effects that were established after the market launch of Orlistat, is not known because these events were recorded voluntarily from a population uncertainties." "" "" ""</seg>
<seg id="2531">"" "" "" "+ It is plausible that treatment with alli can lead to defaults in terms of potential or actual gastrointestinal side effects." "" "" ""</seg>
<seg id="2532">Single doses of 800 mg orlistat and multiple outlets of up to 400 mg three times a day were administered at normal and overweight subjects over a period of 15 days without taking significant clinical findings.</seg>
<seg id="2533">"" "" "" "if the majority of reported cases reported by Orlistat, either no side effects or similar effects as reported at the recommended dose of orlistat." "" "" ""</seg>
<seg id="2534">"" "" "" "based on studies on humans and animals, from a rapid response of any systemic effects that are attributed to the notorious properties of orlistat." "" "" ""</seg>
<seg id="2535">The therapeutic effect focuses in the lumen of stomach and the upper dune bonds by covalent bonds to the active Serin-rest of the gastra and pancreations.</seg>
<seg id="2536">"" "" "" "from clinical trials, 60 mg of orlistat, administered three times a day, the absorption of approximately 25% of the food fetal is blocked." "" "" ""</seg>
<seg id="2537">Two double-blind, randomised, placebo-controlled studies in adults with a BMI ≥ 28 kg / m2 measured the effectiveness of 60 mg orlistat that was taken three times daily in combination with hypokaline and greasy food.</seg>
<seg id="2538">The primary parameter, the change in body weight compared to the starting point (at the time of Randomization) was assessed as follows: as a change in the body weight (table 1) and as part of those study participants (table 2) or more than 10% of their initial weight (table 2).</seg>
<seg id="2539">"" "" "" "though observed in both trials over 12 months, weight loss was observed in the first 6 months." "" "" ""</seg>
<seg id="2540">The average change in total cholesterol was 60 mg -2.4% (initial value 5.20 mmol / l) and placebo + 2.8% (output 5.26 mmol / l).</seg>
<seg id="2541">The average change of LDL cholesterol compared with Orlistat 60 mg -3.5% (output value 3.30 mmol / l) and placebo + 3.8% (output value 3.41 mmol / l).</seg>
<seg id="2542">When the waist circumference was the average change -4.5 cm with Orlistat 60 mg (starting value 103.7 cm) and placebo-3.6 cm (base equivalent: 103,5 cm).</seg>
<seg id="2543">Plasma concentrations of non-metabolized orlistat were not measurable after the oral gift of 360 mg orlistat (&lt; 5 ng / ml).</seg>
<seg id="2544">"" "" "" "7 In general, orlistat could not only be detected in rheumatoid arthritis in plasma and extremely low concentrations (&lt; 10 ng / ml or 0.02 µmol) and without signs of a grief." "" "" ""</seg>
<seg id="2545">"" "" "" "in a study of adipous patients, which was administered at the minimum systemically absorbated dose, e.g. M1 (in position 4 hydrolysed Lactol group), identified nearly 42% of the total plasticism concentration." "" "" ""</seg>
<seg id="2546">"" "" "" "based on conventional studies on safety pharmacology, toxicity in repeated planation, genotoxicity, canonous potential and reproduction, the preclinical data can not recognize any particular risk for humans." "" "" ""</seg>
<seg id="2547">"" "" "" "the holder of the pharmacovigilance system has to ensure that the pharmacovigilance system is described in accordance with the version of July 2007, as described in module 1.8.1. of the application order and before and while the product is available on the market." "" "" ""</seg>
<seg id="2548">"" "" "" "risk-management of risk management is required to conduct studies and additional pharmacovigilance activities as described in the Pharmacovigilance plan, as well as in the pharmacovigilance schedule as well as all other updates to the Council for Human Use (CHMP)." "" "" ""</seg>
<seg id="2549">"" "" "" "according to CHMP guidelines for risk management systems, the updated RMP must be submitted simultaneously with the next PSUR (peril Safety Update Report)." "" "" ""</seg>
<seg id="2550">"" "" "" "furthermore an updated RMP should be submitted: • If new information is available, current security policies, the pharmacovigilance or risk financing activities • available on request to the European Medicines Agency (EMEA)" "" "" ""</seg>
<seg id="2551">"" "" "" "12 PSURs The holder of approval for inclusion in the first year after Commission for order to extend the alli 60 mg of tungsten capsules PSURs every 6 months, then for two years yearly and after that every three years." "" "" ""</seg>
<seg id="2552">Do not use if you are pregnant or breastfeeding under 18 (if you are pregnant or breastfeed if you suffer goods or other blood diluted (disease of the liver on which the bile flow is disrupted) - if you have problems with food intake (chronic cold absorption syndrome).</seg>
<seg id="2553">"" "" "" "• Take three times a day with every main meal. take the capsule one capsule one day before bedtime, take a multivitamintablette (with vitamins A, D, E and K). • You should not use any longer than 6 months." "" "" ""</seg>
<seg id="2554">"" "" "" "application: • Take a capsule 3 times a day with every main meal. • You should take one capsule once daily, before bedtime a multivitamintablette (with vitamins A, D, E and K). • You should not use any longer than 6 months." "" "" ""</seg>
<seg id="2555">"" "" "" "you may want to read these later again. • If you need further information or pharmacist if you have further information or advice, ask your doctor or pharmacist to advise advice." "" "" ""</seg>
<seg id="2556">"" "" "" "you may have to end the intake of alli. • If any of the common side effects have you significantly impaired or you may notice any side effects listed in this manual information, please inform your doctor or pharmacist." "" "" ""</seg>
<seg id="2557">"" "" "" "what should you be aware before taking alli? • Do not be applied • Special attention when taking alli with other medicines • For intake of alli together with food and drinks • pregnancy and lactation • pregnancy and nursing, • Use of machines 3." "" "" ""</seg>
<seg id="2558">"" "" "" "how can you take your weight loss? how can you take your weight loss? O adults from 18 years o How long should I take alli? O if you have taken alli into large quantities, if you have forgotten the intake of alli 4." "" "" ""</seg>
<seg id="2559">What side effects are possible? • severe side effects • Very frequent side effects • Frequent side effects • How can you control nutritional-related accompanying symptoms?</seg>
<seg id="2560">Further information • What alli contains • How alli looks and content of the pack • Pharmaceutical entrepreneurs and manufacturers • Additional information</seg>
<seg id="2561">Alli is used to reduce weight reduction and is applied in overweight adults from 18 years with a body mass index (BMI) from 28 or over. alli should be used in combination with a fat and calorie intake.</seg>
<seg id="2562">The BMI helps you to determine whether you have a normal weight or obese in proportion to your height.</seg>
<seg id="2563">"" "" "" "even if these conditions first do not make you feel uncomfortable, you should still ask your doctor to check the inspection." "" "" ""</seg>
<seg id="2564">"" "" "" "for each 2 kg body weight, which you can remove from a diet in the course of a diet, you can lose an extra kilogram using alli." "" "" ""</seg>
<seg id="2565">"" "" "" "please inform your doctor or pharmacist if you take other medicines or have recently taken it, even if it is not prescription medicine." "" "" ""</seg>
<seg id="2566">Ciclosporin is used in organ transplants in case of severe rheumatoid arthritis and certain severe skin disorders. • Warfarin or other medicines that have a blood thinner effect.</seg>
<seg id="2567">Oral contraceptives and alli • The effects of oral ammunitive means to gesture (pill) is weakened under circumstances or suspended if you have strong diarrhoea (diarrhea).</seg>
<seg id="2568">Please consult your doctor or pharmacist if you use: • Amiodarone to treat heart rhythm disorders. • Amiosis for treating diabetes.</seg>
<seg id="2569">"" "" "" "ask your doctor or pharmacist if you take your medicines for high blood pressure, as you may need medicines for high blood pressure, as you may need to adjust the dosage." "" "" ""</seg>
<seg id="2570">"" "" "" "how to set your calorie destination and fetal limits, you can find out more useful information on the blue pages in section 6." "" "" ""</seg>
<seg id="2571">"" "" "" "if you have a meal or a meal contains no fat, do not take any one. alli can only work when the food contains fat." "" "" ""</seg>
<seg id="2572">"" "" "" "if you take the capsule in conjunction with a meal which contains too much fat, risk related symptoms (see section 4)." "" "" ""</seg>
<seg id="2573">"" "" "" "in order to reconcile your body to the new eating habits, you are already beginning from the first capsule with calorie and greasy diet." "" "" ""</seg>
<seg id="2574">"" "" "" "nutritional supplements are effective as you can understand it anytime, as much you eat and it is probably easier to change your dietary habits." "" "" ""</seg>
<seg id="2575">"" "" "" "to achieve your target weight, you should define two daily goals in advance: one for the calories and one for fat." "" "" ""</seg>
<seg id="2576">"" "" "" "• do not feed greasy, in order to reduce the probability for nutritional-related companions (see Section 4). try to move more before you start taking the capsules." "" "" ""</seg>
<seg id="2577">"" "" "" "remember to ask your doctor if you are not accustomed to your doctor if you are physical activity during taking, and also after taking the intake of alli physically active." "" "" ""</seg>
<seg id="2578">• It must not be taken for more than 6 months. • If you can determine only 12 weeks application of alli not reduction of your weight please ask your doctor or pharmacist about advice.</seg>
<seg id="2579">"" "" "" "under circumstances, you must finish the intake of alli. • At a successful weight loss it is not about to return the diet and return to the old habits." "" "" ""</seg>
<seg id="2580">"" "" "" "• If less than one hour has passed since the last meal, take the intake of the capsule as before. • If more than one hour has passed since the last meal, do not take one capsule." "" "" ""</seg>
<seg id="2581">Flatulence with and without bleaching, sudden or increased stools and soft chair) are attributable to the mode of action (see section 1).</seg>
<seg id="2582">"" "" "" "severe allergic reactions • heaviness allergic reactions, or allergic reactions to the following changes: severe breathes, rash, swelling, swelling in the face, heart rases, circulatory collapse." "" "" ""</seg>
<seg id="2583">29 Very frequent side effects This can occur in more than 1 of 10 people who perform alli. • Bläger (flatulence) with and without any chair • Female chair Informing your doctor or pharmacist if one of these side effects will intensify or you significantly impaired.</seg>
<seg id="2584">Common side effects these can occur in 1 out of 10 people who perform alli. • gastric acid / liquid chair • Create your doctor or pharmacist if you amplify your doctor or pharmacist if one of these side effects are amplified or you significantly impaired.</seg>
<seg id="2585">Effects on blood tests It is not known how often these effects occur. • Increase of certain liver enzyme for patients suffering from warfarin or other blood-diluted (anticoagulating) drugs.</seg>
<seg id="2586">"" "" "" "please inform your doctor or pharmacist if one of the listed side effects will affect you significantly, or you may notice any side effects listed in this manual information." "" "" ""</seg>
<seg id="2587">"" "" "" "the most common side effects are associated with the mode of action of capsules, thereby creating the increases grease from the body." "" "" ""</seg>
<seg id="2588">"" "" "" "these adverse events normally occur within the first weeks after treatment, as you may not yet have been consistently reduced the fat content in the diet." "" "" ""</seg>
<seg id="2589">"" "" "" "with the following basic rules, you can learn to minimize the nutritional-related accompanying diet. • Learn more about the usual fat content of your favorite foods and about the size of portions you usually take." "" "" ""</seg>
<seg id="2590">"" "" "" "if you know exactly how much you eat, the odds that you will exceed your fat limit. • Share your recommended amount of fat evenly over daily meals." "" "" ""</seg>
<seg id="2591">"" "" "" "save the amount of calories and fat that you may have done per meal to take them in form of a fat-rich court or a durable aftercare, learn how to control them with time by adjusting their diet." "" "" ""</seg>
<seg id="2592">• Do not store any more medicines for children under the box. • Do not keep container tightly closed to protect the contents from moisture. • The bottle contains two white-sealed containers with silicones that serve to hold the capsules dry.</seg>
<seg id="2593">If you don't have this in any case. • You can carry your daily dose alli in the blue transport box (Shuttle) to which this pack is enclosed.</seg>
<seg id="2594">"" "" "" "FAMAR, 190 11 Avlona, Greece Catalent UK Packaging Limited, Sedge close, Headway, Great Oakley, Corby, Northampton NN18 8HS, United Kingdom" "" "" ""</seg>
<seg id="2595">"" "" "" "overweight has influence on your health and increases the risk of developing various grave diseases such as: • hypertension • cervical • cervical cancer • osteoarthritis contact your doctor about your risk for these illnesses." "" "" ""</seg>
<seg id="2596">"" "" "" "a lasting weight loss, for example by improving the diet and more movement, can prevent severe disease prevention and has a positive impact on your health." "" "" ""</seg>
<seg id="2597">"" "" "" "choose between meals, which contain a wide range of nutrients and learn to nourish healthy and healthy." "" "" ""</seg>
<seg id="2598">Energy is also measured in kilojoules which can also be found as indication of the packaging of foods. • The recommended calorie intake can be found as many calories you should take maximum per day.</seg>
<seg id="2599">"" "" "" "see the tables below in this section called tables. • The recommended fat intake in grams is the maximum amount of fat, which you should take with any meal." "" "" ""</seg>
<seg id="2600">"" "" "" "what amount for you is suitable, take the below information that indicates the number of calories that is suitable for you. • Due to the mode of action, compliance with recommended fat intake is crucial." "" "" ""</seg>
<seg id="2601">"" "" "" "if you take the same amount of fat as before, this can mean that your body can not process the amount of fat." "" "" ""</seg>
<seg id="2602">"" "" "" "due to adherence to recommended fat intake, you can reduce weight loss and reduce the probability of nutritional-related accompanying symptoms. • You should try to gradually increase gradually." "" "" ""</seg>
<seg id="2603">"" "" "" "34 This reduced calorie intake should allow you to gradually lose weight about 0.5 kg per week, without fruition and disappointments." "" "" ""</seg>
<seg id="2604">"" "" "" "the more active you are, the higher is your recommended calorie intake. •" low physical activity "means that you can work daily 150 kcal per day, e.g. by moving daily or other physical activity, e.g. by 3 km walking, 30 - to 45 minute cycling work or 2 km running in 15 minutes." "" "" ""</seg>
<seg id="2605">"" "" "" "• For long lasting loss, it is necessary to set realistic calorie and fat goals and hold this also meaningful. • Imagine a dietary supplement with information about the calorie and fat content of your meals. • Imagine more to move, before you start using alli." "" "" ""</seg>
<seg id="2606">"" "" "" "the alli program for supporting weight loss combines the capsules with a nutritional plan and a large number of other information materials that can help you to feed calorie and fetters, to be physically active." "" "" ""</seg>
<seg id="2607">"" "" "" "in combination with a customized program to support weight loss, this information can help you to develop a healthier lifestyle and reach your target weight." "" "" ""</seg>
<seg id="2608">"" "" "" "Aloxi is applied for nausea and vomiting (as cisplatin), and vomiting (like cisplatin), and vomiting (like cyclophosphamide, doxorubicine or carboplatin)." "" "" ""</seg>
<seg id="2609">The effectiveness of Aloxi can be increased by the extra gift of a corticosteroids (a medicine that can be used as an antioxidant).</seg>
<seg id="2610">"" "" "" "the application of patients under 18 years of age are not recommended, as the effects in this age group doesn't have enough information." "" "" ""</seg>
<seg id="2611">"" "" "" "this means that the active ingredient reveals the bond of a chemical substance in the body, 5-hydroxytryptamin (5HT, also known as serotonin) to the receptors in the intestines." "" "" ""</seg>
<seg id="2612">"" "" "" "Aloxi was examined in three main studies of 1 842 adults, receiving chemotherapy regimens which are strong or moderate trigger for nausea and vomiting." "" "" ""</seg>
<seg id="2613">"" "" "" "during chemotherapy, a strong trigger for nausea and vomiting were, 59% of patients treated with aldansetron (132 from 223), compared to 57% of patients treated with ondansetron (126 of 221)." "" "" ""</seg>
<seg id="2614">"" "" "" "in chemotherapy, 81% of patients treated with aldansetron (153% of patients treated with ondansetron (153 from 185) were treated with chemotherapy regimens." "" "" ""</seg>
<seg id="2615">"" "" "" "in a comparison with Dolasetron, these values were 63% for Aloxi (119 of 189 patients) and 53% for Dolasetron (101 from 191 patients)." "" "" ""</seg>
<seg id="2616">"" "" "" "March 2005, the European Commission issued the company Helsinn Birex Pharmaceuticals Ltd. a permit for the placing of Aloxi in the entire European Union." "" "" ""</seg>
<seg id="2617">Aloxi is indexed: for prevention of acute nausea and vomiting in strongly fluctuating chemotherapy and prevention of nausea and vomiting in moderate chemotherapy due to cancer disease.</seg>
<seg id="2618">"" "" "" "the effectiveness of Aloxi for prevention of nausea and vomiting, which is induced by a highly sensitive chemotherapy, can be amplified by adding a corticosteroids." "" "" ""</seg>
<seg id="2619">Since Palonosetron can prolong the colon-timeline, patients with amnesty obstipation or signs of a subtle Ileus should be monitored after injection.</seg>
<seg id="2620">"" "" "" "however, like with other 5HT3 antagonists, caution is advisable to extend the QT interval or for patients with which the QT interval is extended or which tend to such an extension." "" "" ""</seg>
<seg id="2621">"" "" "" "except in connection with another chemical product, Aloxi is neither used to measure nausea and vomiting in the days of chemotherapy." "" "" ""</seg>
<seg id="2622">"" "" "" "in preclinical trials, Palonosetron did not inhibit tumors of the five evaluated chemotherapy, cycloatin, cycloabine, doxorubicin and mitomycin C)." "" "" ""</seg>
<seg id="2623">"" "" "" "in a clinical study showed no significant pharmacokinetic interaction between a one-time intravenous dose Palonosetron and a stepless concentration of Metoclopramids, a CYP2D6 inhibitor." "" "" ""</seg>
<seg id="2624">"" "" "" "in a population based on a population of pharmacokinetics (Amiodaron, Cimmindine, Cimmindins, Cimmindins, dioxetine, tral and terbinafin), no significant impact on the Clearance of Palonosetron." "" "" ""</seg>
<seg id="2625">"" "" "" "experiences on the use of Palonosetron by human gestation is not present, therefore, Palonosetron should not be applied during pregnancy, unless it is considered to be treated by the doctor." "" "" ""</seg>
<seg id="2626">"" "" "" "in clinical trials the most common adverse events were observed with a dose of 250 micrograms (a total of 633 patients), which at least possibly had some headaches (9%) and obstipation (5%)." "" "" ""</seg>
<seg id="2627">"" "" "" "very rare cases (&lt; 1 / 10,000) of hypersensitivity and reactions on performance (burning, hardening, complaints and pain) were stated in post-marketing experiences." "" "" ""</seg>
<seg id="2628">"" "" "" "in the group with the highest dosage, similar qualities of adverse events demonstrated as in the other docks groups; there were no dose of activity to observe." "" "" ""</seg>
<seg id="2629">No dialysis trials were carried out due to the great distribution volume but probably no effective therapy with a Aloxi- overdosage.</seg>
<seg id="2630">"" "" "" "in two randomised double-blind studies, a total of 1.132 patients with ≤ 50 mg / m2, orboplatin, ≤ 1,500 mg / m2 doxorubicin and 250 mg. of conoszron (half-time 7 hours) or 100 mg Dolasetron was given intravenously at day 1." "" "" ""</seg>
<seg id="2631">"" "" "" "in a randomised double-blind study, 667 patients were received with ≥ 60 mg / m2 of cyclophosphamide and Dacarbazine, as well as 250 mg / m2 of cyclophosphamide and Dacarbazine, received 32 mg of ondansetron, received at day 1 intravenously." "" "" ""</seg>
<seg id="2632">Results of the studies with moderate chemotherapy and the study with heavy-based chemotherapy are combined in the following tables.</seg>
<seg id="2633">"" "" "" "in clinical trials for indication of chemotherapy-induced nausea and vomiting (CINV), the effects of Palonoszron were comparable with the corresponding effects of ondansetron and Dolasetron." "" "" ""</seg>
<seg id="2634">"" "" "" "after the findings, Palonoszron has the ability to block Izone kanäle into the ventricular de- and repolarization." "" "" ""</seg>
<seg id="2635">"" "" "" "the study conducted during 221 healthy subjects carried out by 221 healthy subjects were the evaluation of the ECG effects of i.v. and administered flonosetron in single doses of 0.25, 0.75 and 2.025 mg." "" "" ""</seg>
<seg id="2636">"" "" "" "after an initial decrease in plasma concentrations, a slow elimination from the body resulted in an average delivery time of approximately 40 hours." "" "" ""</seg>
<seg id="2637">The average maximum plasma concentration (Cmax) and the area under the concentration era curve (AUC0- ∞) is generally in total dose ranges of 0.3- 90 μ g / kg in healthy and cancer patient dosages.</seg>
<seg id="2638">"" "" "" "after intravenous gift of Palonoszron 0,25 mg every second day for a total of 3 doses higher average (± SD) increase of Palonosetron plasma concentration was 42 ± 34%." "" "" ""</seg>
<seg id="2639">"" "" "" "out of pharmacokinetic simulations, that at once daily intravenous gift of 0.25 mg of Palonosetron had reached a total value of 0.75 mg. however, the Cmax was higher after the import of 0.75 mg." "" "" ""</seg>
<seg id="2640">"" "" "" "about 40% are eliminated through the kidneys, and roughly 50% are converted into two primary metabolites who have in comparison to Palonoszron over less than 1% of the antagonistic effect on the 5HT3 receptor." "" "" ""</seg>
<seg id="2641">In-vitro studies regarding the metabolism have shown that CYP2D6 and, in lower extent the Isodic CYP3A4 and CYP1A2 are involved in Metabolism by Palonoszron.</seg>
<seg id="2642">"" "" "" "elimination According to an intravenous single dose of 10 microgram / kg [14C] -Palonosetron were found about 80% of the dose within 144 hours in urine, made approximately 40% of the prescribed dose." "" "" ""</seg>
<seg id="2643">"" "" "" "after a unique intravenous bolt injection the total body was 173 ± 73 ml / min, and renal Clearance 53 ± 29 ml / min." "" "" ""</seg>
<seg id="2644">"" "" "" "although patients with severe liver function disturbs the terminale Eliminationa monday and the average systemic exposure with ponosetron increases, however, it is not justified." "" "" ""</seg>
<seg id="2645">"" "" "" "in clinical trials, effects were observed only after expositions which are considered adequate about the maximum human therapeutic exposition which indicates a low relevance for clinical use." "" "" ""</seg>
<seg id="2646">"" "" "" "10 out of these clinical trials, indications that Palonosetron can be blocked only in very high concentrations of ionic channels, which are involved in ventricular de- and repolarization." "" "" ""</seg>
<seg id="2647">"" "" "" "high doses Palonoszron (each dose entails in about to 30-times of therapeutic exposure of human tumors, endocrine Neoplasmen (in thyroid gland, pancreas, pancreas, epidermis) and skin tumors in rats but not in mice." "" "" ""</seg>
<seg id="2648">"" "" "" "the underlying mechanisms are not fully known, but due to the high dosing and since Aloxi is intended for one-time application, the relevance of these results is minimal." "" "" ""</seg>
<seg id="2649">"" "" "" "" "" "" "" "the owner of this approval must inform the European Commission on the plans for the inclusion of the medicine within the scope of this decision." "" "" ""</seg>
<seg id="2650">"" "" "" "• If any of the common side effects you have significantly impaired or you may notice any side effects listed in this manual information, please inform your doctor." "" "" ""</seg>
<seg id="2651">• Aloxi is a clear and colorless injection solution for injection in a vein. • The substance (Palonosetron) belongs to a group of drugs that can cause nausea and vomiting. • Aloxi is used to prevent nausea and vomiting in connection with cancer.</seg>
<seg id="2652">"" "" "" "21 For using Aloxi with other medicines, ask your doctor if you use other medicines consuming / apply respectively, even if it is not prescribed for prescription medicine." "" "" ""</seg>
<seg id="2653">"" "" "" "pregnant or pregnant, pregnant or think pregnant, your physician will not give you Aloxi, unless you are required." "" "" ""</seg>
<seg id="2654">"" "" "" "before taking all drugs, ask your doctor or pharmacist about advice if you are pregnant or believe, become pregnant." "" "" ""</seg>
<seg id="2655">"" "" "" "in some very rare cases, allergic reactions to Aloxi or burning or pain at the instichment." "" "" ""</seg>
<seg id="2656">"" "" "" "like Aloxi Hats and content of the pack Aloxi injection solution is a clear, colorless solution, and is available in a pack of 1 glass bottle made of glass, containing 5 ml of the solution." "" "" ""</seg>
<seg id="2657">"" "" "" "slanted standards of sensorcerated by the pioneers of the stem." "" "" "" "" "" "" "" "" "" "" "": + 359 2 975 13 95 (6) "" "" "" "</seg>
<seg id="2658">"" "" "" "Latvija Pharmacia TIA 54-5, Head of the Street Riga, LV-1011, Tel: + 37167502185 Lietuva UAB pharmaceutical Swiss guired." "" "" ""</seg>
<seg id="2659">United Kingdom IS Pharmaceuticals Ltd Office Village Chester Business Park Chester CH4 9QZ - UK Tel: + 44 1244 625 152</seg>
<seg id="2660">"" "" "" "in June 2006, the Committee on Human Use (CHMP) approved a negative opinion in which the approval of approval for the treatment of hepatitis C is recommended by Alphat6 million IE / ml injections." "" "" ""</seg>
<seg id="2661">This means that Alphateon should resemble a biological medicine called Roferon-A with the same generally effective ingredient that is already approved in the EU (also called "reference guide").</seg>
<seg id="2662">Alpheon should be used for the treatment of adult patients with chronic (long-lasting) hepatitis C (a viral infection caused by viral infection).</seg>
<seg id="2663">In a microscopic examination the liver tissue damage occurs in addition the values of the liver enzyme Alanine Aminotransfervase (ALT) levels are increased in the blood.</seg>
<seg id="2664">It is produced by a yeast in which an gene (DNA) was introduced to stimulate them to the formation of active substance.</seg>
<seg id="2665">"" "" "" "the manufacturer of Alphsa presented data on the basis of Alpheon with Roferon-A (active substance, composition and purity of the drugs, mode of action, safety and efficacy of hepatitis C)." "" "" ""</seg>
<seg id="2666">"" "" "" "in the study of patients with Hepatitis C, the efficacy of Alphateon was compared to 455 patients." "" "" ""</seg>
<seg id="2667">"" "" "" "in the study, how many patients were measured after 12 of a total of 48 treatment weeks and 6 months after treatment on the drug (i.e. no signs of virus in blood)." "" "" ""</seg>
<seg id="2668">(44-20) 74 18 84 00 Fax (44-20) 74 18 84 16 E-mail: e-mail: / / www.emea.eu.int © EMEA 2006 Reproduction and / or distribution of this document declares. what were the greatest concern that CHMP has caused the permission to fail?</seg>
<seg id="2669">"" "" "" "in addition, concerns are expressed in detail that data on the stability of the active substance and the drug market is not sufficient." "" "" ""</seg>
<seg id="2670">"" "" "" "the number of patients suffering from hepatitis C, which were treated with Alpheon and Roferon-A, was similar in clinical study." "" "" ""</seg>
<seg id="2671">"" "" "" "after setting the treatment with Alphataxing, the disease was retardant on more patients than on the reference medium; Alphateon also had more side effects." "" "" ""</seg>
<seg id="2672">"" "" "" "apart from that, the test included in the study, if the drug forms a immune response (i.e. the body forms a immune response - special proteins - opposed to the medicine), not adequately validated." "" "" ""</seg>
<seg id="2673">"" "" "" "it can be used to treat impezoo (a skin infection) and small infected Lazerations (cracking or cutting down), tensions and paralysed wounds." "" "" ""</seg>
<seg id="2674">Altargo should not be used to treat infections be detectable or probably caused by methicilline-resistant Staphylococcus aureus (MRSA) because algo against this kind of infections might not be.</seg>
<seg id="2675">"" "" "" "Altargo can be applied in patients from age of nine months, but in cases under the age of 18, the skin surface should not be more than 2% of the body surface." "" "" ""</seg>
<seg id="2676">"" "" "" "if the patient does not appealed to treatment for two to three days, the physician should examine the patient again and apply alternative treatments into consideration." "" "" ""</seg>
<seg id="2677">It works by blocking the bacterial Ribosoms (the parts of bacterience in which proteins are produced) and thereby inhibits the growth of bacteria.</seg>
<seg id="2678">The main indicative of the efficacy was performed in all five studies of patients whose infection was delayed by the end of the treatment.</seg>
<seg id="2679">119 (85.3%) of 139 patients under Altargo and 37 (52.1%) of the 71 patients under Placebo spoke to the treatment.</seg>
<seg id="2680">"" "" "" "in the treatment of infected Hautwins, Altargo and Cefalexin showed similar contact: if the results were taken together at Hautwins, about 90% of the patients were treated on the treatment." "" "" ""</seg>
<seg id="2681">"" "" "" "in these two studies, however, that alargo was diagnosed in the treatment of abscowls (vowed cavities in the body tissue) or of infections, which have been proven or presumably taken by MRSA, not effective enough." "" "" ""</seg>
<seg id="2682">The most common side effect with altargo (which was observed in 1 to 10 of 100 patients) is a irritation at the location.</seg>
<seg id="2683">"" "" "" "finally, the Committee for Human Use (CHMP) reached the conclusion that the advantages of altargo in the short-surface skin infections could be outweigh the risk: • Impezoo, • infected small ingenations, tensions or stitched wounds." "" "" ""</seg>
<seg id="2684">"" "" "" "in May 2007, the European Commission issued Glaxo Group Ltd. a approval for Intargo in the entire European Union." "" "" ""</seg>
<seg id="2685">"" "" "" "patients receiving any improvement within two to three days, should be examined even again and considered to be considered an alternative therapy (see Section 4.4)." "" "" ""</seg>
<seg id="2686">"" "" "" "in case of sensibility or severe local irritation, the treatment of retapamulin ointment, the treatment is canceled and the ointment is carefully conscientious and an appropriate alternative therapy of infection." "" "" ""</seg>
<seg id="2687">Retapamulin is not intended to be used to treat infections where MRSA is known as pathogen or suspects (see Section 5.1).</seg>
<seg id="2688">In clinical studies with secondary infected wounds the effectiveness of retapamulin in patients with infections found by a methicillin-resistant Staphylococcus aureus (MRSA) were insufficient.</seg>
<seg id="2689">"" "" "" "an alternative therapy is to be considered, if after a 2- or 3-day treatment no improvement or deterioration of the infected place." "" "" ""</seg>
<seg id="2690">The effects of simultaneous use of retapamulin and other topical means on the same skin area has not been studied and the simultaneous application of other topical drugs is not recommended.</seg>
<seg id="2691">"" "" "" "due to the low plasma concentrations, which were reached in human application based on agre skin or infected superficial wounds, is a clinically relevant inhibition in vivo (see section 5.2)." "" "" ""</seg>
<seg id="2692">3 After concurrent gift of 2 times a day 200 mg Ketoconazol the average Retapamulin AUC (0-24) and Cmax after topical application of 1% retapamulin ointment increased by 1% retardine of healthy adult males by 81%.</seg>
<seg id="2693">"" "" "" "due to the low systemic exposure to topical application in patients, dose adaptations are not required if topical retapamulin are applied during a systemic treatment with CYP3A4 Inhibitors." "" "" ""</seg>
<seg id="2694">"" "" "" "animal studies have shown a reproduction of reproduction according to oral intake, and are insufficient in terms of statement on the birth and fetal / postnatal development (see paragraph 5.3)." "" "" ""</seg>
<seg id="2695">Retapamulin ointment should only be applied during pregnancy when a topographic anti-bacterial therapy is clearly indicated and the use of retapamulin is the gift of a systemic antibiotic.</seg>
<seg id="2696">"" "" "" "in decision, whether the breastfeeding is continued / terminated or the therapy with Altargo should be continued / killed, between the benefit of a nursing child and the benefit of altargo therapy for the woman." "" "" ""</seg>
<seg id="2697">"" "" "" "in clinical trials of 2150 patients with superficial skin infections, the altargo, the most frequently reported side effects of irritation, was about 1% of patients entered." "" "" ""</seg>
<seg id="2698">Mode of action Retapamulin is a semisynthetic derivatives of Pleuromutilin, a substance that is isolating through fermentation from Clitopilus passeckerianus (formerly called Pleurotus passeckerianus).</seg>
<seg id="2699">The mode of action of retapamulin is based on the selective inhibit of bacterial protein synthesis against a certain liaison of the bacterial Ribosoms unit which differs from the ties of other ribosomal interagierating antibacterial substances.</seg>
<seg id="2700">Data suggest that the binding post-Bosnian protein L3 is involved and in the region of the ribosom P liaison office and the PeptidyltransferaseWeb area.</seg>
<seg id="2701">By binding on this binding pandromutiline to inhibit the peptidyltiline to block partially P-binding interactions and prevent normal education of active 50s ribosom sub units.</seg>
<seg id="2702">"" "" "" "should be due to the local prevalence of resistance in the application of retapamulin at least some infection forms, an advice should be targeted by experts." "" "" ""</seg>
<seg id="2703">"" "" "" "there were no differences in the in-vitro activity of retapamulin to S.aureus, regardless of whether the Isolate were sensitive or resistant to methicillin." "" "" ""</seg>
<seg id="2704">In the case of failure to treatment with S.aureus the presence of tribes with additional virulence factors (such as PVL = Panton-Valentine Leucocidin) should be considered.</seg>
<seg id="2705">"" "" "" "in a study of healthy adults, 1% Retapoculin ointa daily was put on intact and applied skin for up to 7 days." "" "" ""</seg>
<seg id="2706">"" "" "" "out of 516 patients (adults and children), the 1% retapoculin daily received twice a day for topical treatment of secondary infected traumatic wounds, individual plasma samples were obtained." "" "" ""</seg>
<seg id="2707">"" "" "" "in days 3 or 4, sampling during adult patients were performed before mediation and in children between 0-12 hours after the last application." "" "" ""</seg>
<seg id="2708">However the maximum individual systemic recording at humans after topical application of 1% ointment is reduced to 200 cm2 (Cmax = 22 ng / ml; AUC (0-24) = 238 ng (h / ml) 660-times lower than the retapamulin IC50 for PGP inhibitors.</seg>
<seg id="2709">Metabolism of the human liver microsoma in human liver microsomes was primarily mediated by CYP2C8 and CYP2D6 (see Section 4.5).</seg>
<seg id="2710">"" "" "" "in studies on oral toxicity in rats (50, 150 or 450 mg / kg), which were conducted over 14 days, there were signs of adaptive liver and thyroid changes." "" "" ""</seg>
<seg id="2711">In-vitro examination on genomation and / or chromosomal effects in the mouse-lymphoma test and in the rats-microkernel test for in-vivo test chromosomal effects.</seg>
<seg id="2712">There was neither male nor female signs of reduced fertility at oral dosages of 50, 150 or 450 mg / kg / day so that the most appreciated exposition in humans (topical application on 200 cm2) was achieved:</seg>
<seg id="2713">In an embryotic oxicity study at oral dosages of ≥ 150 mg / kg / day (according to the ≥ 3 times the estimated human exposure (see above)); developmental toxicity (reduced body weight of the fetus and delayed Ossification) and maternally Toxicity.</seg>
<seg id="2714">"" "" "" "the holder of the approval must be ensured that a pharmacovigilance system is present as in the 1.8.1 of the application application (version 6.2), before the product is marketed and as long as the product is applied." "" "" ""</seg>
<seg id="2715">"" "" "" "the holder was obliged to perform more detailed studies and additional pharmacovigilance activities, as described in version 1 of the Risk Management Plan (RMP) and all additional updates of the RMP, which will be arranged with CHMP." "" "" ""</seg>
<seg id="2716">"" "" "" "as described in CHMP" Guideline on Risk Management Systems for Human use, "the updated RMP is scheduled to be submitted simultaneously with the next Periodic Safety Update Report." "" "" ""</seg>
<seg id="2717">"" "" "" "irritation or other signs and symptoms show in the treated position, you should finish the application of Altargo and talk to your doctor." "" "" ""</seg>
<seg id="2718">"" "" "" "do not apply other ointments, creams or lotions on the area that is treated with Altargo, if not expressly prescribed by your doctor." "" "" ""</seg>
<seg id="2719">"" "" "" "it must not be applied in the eyes, mouth or lips, in the nose or in the female genital area." "" "" ""</seg>
<seg id="2720">"" "" "" "if the ointment comes from reviewing on one of these faces, wash the spot with water and ask your physician to advice if complaints occur." "" "" ""</seg>
<seg id="2721">"" "" "" "after applying the ointment, you may cover the affected area with a sterile bandage or a Gazebo cover, unless your doctor has advised you to cover the area." "" "" ""</seg>
<seg id="2722">"" "" "" "it is offered in an aluminium tube with a plastic lock that contains 5, 10 or 15 grams of ointment, or in a wallet, containing 0.5 g ointment." "" "" ""</seg>
<seg id="2723">"" "" "" "Ambirix is used to protect hepatitis C and hepatitis B (diseases which affect the liver) in children between one and 15 years, which are not immune to these two diseases." "" "" ""</seg>
<seg id="2724">"" "" "" "Ambirix is applied to one of two doses of existing vaccines, whereby a protection against hepatitis B may only be achieved before entering the second dose." "" "" ""</seg>
<seg id="2725">"" "" "" "for this reason, Ambirix may only be used when immunisation consists of a low risk of hepatitis B infection and ensures that it can be routed from two doses to an end." "" "" ""</seg>
<seg id="2726">"" "" "" "if a injector is requested against hepatitis C or B, Ambirix or any other Hepatitis A- or -B vaccine can be given." "" "" ""</seg>
<seg id="2727">"" "" "" "vaccines have an effect on the immune system (the natural defense of the body)," as it can fight against a disease. "" "" "" "</seg>
<seg id="2728">"" "" "" "after receiving a child, the immune system recognizes the viruses and surface antigens as" alien "and creates antibodies against it." "" "" ""</seg>
<seg id="2729">"" "" "" "Ambirix contains the same components as the vaccines have been accredited since 1996, and the vaccines have been accredited since 1997." "" "" ""</seg>
<seg id="2730">"" "" "" "the three vaccines are applied to protect against the same diseases, however, Twinrix adult and Twinrix children are administered in the framework of a three doses of existing vaccines." "" "" ""</seg>
<seg id="2731">"" "" "" "because Ambirix and Twinrix adult contains identical ingredients, some of the data provided by Twinrix adult is also used as proof of the application of Ambirix." "" "" ""</seg>
<seg id="2732">The main indicator for efficacy was the proportion of vaccinated children who had developed a month after the last injection of protective antibodies.</seg>
<seg id="2733">"" "" "" "in an additional study with 208 children, the efficacy of the vaccine was compared with six months and a 12 month distance between the two injections." "" "" ""</seg>
<seg id="2734">Ambirix carried out between 98 and 100% of vaccinated children a month after the last injection of protecting antibodies against hepatitis A and B.</seg>
<seg id="2735">"" "" "" "the additional study showed that the level of protection of Ambirix was similar to a six-month distance between the injection of the injection." "" "" ""</seg>
<seg id="2736">"" "" "" "the most common side effects of Ambirix (observes more than 1 of 10 vaccine doses) are headache, loss of appetite, redness, math (fatigue) and irritability." "" "" ""</seg>
<seg id="2737">"" "" "" "Ambirix may be in patients that are potentially sensitive (allergic) to the active agents, one of the other components or Neomycin (an antibiotic) are not applied." "" "" ""</seg>
<seg id="2738">"" "" "" "in August 2002, the European Commission issued GlaxoSmithKline Biologame s.a. a permit for Inductive ambirix in the entire region." "" "" ""</seg>
<seg id="2739">"" "" "" "the standardization plan for the basic immunisation with ambirix consists of two vaccine doses, whereby the first dose is given at the date of choice and the second dose to be given after the first dose." "" "" ""</seg>
<seg id="2740">"" "" "" "if a refreshment is requested for Hepatitis B as well as for Hepatitis B, it can be vaccinated by means of the corresponding monovalent vaccines or with a combination of combination." "" "" ""</seg>
<seg id="2741">The anti-hepatitis B coating (anti-hepatitis) anti-hepatitis B surface antigen levels (anti-HBAMF) and anti-hepatitis C virus (anti-HAV) antibodies lie in the same size as after vaccination with the respective monovalent vaccines.</seg>
<seg id="2742">"" "" "" "it is not yet completely secured if immuncompetent individuals who have demanded on a hepatitis A- impfung, which may be protected by immunological memory as well as protection against the immunological memory." "" "" ""</seg>
<seg id="2743">"" "" "" "3 As in all injections, an anaphylactic reaction after the injection of the vaccine therapy options should always be available immediately after medical treatment." "" "" ""</seg>
<seg id="2744">"" "" "" "if a fast protection against hepatitis B is necessary, the standardization scheme is recommended with the combination material that contains 360 ELISA units formalininactivated hepatitis B virus and 10 µg of recombinant hepatitis B surface." "" "" ""</seg>
<seg id="2745">"" "" "" "in hematalysis patients and persons with disturbances of the immune system, no harmful anti-HAV- and anti-HBS antibody is reached, so that in these cases the gift of other vaccine doses may be required." "" "" ""</seg>
<seg id="2746">"" "" "" "since an intradermal injection or intramuscular administration could lead to a subtle vaccination, these injections should be avoided." "" "" ""</seg>
<seg id="2747">"" "" "" "in cases of throcytopenia or blood coagulation, Ambirix can be injected into an exception of subcutaneous injections, as in these cases, after intramuscular administration to occur." "" "" ""</seg>
<seg id="2748">If Ambirix was given in the second year of a separate injection at the same time with a combined diphtheria-, tetrains and azemophilus influenza type vaccine was the immune response to all antigens (see section 5.1).</seg>
<seg id="2749">"" "" "" "in patients with immunossuppressful therapy or in patients with immune defects, it may be assumed that possibly no sufficient immune response is achieved." "" "" ""</seg>
<seg id="2750">"" "" "" "in a clinical study conducted with 3 vaccine doses of this formulation in adults, the frequency of pain, redness, swelling, math, gastroenteritis, headache and fever was comparable to the frequency that was observed in the earlier Thiomerang sal- and preservative vaccine formulation." "" "" ""</seg>
<seg id="2751">"" "" "" "in clinical trials, 2029 vaccine doses were administered at a total of 1027 vaccination at the age of 1 to 15 years." "" "" ""</seg>
<seg id="2752">"" "" "" "in a study with 300 participants at the age of 12 to 15, the tolerability of Ambirix was compared with the 3-doses of combination." "" "" ""</seg>
<seg id="2753">"" "" "" "only exceptions were the higher frequencies of pain and maturation on a calculation basis per vaccination dose Ambirix, but not on a calculation basis per person." "" "" ""</seg>
<seg id="2754">"" "" "" "pain was observed after the administration of Ambirix at 50.7% of the test subjects, compared with 39.1% in subjects according to the gift of a 3-doses of combination." "" "" ""</seg>
<seg id="2755">"" "" "" "after the entire vaccine cycle, 66.4% of probands were given to the ambirix meeting with pain, compared with 63,8% in the test subjects which had been vaccinated with the 3-dose." "" "" ""</seg>
<seg id="2756">"" "" "" "however, the frequency of maturiosity was comparable per proband (i.e. above the whole vaccine) received 39.6% of volunteers, compared with 36.2% among the subjects, which received the 3 doses of combination." "" "" ""</seg>
<seg id="2757">"" "" "" "the incidence of pronounced pain and matity was low, comparable to the combination of combination of combination with the 3 doses should be observed." "" "" ""</seg>
<seg id="2758">"" "" "" "in a comparative study with 1- and 11-year-old vaccination, the occurrence of locomotive response and general actions with 360 ELISA units formalinert activated hepatitis B virus and 10 µg of recombinant hepatitis B surface treatment was observed." "" "" ""</seg>
<seg id="2759">"" "" "" "however, after vaccination with ambirix an frequent occurrence of pain (at the injection site) per dose, not per commission, was reported." "" "" ""</seg>
<seg id="2760">"" "" "" "the proportion of vaccines that reported on severe side effects during the 2 doses of intracorneal inasoneme with the combination of 360 ELISA- units formalininactivated hepatitis B virus and 10 µg of recombinant hepatitis B surface finishing, was statistically different." "" "" ""</seg>
<seg id="2761">"" "" "" "in clinical trials that were conducted at vaccines at age 1 to including 15 years, Seroconversionrates were given a month after the first dose and 100% a month following the first dose (i.e. in month 7)." "" "" ""</seg>
<seg id="2762">"" "" "" "after the first dose and 100% a month after the first dose and a month after the second dose, the Seroconversional rates were given 100% a month after the second dose (i.e. in month 7)." "" "" ""</seg>
<seg id="2763">"" "" "" "7 In a comparative study, which was conducted at 12 - including 15-year-old, 142 two doses of Ambirix and 147 received the standard combination fuel with three doses." "" "" ""</seg>
<seg id="2764">"" "" "" "for the 289 persons, whose immunogenicity was evaluated (SP in the table below) against hepatitis B in the month 2 and 6, according to the gift of the 3-dose implicates significantly higher than with ambirix." "" "" ""</seg>
<seg id="2765">"" "" "" "the immune response, which were achieved in a clinical study study at 1- and 11-year-old one month after the ending of the full vaccine series (i.e., month 7) are listed in the following table." "" "" ""</seg>
<seg id="2766">"" "" "" "in both trials, the vaccinations received either a 2 doses scheme with ambirix or a 3-doses scheme with a combination of 360 ELISA units formalinert activated hepatitis B virus and 10µg of recombinant hepatitis B surface." "" "" ""</seg>
<seg id="2767">"" "" "" "for people who were at the time of the priorization of 12 to 15 years old, the persistence of anti-HAV- and Anti-HBS antibody could be detected at least 24 months after the immunisation with ambirix in the 0-6 months vaccination scheme." "" "" ""</seg>
<seg id="2768">The immune response to both antigens was comparable to both antigens of 3 doses with a combination of combination of a combination of 360 ELISA units which was found in a combination of 360 ELISA units which has been ascerated in a dose volume of 0.5 ml.</seg>
<seg id="2769">"" "" "" "in a clinical study from 12- to including 15-year-old-olds, the persistence of anti-HAV- and anti-HBS-antibodies are comparable to that in the 0-12 months vaccination scheme." "" "" ""</seg>
<seg id="2770">If the first dose of ambirix in the second year of life coincided with the chimpfung of a combined diphtheria-, tetrains and azellular disease (DTPa-IPV / HIB) or with the first dose of a combined measles-mumps vaccine was the immune response to all antigens.</seg>
<seg id="2771">A clinical study conducted with 3 doses of the present formulation in adults was shown for the present formulation similar to Seroprotek- and seroconversioning as for the earlier formulation.</seg>
<seg id="2772">"" "" "" "the vaccine is to examine both before and after the resusencode by eye permissions, to any other foreign particles and / or physical visible changes." "" "" ""</seg>
<seg id="2773">"" "" "" "according to Article 114 of the Directive 2001 / 83 / EC, the state-release release of a state laboratory or a laboratory is authorized to authorise this purpose." "" "" ""</seg>
<seg id="2774">14 FERTIGSPRITZE OHNE 1 FERTIGSPRITZE WITHOSHORRITZEN WITHOSHORRITZEN WITHOSHORRITZEN WITHOSHORRITZEN WITHOSHORRITZEN WITHOSHORRITZEN WITHOSHORRITZEN WITHOSHORRITZEN WITHOSHORRITZEN</seg>
<seg id="2775">Suspension for injection 1 preinjection without needle-injection moulds with needle-10 presplases without needles 10 presplases without needles 1 dose (1 ml)</seg>
<seg id="2776">EU / 1 / 02 / 224 / 224 / 224 / 224 / 224 / 224 / 224 / 224 / 224 / 224 / 224 / 224 / 004 10 pre-injecting with needles 1 / 1 / 02 / 01 / 004 10 ready injection with needles 1 / 1 / 02 / 004 10 ready injection without needles</seg>
<seg id="2777">"" "" "" "the hepatitis-A virus is usually transmitted through viral containing foods and beverages, but can also be transmitted through other ways such as by bath in water-temperate waters." "" "" ""</seg>
<seg id="2778">"" "" "" "you may feel very tired, have a dark urine, an inflamed face, yellow skin and / or eyes (jaundice) and other symptoms that possibly make a stationary treatment necessary." "" "" ""</seg>
<seg id="2779">"" "" "" "as with all vaccines, Ambirix can not fully protect from an infection with hepatitis B or hepatitis B virus, even if the complete vaccine series has been completed with 2 doses." "" "" ""</seg>
<seg id="2780">If you / your child are infected with Hepatitis B or Hepatitis B virus infected with hepatitis B or Hepatitis B virus (although you / her child does not feel uncomfortable or ill) may not be vaccination from vaccination.</seg>
<seg id="2781">"" "" "" "a protection against other infections, liver damage or symptoms which are similar to those of hepatitis B or hepatitis B infection, can not be conveyed." "" "" ""</seg>
<seg id="2782">"" "" "" "• When your child has an allergic reaction to ambirix, or any part of this vaccine, including Neomycin (an antibiotic) has shown." "" "" ""</seg>
<seg id="2783">An allergic reaction can occur through itching rains, breath-not or stimulation of the face or tongue. • if you have an allergic reaction to an earlier vaccination against hepatitis C or hepatitis B. • If you / your child have a severe infection with fever.</seg>
<seg id="2784">"" "" "" "• If you want to quickly have a protection against hepatitis B, i.e. within six months and usually intended to take the second vaccination." "" "" ""</seg>
<seg id="2785">"" "" "" "during a possible risk of infection with hepatitis B between the first and second vaccination, the doctor will advise you / your child from one vaccination with ambirix." "" "" ""</seg>
<seg id="2786">"" "" "" "instead, it will recommend to you / your child 3 injections of a combined Hepatitis B / Hepatitis B vaccine from a combined content of effective ingredients per vaccine doses (360 ELISA units of a recombinant hepatitis B surface antigens)." "" "" ""</seg>
<seg id="2787">"" "" "" "the second vaccine dose of this vaccine is administered at low content, usually administered a month after the first dose and should give you a vaccination against end of the vaccine series." "" "" ""</seg>
<seg id="2788">"" "" "" "sometimes, Ambirix is injected in people who suffer from severe blood clamination to suffer from the skin and not into the muscle or treatment in your own body or if you / your child are undertaking a haflalysis / undertakes." "" "" ""</seg>
<seg id="2789">"" "" "" "Ambirix can be given in these cases, but immune response of these people may not be sufficient to see that a blood test can be necessary to see how strongly responding to vaccination is." "" "" ""</seg>
<seg id="2790">"" "" "" "21 Be your doctor if you / your child is taken away for further drugs (including those that have been given without prescription) or if you have been given without prescription, or if you have been planned or have planned them in the near future." "" "" ""</seg>
<seg id="2791">"" "" "" "however, in this case the immune response to the vaccine is not sufficient and therefore the person is not protected against one or both hepatitis A and B viruses." "" "" ""</seg>
<seg id="2792">"" "" "" "if another vaccine must be given at the same time with ambirix, should be vaccinated in separate places and if possible different limbs." "" "" ""</seg>
<seg id="2793">"" "" "" "if Ambirix should be given at the same time or shortly before or after an injection of Immaclobulys, it is likely that the reaction to the vaccine will still be sufficient." "" "" ""</seg>
<seg id="2794">"" "" "" "usually, ambirix is not given pregnant or lactating women, except it is urgently necessary to vaccinated both against hepatitis C and hepatitis B." "" "" ""</seg>
<seg id="2795">Important information on certain other components of Ambirix Please tell your doctor if your child has already shown an allergic reaction to Neomycin (antibiotic).</seg>
<seg id="2796">"" "" "" "if you miss the agreed date for the second vaccination, contact your doctor and make a new appointment as soon as possible." "" "" ""</seg>
<seg id="2797">♦ Very frequent (more than 1 case per 10 doses): • pain or discomfort at the instichment or redness • maternity • Oaches • Immersion • Imlack of appetite</seg>
<seg id="2798">♦ frequent (up to 1 case per 10 doses): • swelling at the injection site • fever (over 38 ° C) • Use of gastrointestinal discomfort</seg>
<seg id="2799">"" "" "" "further adverse events, the days or weeks after vaccination with comparable combined or single vaccinations against hepatitis C and hepatitis B are very rare (less than 1 case per 10.000 branches) have been reported," "" "" ""</seg>
<seg id="2800">"" "" "" "these include local or extensive precipitation, that can be or bashable, swelling of the eye-partial or swallowing, sudden blood pressure and awareness." "" "" ""</seg>
<seg id="2801">"" "" "" "flu-like complaints, including chills, muscle and joint pain seizures, dizziness, failure to harm or mobility of some body parts, strong headaches and stiffness of neck, interruption of normal brain functions" "" "" ""</seg>
<seg id="2802">Impotence inflammation of other blood vessels Unwell or disease-inflammations of liver function tests. liver transducts increases blood sugar or bruising (blue stains) caused by waste of blood platelet.</seg>
<seg id="2803">"" "" "" "23 Informing your doctor or pharmacist if one of the listed side effects you / your child significantly impaired, or you may notice any side effects listed in this package age." "" "" ""</seg>
<seg id="2804">Ambirix is available in packs of 1 and 10 with or without needles and in packs of 50 without needles.</seg>
<seg id="2805">"" "" "" "based on the data, which has become known for the first permit for the first license, CHMP has reported that the benefit-risk ratio for ambirix remains positive." "" "" ""</seg>
<seg id="2806">"" "" "" "however, since ambirix was placed in traffic in a member state (in the Netherlands since May 2003), the available safety data for this medicine is limited by low patient-exposure." "" "" ""</seg>
<seg id="2807">"" "" "" "ammonaps can be used in patients at age over one month, with hyperammonium oxide (brain damage due to high levels of ammoniority)." "" "" ""</seg>
<seg id="2808">Amneaps is - divided into several individual doses to the meals - swallowed under the food mixed or over a Gastrostomieships (by the abdominal wall in the stomach's leading hose) or administered by the nose into the stomach's leading hose).</seg>
<seg id="2809">"" "" "" "it was not a comparative study, since ammonite could not be compared with another treatment or placebo (a headway or without active substance)." "" "" ""</seg>
<seg id="2810">"" "" "" "Ammonaps can also cause loss of appetite, a abnormal acid content in blood, depression, irritability, lack of flavor, vomiting, nausea, constipation, rash or weight gain." "" "" ""</seg>
<seg id="2811">The Committee on Human Use (CHMP) reached the conclusion that ammonaps in patients with regard to high levels of ammonia is effectively prevented.</seg>
<seg id="2812">"" "" "" "ammonrapeseed was approved under" exceptional circumstances, "due to the disease of the disease, limited information on this medicine was presented at the time of approval." "" "" ""</seg>
<seg id="2813">"" "" "" "the use is indicated in all patients, where a complete enclman is already manifested already in newborn (within the first 28 life days)." "" "" ""</seg>
<seg id="2814">"" "" "" "in patients with a late-solid form (incomplete encirl defect, which manifests itself after the first life of life), there is an indication of hyperacidity asephalopathy." "" "" ""</seg>
<seg id="2815">"" "" "" "for babies, for children who are not able to swallow tablets or for patients with swallowing disorders AMMONAPS are also available in granular form." "" "" ""</seg>
<seg id="2816">"" "" "" "the daily dose is calculated individually, considering the protein tolerance and the daily protein intake of the patients." "" "" ""</seg>
<seg id="2817">According to previous clinical experiences the normal daily dose of sodium phenylbutyrate: • 450 - 600 mg / kg / day in children with a body weight of less than 20 kg • 9.9 g / m ² / day in children with a weight of 20 kg as well as for growing and adults.</seg>
<seg id="2818">In patients who suffer from an early respiratory lack of carbamide phosphatsynthetase or ornithintranscarbamylase is the substitution of Cité lin or Arginine is required in a dose of 0.17 g / kg / day or 3.8 g / m ² / day.</seg>
<seg id="2819">Patients with an ininine uccinatsynthetase deficiency needs to receive arginine in a dose of 0,4-0.7 g / kg / h or 8,8 - 15,4 g / m ² / day.</seg>
<seg id="2820">"" "" "" "AMMONAPS tablets are not allowed to treat patients with swallowing disorders, as a risk for the emergence of oesophusulcera if the tablets are not absorbed immediately into the stomach." "" "" ""</seg>
<seg id="2821">Each tablet AMMONAPS contains 62 mg (2.7 mmol) sodium, according to 2.5 g (108 mmol) sodium per 20 g sodium phenylbutyrate which corresponds to the maximum daily dose.</seg>
<seg id="2822">"" "" "" "therefore, AMMONAPS should therefore be applied to patients with congestive heart failure or severe congestive heart failure and with sodium discharge and eyelet formation only with caution." "" "" ""</seg>
<seg id="2823">"" "" "" "since Metabolism and excretion of sodium phenylbutyal occurs over the liver and kidneys, AMMONAPS should only be used with extreme caution when patients with liver or kidney failure." "" "" ""</seg>
<seg id="2824">The meaning of these results in relation to pregnant women is not known; the use of AMMONAPS during pregnancy is therefore contraindicated (see 4.3).</seg>
<seg id="2825">"" "" "" "with subcutaneous injection of phenylacetate in high doses (190 - 474 mg / kg), a slowdown of neuronal proliferation and increased loss of neurons came." "" "" ""</seg>
<seg id="2826">"" "" "" "also, a delayed maturation of cerebral synapses and a reduced number of functioning nerves in the brain and thus a disability of brain growth." "" "" ""</seg>
<seg id="2827">It could not be noticed if phenylacetate is eliminated in humans into the breast milk and for this reason the use of AMMONAPS is contraindicated during lactation period (see 4.3).</seg>
<seg id="2828">"" "" "" "in clinical trials with AMMONAPS, at least 56% of patients entered at least an undesirable event (AU) and 78% of these adverse events were assumed that they were not connected with AMMONAPS." "" "" ""</seg>
<seg id="2829">"" "" "" "the frequency is defined as follows: very common (≥ 1 / 10), often (≥ 1 / 100, &lt; 1 / 10) and occasionally (≥ 1 / 1000; &lt; 1 / 100)." "" "" ""</seg>
<seg id="2830">"" "" "" "an unlikely-toxic reaction to AMMONAPS (450 mg / kg / day) was reported by an 18-year old anoretinal female patient, with lactic hypokalemia, heavier hypokalemia, peripheral new ropathy and pancreatitis." "" "" ""</seg>
<seg id="2831">"" "" "" "in case of an overdose, an overdose of 10 g (1370 mg / kg) was observed with an accidental dose of 10 g (1370 mg / kg)." "" "" ""</seg>
<seg id="2832">These symptoms coincide with the accumulation of phenylacetate that showed intravenous administration of doses of up to 400 mg / kg / day a dosislimiting neurotoxicity.</seg>
<seg id="2833">Phenylacetate is a metabolized active compound associated with acetylacetylglutamine using acetylacetylglutamine which is excreted over the kidneys.</seg>
<seg id="2834">Stöchiometrically is comparable with urea (both links contain 2 nitrogen atoms); phenylacetylglutamine is therefore also suitable as an alternative carrier for excretion of excess nitrogen.</seg>
<seg id="2835">5 patients with dysfunctions of the urinary bladder can be assumed that a sodium phenylbutyrate between 0.012 and 0.15 g phenylacetylglutamine can be produced for each gram.</seg>
<seg id="2836">"" "" "" "it is of meaning that the diagnosis is early early and the treatment is started, in order to improve survival chances and clinical results." "" "" ""</seg>
<seg id="2837">"" "" "" "the prognosis of the early modified form of the disease with the occurrence of the first symptoms in newborn and primary amino acids, and the disease led to death with peritoneal dialysis and essential amino acids within the first year of life." "" "" ""</seg>
<seg id="2838">"" "" "" "using hematalysis, the use of alternative trails in nitrogen oxidiate, sodium benzodiate and sodium phenylacetate), proteinated cooperative and possibly substitution of essential amino acids (however, within the first life of life) diagnosed patients to 80%." "" "" ""</seg>
<seg id="2839">"" "" "" "patients suffering from patients whose illness was diagnosed in pregnancy and the survival rate was 100%, but even in those patients it occurred with many too mental disabilities or other neurological deficits." "" "" ""</seg>
<seg id="2840">In patients with a late-solid form of the disease (including female patients with the heterozygous form of the Ornithintranscarbamylase) that were treated permanently with sodium phenylbutyal and a proteinated diet. the survival rate was 98%.</seg>
<seg id="2841">"" "" "" "already existing neurological deficits are hardly reversible, and in some patients a further deterioration of the neurological status may occur." "" "" ""</seg>
<seg id="2842">It is known that phenylbutylates is oxidized to phenylacetate which is conjugated in liver and kidneys with glutamine and phenylacetylglutamine is formed.</seg>
<seg id="2843">The concentrations of phenylbutyal and its metabolites in plasma and urine were determined by sober healthy adults and in patients with liver cirrhosis of up to 20 g / day (not controlled studies).</seg>
<seg id="2844">The behaviour of phenylbutyal and its metabolites was also examined in cancer patients (up to 2 g / m ²) or phenylacetate in cancer patients.</seg>
<seg id="2845">"" "" "" "after an oral solo dose of 5 g sodium phenylbutyal in tray form, 15 minutes after taking measurable plasma concentrations have been established by phenylbutyrat." "" "" ""</seg>
<seg id="2846">In the majority of patients with urea cyclical disturbances or hemoglobinaries (300-650 mg / kg / day up to 20 g / day) the next morning is no phenylacetate in the blood plasma bar.</seg>
<seg id="2847">"" "" "" "three of six patients with liver cirrhosis, which were treated with sodium phenylbutyltin (20 g / day oral in three single doses) were treated five times higher than after the first gifts on the third day." "" "" ""</seg>
<seg id="2848">Excretion The drug is excreted over the kidneys within 24 hours to about 80 - 100% of the conjugated product phenylacetylglutamine.</seg>
<seg id="2849">"" "" "" "according to the results of the Micronucleus test, sodium phenylbutyal with toxic and non-toxic effects (examination 24 and 48 h after oral administration of an individual dose of 878 to 2800 mg / kg)." "" "" ""</seg>
<seg id="2850">AMMONAPS Granules is either taken oral (infants and children not swallow by swallowed or patients with swallowing disorders) or over a gastrostomieships or a nossonville.</seg>
<seg id="2851">According to previous clinical experiences the normal daily dose of sodium phenylbutyrate: • 450 - 600 mg / kg / day in newborns, babies and children with a weight of less than 20 kg • 9.9 g / m ² / day in children with a weight of 20 kg as well as for growing and adults.</seg>
<seg id="2852">"" "" "" "the concentration of ammonia, arginine, essential amino acids (especially branched in amino acids), carnitine and serum proteine in the plasma should be held within the normal area." "" "" ""</seg>
<seg id="2853">In patients who suffer from an early respiratory lack of carbamide phosphatsynthetase or ornithintranscarbamylase is the substitution of Cité lin or Arginine is required in a dose of 0.17 g / kg / day or 3.8 g / m ² / day.</seg>
<seg id="2854">AMMONAPS Granules contains 124 mg (5.4 mmol) sodium per gram of sodium phenylbutyal each containing 2.5 g (108 mmol) sodium per 20 g sodium phenylbutyrate which corresponds to the maximum daily dose.</seg>
<seg id="2855">"" "" "" "when rat federates were subjected to phenylacetate (active metabolition of phenylbutyltin), there came to lesions in the pyramids of the cortex." "" "" ""</seg>
<seg id="2856">"" "" "" "an unlikely-toxic reaction to AMMONAPS (450 mg / kg / day) was reported by an 18-year old anoretinal female patient, with lactic hypokalemia, heavier hypokalemia, peripheral new ropathy and pancreatitis." "" "" ""</seg>
<seg id="2857">Stöchiometry is comparable with urea (both links contain 2 nitrogen atoms); phenylacetylglutamine is therefore also suitable as an alternative support for excretion from excess.</seg>
<seg id="2858">"" "" "" "on the basis of investigations on the excretion of phenylacetylglutamine in patients with disorders of the urinary bladder can be produced, between 0.012 and 0.15 g phenylacetylglutamine nitrogen can be produced." "" "" ""</seg>
<seg id="2859">"" "" "" "already existing neurological deficits are barely reversible, and in some patients a further deterioration of the neurological status may occur." "" "" ""</seg>
<seg id="2860">"" "" "" "after an oral solo dose of 5 g sodium phenylbutyal in granular form, 15 minutes after taking measurable plasma concentrations have been established by phenylbutyrat." "" "" ""</seg>
<seg id="2861">"" "" "" "during the duration of durability, the patient can uniquely store the finished product for a period of 3 months at a temperature of over 25 ° C." "" "" ""</seg>
<seg id="2862">In this procedure the small measuring spoon contains 0.95 g; the average measuring spoon 2.9 g and the large measuring spoon 8.6 g of sodium phenylbutyal.</seg>
<seg id="2863">If a patient must receive the medication over a probe you can also dissolve AMMONAPS before use in water (the solubility of sodium phenylbutyal amounts up to 5 g in 10 ml of water).</seg>
<seg id="2864">"" "" "" "in patients with these rare diseases certain liver enzymes are missing, so that they accumulate the sticking waste products which accumulate after consumption of proteins in the body." "" "" ""</seg>
<seg id="2865">"" "" "" "if using laboratory tests, you will need to inform the doctor that you can use AMMONAPS, as sodium phenylbutyal can influence the results of specific laboratory tests." "" "" ""</seg>
<seg id="2866">Taking AMMONAPS with other medicines Please inform your doctor or pharmacist if you have taken other medicines or if it is not prescribed for prescription medicine.</seg>
<seg id="2867">"" "" "" "during lactation period, you must not take AMMONAPS as the medicine could harm the breast milk and harm your baby." "" "" ""</seg>
<seg id="2868">"" "" "" "in rare instances, fusions, headache, flavours, indulgence of autism, disintegration, memory disorders and worsening existing neurological states were observed." "" "" ""</seg>
<seg id="2869">"" "" "" "when you determine one of these symptoms, you immediately get in contact with your doctor or to your hospital's quotes for the purpose of an appropriate treatment." "" "" ""</seg>
<seg id="2870">"" "" "" "if you forget the dose of AMMONAPS, take the appropriate dosage as soon as possible with the next meal." "" "" ""</seg>
<seg id="2871">"" "" "" "changes in blood bilty (red blood cells, throatocytes), diminished appetite, cause pain, vomiting, nausea, constipation, kidney failure, weight gain and anomal laboratory values." "" "" ""</seg>
<seg id="2872">"" "" "" "please inform your doctor or pharmacist if one of the listed side effects will affect you significantly, or you may notice any side effects listed in this manual information." "" "" ""</seg>
<seg id="2873">"" "" "" "you may not use AMMONAPS following the box on the cardboard and the container," using the specified use date. "" "" "" "</seg>
<seg id="2874">"" "" "" "like AMMONAPS, the contents of AMMONAPS tablets are of white colour and oval shape and they are equipped with the embossing" UCY 500. "" "" "" ""</seg>
<seg id="2875">"" "" "" "30 If at you laboratory investigations, you will need to inform the doctor that you can take AMMONAPS, as sodium phenylbutyal can influence the results of specific laboratory tests." "" "" ""</seg>
<seg id="2876">Taking AMMONAPS with other medicines Please inform your doctor or pharmacist if you have taken other medicines or if it is not prescribed for prescription medicine.</seg>
<seg id="2877">You should take AMMONAPS in the same individual doses of oral or via a gastric (hose that runs through the abdominal wall directly into the stomach) or a Nasensonde (hose that is caused by the nose into the stomach).</seg>
<seg id="2878">31 • Take a small measuring spoon of granulate. • finish in a straight edge using a measuring spoon. • The exact number of spoons of granulates can be removed from the container. • Take the recommended number of spoons granules from the container.</seg>
<seg id="2879">Angiox is applied to treat patients with acute coronarsydromes "(ACS, reduced blood supply to the heart) or for instance in unstable angina (a heart attack) or myocardial infarction (a anomal measuring value for the electrocardiogram or ECG).</seg>
<seg id="2880">"" "" "" "if Angiox is applied to preventing blood clots in patients who are given a higher dose, and the infusion can be continued till four hours after the procedure." "" "" ""</seg>
<seg id="2881">"" "" "" "in patients with angina or heart attack, this can contribute to the heart of blood flow and increase the effectiveness of a PCI." "" "" ""</seg>
<seg id="2882">Nearly 14 000 patients participated in the main study on the treatment of ACS with the effect of angidetox with a glycoprotein-IIb / IIIA-inhibitor (GPI) with conventional combination treatment with Heparin (another anticoagulum) and a GPI was compared.</seg>
<seg id="2883">"" "" "" "during the PCI the patient was often used a Stent (a short tube that obtains in the artery, and in addition, they received other medicines to prevent blood clots, such as Abciximab and Aspirin." "" "" ""</seg>
<seg id="2884">The treatment of ACS was Angiox - with or without the Gift of GPI - for preventing new events (deaths, heart attacks or reascularisation) after 30 days or one year as well as conventional treatment.</seg>
<seg id="2885">"" "" "" "in patients who subjected to a PCI to all indicators such as Heparin, with the exception of severe bleeding, with which there was much more effective than heparin." "" "" ""</seg>
<seg id="2886">"" "" "" "Angiox may not be applied in patients who may possibly be sensitive (allergic) to Bivalirudine, other brain plants or one of the other ingredients." "" "" ""</seg>
<seg id="2887">"" "" "" "furthermore, it must not be applied in patients who recently had a blood flow as well as with people with strong hypertension or kidney problems or a cardiac infection." "" "" ""</seg>
<seg id="2888">The Committee on Human Use (CHMP) reached the conclusion that Angiox is responsible for the treatment of ACS and during a PCI is an acceptable replacement for Heparin.</seg>
<seg id="2889">"" "" "" "in September 2004, the European Commission issued the Medicines Company UK Ltd with approval for Injection of Angiox across the European Union." "" "" ""</seg>
<seg id="2890">For the treatment of adult patients with acute coronarsydromes (unstable / NSTEMI) for an emergency handle or if an early intervention is provided.</seg>
<seg id="2891">The recommended initial dose of angiox in patients with ACS is an intravenous bolt of 0,1 mg / kg was followed by an infusion of 0.25 mg / kg / h.</seg>
<seg id="2892">"" "" "" "if an additional PCI is carried out in a row, additional Bolus should be given of 0.5 mg / kg and the infusion for the duration of the surgery is increased to 1.75 mg / kg / h." "" "" ""</seg>
<seg id="2893">"" "" "" "according to the PCI requirements, the reduced infusion dose ranges from 0,25 mg / kg / h for 4 to 12 hours." "" "" ""</seg>
<seg id="2894">"" "" "" "immediately before the procedure, a slurry of 0.5 mg / kg was administered, followed by an infusion of 1.75 mg / kg / h for the duration of the procedure." "" "" ""</seg>
<seg id="2895">The recommended dose of angiox in patients with a PCI consists of an initial intravenous bolt of 0.75 mg / kg of body weight and a weight of 1.75 mg / kg body weight / h at least for the duration of the surgery.</seg>
<seg id="2896">"" "" "" "the safety and effectiveness of a sole bolus-gift of Angiox was not examined and is not recommended, even if a short PCI procedure is planned." "" "" ""</seg>
<seg id="2897">If this value (ACT after 5 minutes) was shortened to under 225 seconds and should take a second bolt of 0.3 mg / kg / body weight.</seg>
<seg id="2898">"" "" "" "in order to reduce the occurrence lower ACT values, the constituted and diluted product should carefully be mixed with intravenously before application." "" "" ""</seg>
<seg id="2899">"" "" "" "once the ACT value amounts to more than 225 seconds, another monitoring is not required, provided that the 1.75 mg / kg infusion dose is given correctly." "" "" ""</seg>
<seg id="2900">Patients with moderate kidney failure (GFR 30-59 ml / min) (whether treated with Bivalirudin against ACS or not) should be used to use a lower infusion rate of 1.4 mg / kg / h.</seg>
<seg id="2901">"" "" "" "if the ACT value is under 225 seconds, a second bolt dose of 0.3 mg / kg can be given once again and the ACT 5 minutes after the second bolt dose." "" "" ""</seg>
<seg id="2902">"" "" "" "in patients with moderate kidney damage, included in the phase III- PCI study (replace-2), the ACT value was 5 minutes according to the gift of Bivalirudin-Bolus without dose adjustment to average, 366 ± 89 seconds." "" "" ""</seg>
<seg id="2903">3 patients with severe kidney damage (GFR &lt; 30 ml / min) and on dialysis patients is contraindicated (see section 4.3).</seg>
<seg id="2904">"" "" "" "the treatment with angiox can be induced after completion of the intravenous injection of infractured heparin or 8 hours after the completion of the subcutaneous injection of lower Heparin." "" "" ""</seg>
<seg id="2905">• known hypersensitivity to the active substance or other ingredients or against deudine bleeding caused by a disturbance of hemostasis and / or irreversible effects of cardiac disease. • severe kidney damage (GFR &lt; 30 ml / min) and dialysis patients</seg>
<seg id="2906">"" "" "" "patients are carefully monitored during the treatment with regard to symptoms and signs of a hemorrhage, especially if Bivalirudine is given in combination with another anticoagulant (see Section 4.5)." "" "" ""</seg>
<seg id="2907">"" "" "" "even if the PCI-patient occur under Bivalirudin most of the arteries of the arterial points can occur in patients who occur in percutaneous coronarintervention (PCI), while the treatment of principle occur everywhere." "" "" ""</seg>
<seg id="2908">"" "" "" "in patients receiving warfarin and treated with bivalent (International standardization), in order to ensure that the value after deposition treatment with bivalirudine should be achieved before the treatment existing level." "" "" ""</seg>
<seg id="2909">"" "" "" "proceeding from the knowledge of the mechanism of anti-coagulants (Heparin, Warfarin, Thrombolytics or Thrombocyte units) can be assumed that these compounds increase blood risk." "" "" ""</seg>
<seg id="2910">The combination of Bivalirudin with Thrombocytenants or anticoagulants are the clinical and biological hemostaseparameters of each case regularly to control.</seg>
<seg id="2911">"" "" "" "the experimental studies are insufficient in relation to the pregnancy, the embryonic / fetal development, infeed or postnatal development (see section 5.3)." "" "" ""</seg>
<seg id="2912">4612 were randomized to Bivalirudine alone. GPIIb / IIIA Inhibitor and 4603 were randomized to either unfractured heparin or Enoxaparin plus GPIIb / IIIA Inhibitor.</seg>
<seg id="2913">"" "" "" "in the Bivalirudin Group as well as in patients with Heparin, there were more likely to adverse events than in male or younger patients." "" "" ""</seg>
<seg id="2914">Severe bleeding were performed after the ACUITY and Timi standards for severe bleeding as shown in table 2.</seg>
<seg id="2915">Both light and heavy hemorrhages performed under Bivalirudin alone significantly lower than in the groups with Heparin plus GPIIb / IIIA-inhibitor and GPIIb / IIIa- Inhibitor (see table 2).</seg>
<seg id="2916">A ACUITY severe bleeding was defined as one of the following events: intraocular, retroperitoneal, intraocular bleeding or hemorrhage. the reduction of hemoglobined of ≥ 3 g / l with well-known hemorrhage or redistribution of blood products to transfusion.</seg>
<seg id="2917">"" "" "" "further, less frequently observed blood glocalities that were up to more than 0.1% (occasionally) were" other scores, retroperitoneal, gastrointestinal, ear, nose or neck. "" "" "" "</seg>
<seg id="2918">"" "" "" "the following data on adverse events are based on data from a clinical study of Bivalirudine, with 6,000 patients who undergo a PCI." "" "" ""</seg>
<seg id="2919">"" "" "" "both in the Bivalirudin Group and in patients treated with Heparin, there were more likely to adverse events than in male or younger patients." "" "" ""</seg>
<seg id="2920">"" "" "" "both light and heavy hemorrhages continued to significantly lower than in the comparison group under Heparin plus GPIIb / IIIA-inhibitor." "" "" ""</seg>
<seg id="2921">"" "" "" "the following effects listed above are listed above, according to a comprehensive application in practice and are summarised in Table 6 according to systems." "" "" ""</seg>
<seg id="2922">"" "" "" "in case of overdosing, treatment with bivalent (Bivalirudin) is able to break in immediately and to monitor the patient with regard to signs of hemorrhage." "" "" ""</seg>
<seg id="2923">Angiox contains Bivalirudin, a direct and specific Thrombininor which binds both in the catalytic centre and on the animal-binding region of Thrombin regardless of whether the thrombin is bound to a liquid phase or to straight clots.</seg>
<seg id="2924">"" "" "" "the binding of Bivalirudin to Thrombin, and with that its effect, is reversible because Thrombin develops slowly up the binding of Bivalirudine-arg3-Pro4 through which the function of the active center of thrombin regenerates." "" "" ""</seg>
<seg id="2925">"" "" "" "moreover, through BivalIrudin with serum of patients, the throcytopenia / heparininduced throcytopenia / heparininduced thrombosis syndrome (HIT / HITTS) was induced." "" "" ""</seg>
<seg id="2926">"" "" "" "in healthy subjects and patients Bivalirudin shows dose-dependent anticoagulatory effects that is occupied by the extension of ACT, aPTT, PT, INR and TT." "" "" ""</seg>
<seg id="2927">"" "" "" "if the patient was performed below a PCI, an additional bolt of 0,5mg / kg Bivalirudine should be given and the infusion for the duration of the surgery is increased to 1.75mg / kg / h." "" "" ""</seg>
<seg id="2928">In the arm A of the ACUITY study was administered in mutated Heparin or Enoxaparin according to the relevant guidelines for the treatment of acute Angina / non-ST-uplift system (IA / NSTEMI).</seg>
<seg id="2929">Patients in arm A and B were also randomized to obtain a GPIIb / IIIA or either before the beginning of angiography (at the time of Randomization) or in the PCI.</seg>
<seg id="2930">"" "" "" "in the ACUITY study, the characterisation of high risks who required a angiography was made within 72 hours, evenly over the 3 treatment arms." "" "" ""</seg>
<seg id="2931">"" "" "" "about 77% of patients had a recurring ischaemia, 70% had dynamic EKG- changes or increased kardials biomarkers, 28% had diabetes and about 99% of patients suffering within 72 hours of angiography." "" "" ""</seg>
<seg id="2932">The primary analysis and results from the ACUITY study for the 30-day and the 1- End of the year for the total population (ITT) and for the patients who received Aspirin and Cloak dogrel (before the angiography or before the PCI) are shown in tables 7 and 8.</seg>
<seg id="2933">ACUITY study; 30-days and 1-year risk difference for combined mixing endpoint and its components for patients who received Aspirin and Cloak dogrel according to protocol *</seg>
<seg id="2934">Patients who received Aspirin and Cloak dogrel according to the protocol arm A arm B Arm C UFH / Enox Bival + GPIIb / IIIA + GPIIb / IIIA risk Diff.</seg>
<seg id="2935">The frequency of bleeding both in ACUITY- and in Timi-scale for the entire population (ITT) and for patients who received Aspirin and Cloak dogrel according to protocol is shown in Table 9.</seg>
<seg id="2936">In the protocol (N = 2911) GPIIb / IIIA (N = 2911) GPIIb / IIIA (N = 2911)) GPIIb / IIIA (N = 4604) (N = 4604) (N = 4604) (N = 4604) (N = 4604)%</seg>
<seg id="2937">* Cloak dogrel before angiography or before PCI 1 A ACUITY severe bleeding was defined as one of the following events: intraocular and surgical intervention in the point of tension or hemocclusion of hemoglobined hematoma with a well-known hemorrhage and hematoma of blood sugar for transfusion.</seg>
<seg id="2938">"" "" "" "the 30 days results, based on four-fold overall points of a randomised double-blind study with more than 6,000 patients undergone a PCI (replace-2), are displayed in table 10." "" "" ""</seg>
<seg id="2939">"" "" "" "clinical trials with a small number of patients delivered limited information on the application of Angiox in patients with HIT / HITTS." "" "" ""</seg>
<seg id="2940">The pharmacokinetic properties of Bivalirudine were evaluated in patients who subjected to a percutaneous coronarintervention (PCI) as well as in patients with ACS.</seg>
<seg id="2941">It is expected that Bivalirudin as Peptid is expecting a Katabolism in its amino acid composition with subsequent recovery of amino acids in the body pool.</seg>
<seg id="2942">"" "" "" "primary metabolite, resulting from the split of the Arg3-Pro4 binding by Thrombin, is not effective due to the loss of its affinity to the catalytic center of thrombin." "" "" ""</seg>
<seg id="2943">"" "" "" "the elimination is performed in patients with normal kidney function, following a process of termination with a season of 25 ± 12 minutes." "" "" ""</seg>
<seg id="2944">"" "" "" "based on conventional concepts for safety pharmacology, toxicity in repeated declaratory, genotoxicity or reproduction of reproduction the preclinical data do not recognize any particular hazards for human beings." "" "" ""</seg>
<seg id="2945">The toxicity in animals with repeated or continuous exposure (1 day to 4 weeks at a exposure to 10-Faak of clinical steady state plasma concentration) limited to overlap pharmacological effects.</seg>
<seg id="2946">Adverse events due to a long-term physiological burden as response to a non-homeostatic coagulation were comparable to those in clinical use even with very much higher dosage.</seg>
<seg id="2947">"" "" "" "unless the manufacture of the ready made solution is not controlled by controlled and validated aseptic conditions, it is no longer stored for 24 hours at 2 ° C to 8 ° C." "" "" ""</seg>
<seg id="2948">Angiox is an antifreeze-free powder in single dose casks of type 1-glass to 10 ml. sealed with a butylrubber boots up and sealed with a cap made of pressed aluminum.</seg>
<seg id="2949">5 ml of mortal water for injection purposes will be given in a diarrhoa bottle of andox and easily wiped up all completely and the solution is clear.</seg>
<seg id="2950">5 ml of sodium chloride solution for injection or with 9 mg / ml (0.09%) sodium chloride solution for injections in a total volume of 50 ml to receive a concentration of 5mg / ml Bivalirudin.</seg>
<seg id="2951">"" "" "" "the holder of approval for the insightedness of investigation is consistent with the studies and pharmacovigilance activities described in the Pharmacovigilance plan, as well as in version 4 of the risk management plan (RMP) and all subsequent changes of the RMP, assigned to CHMP, performed by CHMP." "" "" ""</seg>
<seg id="2952">"" "" "" "according to CHMP Guideline to risk management systems for dental implants, the revised RMP is to be submitted simultaneously with the next Periodic Safety Update Report (PSUR)." "" "" ""</seg>
<seg id="2953">• Patients with breast pain caused by heart disease (acute coronardro- ACS) • Patients that are operated on the treatment of closures in the blood vessels (angioplasty and / or percutaneous coronarangioplasty - PCI).</seg>
<seg id="2954">• You are pregnant or suspicious that you could be pregnant or you intend to be pregnant or breastfeeding.</seg>
<seg id="2955">"" "" "" "there were no investigations about the effects on the traffic relationship and the ability to serve machines, but you know that the effects of this medication are only short notice." "" "" ""</seg>
<seg id="2956">"" "" "" "should a bleeding occur, the treatment with angiography is canceled. • In front of the start of injection or infusion you will inform your doctor about the possible signs of an allergic reaction." "" "" ""</seg>
<seg id="2957">Such reactions are rare (they occur in less than 1 out of 1000 treated patients). • A particularly careful monitoring process is carried out when you supply the heart with blood (this treatment is called beta or gamma-brachytherapy). • The dose that you will receive from your body weight and type of therapy you get.</seg>
<seg id="2958">• 0,1 mg / kg body weight as injections followed by an infusion (0.25 mg / kg body weight) per hour (0,1 mg / kg body weight per hour means a quarter of a millimeter of body weight for every kilogram bodyweight per hour).</seg>
<seg id="2959">"" "" "" "likely, if Angiox is administered in combination with other gerating or antithrombotical drugs (see Section 2" For using Angiox with other medicines ")." "" "" ""</seg>
<seg id="2960">These are occasional side effects (in less than 1 out of 100 treated patients). • thrombosis (blood clots) that might lead to severe complications such as a heart attack.</seg>
<seg id="2961">This is an occasional side effect (less than 1 out of 100 treated patients). • pain, bleeding and effusion of blood at the point-agency (after a PCI treatment).</seg>
<seg id="2962">"" "" "" "please inform your doctor if one of the listed side effects will affect you, or you may notice any side effects listed in this manual information." "" "" ""</seg>
<seg id="2963">Angiox may not be used on the label on the label on the label and the box using "using the specified expiration date.</seg>
<seg id="2964">Polska The Medicines Company UK Ltd Tel.: + 800 843 633 26 LUB + 41 61 564 1320 demonstrator: + 30 210 5281700 E-mail:</seg>
<seg id="2965">"" "" "" "Apidra is used to treat adults, teenagers and children aged six years with diabetes, having a treatment with insulin." "" "" ""</seg>
<seg id="2966">Apidra is injected to subcutaneous (under the skin) into the abdominal wall or arm as a permanent infusion with an insulin pump.</seg>
<seg id="2967">"" "" "" "diabetes is a disease when the body does not insufficient insulin for the glucose of glucose (sugar), or the insulin can not be effective." "" "" ""</seg>
<seg id="2968">"" "" "" "insulin-isin differs very slightly from humankind, and the change means that it acts faster and a shorter duration of activity has a short-effective human insulin." "" "" ""</seg>
<seg id="2969">"" "" "" "in combination with diabetes type 1 diabetes, Apidra has been investigated in patients with type 1 diabetes, in which the body can produce no insulin, in two studies with 572 children aged four and 17 years." "" "" ""</seg>
<seg id="2970">"" "" "" "in case of type 2 diabetes, in which the body of insulin has not been effectively processed, Apidra was studied in a study with 878 adults." "" "" ""</seg>
<seg id="2971">The main indicator for efficacy was the change in the concentration of the substance glycerylified hemoglobin (HbA1c) in the blood which indicates how well the blood sugar is adjusted.</seg>
<seg id="2972">"" "" "" "in the first study of adults with type 1 diabetes, a reduction of 0.14% (from 7.3% to 7.46%) was detected in a reduction of 0.14% compared with insulin for six months." "" "" ""</seg>
<seg id="2973">In adults with type 2 diabetes the reduction in HbA1c concentration was 0.46% after six months with Apidra compared to 0.30% in human normal insulin.</seg>
<seg id="2974">"" "" "" "Apidra should not be applied to patients who are potentially sensitive (allergic) against insulin-ulisin or one of the other ingredients, or in patients who are already suffering from hypoglycemia." "" "" ""</seg>
<seg id="2975">"" "" "" "the cans of Apidra may be adapted, if it is administered along with a number of other medicines which can affect the glucose level." "" "" ""</seg>
<seg id="2976">"" "" "" "in September 2004, the European Commission issued Sanofi-Aventis Deutschland GmbH, approved an approval for the placing of Apidra in the entire European Union." "" "" ""</seg>
<seg id="2977">Apidra is used as subcutaneous injection either in the field of abdominal wall or to apply subcutaneous to continuous infusion to the area of abdominal de- CKE.</seg>
<seg id="2978">"" "" "" "due to reduced glucose levels and decreased insulin production, the insulin requirement may be reduced in patients with a limitation of the liver function." "" "" ""</seg>
<seg id="2979">"" "" "" "any change of active substance, the brand (normal, NPH, zinc-delayed, etc.), the type of insulin (animal insulin, etc.), can change the insulin demand change." "" "" ""</seg>
<seg id="2980">"" "" "" "3 A insufficient dosage or treatment, in particular in patients with an insulinable diabetes, can lead to hyperglycaemia and a diabetic itetoids, which conditions are potentially lithreatening." "" "" ""</seg>
<seg id="2981">"" "" "" "the conversion of a patient on another insulin type or a insulin pump should be done under strict medical supervision, and may require a change in the dosage." "" "" ""</seg>
<seg id="2982">"" "" "" "the timing of a hypoglycemia depends on the mode profile of the used insulin, and can therefore change in changing the treatment schemas." "" "" ""</seg>
<seg id="2983">"" "" "" "in addition to the substances that increase blood glucose levels and increase the tendency to hypoglycemics, fibromycotoxin, anticoxylic acid, propoxylic acid, salicylates and sulfonamide antibiotics." "" "" ""</seg>
<seg id="2984">"" "" "" "in addition, under the effect of symphaolytics such as beta-blockers, Clonidine, guanethidine and Reserpine may be weakened or missing the symptoms of adrenticism." "" "" ""</seg>
<seg id="2985">"" "" "" "the experimental studies for reproduction of reproduction showed no differences between Insu- linglulisin and humanization regarding the pregnancy, the embryonic / fetal development, the birth or postnatal development (see paragraph 5.3)." "" "" ""</seg>
<seg id="2986">"" "" "" "it is not known whether there is insulin injisin to human breast milk, but in general insulin occurs neither into the breast milk, nor is it resorated after oral application." "" "" ""</seg>
<seg id="2987">"" "" "" "in the following countries that are reported from clinical trials listed, grouped according to systems organically and classified according to decreasing the frequency of their assignment (very rare: ≥ 1 / $10,000; very rare: ≥ 1 / 10,000; very rare: ≥ 1 / 10,000;" "" "" ""</seg>
<seg id="2988">"" "" "" "cold - weld, cool and cool skin, fatigue, nervousness or tremor, anxiety, nervousness or sponges, confusion, concentration disorders, dizziness, nausea, nausea and palpitations." "" "" ""</seg>
<seg id="2989">Lipocyrophy Will be missed to continuously change the injection of injections inside the injection area in the result of a lipodystrophy at the injection site.</seg>
<seg id="2990">Severe Hypoglycasions with awareness can be given by an intramuscular or subcutaneous injection of Glukagon (0.5 to 1 mg) which is given by a doctor or administered intravenous gift of glucose by a doctor.</seg>
<seg id="2991">"" "" "" "following a gluing injection, the patient should be supervised in a hospital to determine the pre- matter for the heavy hypoglycaemia and to avoid similar episodes." "" "" ""</seg>
<seg id="2992">Insulin lowers blood sugar level by stimulating the peripheral glucose absorption (especially through skeletal musculature and fat) and by inhibiting glucose in the liver.</seg>
<seg id="2993">"" "" "" "studies with healthy volunteers and patients with diabetes have shown that at subcutaneous gauging of insulin, the activity takes place faster and the duration of activity is shorter than with hugely normal insulin." "" "" ""</seg>
<seg id="2994">In a study of 18 male people aged 21 to 50 years with type 1 diabetes melliulisin in the therapeutic relevant dosing range of 0.075 to 0.15 E / kg showed a proportional increase of a gluing effect result in precisely how human insulin.</seg>
<seg id="2995">Insulin lulisin has twice as fast influence how normal humaneness and achieves full draught effects about 2 hours earlier than humanised classification.</seg>
<seg id="2996">"" "" "" "data from the data was obvious that during an application of insulin lulisin 2 minutes before the meal, a comparable posterior glycaemic control is performed as was given 30 minutes before meal." "" "" ""</seg>
<seg id="2997">Insulin was charged isinglulisin 2 minutes before meal and was given a better postprandiral control than with human normal insulin for 2 minutes before meal.</seg>
<seg id="2998">Insulin is considered insulin delivery in 15 minutes after the meal. a comparable glycaemic control is given as in human normal insulin which is given 2 Mi- grooves in front of the meal (see picture 1).</seg>
<seg id="2999">Isinglulisin with gift 2 minutes (GLULISIN - before beginning of the meal was given a 30 minutes (NORMAL - 30 min.) before the meal was given (Figure 1A) and compared to human normal insulin for 2 minutes (NORMAL - previously) was given before a meal (Figure 1B).</seg>
<seg id="3000">Insulin lulisin in gift 15 minutes (GLULISIN - after the beginning of the meal) compared to human northern-malfunction which was given in 2 minutes (NORMAL - previously) before the meal (Figure 1C).</seg>
</doc>
</tstset>
